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Aortic stenosis is the commonest valve disease requiring intervention in the 
developed world. Current guideline-based management strategies are based 
on historical observational data or expert opinion and may leave many patients 
with irreversible myocardial damage and adverse outcomes following valve 
intervention. The aims of this thesis are to investigate novel cardiac magnetic 
resonance techniques and how they can be applied to improve our decision 
making around the timing of valve intervention. 
 
Methods and Results 
Cardiac magnetic resonance imaging can detect two forms of myocardial 
fibrosis non-invasively; diffuse fibrosis using T1 mapping and replacement 
fibrosis with the late gadolinium enhancement technique. I devised a novel 
measure of diffuse fibrosis, the indexed extracellular volume (iECV) and 
showed that these techniques can be used to divide patients into three 
categories according to the type and amount of fibrosis present: no fibrosis, 
diffuse fibrosis and replacement fibrosis.  Moreover, I demonstrated that there 
was evidence of increasing left ventricular decompensation across these three 
groups.  
 
How fibrosis and left ventricular hypertrophy change over time has not been 
well studied in patients with aortic stenosis. Using serial imaging scans, I 
showed that hypertrophy and diffuse fibrosis gradually progress over time, 
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whilst replacement fibrosis accumulates rapidly once first established. 
Following valve replacement, cellular hypertrophy regresses faster than 
diffuse fibrosis, but replacement fibrosis appears permanent and irreversible. 
 
I then proceeded to investigate T1 mapping measures in a large international 
multicentre cohort of patients with aortic stenosis scheduled for valve 
replacement. I showed that extracellular volume-based T1 mapping measures 
were comparable across centres and therefore confirmed that multicentre 
studies are feasible. Extracellular volume fraction was associated with a 
decompensating ventricle and emerged as a powerful independent predictor 
of all-cause mortality in this group. 
 
Finally, I investigated the use of novel hybrid magnetic resonance and positron 
emission tomography imaging in patients with aortic stenosis, showing that 
this technique is feasible and well-tolerated. I tested novel attenuation 
correction and motion correction methods and showed that this technique can 




I have defined the longitudinal changes in hypertrophy and myocardial fibrosis 
in aortic stenosis and validated extracellular volume measures as prognostic 
markers in this group. Moreover, I have described novel magnetic resonance 
and positron emission tomography techniques and their potential to aid the 




Aortic stenosis is the narrowing of the main outlet heart valve that controls 
blood flowing out of the heart and around the body. This narrowing increases 
the pressure load of the heart leading to thickening of the heart muscle over 
time. Working out when is the best time to offer surgery to replace the 
narrowed valve can be challenging. MRI scans of the heart can pick up 
scarring of the heart muscle, which is not seen with other tests. We know that 
finding a discrete area of heart muscle scarring in patients is associated with 
a higher risk of death and having symptoms, but we are less clear on the 
importance of finding a diffuse pattern of scarring.  
 
I investigated the importance of patterns of scarring in patients recruited to a 
research study in Edinburgh. I found that patients with discrete areas of scar 
had the highest chance of dying, and those with a diffuse scarring pattern had 
an intermediate chance of dying compared with those with no scarring.  
 
I also performed multiple MRI scans in patients with aortic stenosis to see how 
thickening and scarring of the heart muscle changed over time. I found that 
heart muscle thickening and diffuse scarring increased slowly over time, but if 
a discrete scar formed, accelerated new scar formation was observed on the 
next MRI scan. After valve surgery, both heart muscle thickening and diffuse 
scarring got better, but the discrete scars did not, meaning this type of scarring 
is permanent.  
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I then looked at diffuse scars in a large study of 400 patients with aortic 
stenosis who were waiting for valve replacement operations from several 
hospitals around the world. I found that the measurements of diffuse scarring 
from different MRI scanners could be compared, and that patients with diffuse 
heart muscle scarring were at a higher risk of dying regardless of their age, 
gender and overall heart pump function.  
 
Finally, I tested a new type of MRI scanner that is combined with a PET 
(positron emission tomography) camera, where an injection of low-dose 
radioactivity is given, allowing us to track where the injection has travelled to 
in the body. I showed that this type of scanner gives us good images and 
measurements in people with aortic stenosis, but more research is needed. 
 
In summary I have developed several new and powerful imaging techniques 
for assessing patients with aortic stenosis that hold promise in optimising the 






This thesis represents the research I performed at the Clinical Research 
Facility, Edinburgh Imaging at the Queens Medical Research Institute, Little 
France Campus and the Royal Infirmary of Edinburgh between August 2015 
and August 2018. 
 
I personally performed the final follow-up visits of patients in the CMRAS study 
and supervised the cardiovascular magnetic resonance (CMR) scans. For the 
Progression Analysis (Chapter 4) I reanalysed all of the CMR scans from both 
Edinburgh and Quebec cohorts. I had not recruited or collected any data from 
the Quebec patients. I was not involved in patient recruitment for the ECV400 
study (Chapter 5) but did collate the data from the international centres and 
performed CMR analysis of all of the scans. I recruited all participants in the 
PASS study (Chapter 6) and supervised the MR/PET scans. I performed the 
statistical analyses for all included data.  
 
Chapters 3 and 4 have been published in high-impact peer reviewed journals. 
I was the first co-author for both of these papers. Chapters 5 and 6 are in the 
process of submission for publication at the time of thesis submission. In all 
chapters, I performed the primary statistical analysis and drafted the 
manuscripts.  
 
I have also set up (as Principal Investigator) the EVOLVED (Early Valve 
Replacement guided by Biomarkers of Left Ventricular Decompensation in 
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Asymptomatic Patients with Severe Aortic Stenosis) clinical trial. This is a 
multicentre randomised controlled blinded end-point trial investigating whether 
early valve intervention leads to improved clinical outcomes in patients with 
asymptomatic severe AS and evidence of mid-wall late gadolinium 
enhancement on CMR. I personally drafted the protocol with assistance from 
Edinburgh Clinical Trials Unit, obtained Research Ethics Committee and NHS 
R&D approval and have set up over ten U.K. sites. I have screened and 
recruited patients in Edinburgh over the last 12 months of my PhD. The 
EVOLVED trial is detailed in Chapter 7 and the protocol included as an 
appendix.  
 
This thesis has not been accepted in any previous applications for a degree 
and all sources of information have been acknowledged. The research was 
undertaken in accordance with the Declaration of Helsinki and the regulations 
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OVERVIEW 
Aortic stenosis is the most common valve disease requiring surgical 
intervention in high-income countries (1). It is characterised by progressive 
thickening, fibrosis and calcification of the leaflets leading to restriction and 
valve obstruction (2). The consequent increase in left ventricular afterload 
leads to a hypertrophic response of the left ventricle, normalising wall tension 
and maintaining cardiac output. However, with progressive valvular stenosis, 
this hypertrophic response eventually decompensates resulting in symptom 
development, heart failure and death. 
 
With no medications proven to attenuate or reverse stenosis progression, the 
only available treatment is valve replacement. This should ideally be 
performed when the risks of the disease process (i.e. sudden cardiac death, 
irreversible functional impairment and heart failure) outweigh those of 
intervention (i.e. procedural risk, long-term complications and potential need 
for reoperation). However, we frequently lack robust evidence to make 
accurate assessments of such risk. Deciding on the timing of valvular 
intervention is therefore difficult in many patients and contemporary clinical 
guidelines are often underpinned by historical observational data rather than 
high-quality randomised controlled trials. I will review our current 
understanding of the pathophysiology of aortic stenosis, describe and examine 
the evidence behind current guideline recommendations, and explore potential 
future strategies to optimise the timing of valve intervention, focussing on the 
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assessment of left ventricular decompensation using cardiac magnetic 






PATHOPHYSIOLOGY OF VALVULAR STENOSIS AND THE 
HYPERTROPHIC RESPONSE 
 
Since the original description of aortic stenosis by Mönckeberg in 1904, the 
decline in rheumatic fever and ageing population have led to a demographic 
transition towards fibrocalcific disease. For many years, fibrocalcific aortic 
stenosis was viewed as a degenerative disease where progressive “wear and 
tear” led to structural damage and passive valvular calcification. However, 
contemporary thinking is that fibrocalcific aortic stenosis develops as part of a 
series of intricate and highly regulated inflammatory, fibrotic and osteogenic 
processes. The pathophysiological processes driving aortic valve stenosis can 
be divided into two phases (2). The initiation phase is characterised by 
endothelial injury accompanied by infiltration of lipids, lipid oxidation and pro-
inflammatory response. Despite the clear similarities with atherosclerosis, 
three large randomised trials have failed to show any effect of statins on 
disease progression or clinical outcome. The second phase, or propagation 
phase, is characterised by the appearance of osteoblast-like cells which co-
ordinate progressive valvular calcium and bone matrix deposition. This 
osteogenic phenotype involves many signalling molecules involved in bone 
formation and is both self-perpetuating and highly regulated (2). Advances in 
imaging now allow for non-invasive assessment of both the burden and activity 
of calcification in the valve (3,4). However the severity of aortic valve 






The traditional focus of aortic stenosis assessments has been on the valve. 
However, the left ventricular myocardial response to pressure overload is 
equally important (6), particularly as the correlation between 
echocardiographic measures of aortic stenosis severity and the degree of 
myocardial hypertrophy is moderate at best (7). Whilst left ventricular 
hypertrophy maintains wall stress and cardiac output for many years, it 
eventually decompensates, with cell death and myocardial fibrosis identified 
as key processes (8). Many imaging and biomarker surrogates of these 
processes have been investigated providing significant prognostic information 





CURRENT GUIDELINE RECOMMENDED TREATMENT 
STRATEGIES AND THEIR LIMITATIONS 
 
Broadly speaking, contemporary clinical guidelines recommend aortic valve 
intervention when stenosis severity is deemed severe and there is evidence 
of left ventricular decompensation, using either direct objective or surrogate 
symptomatic measures (Figure 1.1 and Table 1.1) (9,10). Haemodynamic 
severity is best assessed using echocardiography but can be challenging 
when measures of severity are discordant or low-flow states exist. New 
recommendations for confirming AS severity are given in the 2017 
ESC/EACTS guideline update (5). Detailed discussion of low-flow states is 
beyond the scope of this thesis but can be found elsewhere (11). 
 
Presence of Aortic Stenosis-related Symptoms 
It is universally accepted that the development of patient symptoms (exertional 
dyspnoea, angina or syncope, Table 1.2) serves as an indicator of left 
ventricular decompensation and a dismal prognosis without intervention. This 
was first described in the seminal paper by Braunwald and Ross in 1968 and 
forms the underlying framework of how we manage patients today. However, 
this finding was based on retrospective data from just 12 patients with a 
mixture of bicuspid and rheumatic valve disease and a mean age of death of 
63 years. The changing demographics of aortic stenosis make it difficult to 
interpret the current relevance of these historical data to the patients seen in 
current practice who are frequently in their eighth or ninth decades. Symptom 
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assessment can be highly challenging in these patients due to the high 
prevalence of both co-morbidity, which may cause symptoms to be falsely 
attributed to aortic stenosis, and physical inactivity, which can conceal 
exertion-related problems.  
 
Exercise testing may help unmask symptoms in many patients and is safe 
when performed in stable patients (12). ESC guidelines recommend surgery 
in patients with severe aortic stenosis and typical symptoms on exercise test 
(class I, level C) or a fall in systolic blood pressure at peak exercise (class IIa, 
level C). This recommendation is based largely on observational data 
demonstrating that a positive exercise test is a strong predictor of sudden 
death or symptom development (13). However, these data are limited, 
consisting of a series of relatively small observational studies with inherent risk 
of bias and heterogeneity as to what constituted an abnormal test. According 
to a recent meta-analysis, whilst the negative predictive value of stress testing 
for subsequent cardiac events is reasonable (79%), the positive predictive 
value is modest (66%) (12). Exercise testing has other major limitations, up to 
20% of patients will be unable to perform the test due to poor mobility, whilst 
pre-existing ECG abnormalities are present in up to 50% of patients 
confounding test interpretation (14). It is worth noting that exercise testing may 
also detect abnormalities caused by co-existent coronary disease which is an 




Impaired Left Ventricular Ejection Fraction 
Development of left ventricular systolic impairment, as identified by a reduced 
left ventricular ejection fraction, is an inevitable consequence of progressive 
and untreated valvular stenosis, assuming sudden death does not occur. 
Although the risk of perioperative mortality is elevated in the setting of reduced 
ejection fraction, these patients have a dismal prognosis without intervention 
and improved long-term outcomes with valve replacement earning a class I, 
level C recommendation in clinical guidelines (9,10).  
 
In clinical practice, patients with aortic stenosis can develop a reduction in 
ejection fraction for a variety of reasons and it remains important to consider 
the mechanism of this reduction and whether it is reversible. Reductions in 
ejection fraction occur as a direct response to increases in afterload and will 
reverse following valve replacement. By contrast the ejection fraction does not 
improve in approximately 25% of patients (9,10,16,17) who are more likely to 
remain symptomatic and who have adverse long term outcomes (twice as 
likely to die over 5 years follow-up) (18). In these patients, persistent systolic 
dysfunction appears related to the development of irreversible scar due to 
either myocardial infarction or decompensation of the hypertrophic response 
(19). In sick, frail patients such information may govern whether valve 




Very Severe Aortic Stenosis 
Patients with critical aortic stenosis appear to have a particularly poor 
prognosis, similar to that of symptomatic severe aortic stenosis (20). Indeed 
patients with peak aortic jet velocities of >5.0 and >5.5 m/s demonstrate a 2-
year event free survival of 43% and 25% respectively compared with 70% in 
those with Vmax 4.0-4.9 m/s (21). The ESC/EACTS guidelines therefore 
recommend consideration of aortic valve replacement in patients with Vmax 
>5.5 m/s if the estimated surgical risk is low (class IIa, level C). However, these 
observational studies mostly examined the composite endpoint of mortality 
and referral for aortic valve intervention with a strong risk of referral bias and 
event rates mainly driven by decisions to perform surgery.  
 
Rapid Haemodynamic Progression 
Although the average rate of progression (measured by peak aortic-jet 
velocity) is 0.24±0.30 m/s/year, this rate is highly variable (22). Moreover, it is 
subject to scan-rescan variation in peak velocity measurements, which can be 
high in clinical practice. Patients with rapid progression (>0.3 m/s/year) and 
significant valve calcification have a rate of symptom development or mortality 
of 79% at 2 years (23). As a result, referral for surgical intervention in these 
patients is given a class IIa, level C recommendation in the latest guidelines. 
However again this is based on limited observational data and this strategy 
requires standardised high-quality echocardiography over several years to 





Elevation of Brain Natriuretic Peptide Levels 
Brain natriuretic peptide (BNP) is the first cardiac biomarker to be included in 
the decision-making algorithm for aortic valve replacement. Early studies 
investigating natriuretic peptides in aortic stenosis showed promise but were 
criticised for their small size, observational nature and use of softer outcome 
endpoints (24,25). In addition, many patients were symptomatic and the 
variation in normal BNP with age and sex were not accounted for. A more 
recent study of 565 patients with asymptomatic moderate-to-severe aortic 
stenosis identified that a BNP ratio (measured BNP value divided by upper 
limit of normal for patient’s age and sex) of >1 was independently predictive of 
mortality and a ratio of >3 had a hazard ratio of 7.3 for survival in patients with 
asymptomatic severe aortic stenosis (26). As such the latest clinical guidelines 
reflect these data with a level IIa, class C recommendation for aortic valve 
replacement if the BNP ratio is persistently above 3 and overall surgical risk is 
low. However, BNP is a non-specific marker of cardiac dysfunction and its 
utility, like each of the other measures, has yet to be tested in a randomised 
controlled trial. 
 
The recently published ESC clinical guidelines also removed two previous IIb 
indications for AVR in asymptomatic patients; an increase in mean aortic 
gradient of >20 mmHg with exercise, or the finding of excessive LV 
hypertrophy in the absence of hypertension.   
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Figure 1.1: ESC/EACTS algorithm for management of severe aortic 





AS, aortic stenosis; LVEF, left ventricular ejection fraction; SAVR, surgical aortic 




Table 1.1: Recommendations for Intervention in patients with severe 
aortic stenosis (ESC/EACTS guidelines 2017) 
   
Symptomatic Severe AS (surgical AVR or TAVI) Class Level 
Indicated in severe high gradient aortic stenosis (AV 
Vmax >4m/s or mean gradient >40mmHg) 
I B 
Indicated in patients with low-flow low-gradient severe 
AS with reduced ejection fraction and evidence of 
contractile reserve excluding pseudosevere AS 
I C 
Should be considered in patients with low-flow low-
gradient severe AS with preserved ejection fraction 
after careful confirmation of severe AS. 
IIa C 
Should be considered in patients with low-flow low-
gradient severe AS with reduced ejection fraction 
without evidence of contractile reserve especially where 
CT calcium scoring confirms severe AS  
IIa C 
Should NOT be performed in patients with severe 
comorbidities where the intervention is unlikely to 
improve quality of life or survival 
III C 
   
Asymptomatic Severe AS (surgical AVR only)   
Indicated in patients with severe AS and left ventricular 
systolic dysfunction (LVEF <50%) not due to another 
cause 
I C 
Indicated in patients with abnormal exercise test 
showing symptoms on exercise clearly related to aortic 
stenosis  
I C 
Should be considered in patients with abnormal 
exercise test showing a decrease in blood pressure 
below baseline 
IIa C 
Should be considered if the surgical risk is low and one 
of the following abnormalities is present: 
• Very severe aortic stenosis (AV Vmax >5.5m/s) 
• Severe valve calcification with a rate of 
progression ≥0.3m/s/year  
• Markedly elevated BNP (> threefold above age- 
and sex– corrected normal range) confirmed by 
repeated measurements without other 
explanations 
• Severe pulmonary hypertension (systolic 
pulmonary artery pressure >60mmHg at rest 





AS, aortic stenosis; AV, aortic valve; BNP, b-type natriuretic peptide; CT, computed 




Table 1.2: Symptomatology of Severe Aortic Stenosis 
 
Symptom: Aetiology: Potential questions to ask: 
Angina Supply-demand 
imbalance: co-existent 
coronary disease and 
fixed cardiac output 
versus hypertrophied 
myocardium  
“do you get chest pain or 
discomfort when walking or 





Reduced LV compliance 




“can you walk ask many stairs 
as this time last year?” 








Fixed cardiac output, 
skeletal muscle 
vasodilation on exertion 
and resultant cerebral 
hypoperfusion  
“have you felt lightheaded like 
you might faint? 
“have you had any fainting or 
blackout episodes?” 
Palpitation Development of atrial or 
ventricular arrhythmia, 
myocardial scarring 




BALANCING COMPETING RISKS 
There are clear limitations with many of our guideline-advocated strategies. 
Most are based upon limited observational data and supported by level C 
recommendations. There is therefore a need for randomised controlled trials 
assessing the optimal timing of surgery and novel objective methods to guide 
this major clinical decision. Ideally, intervention would be performed in patients 
just as the left ventricle is starting to decompensate but before substantial 
irreversible damage has accrued and at a time when the short and long-term 
risks of the intervention are outweighed by the risks of not intervening (Figure 
1.2 and Table 1.3). An understanding of these competing risks is therefore 
critical.  
 
1. Risks of valve intervention 
Surgical aortic valve replacement remains the standard of care for valvular 
intervention, with improvements in surgical and post-operative care driving 
peri-operative mortality down to ~1-3%. Other important perioperative 
complications include conduction disease requiring permanent pacemaker 
insertion (1.5-8.6% (27)) and cerebrovascular accidents (2.4-8.1% (28-30)). 
There is also the risk of cognitive decline (due to peri-operative cerebral 
hypoperfusion, microemboli or anaesthetic agent neurotoxicity (30)). An 
individual’s risk of these complications can be estimated using surgical risk 
calculators such as EUROSCORE II and the Society of Thoracic Surgeons 
score. An argument in favour of early surgery is that operative risk is lower in 
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younger patients that are asymptomatic, have less co-morbidity and normal 
left ventricular function.  
 
The emergence of minimally invasive transcatheter aortic valve insertion 
(TAVI) over the last 10 years has completely changed the landscape for 
decision making regarding valve intervention in symptomatic patients. Current 
trials show non-inferiority of this percutaneous technique compared with 
surgical intervention in both high and intermediate-risk patients (29,31-34) and 
procedural risk may further reduce with increasing clinical experience and 
advances in prosthesis design and delivery. Indeed, major vascular 
complications have decreased substantially (from >10% to <5% (35)) as have 
stroke rates which are between 2-3% in contemporary cohorts (35). However 
the requirement for permanent cardiac pacing following the procedure remains 
consistently higher than surgical intervention at >10% (35) and whilst TAVI 
allows for rapid patient recovery and mobilisation, the long term durability of 
these bioprostheses has not been demonstrated (36). This will be key before 
their widespread use in younger or asymptomatic patient groups can be 
recommended.  
 
Performing valve intervention introduces small but significant annual risks 
associated with the presence of a prosthetic valve. These risks are heavily 
influenced by valve type, with both anticoagulant-related major bleeding (1.8-
2.6% per year) and thromboembolism (0.7-1.0% per year) more frequent with 
mechanical valves (37). In addition, there is an increased risk of endocarditis 
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(1-3% during the first year then <0.5% per year (38)) which has a high 
associated morbidity and mortality. Whereas structural valve degeneration is 
exceedingly rare in mechanical valves, bioprosthetic valves have a limited 
lifespan which can be difficult to predict. In these patients, valve degeneration 
usually starts to occur 10 years following implantation (39), and occurs more 
rapidly in younger patients (40). This is an extremely important issue if 
bioprosthetic valves are to be utilised in younger asymptomatic patients. 
Ongoing research into decellularisation techniques and tissue engineering 
may lead to improved bioprosthetic valve longevity, whilst advances in 
mechanical valve design might eventually eliminate the need for 
anticoagulation and associated bleeding risk. In addition, the use of a 
transcatheter valve inside a surgical bioprosthetic valve (so called valve-in-
valve TAVI) may reduce the risk of future procedures should valve 
degeneration occur.  
 
2. Risks of not intervening 
The risk of sudden cardiac death in patients with asymptomatic severe aortic 
stenosis managed conservatively is ~1% per year and occurs without 
preceding symptoms in 70% of cases (41-43). Once symptoms develop, 
further clinical deterioration can be rapid with a significant risk of sudden death 
whilst awaiting intervention (4% at 1 month, 12% at 6 months)(44).  
 
Delaying aortic valve intervention until there is evidence of advanced left 
ventricular decompensation results in greater perioperative risks (43). 
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Observational studies have quoted increased perioperative mortality (9-19% 
(9,18,45)) in patients who have developed left ventricular systolic impairment 
and advanced myocardial fibrosis (46). Further risk stratification can be 
performed using stress echocardiography to assess myocardial contractile 
reserve, with lower perioperative risks if contractile reserve is present (5% 
versus 22-32% (10,47)). However, given the dismal prognosis of untreated 
AS, even patients without contractile reserve have improved long-term survival 
if they survive the perioperative period (9,10).  
 
The highest burden in mortality and morbidity related to delaying valve 
intervention appears to occur in the months and years following AVR, 
particularly in those patients who have evidence of left ventricular 
decompensation.  As discussed, patients with an impaired ejection fraction 
prior to AVR have a poor long term prognosis (18), whilst in a recent study of 
aortic stenosis patients with a high probability of LV decompensation, more 
than half were either dead or admitted to hospital with heart failure within 2 
years (48). Both these observations may reflect the development of 





Figure 1.2: Optimising the timing of aortic valve intervention in 





Table 1.3: Estimates of clinical risks associated with watchful waiting 






Risk estimate Risks associated with 
early intervention 
Risk estimate 
Sudden cardiac death 1.0-1.5% per year 
(41-43) 









4% at 1 month,  












































Lack of improvement 
in ejection fraction 
following intervention 
25-50% (9,10) Long term prosthetic 
valve complications 
-thromboembolism 
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POTENTIAL FUTURE STRATEGIES FOR DECIDING ON 
TIMING OF AORTIC VALVE INTERVENTION 
 
Several different strategies for optimising the timing of valve replacement in 
aortic stenosis have been proposed, many of which are currently being 
evaluated within the context of randomised controlled trials (Figure 1.3 and 
Table 1.4). Many of these target asymptomatic patients and it should be 
recognised that many patients who feel otherwise fit and healthy might not 
want to undergo major heart surgery.  
 
1. All-comers with severe aortic stenosis 
Historical teaching has been that “aortic valve replacement is the most 
common cause of death in patients with asymptomatic severe aortic stenosis”. 
However, improving outcomes following surgical and transcatheter valve 
interventions are challenging this doctrine. Performing valve intervention on all 
asymptomatic patients with severe aortic stenosis is a simple and pragmatic 
solution that does not seek to identify the point at which left ventricular 
decompensation occurs. Although some patients will undergo intervention 
earlier than they may have required (and therefore be exposed unnecessarily 
to the problems associated with prosthetic valves), the risks associated with 
contemporary intervention techniques are low and no patient should be left 
with irreversible left ventricular decompensation. This strategy is supported by 
evidence from the Japanese Contemporary outcomes after sURgery and 
medical tREatmeNT in patients with severe Aortic Stenosis (CURRENT AS) 
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registry. Propensity-score matching was used to compare 291 asymptomatic 
patients who underwent early surgery with 291 patients who were managed 
conservatively. Those who received early AVR had a reduced all-cause 
mortality at 5 years (15%) compared with those who were initially managed 
conservatively (26%). Heart failure hospitalisation was also reduced in the 
early intervention group (4% versus 20%). However, propensity matching may 
not have accounted for all potential influences on outcomes and a significant 
proportion of the conservatively managed patients who developed symptoms 
were not referred for intervention, undoubtedly contributing to the worse 
observed survival in this group: confounding by indication. Three randomized 
controlled trials (AVATAR, ESTIMATE and EARLY-TAVR, Table 1.4) are 
currently recruiting which will examine whether valve intervention in 
unselected asymptomatic severe aortic stenosis patients can improve clinical 
outcomes.  
 
2. Refined assessment of valve structure and function 
An alternative strategy is to operate only in asymptomatic patients with very 
high peak aortic-jet velocities. Peak velocities >4.5 m/s are associated with 
increased referral for surgical intervention (21) but also increased rates of peri-
operative death and cardiac death in a prospective cohort study with 
propensity matching (42). The RECOVERY randomised controlled trial will 
examine whether early aortic valve replacement in asymptomatic patients with 
velocities >4.5 m/s and a negative exercise test leads to improved patient 
outcomes compared to watchful waiting (Table 1.4).  
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The total haemodynamic load seen by the left ventricle can also be quantified 
by calculating the valvuloarterial impedence (ZVa= (systolic blood pressure + 
mean AV gradient) / indexed LV stroke volume). This measure is an 
independent marker of adverse outcome in asymptomatic patients (50) and 
warrants further study for its use in determining the timing of intervention. 
 
Another approach is to quantify valvular calcium burden using CT calcium 
scoring. Validated sex-specific thresholds for severe aortic stenosis have been 
proposed (2000 Agatston units [AU] for men, 1300 AU for women) (5), which 
provide powerful prediction of clinical events of incremental value to 
echocardiographic assessments (3). Performing valve intervention on the 
basis of severe valvular calcification on CT might therefore represent an 
attractive alternative strategy. 
 
3. Imaging and biomarkers of left ventricular decompensation  
The two broad strategies listed above largely ignore any detailed assessment 
of the left ventricular response to pressure overload beyond assessment of LV 
ejection fraction. Reductions in ejection fraction are a late, non-specific and 
often irreversible feature in aortic stenosis, and this has led to interest in 
alternative methods for detecting left ventricular decompensation (Figure 1.4) 





Figure 1.3: Comparison of EARLY-TAVR and EVOLVED randomised-
controlled trial designs 
 
Currently recruiting randomised controlled trials generally fall into two groups; those 
investigating valve intervention in all asymptomatic patients with severe aortic 
stenosis (e.g. EARLY-TAVR) and those looking to target intervention based on 




AS, aortic stenosis; CMR, cardiac magnetic resonance; hs, high-sensitivity; LV, left 





Figure 1.4: Imaging and biomarker assessments of stage of valvular 
stenosis and myocardial response to increased afterload 
 
Progressive haemodynamic obstruction as a result of aortic leaflet restriction is 
assessed using echocardiography. However, specific valvular pathologies such as 
fibrosis and calcification can be assessed using computed tomography methods. 
Ejection fraction is a poorly sensitive marker of myocardial decompensation with 
abnormalities in Doppler measures, longitudinal strain and systolic function all 
detectable prior to this. However, these measures, along with biomarkers such as 
troponin and BNP, are non-specific and may be abnormal as a result of co-existent 
myocardial pathology such as coronary heart disease. T1 mapping methods and late 





Table 1.4: Current and planned randomised-controlled trials investigating timing of aortic valve intervention 
Strategy Proposed or ongoing 
trials 
Population Intervention Primary 
outcome 








(Aortic Valve Replacement 
Versus Conservative 
Treatment in Asymptomatic 
Severe Aortic Stenosis) 
312 patients with 
asymptomatic severe 
AS and STS score 












(Early Surgery for Patients 
with Asymptomatic Aortic 
Stenosis) 
360 patients with 
asymptomatic severe 
AS, normal ETT and 












 EARLY TAVR 
(Evaluation of Transcatheter 
Aortic Valve Replacement 
Compared to SurveilLance 
for Patients with 
AsYmptomatic Severe 
Aortic Stenosis) 
1109 patients aged 
>65 with asymptomatic 
severe AS, trileaflet 
valve morphology and 
favourable ileo-femoral 























- higher peak 
velocity threshold 
RECOVERY 
(Early Surgery Versus 
Conventional Treatment in 
Very Severe Aortic 
Stenosis) 
145 patients with very 
severe AS (Vmax 
>4.5m/s, AVA 

















assessment of LV 
decompensation 
EVoLVeD 
(Early Valve Replacement 
Guided by Biomarkers of LV 
Decompensation in 
Asymptomatic Patients with 
Severe AS) 
400 patients with 
asymptomatic severe 
AS, normal LVEF and 
mid-wall fibrosis on 
cardiac MRI 














ETT, exercise tolerance test; LV, left ventricle; MACE, major adverse cardiovascular events; SAVR, surgical aortic valve replacement; STS, Society of 
Thoracic Surgeons; TAVI, transcatheter aortic valve insertion
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Simple cardiac biomarkers beyond BNP are being investigated in aortic 
stenosis as markers of LV decompensation. Cardiac troponin is a structural 
protein present in cardiomyocytes which is released into the bloodstream 
during myocardial injury and can now be detected at very low plasma 
concentrations using high-sensitivity assays. In aortic stenosis, troponin I 
concentrations are associated with a more advanced left ventricular 
hypertrophic response, diffuse and replacement myocardial fibrosis and worse 
long-term clinical outcomes (AVR or cardiovascular death) in patients with 
aortic stenosis (54,55). They are thought to reflect the cardiomyocyte death 
that drives progressive left ventricular decompensation alongside myocardial 




The 12-lead electrocardiogram (ECG) is useful in the assessment of patients 
with AS. Although unable to directly detect valve stenosis, the secondary left 
ventricular hypertrophy leads to characteristic ECG changes, which are 
specific but poorly sensitive for the presence of significant left ventricular 
hypertrophy. These include left axis deviation, increasing QRS voltage in both 
chest and limb leads, change in ST or T wave vector, and broadening of the 
QRS duration. Furthermore, the presence of ST depression in the lateral 
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leads, representing LV strain, has been shown to correlate with an increased 
LV mass, high-sensitivity troponin value, and both diffuse interstitial and mid-
wall replacement fibrosis (positive predictive value of ECG strain for mid-wall 
fibrosis was 100%) (56). The ECG-strain pattern is also a powerful 
independent predictor of AVR or cardiovascular death (56). Although highly 
specific, the poor sensitivity of ECG measures for detecting LV 




Prior to reduction in global LV ejection fraction, echocardiography can detect 
alteration in various measures of diastolic and longitudinal systolic function in 
patients with aortic stenosis which appear related to the presence of 
myocardial fibrosis (7). Reduced left ventricular global longitudinal strain 
(GLS) can be observed in asymptomatic patients with aortic stenosis, acting 
as an independent predictor of mortality (52). However, several of these 
measures still require standardisation across vendor platforms and all suffer 
from significant overlap between results in healthy individuals and those with 
aortic stenosis. Moreover, these imaging markers are not specific to valvular 
heart disease and, like symptoms, might equally reflect co-morbidity such as 




CARDIAC MAGNETIC RESONANCE IMAGING IN AORTIC 
STENOSIS 
 
Echocardiography is the first line imaging tool used to investigate patients with 
known or suspected aortic stenosis as it is low-cost, readily available in most 
secondary care settings and provides important information on valve function 
by use of Doppler flow assessment. However, advanced imaging techniques 
are increasingly being used to provide a more detailed assessment of the left 
ventricle itself. Cardiac magnetic resonance (CMR) imaging provides gold-
standard measurements of LV mass, volume and ejection fraction due to 
superior spatial resolution. It also provides detailed views of the AV and can 
reliably identify anatomical variants such as congenitally bicuspid valves. This 
is particularly valuable in patients with poor acoustic windows, prohibiting 
adequate assessment by echocardiography (Figure 1.5).  
 
Although pressure overloaded states such as hypertension and AS induce 
concentric LV remodelling and hypertrophy, several studies using CMR have 
suggested that asymmetric phenotypes (defined as left ventricular wall 
thickness >1.5 times the opposing segment) are present in up to 25% of 
patients (57). While the exact mechanism is unknown, it is possible that 
increased wall stress could exacerbate a pre-existing genetic tendency 
towards a hypertrophic cardiomyopathy phenotype. Regardless, LV mass is 
most accurately calculated using CMR where the entire volumetric data of the 
LV is quantified.  
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There is also heterogeneity in the range of the LV hypertrophic response, 
which individual patients develop for a given severity of valve stenosis. Several 
studies have shown a poor correlation between the degree of LV hypertrophy 
and the severity of valvular stenosis (as assessed on echocardiography using 
aortic valve area, peak or mean gradient) (57-59). This variation is partly 
explained by sex differences and clinical factors such as co-existent 
hypertension, age, obesity, metabolic syndrome and polymorphisms in the 
angiotensin-converting enzyme gene. Importantly, LV mass index, whether 
calculated using echocardiography or CMR, is an independent predictor of 
adverse cardiovascular events or all-cause mortality (57,60,61). This 
emphasizes the importance to assess both the valve and myocardium 
independently.  
 
CMR is able to assess potentially more sensitive measures of left ventricular 
dysfunction. Although reduced LVEF is strongly associated with a poor 
prognosis in patients with AS, this is a late finding and is preceded by 
impairment of diastolic function, longitudinal strain and longitudinal systolic 
function (subendocardial myocardial fibres oriented in a longitudinal direction 
are affected first by pressure overload). Although no standardised method yet 
exists, longitudinal systolic function can be measured using CMR by assessing 
the mitral valve annular excursion between systole and diastole (62). In 
addition, CMR is able to assess regional and global myocardial strain, using 
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techniques such as myocardial tissue tagging, velocity encoding or tagged 
cine displacement encoding with simulated echoes (DENSE) (63).  
 
Importantly, CMR provides a crucial advantage over other imaging techniques 
in that it offers tissue characterisation and assessment of myocardial fibrosis. 
The gold-standard assessment of fibrosis is invasive endomyocardial biopsy 
but this is susceptible to sampling error and associated with a small but 
significant risk of complications (64). Cardiac magnetic resonance can provide 
non-invasively whole-heart detection and quantification of myocardial fibrosis 
using two methods: late gadolinium enhancement (LGE) which detects 
replacement fibrosis, and T1 mapping for diffuse fibrosis.  
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Figure 1.5: Multiparametric cardiac imaging with cardiac magnetic 
resonance 
 
Cardiac magnetic resonance offers high spatial resolution imaging of the left ventricle 
and aortic valve (3 chamber cine and short axis cines) in addition to providing tissue 
characterisation. The late gadolinium enhancement (LGE) method can detect 
replacement myocardial fibrosis in a mid-wall pattern (red arrows) and native and 
post-contrast T1 mapping can identify diffuse fibrosis by estimating the T1 time of 
tissues which is altered in the presence of fibrosis. Focal replacement fibrosis is also 









LATE GADOLINIUM ENHANCEMENT TECHNIQUE 
 
The late gadolinium enhancement (LGE) technique is now well established in 
clinical practice and is often used for both diagnostic and prognostic purposes 
in both ischaemic and non-ischaemic cardiomyopathies, particularly in cases 
of diagnostic uncertainty. This method uses T1-weighted imaging sequences 
performed 10-20 min following an intravenous bolus of gadolinium-based 
contrast agent. Gadolinium chelate complexes are too large to cross cell 
membranes and therefore distribute in the extracellular space where they 
accumulate in areas of extracellular volume expansion. The inversion time of 
the sequence is manually set to so that there is minimal or no signal generated 
from normal myocardium (so called “nulling”). A qualitative difference can be 
appreciated between “nulled” normal myocardium, which appears black, and 
areas of extracellular matrix expansion as seen in focal replacement fibrosis, 
which then appear bright on T1-weighted sequences. These focal areas of 
replacement fibrosis are likely a consequence of increased coronary flow 
resistance and repeated ischaemia in the regions of left ventricular 
hypertrophy and tend to occur in a mid-wall distribution (65). This can usually 
be differentiated from myocardial infarction, which is another common cause 
of focal replacement fibrosis that characteristically occurs in a subendocardial 
distribution.  
 
Mid-wall replacement fibrosis is detectable on CMR in 29-62% of patients with 
AS (46,49,66) depending on the population studied. Subendocardial LGE, 
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suggesting previous myocardial infarction, is also commonly seen in patients 
with AS (10 to 28% (46)) as patients are often elderly with vascular risk factors 
and, therefore, have co-existent ischemic heart disease. Interestingly, the 
presence of mid-wall LGE appears more closely related to the degree of left 
ventricular hypertrophy rather than the severity of valve narrowing.  
Importantly, several studies have shown no regression in replacement fibrosis 
following relief of LV pressure overload associated with AV replacement 
(19,67,68), suggesting that this type of fibrosis is irreversible. As well as being 
a potential substrate for re-entrant arrhythmias, mid-wall fibrosis also 
correlates with myocardial injury as measured by high-sensitivity cardiac 
troponin I (54) and predicts functional recovery following surgery.  Perhaps 
most importantly, the presence of mid-wall fibrosis has been shown to be a 
strong independent predictor of all–cause mortality in three separate studies 
(19,46,49,69), underlining its utility as an objective marker of LV 
decompensation in AS.  
 
One notable disadvantage of the late gadolinium enhancement technique is 
the inability to detect diffuse interstitial myocardial fibrosis as this relatively 
homogeneous process provides no normal myocardium for visual contrast. 
Therefore, a considerable interest exists in the use of T1 mapping methods to 
quantify fibrosis burden in AS patients (Figure 1.6). This may potentially 
identify the optimal time-point to perform aortic valve intervention before the 
development of irreversible pressure overload-induced pathological changes 
to the ventricle. 
 52 
Figure 1.6: T1 mapping and Late Gadolinium Enhancement in Aortic 
Stenosis 
 
Left column: a healthy control patient with normal myocardium, extracellular volume 
values and no late gadolinium enhancement. Middle column: a patient with severe 
aortic stenosis with raised extracellular volume indicating diffuse fibrosis. Right 
column: a patient with severe aortic stenosis with asymmetrical anteroseptal left 
ventricular hypertrophy, a raised extracellular volume and mid-wall late gadolinium 
enhancement (white arrows).   
 





T1 mapping techniques enable the detection and quantification of diffuse 
myocardial fibrosis, an earlier form thought to precede replacement 
myocardial fibrosis. This process is characterised by collagen deposition and 
associated expansion of the extracellular volume (ECV). This progressive 
change may occur due to an increased requirement for extracellular matrix to 
support the hypertrophied myocytes as a consequence of an increased LV 
afterload, likely triggering increased myofibroblast collagen synthesis.  
 
A variety of T1 mapping sequences exist, being based on either inversion 
recovery or saturation recovery sequences. The sequence most commonly 
used is the MOdified Look-Locker Inversion recovery (MOLLI) which samples 
the T1 recovery curve following inversion pulses over multiple consecutive 
heart beats (70). This allows the T1 value (the time taken to recover 63% of 
longitudinal magnetisation following inversion, a property of different tissues) 
to be estimated (Figure 1.7). A Shortened MOLLI (ShMOLLI) sequence has 
also been developed which does not allow for complete recovery of 
longitudinal magnetisation following each inversion pulse and can therefore be 
acquired over fewer heartbeats. This means the breathhold duration is 
significantly shorter and ShMOLLI may also give more accurate T1 estimation 
at higher heart rates (71). The SAturation recovery single-sHot Acquisition 
(SASHA) sequence is less commonly used (72). Importantly, the T1 values 
generated will vary by sequence and magnetic field strength and this has led 
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to difficulties conducting clinical trials over multiple research centres especially 
given the ongoing iterative development of T1 mapping sequences. 
 
A variety of T1 mapping measures exist that have been studied in literature. 
The evidence for and utility of each of these measurements in the assessment 
of patients with AS will be examined in detail. 
 
Native T1 
Native T1 describes the use of T1 mapping sequences to estimate tissue T1 
values without the use of gadolinium contrast. The sole use of native T1 has 
many advantages; it has good reproducibility in some studies involving 
patients with AS (73) and scanning times are shorter than the equivalent 
contrast-based approaches. Native T1 is particularly attractive in patients with 
advanced renal impairment (estimated glomerular filtration rate <30 
mL/min/1.73 m2) in whom gadolinium-based contrast is contraindicated.  
 
T1 values vary according to the molecular composition and water content in 
any of the tissue compartments of imaged tissue. In some conditions such as 
hypertrophic cardiomyopathy, the most significant changes are intracellular 
with sarcomeric and myocyte disarray. Much of the current literature regarding 
AS focuses on the extracellular compartment where extracellular matrix 
expansion with collagen deposition (myocardial fibrosis) causes an increase 
in native T1 values. Deposition of other proteins, such as those causing 
amyloidosis can show marked increase in native T1 values. However, water 
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content, whether intra or extravascular, is an important determinant of native 
T1. For example, patients with myocarditis have raised native T1 values in 
areas of myocardial inflammation due to the presence of myocardial oedema. 
The intravascular compartment is often overlooked as highlighted in a study 
using adenosine stress CMR. Patients with severe AS have increased resting 
coronary flow volume and reduced flow reserve (74). Native T1 values were 
greater in AS patients compared with controls, but both increased to a similar 
level during pharmacological stress. The authors suggest this demonstrates 
increased resting coronary flow volume in AS patients with consequent 
reduced flow reserve and may partially explain higher resting native T1 values 
in AS patients (67). However this explanation contradicts our current 
understanding of the pathophysiology of LV decompensation that vascular bed 
expansion is insufficient to supply the hypertrophied myocardium leading to 
ischaemia (75-77).  
 
In general, native T1 has demonstrated a good correlation with diffuse 
myocardial fibrosis on histological analysis (as assessed by collagen volume 
fraction (78-80)) although this has not been a universal finding (81). Moreover, 
histological analysis has only been performed on myocardial biopsy samples 
obtained at the time of surgical valve replacement and therefore T1 mapping 




Bull and colleagues first investigated the use of native T1 in 109 patients with 
moderate or severe aortic stenosis. Native T1 values were raised in patients 
with aortic stenosis compared to 33 age and sex matched controls. Both AV 
area and indexed LV mass were independently associated with native T1 
values. (78). Several other studies have shown that native T1 is able to 
differentiate patients with AS from controls albeit with considerable overlap in 
values between the two groups (73,82,83). Chin and colleagues investigated 
various T1 mapping measures at 3 tesla (3T) in 20 patients with AS and 20 
healthy volunteers. While native T1 had excellent intra and inter–observer 
variability and acceptable scan-rescan reproducibility, it was unable to 
discriminate between AS and control subjects (82). This finding may have 
been due to a wider spectrum of AS severity in this study (mild to severe) 
compared to the previous studies, which involved patients with more severe 
disease.  
 
The accumulation of diffuse myocardial fibrosis leads to progressive 
impairment in LV function. Although no studies have yet shown a link between 
native T1 and reduced ejection fraction in aortic stenosis, native T1 has been 
associated with these earlier measures of left ventricular dysfunction. Lee and 
colleagues assessed 80 asymptomatic patients with moderate or severe aortic 
stenosis using 3T cardiac magnetic resonance and included 
echocardiographic speckle tracking imaging. Native T1 values showed a good 
correlation with measures of impaired global longitudinal strain and diastolic 
dysfunction (mean e’ and left atrial volume) (79).  
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The immediate priority for introducing native T1 in clinical practice will be to 
establish normal native T1 values in healthy hearts and, therefore, to define 
cut-off values of abnormal levels of fibrosis in cardiac pathology. To date, two 
studies have attempted to do this in patients with AS. Lee and colleagues 
showed that at 3T, a cut off of 1190 ms could discriminate between moderate 
and severe AS with c-statistic of 0.704 (79). However, given the poor 
correlation between AS severity and the LV remodelling response, it may be 
more useful to identify native T1 cut-offs that predict future adverse events.  In 
another recent study of 40 patients undergoing AV replacement (AS 77.5% 
and aortic regurgitation 15%) or root replacement (7.5%) with concurrent 
myocardial biopsies, Kockova and colleagues defined an optimum native T1 
cut-off value of 1010 ms, generating a sensitivity of 90%, specificity of 73% 
and c-statistic of 0.82 to detect severe diffuse fibrosis on histology (defined as 
collagen volume fraction of >30%) (80).  
 
A recent study has demonstrated the prognostic power of native T1. One 
hundred and twenty-seven patients with moderate or severe aortic stenosis 
were imaged with native T1 mapping at 3T. When split into tertiles of native 
T1, there was an increasing event rate (all-cause mortality and hospitalisation 
for heart failure) across the tertiles with an increase in events both pre and 
post valve replacement. Native T1 predicted events independent of Euroscore 
II and presence of LGE on the multivariable analysis (83).  
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The major limitation of native T1 is that the values obtained are specific to the 
sequence, scanner and magnetic field strength. As such, a reliable 
comparison between the clinical centres is challenging and has limited the 
development of validated reference ranges to define health and disease 
states, which in turn limits clinical applicability.  
 
Post-contrast T1 and the Partition Coefficient 
Intravenous gadolinium shortens the T1 values and localizes the extracellular 
space. These behaviours can be utilized in conjunction with T1 mapping to aid 
further in the assessment of diffuse myocardial fibrosis. The use of equilibrium 
CMR (where a constant intravenous gadolinium-based contrast media infusion 
is used to create contrast equilibrium) have been supplanted by dynamic 
equilibrium techniques (where imaging is performed at a set time following 
bolus administration when it is assumed to be a dynamic equilibrium between 
myocardial and blood gadolinium concentrations). However, the isolated post-
contrast T1 values are highly dependent on an individual’s gadolinium kinetics 
and the varying time to image post contrast administration results in poor scan-
rescan reproducibility, limiting its clinical use (82). 
 
Correction to post-contrast T1 values can be performed by calculating the 
partition coefficient (l), which calculates the ratio of myocardial T1 to blood T1 
and corrects for the variation caused by an individual’s gadolinium contrast 
kinetics. It has a much improved scan-rescan variability compared to the 
isolated post-contrast T1 and differentiates AS from control subjects (82).  
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Extracellular Volume Fraction 
The further use of the haematocrit to calculate the blood volume in turn allows 
the myocardial volume to be estimated (assuming contrast equilibrium 
between these two compartments). As gadolinium is purely extracellular, its 
distribution in the myocardial volume is equal to the extracellular volume (ECV) 
and this measure is termed ECV fraction (ECV%, Figure 1.8). Although the 
extracellular space contains not just collagen but other extracellular matrix 
components, including myocardial capillaries, the ECV% measure has been 
shown to correlate well with histological collagen volume fraction on 
myocardial biopsy samples in multiple studies of AS patients undergoing aortic 
valve replacement (80,84-86). 
 
Extracellular volume fraction was first validated in AS in 2010 by Flett and 
colleagues who used equilibrium contrast CMR at 1.5T to investigate 18 
patients with severe AS who underwent myocardial biopsy at the time of AV 
replacement. Extracellular volume fraction strongly correlated (r2=0.86) with 
collagen volume fraction as assessed by picrosirius red quantification on 
histology (85). Equilibrium contrast CMR involved a highly complex protocol, 
requiring an extra 30-90 minutes of patient time in the radiology department.  
 
Flett and colleagues went on to examine further the utility of ECV% using 
similar methods in 63 patients with severe AS undergoing AV replacement and 
30 healthy controls (87). Diffuse myocardial fibrosis was estimated using a line 
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of best fit correlation between histological fibrosis (collagen volume fraction) 
and CMR obtained ECV% values from their previous study (85). Patients with 
AS had more diffuse myocardial fibrosis compared to control subjects (18 
versus 13%) although these values overlapped significantly. Diffuse fibrosis 
was associated with diastolic dysfunction and impaired functional status as 
measured by 6-minute walk test independent of age, sex, LVEF, AV area and 
presence of LGE (87).  
 
ECV% has excellent reproducibility and appears to have superior inter-
observer, intra-observer and scan-rescan reproducibility compared to other T1 
measures at 3T (82). This study used simplified dynamic equilibrium 
sequences using a contrast bolus injection with imaging performed 10-20 min 
post administration, which have been shown to give comparable results to the 
more complex equilibrium contrast infusion techniques. These bolus 
techniques have, therefore, almost universally been adopted. ECV% was also 
found to be significantly greater in patients with AS compared to healthy 
controls although a large degree of overlap was observed. Similar findings 
have been observed in other studies (87,88); however, the control populations 
in these studies were younger and common co-morbidities such as 
hypertension or diabetes were excluded. In another study, ECV% was unable 
to differentiate between patients with asymptomatic moderate or severe aortic 
stenosis in age, gender and co-morbidity matched controls; nevertheless, this 
study may have been under-powered (73). 
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As with native T1, establishing the normal range of ECV% values in healthy 
controls and disease specific cut-offs is essential for clinical utility. ECV% is 
much less dependent on scanning sequence and magnetic field strength but 
some variability may remain (84). The study by Kockova and colleagues 
showed that a cut-off ECV% of ≥0.32 was able to detect severe myocardial 
fibrosis (defined as >30% by histology) with a sensitivity of 80%, specificity of 
90% and c-statistic of 0.85. The clinical utility of this cut-off and long-term 
prognostic value are unknown. Defining the clinically relevant cut-off values 
remains key. Overall, a higher ECV% has been shown to be predictive of all-
cause mortality and heart failure admissions in heterogeneous populations 
with cardiac disease (excluding hypertrophic cardiomyopathy and 
amyloidosis); (89) however, this has not been examined in an aortic stenosis 
population to date.  
 
Indexed Extracellular Volume  
The limitation of current T1 measurement is that they universally show a 
substantial overlap between AS patients and healthy controls, limiting their 
clinical application. Although ECV% is conceptually a particularly attractive 
measure, it assesses diffuse fibrosis as a percentage of the left ventricular 
myocardial volume and, therefore, a measure of relative fibrosis. Compared to 
other myocardial pathology, this may be of less use in AS which is 
characterised by a reactive increase in both LV mass and diffuse myocardial 
fibrosis in response to sustained pressure overload. As such, the relative 
fibrosis may not change as disease progresses. An absolute measure of whole 
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heart fibrosis, such as the indexed extracellular volume (extracellular volume 
fraction x end-diastolic myocardial volume) may therefore be more useful in 
staging disease and tracking changes in fibrosis over time.  
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Figure 1.7: T1 mapping using a 3(3)-3(3)-5 MOdified Look-Locker 
Inversion recovery sequence 
 
A T1 map is generated using a MOdified Look-Locker Inversion recovery (MOLLI) 
sequence. The sequence description denotes the number of heartbeats over which 
consecutive readouts occur with no readouts occurring for the number of heartbeats 
in brackets which allows for magnetisation recovery. Following a 180-degree 
inversion pulse, T1 readouts are performed at the same point in the cardiac cycle on 
consecutive heartbeats (usually end-diastole). Two further inversion recovery 
experiments are performed with different inversion times (TI) and the raw images are 
ordered by inversion time. The signal is then plotted against TI for each voxel and a 
best-fit curve is generated. The T1 value for each voxel (time taken to recover 63% 
of longitudinal magnetisation) is the estimated and displayed visually as a T1 map.    
 
 
ECG, electrocardiogram; RF, radiofrequency; TI, inversion time  
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Figure 1.8: Different forms of T1 mapping available 
 
Native T1 maps are produced as detailed above (Figure 1.7). This process can then 
be repeated 10-20 minutes following intravenous contrast administration to generate 
post-contrast T1 maps. Note that T1 is shortened in the presence of gadolinium. 
Extracellular volume fraction can be calculated either using regions of interest drawn 
onto myocardium and blood pool on pre and post contrast maps (shown below, red 
endocardial contour, green epicardial contour, orange blood pool region of interest) 
or by combining the native and post contrast maps to generate an ECV map where 
the ECV for each voxel is demonstrated. Myocardial regions of interest are usually 
offset to avoid signal contamination by either blood pool or epicardial fat (10% contour 
offset shown below).  
 
 
ECV, extracellular volume fraction; ms, millisecond  
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HYBRID MAGNETIC RESONANCE IMAGING / POSITRON 
EMISSION TOMOGRAPHY TECHNIQUES 
 
Positron emission tomography in aortic stenosis 
Positron emission tomography involves the intravenous administration of 
radioactive tracer compounds that allow the activity of specific disease 
processes to be measured in-vivo. This technique has been previously 
investigated in aortic stenosis using two radiotracers to measure inflammation 
(18F-fluorodeoxyglucose [18F-FDG]) and calcification activity (18F-sodium 
fluoride [18F-NaF) in the aortic valve. Hybrid PET/CT scanners then allow the 
activity of these two key processes to be compared with macroscopic findings 
such as the presence of established regions of macrocalcification on CT.  
 
18F-Fluorodeoxyglucose 
18F-FDG PET is widely used to image vascular inflammation. This PET tracer 
is a glucose analogue, which accumulates in metabolically active cells such 
as vascular macrophages. Indeed an excellent correlation between 
macrophage burden on histology (CD68 staining on immunohistochemistry) in 
carotid atheroma (90) and the 18F-FDG signal has been observed. In aortic 
stenosis, 18F-FDG activity is higher in patients compared with control subjects, 
demonstrating a modest correlation with severity of valvular disease (91). Of 
interest, no correlation with CD68 staining of explanted valves was observed 
suggesting that 18F-FDG uptake is occurring in other metabolically active cells, 
although this study was limited by a low sample size (4). Perhaps the biggest 
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limitation of this technique is the effect of physiological myocardial 18F-FDG 
uptake, which frequently contaminates signal originating from the aortic valve. 
 
18F-Fluoride 
18F-Fluoride has been used as a bone tracer for 50 years as it binds to 
hydroxyapatite and reflects regions of increased bone activity. In the 
vasculature it binds preferentially to regions of newly developing 
microcalcification because the surface area of hydroxyapatite in these 
nanocrystalline regions is at its highest. By contrast, in regions of 
macrocalcification, much of the hydroxyapatite is internalised and not available 
for binding (92). In aortic stenosis, 18F-fluoride acts as a marker of calcification 
activity correlating with histological staining for alkaline phosphatase (r=0.65) 
and osteocalcin (r=0.68)(4) and predicts where novel regions of macroscopic 
calcium are going to form. Tracer uptake increases with more advanced aortic 
stenosis (91), offers powerful prediction of disease progression at 1 and 2 
years, has some incremental value to computed tomography (4,93) and acts 
as an independent predictor of adverse clinical events (93). This technique 
holds promise in better understanding the role of calcification in aortic 
stenosis, for example a recent PET study demonstrated that, whilst 
calcification activity in aortic stenosis is greater than inflammation, the reverse 
is true in atherosclerosis, potentially explaining the differential effects of statins 
in these two conditions (94). With further research, 18F-fluoride PET may prove 
of clinical utility in identifying patients likely to progress rapidly towards surgery 
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and as an efficacy end-point in clinical trials of novel therapies (e.g. SALTIRE 
2: NCT02132026).  
 
Hybrid MR/PET imaging 
Although PET/CT offers excellent anatomical resolution, it is associated with 
a substantial radiation dose. Hybrid MR/PET imaging offers numerous 
advantages over PET/CT; simultaneous acquisition of PET and MR data for 
more accurate co-registration, reduction in radiation exposure, additional 
functional imaging and myocardial tissue characterisation. Commercial 
MR/PET platforms have recently become available; the key technological 
advancement making this possible has been the development of semi-
conductor based PET detectors, which are not affected by a strong magnetic 
field unlike the photo-multiplier tubes historically used in PET scanners (95). 




PET activity is detected and localised by deriving the line of response from the 
detection of two photons by the ring of PET detectors that correspond to a 
single annihilation event (coincidence event). However, coincidence events 
can be missed by attenuation of photons in radiodense tissues or scatter 
outside the field of view, and this may result in underestimation of PET activity 
from tissues deep within the body or next to radiodense structures. As such, 
attenuation maps (µ-maps) that contain the radiodensity for 511 keV photons 
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(the energy of photons produced by an 18F positron-electron annihilation 
event) of each voxel within the PET field-of-view must be produced. This has 
historically been performed using an external source 68Germanium 
transmission scan or more recently with a CT µ-map (using 80-140 keV where 
a correction factor must be applied to convert to the radiodensity for 511 keV 
photons) (96). The µ-map is then used in the MR attenuation correction 
(MRAC) process during post-processing to produce a valid representation of 
regional PET activity.  
 
Attenuation correction in MR/PET poses additional challenges as no external 
ionising radiation source is present to generate the µ-map. Instead the most 
common approach has been using a multi-point Dixon sequence for 
segmentation of the imaged field of view into four classes: air (background), 
lung, fat and soft tissue. A separate linear attenuation coefficient (LAC, which 
estimates the attenuation for 511 keV photons) for each tissue class is then 
applied to each voxel as appropriate. Of note, this sequence does not segment 
calcium or bone into a separate class. Potential solutions to this include 
ultrashort echo time (UTE) sequences and the addition of major bones as a 
separate tissue class using a patient-specific atlas (97).  
 
MRAC µ-maps are usually acquired during breath-held expiration which do not 
correspond well with the average position of intrathoracic organs during 50-60 
min of free-breathing PET acquisition and can result in significant image 
artefact on the final co-registered images. MRAC using a free-breathing 
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golden angle radial spoiled GRE acquisition has been proposed as a solution 
and initial experience suggests this results in improved image quality with a 
reduction in PET artefacts (98). 
 
Identification of co-existent myocardial pathology 
One further advantage of hybrid MR/PET techniques is the identification and 
characterisation of coexistent myocardial pathology. Transthyretin cardiac 
amyloidosis is an increasingly recognised condition in the elderly due to the 
availability of more advanced imaging methods in clinical practice. 
Transthyretin (TTR) is a 127-amino acid plasma protein predominantly 
produced by the liver that exists as a tetramer of four identical subunits and 
acts as a binding protein for thyroxine and retinol-binding protein (99). 
Although several gene mutations have been identified that lead to 
destabilisation of the TTR tetramer, amyloid fibril assembly and cardiac 
deposition occurs most frequently in individuals with non-mutated “wild-type” 
TTR (wtTTR, also called senile systemic amyloidosis). Why some individuals 
with wtTTR develop clinically significant cardiac deposition of amyloid fibrils is 
not understood, but this process is associated with advancing age and 
appears more common in men (100). Over time, ongoing amyloid deposition 
leads to ventricular thickening, progressive diastolic dysfunction and cardiac 
rhythm disturbance eventually resulting in systolic dysfunction, symptomatic 
heart failure and death. A novel disease-modifying treatment for TTR cardiac 
amyloidosis has recently become available (101) and other agents are 
currently undergoing phase 2/3 clinical trials (102).  
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Cardiac amyloidosis has historically been suspected when concentric LV 
hypertrophy with a speckled appearance to the myocardium is visualised on 
echocardiography (103). However, this speckled-appearance is much less 
specific to amyloidosis using modern echocardiography machines that utilise 
harmonic imaging. Other imaging findings of pericardial effusion and thickened 
interatrial septum and AV valves, have poor sensitivity and specificity for 
amyloidosis, particularly in patients with aortic stenosis (104).  
 
Whilst historically requiring invasive myocardial biopsy for confirmation, the 
variety of modern imaging techniques now available enable a diagnosis of 
cardiac amyloidosis to be made non-invasively in most patients. Histological 
confirmation of subtype (TTR versus AL amyloid) is still important as both 
treatment and prognosis are different. Global longitudinal strain, as measured 
using transthoracic echocardiography is significantly reduced in cardiac 
amyloidosis, with characteristic sparing of the apex giving a “bull’s eye” 
appearance (105). In addition to providing more accurate measures of LV 
volumes, mass and ejection fraction, CMR also offers tissue characterisation 
with LGE and T1 mapping techniques. Two LGE patterns are recognised in 
patients with cardiac amyloidosis, circumferential subendocardial and 
transmural, with increasing burden portending a worse survival (106). Phase-
sensitive inversion recovery (PSIR) techniques are superior to magnitude only 
imaging in this setting as the tissue with the longest TI is always nulled 
ensuring diagnostic images where transmural involvement is present (106). 
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T1 mapping techniques are of particular interest in the diagnosis of cardiac 
amyloidosis as gross extracellular deposition of amyloid usually results in 
dramatic increases in both native T1 and ECV% which overlap minimally with 
other pathologies. In one recent study, both native T1 (area under curve (AUC) 
0.87) and ECV% (AUC 0.91) were able to differentiate cardiac amyloidosis 
from hypertrophic cardiomyopathy with high diagnostic accuracy. Moreover, 
ECV% predicted all-cause mortality independent of measures including BNP, 
LV ejection fraction and LGE (107).  
 
Bone scintigraphy has also proven a powerful tool in diagnosing cardiac 
amyloidosis. Although the underlying mechanisms are unclear, 
99mTechnicium-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD), 
along with other bone radiotracers has high diagnostic sensitivity and 
specificity for the presence of TTR cardiac amyloidosis (108). Uptake is 
qualitatively assessed by the Perugini score (0-3, 0= no cardiac uptake, 1= 
cardiac uptake less than bone uptake, 2= cardiac uptake equal to or greater 
than bone uptake, 3= cardiac uptake with attenuation or absence of bone 
uptake). Although a score of 2 or 3 is considered diagnostic for cardiac 
involvement, DPD scan grading offers no further prognostic information (109). 
This test is highly specific for TTR amyloidosis, although one study suggested 





Prevalence of co-existent TTR amyloidosis and aortic stenosis 
Given that the imaging features on standard echocardiography are similar to 
that seen in advanced aortic stenosis, a diagnosis of amyloidosis is often not 
considered in these patients. In fact, the prevalence of coexistent amyloidosis 
has been estimated at between 6 and 16% of severe AS populations 
(104,111). Interestingly in one recent study, of the 6 aortic stenosis patients 
with confirmed TTR amyloid deposition on histological analysis of myocardial 
biopsies, only two had clear imaging features diagnostic of CMR whereas the 
other four had features that were compatible with a sole diagnosis of severe 
aortic stenosis (104). All patients who survived to 99mTc-DPD imaging (4 out 
of 6) had positive scans (although 50% of these were only Perugini grade 1). 
This suggests that the sensitivity of CMR in the early diagnosis of cardiac TTR 
amyloidosis may be improved by the addition of a PET with a bone radiotracer 
such as 18F-NaF. One small study demonstrated this proof-of-concept; 4 
patients with biopsy proven TTR cardiac amyloidosis, along with 3 AL-amyloid 
and 7 healthy control subjects were imaged with MR/PET using 386 
megabequerels (MBq) 18F-NaF. Myocardial target-to-background-ratio (TBR) 
was significantly greater in the TTR group (1.14±0.24) compared with AL 
(0.77±0.06) or healthy controls (0.68±0.04, Figure 1.9) (112). Importantly, 18F-
NaF appears to discriminate between TTR and AL amyloidosis which would 
be another incremental advantage over standard CMR imaging. 
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Figure 1.9: Hybrid MR/PET with 18F-sodium fluoride in a patient with 
familial TTR amyloidosis 
 
Short axis LGE image fused with PET data showing increased 18F-NaF uptake in the 
inferolateral wall co-localising to areas of LGE (white arrows). Maximum myocardial 
target to background ratios (TBR) were 48% greater than AL amyloid and 68% higher 
than control subjects (A), both of whom demonstrated TBR values below 1. Dynamic 
imaging assessing TBR mean values (B) showed optimal separation of values ³ 60 
minutes.  







Aortic stenosis is characterised by both valvular stenosis and the resultant left 
ventricular response, namely myocyte hypertrophy eventually leading to cell 
death, myocardial fibrosis and systolic dysfunction. Valve intervention can 
alleviate the dismal clinical course of advanced aortic stenosis, but the optimal 
timing of intervention is controversial, based on historical observational data 
and expert opinion. Risks of valve intervention must be balanced against the 
risks of sudden death or long-term complications due to ventricular 
decompensation. The ideal time to intervene is just before the onset of 
irreversible left ventricular pathological changes.  
 
CMR imaging provides non-invasive multiparametric assessment of the left 
ventricle which can identify focal replacement fibrosis using late gadolinium 
enhancement and diffuse fibrosis with T1 mapping methods. The addition of 
PET imaging using hybrid MR/PET scanners also provides added information 
about metabolic processes and may be able to identify co-existent myocardial 
pathology. Further work is required to explore how these novel imaging 




THESIS AIMS AND HYPOTHESES 
 
The aims of this thesis are: 
 
 
1. To explore the utility of T1 mapping measures as surrogate markers of 
diffuse fibrosis burden, left ventricular decompensation and predictors 
of adverse outcomes 
 
2. To characterise the progression of myocardial hypertrophy, diffuse and 
replacement fibrosis over time in asymptomatic severe AS and how 
these processes are influenced by relief of pressure overload with valve 
replacement 
 
3. To assess the prognostic utility of T1 mapping measures and their 
associations with other markers of LV decompensation in a large 
multicentre cohort of symptomatic patients with severe aortic stenosis 
undergoing aortic valve replacement procedures 
 
4. To investigate MR/PET imaging in aortic stenosis patients for 
assessment of AS severity, disease activity and the presence of LV 




The hypotheses of this thesis are: 
 
 
1. T1 mapping can identify a group of patients with abnormally increased 
diffuse fibrosis who have an intermediate measures of LV 
decompensation between normal levels of fibrosis and those with 
advanced replacement fibrosis (Chapter 3). 
 
2. In the natural history of aortic stenosis, both cellular hypertrophy and 
diffuse fibrosis progress at a steady rate and new areas of late 
enhancement develop between interval scans. Following valve 
replacement, cellular hypertrophy and diffuse fibrosis regress but 
replacement fibrosis is irreversible (Chapter 4). 
 
3. Extracellular volume-based T1 mapping measures are independently 
associated with measures of disease severity and worse clinical 
outcome in a large cohort of patients undergoing valve intervention 
(Chapter 5). 
 
4. MR/PET imaging with free-breathing attenuation correction is feasible 
and reproducible in aortic stenosis and may be able to quantify 
calcification activity in the aortic valve and identify cases of co-existent 











Patients with mild to severe aortic stenosis were recruited to an observational 
research study (Role of Fibrosis in Aortic Stenosis, NCT01755936, “CMRAS 
study”). These patients were prospectively recruited at the Edinburgh Heart 
Centre, United Kingdom. Written informed consent was provided by all 
participants and the ethical approval was obtained from the South East 
Scotland Research Ethics Committee. The study was conducted in 
accordance with the Declaration of Helsinki.  
 
The exclusion criteria were: (1) moderate or severe other valve disease; (2) 
significant comorbidities with a predicted life expectancy of less than 1 year; 
(3) contraindications to CMR imaging (such as implantable cardiac devices); 
(4) significant renal impairment precluding intravenous gadolinium contrast 
administration (estimated glomerular filtration rate <30 mL/min/1.73m2) and 
(5) inherited or acquired cardiomyopathy. The presence of coronary heart 
disease was defined as clinical symptoms of angina (in non-severe aortic 
stenosis), previous myocardial infarction, obstructive coronary artery disease 
on anatomical imaging or evidence of significant ischaemia on functional 
imaging.  
 
Patient populations from other centres were included for specific analyses 
(Chapters 4 and 5) as detailed below: 
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Chapter 4: To investigate the progression of hypertrophy and myocardial 
fibrosis, only those patients with repeat CMR from the CMRAS study were 
included. These were combined with similar patients from an observational 
study in Quebec, Canada (PROGRESSA, NCT01679431). 
 
Chapter 5: In order to investigate the prognostic utility of ECV-based T1 
mapping measures, a large international multicentre cohort was formed. 
Inclusion criteria were patients with severe aortic stenosis scheduled for aortic 
valve intervention who underwent CMR imaging prior to their procedure. This 
included patients from the Edinburgh CMRAS cohort, as well as additional 
data from Leeds, Leicester, Oxford and London. Further patients meeting the 
inclusion criteria from Berlin (Germany), Quebec (Canada), Pittsburgh (U.S.A) 
and Seoul (South Korea) were included. All patients were enrolled in 
observational studies in accordance with local research ethics governance 
and conforming to the Declaration of Helsinki. Appropriate legal agreements 
were produced to cover the international transfer of anonymised data.  
 
A separate cohort of patients and healthy volunteers were recruited to 
investigate the utility of PET/MRI in aortic stenosis (“PASS” study, Chapter 6). 
These participants were aged 70 or over and the aortic stenosis patients had 
been referred for aortic valve intervention. The exclusion criteria were (1) 
moderate of severe other valve disease; (2) contraindications to CMR imaging 
(such as implantable cardiac devices); (3) significant renal impairment 
precluding intravenous gadolinium contrast administration (estimated 
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glomerular filtration rate <30 mL/min/1.73m2); (4) acute valvular heart disease 
and (5) acute pulmonary oedema or cardiogenic shock.  
 





Transthoracic echocardiography is the primary non-invasive imaging method 
for assessment of valvular stenosis. This modality uses ultrasonography to 
produce 2D cardiac images in a variety of imaging planes with high temporal 
and spatial resolution. In addition, the use of colour flow mapping alongside 
both pulsed and continuous wave Doppler techniques enables detailed 
assessment of severity of valve stenosis (113). Both peak and mean valvular 
gradient can be measured using continuous wave Doppler aligned to the blood 
flow through the aortic valve, and effective aortic valve area can then be 
calculated using the continuity equation (aortic valve area = Doppler stroke 
volume / aortic valve velocity-time integral; Doppler stroke volume = left 
ventricular outflow tract velocity-time integral x left ventricular outflow tract 
area).  
 
Comprehensive transthoracic echocardiography was performed in all patients 
(iE33, Philips Medical Systems, The Netherlands).  Careful attention was 
given in the assessment of aortic stenosis severity. The left ventricular (LV) 
outflow tract diameter was measured in the parasternal long-axis view, at the 
insertion of the aortic cusps from the inner edge of the septal endocardium to 
the inner edge of the anterior mitral leaflet in mid-systole.  Left ventricular 
outflow tract velocity-time integral was measured in the apical 5-chamber view 
using pulsed-wave Doppler just proximal to the aortic valve, with care taken to 
obtain a laminar spectral tracing. The peak aortic jet velocity and mean 
transvalvular gradient were derived from the aortic valve velocity-time integral, 
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using continuous-wave Doppler. The highest aortic jet velocity and mean 
transvalvular gradient were determined in multiple acoustic windows using 
both standard and standalone doppler probes. The mean of 3 readings (5 if 
the patient had atrial fibrillation) was recorded.  Aortic valve area was 
calculated using the continuity equation.  
 
Trans-mitral early (E) and late diastolic velocities, as well as, deceleration time 
of early filling velocity were measured at the tips of the mitral valve leaflets 
using pulsed-wave Doppler.  The mean early diastolic velocities of the medial 
and lateral mitral annulus (e’) were measured using pulsed-wave tissue 
Doppler imaging. Diastolic function was assessed as recommended in recent 
guidelines (114).  
 
Echocardiography is highly reproducible when performed by experienced 
operators. We have previously demonstrated excellent intraobserver (4.9%) 
and interobserver (6.9%) variability of aortic valve area measurement in our 
centre  (115).  
  
 83 
CARDIOVASCULAR MAGNETIC RESONANCE 
 
Magnetic resonance imaging utilises a strong static magnetic field, variable 
gradient magnetic fields and radiofrequency energy to produce highly detailed 
3-dimensional images. Protons (most abundantly found in biological tissue as 
part of water molecules) will align their magnetic moments in the presence of 
a strong magnetic field producing a net magnetisation. This magnetisation can 
be altered (excitation) by the use of radiofrequency energy applied at the 
correct frequency, following which the excited tissue returns to equilibrium in 
a process called relaxation. This signal can be detected by radiofrequency 
receiver coils and is spatially localised and encoded by the application of 
variable gradient magnetic fields. Decoding of the signal is then performed to 
generate an MR image. This technology is increasingly being used in cardiac 
imaging where a combination of ECG gating with patient breath-holding or 
respiratory navigated sequences can produce high-resolution images in spite 
of cardiac and respiratory motion.  
 
Cardiovascular magnetic resonance (CMR) imaging in Edinburgh was 
performed at 3T (MAGNETOM Verio, Siemens AG, Erlangen, Germany) in the 
Edinburgh Imaging Facility at the Queen’s Medical Research Institute. 
Localiser views were first obtained to determine the position and orientation of 
the heart within the thorax. Multiple cine acquisitions were performed a 
balanced steady-state free precession sequence to obtain both long and short-
axis cine images. Short axis cines were acquired extending from the mitral 
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valve to the left ventricular apex (8-mm parallel slices with 2-mm spacing; 
temporal resolution £45 ms) and used to determine left ventricular volumes, 
mass and systolic function. 
 
Focal replacement and diffuse interstitial myocardial fibrosis were assessed in 
all patients using late gadolinium enhancement (LGE) and myocardial T1 
mapping, respectively. Late gadolinium enhancement was performed 15 min 
following gadobutrol (Gadovist, Bayer Pharma AG, Germany, 0.1 mmol/kg) 
using an inversion-recovery fast gradient-echo sequence performed in two 
phase-encoding directions to differentiate true late enhancement from artefact. 
The inversion time was optimized to achieve satisfactory nulling of the 
myocardium.  
 
Diffuse myocardial fibrosis was assessed using Modified Look-Locker 
Inversion-recovery with built-in motion correction. A heart beat acquisition 
scheme of 3(3)-3(3)-5 was used (flip angle 35°; minimum TI 100 ms; TI 
increment of 80 ms; time delay of 150 ms) (70,116,117). A gradient echo field 
map and associated shim were performed to minimize off-frequency artefact.   
 
For the analysis in Chapter 4, included patients from Quebec were scanned 
locally at either 1.5 or 3T (ACHIEVA and INGENIA, Philips Healthcare, Best, 
the Netherlands). All patients were rescanned using standardised imaging 
protocols (Short axis cine imaging: 8 mm parallel slices with no gap. Typical 
parameters at 1.5T were FOV 380 mm, TR/TE 3.2/1.6 ms, flip angle 60º and 
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NEX of 1, in-plane spatial resolution of 1.6 x 2 mm. Equivalent acquisition 
parameters at 3T were FOV 380 mm, TR/TE 2.8/1.3 ms, flip angle 45º, and 
NEX of 1, in-plane spatial resolution of 1.7 mm x 2 mm, 7-mm slice thickness, 
0-mm gap.). Late enhancement was performed using 0.2 mmol/kg gadobutrol 
contrast. T1 mapping was performed using a MOLLI acquisition scheme of 




For the international multicentre analysis in Chapter 5, patients were imaged 
using local scanners and protocols which are summarised in Table 2.1. 
Further details are contained within Chapter 5. 
 
CMR offers superior accuracy and reproducibility when assessing left 
ventricular volume and mass compared with echocardiography (119). In 
particular, excellent intra- and inter-observer variability has been 
demonstrated for left and right ventricular volume and mass measurements, 
with slightly worse values for ejection fraction, where potential measurement 
errors from multiple measurements are compounded (Table 2.2) (120).  
 
Both native T1 and extracellular volume fraction (ECV%) have excellent intra- 
and inter-observer reproducibility at 3T as demonstrated at our centre, with 
ECV% having superior scan-rescan reproducibility compared to other T1 
mapping measures (Table 2.3) (82).  
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Table 2.1: ECV400 study - cardiac magnetic resonance technical details 
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Table 2.2: Reproducibility of Cardiovascular Magnetic Resonance 
Imaging Measures of Left and Right Ventricular Size and Function 
(n=60) 
 





   Intra-observer 
Inter-
observer 
Indexed left ventricular 
end-diastolic volume, 
mL/m2 
3.6 8.2 0.993 0.989 
Indexed left ventricular 
end-systolic volume, 
mL/m2 
10.5 8.4 0.967 0.939 
Indexed left ventricular 
stroke volume mL/m2 6.6 8.0 0.976 0.973 
Left ventricular ejection 
fraction, % 5.8 9.4 0.824 0.789 
Indexed left ventricular 
mass, g/m2 5.3 7.7 0.985 0.981 












11.8 19.2 0.969 0.947 
Right ventricular 
ejection fraction, % 8.0 10.7 0.874 0.810 
 




Table 2.3: Reproducibility of T1 mapping measures at 3 Tesla (n=40) 
 
 







Blood pool native T1, ms 1.00 1.00 0.65 
Myocardial native T1, ms 0.99 0.99 0.72 
Blood pool post-contrast T1, ms 1.00 1.00 0.58 
Myocardial post-contrast T1, ms 1.00 1.00 0.56 
Partition coefficient 0.99 0.94 0.93 
Extracellular volume fraction, % 1.00 0.97 0.96 
 
Adapted from Chin et al, Eur Heart J Cardiovasc Imaging 2014 (82).  
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HYBRID MAGNETIC RESONANCE IMAGING / POSITION 
EMISSION TOMOGRAPHY  
 
Positron emission tomography (PET) allows for the localization and 
assessment of activity of functional metabolic processes. For example, the 
radioactive isotope fluorine-18 decays via positron emission to oxygen-18 with 
a half-life of 109.8 mins. This positron travels a short distance (usually <1 mm, 
maximum 2-3 mm (121)) before interacting with an electron in an annihilation 
event that creates two gamma ray photons travelling in opposite (180 degrees) 
directions. When multiple positron decays occur in this way inside a ring of 
detectors, the emission source can be spatially localised with a high degree of 
accuracy (4-6 mm (121,122)). PET is an extremely sensitive technique 
requiring only very small amounts of radiotracer (10-6 – 10-9 g) which have 
essentially no pharmacological effects, allowing the measurement of 
metabolic processes without disturbing these processes (123). As discussed 
in chapter 1, integration of PET with magnetic resonance imaging (MR/PET) 
allows accurate co-registration of PET data but optimizing methods of 




MR/PET imaging was performed at 3T using a Siemens Biograph mMR 
scanner (Siemens AG, Erlangen, Germany). The body transmission coil, a 
flexible 6-channel body arrayed receiver, and a 6-channel spine arrayed 
receiver mounted in the scanner table were used to acquire MR data. PET 
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data were acquired in list-mode 60 min after intravenous injection of 250 MBq 
of 18F-sodium fluoride. Both 3D Dixon VIBE (124) and free-breathing radial 
gradient echo (GRE, Siemens work-in-progress #793F) sequences were 
acquired for MR attenuation correction (MRAC). MRAC maps were generated 
using the method described by Robson et al (98). The MR protocol included 
standard long- and short-axis cine imaging. Coronary magnetic resonance 
angiography (CMRA) was performed using a non-contrast ECG-gated 
respiratory-navigated motion corrected (MC) proprietary sequence (iNAV-
based MC CMRA, Kings College London, UK (125)) to achieve a high-
resolution isotropic 3D data volume encompassing proximal coronary arteries, 
aortic valve and left ventricular myocardium which could be fused with the PET 
dataset. T1 mapping was performed using a MOLLI sequence (native 5(3)-3, 
post contrast 4(1)-3(1)-2, MyoMaps product, Siemens) using a single 4-
chamber slice both before and 15-20 minutes after 0.1 mmol/kg of intravenous 
gadobutrol contrast (Gadovist, Bayer Pharma AG, Germany). Late gadolinium 
enhancement was performed approximately 10 min following contrast injection 
using phase-sensitive inversion recovery sequences (short axis stack and 4 
chamber views). 
 
The Biograph mMR scanner has a spatial resolution of 4.3 mm (full-width-at-
half-maximum) (126). We have previously demonstrated excellent intra- and 
inter-observer variability for aortic valve standardized uptake values (SUVmax) 
using PET/CT (intraclass correlation coefficients 1.00 and 0.99 respectively 
(91)) but this has not been assessed to date using MR/PET.  
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ELECTROCARDIOGRAM 
In all patients recruited at Edinburgh Royal Infirmary, a standard 12-lead 
electrocardiogram was performed (10 mm/mV, 25 mm/s) using the same 
machine (Philips Pagewriter TC50, Philips Medical Systems, Massachusetts, 
U.S.A). An electrocardiographic diagnosis of left ventricular hypertrophy was 
determined by a Romhilt-Estes system score of greater than or equal to 5 
(127). Left ventricular strain was defined as down-sloping ST-segment 






Plasma cardiac troponin I concentrations were determined in the CMRAS 
study using the ARCHITECT STAT high-sensitivity cTnI assay (Abbot 
Laboratories, Abbott Park, Il, USA) (54). The lower limit of detection of this 
assay is 1.2 ng/L with a 10% inter-assay coefficient of variation at 4.7 ng/L. 
 
The brain natriuretic peptide (BNP) concentration was determined with Triage 
BNP assay (Biosite Inc., San Diego, CA, USA) for the CMRAS patients 
detailed in Chapter 3. 
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INTRA-OPERATIVE MYOCARDIAL BIOPSY AND 
HISTOLOGICAL ANALYSIS 
 
All patients who were enrolled in either CMRAS or PASS studies who 
underwent surgical aortic valve replacement were approached regarding intra-
operative myocardial biopsy at the time of surgery. Biopsies were obtained 
from the basal muscular septum 2 cm below the outflow tract using a 14-gauge 
coaxial needle (BD Carefusion, Tru-cut needle) and samples were then fixed 
in 10%-buffered formalin and embedded in paraffin.  
 
Processed samples were stained with picrosirius red and analysed using an 
automated segmentation tool (Image-pro plus 7, Rockville, MD, USA, an 
average eight regions per sample) to quantify myocardial fibrosis by calculated 
the area stained with picrosirius red as a percentage of the total myocardial 
area.  
 
For samples from the PASS study, histological analysis to determine the 
presence of amyloidosis was performed at the National Amyloidosis Centre, 
Royal Free Hospital, London, UK. All samples were staining with Congo red 
and analysed using bright-field and cross-polarised light. If a diagnosis of 
cardiac amyloidosis was suggested by the presence of apple-green 
birefringence, immunohistochemistry was then performed using a TTR 






Cardiovascular magnetic resonance 
For the original baseline CMRAS data (Chapter 3), the left ventricular volumes 
mass and function were analysed using Argus Ventricular Function software 
(Siemens AG Healthcare Sector, Erlangen, Germany). Both papillary muscles 
and minor trabeculations were included in the LV intracavity volume 
measurement (and therefore excluded from the mass measurement). The 
presence of myocardial late gadolinium enhancement was determined by two 
experienced cardiologists (Dr Marc Dweck and Dr Calvin Chin). Quantitative 
analysis using a threshold of >2 standard deviations above the mean value in 
a region of normal myocardium was performed using QMASS software (Medis 
Medical Imaging Systems, Leiden, the Netherlands). Areas of inversion 
artefact were excluded as were areas of partial voluming with blood pool or 
epicardial fat. The motion-corrected scanner generated short-axis T1 maps at 
mid-ventricular level were used for the quantitative T1 mapping analysis 
(OsiriX version 4.1.1, Geneva, Switzerland). Placement of regions of interest 
were standardised so as to avoid partial voluming effects with blood pool or 
epicardial fat. These regions were then copied onto the post-contrast maps 
with adjustment to allow for artefacts (Figure 2.1).  
 
All image analysis in Chapters 4 through 6 were performed using CVI42 
software (Circle Cardiovascular Imaging Inc., Calgary, Canada). This involved 
reanalysis of the relevant baseline CMR scans from the CMRAS cohort 
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included in Chapters 4 and 5. Volumetric image analysis was performed by a 
single reporter (RJE) in two studies (Chapters 4 and 6) and for the final study 
(ECV400 study, Chapter 5) was performed by several reporters. All scans 
were analysed in line with an image analysis protocol (see appendix) and was 
performed according to Society for Cardiovascular Magnetic Resonance 
(SCMR) guidelines (128). Basal ventricular slices were included if >50% of the 
LV blood pool was surrounded by myocardium. Papillary muscles and minor 
trabeculations were included in the left ventricular mass measurements and 
excluded from the intracavity volume measurements again as per SCMR 
guidelines (128). 
 
The left ventricular wall thickness was measured in each of the 16 myocardial 
segments (excluding the LV apex) and the maximum value recorded. No 
standardised measure of left ventricular longitudinal function has been 
recommended in current literature. In these studies, it was determined by 
measuring the difference in the distance between the mitral valve plane and 
the epicardial left ventricular apex in end-systole and end-diastole. The final 
value was calculated as the mean value of the recorded measurements in both 
4-chamber and 2-chamber views. Left atrial volume was calculated using the 
bi-plane area-length method by tracing the endocardial LA contour in end-
ventricular systole in both 2 and 4 chamber long-axis views (129). 
 
The presence of mid-wall myocardial fibrosis was determined qualitatively by 
two independent and experienced operators (MRD and RJE) in Chapters 4 
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and 6 and by a single observer in Chapter 5 (RJE).  The distribution of mid-
wall fibrosis was described according to the standard 17-segment model 
recommended by the American College of Cardiology/American Heart 
Association. A variety of recommended semi-automated LGE quantification 
methods were used, including signal intensity thresholds (of >2, 3 or 5 
standard deviations above the mean value in a region of normal myocardium) 
and the full-width half-maximum technique (128,130). Areas of inversion 
artefact, infarct pattern LGE or signal contamination by epicardial fat or blood 
pool were manually excluded. Sub-endocardial LGE was also identified and 
quantified using the same analysis technique. 
 
T1 mapping analysis was performed on basal and mid-ventricular short axis 
images (Chapter 4), a single mid-ventricle short axis image (Chapters 5) or a 
4-chamber image (Chapter 6). Analysis of the short axis slices was performed 
using manually drawn endocardial and epicardial contours on the native 
motion-corrected myocardial T1 maps with 10% offsetting applied to avoid 
partial volume effects. The right ventricular insertion points were identified 
leading to automatic segmentation as per the 17 segment AHA/ACC model 
(131). No analysis was performed on the apical myocardial segments as these 
are most susceptible to partial volume effects. These contours were 
subsequently copied onto corresponding 20-min post-contrast maps with 
minor adjustments made to avoid partial volume effects and artefact (Figure 
2.2). Segments demonstrating mid-wall late enhancement were included in 
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the overall T1 analysis whereas those containing infarct pattern LGE were 
excluded as per recent post-processing guidelines (132).  
 
Analysis of the 4-chamber T1 maps was performed by drawing a region of 
interest (ROI) in the mid-ventricular septum, again taking care to offset the 
contours to avoid partial voluming with blood pool. Another ROI was drawn in 
the centre of the blood pool. These ROIs were copied onto the post contrast 
maps.  
 
The extracellular volume fraction (ECV%) was then calculated according to: 
ECV% = partition coefficient x [1 - haematocrit], where partition coefficient = 
[∆R1myocardium / ∆R1blood-pool] and ∆R1 = (1/post-contrast T1) - (1 / pre-
contrast T1). Haematocrit was sampled at the time of cardiovascular magnetic 
resonance imaging (87,133).  The indexed extracellular volume (iECV) in each 
patient was derived using the following: ECV% x left ventricular end-diastolic 
myocardial volume indexed to body surface area (using the Mosteller formula), 
where left ventricular myocardial volume = left ventricular mass /1.05 g/mL (7).  
 
Positron emission tomography 
Analysis of the PET was performed using FusionQuant software (Cedars-Sinai 
Medical Center, Los Angeles, U.S.A). The full list mode acquisition was 
reconstructed using an Ordered Subsets Expectation Maximization (OSEM) 
algorithm with the following parameters: 256x256 field of view, 4 iterations, 21 
subsets, 5mm Gaussian filter, zoom 1. No ECG gating was applied.  PET data 
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was first reconstructed applying the standard 3D Dixon VIBE MRAC method 
(4 tissue class segmentation; air, lung, soft tissue and fat). PET data was also 
reconstructed when applying a custom MRAC map derived from the free-
breathing radial GRE sequence (2 tissue classes: background [air and lung] 
and soft tissue [soft tissue and fat] (98)). PET reconstructions were fused with 
the iNAV-based MC CMRA sequence (Kings College London, UK (125)). As 
the MR and PET data was acquired simultaneously and co-registered, in 
theory no manual correction was required. However, in cases where co-
registration was imperfect, small manual corrections were performed by 
aligning PET uptake in the ventricular cavities, aorta and aortic valve with 
these structures on the MR angiogram. Radiotracer uptake was analysed 
using a standardised protocol (see appendix). In brief, regions of interest (ROI) 
were drawn on the co-registered image around the perimeter of the aortic 
valve on co-axial short-axis views. Standardised uptake values (SUV, mean 
and maximum) were then calculated for these ROIs and were corrected for 
blood pool activity (measured in the right atrium (134)) to generate tissue-to-
background ratios (TBR). Myocardial SUV values were also measured in the 
septal myocardium at mid cavity level.   
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Regions of interest (outlines in green) were drawn in each of the six myocardial 
segments, taking care to avoid partial voluming with blood pool or epicardial fat. A 
separate region was drawn in the blood pool, avoid papillary muscles. These regions 
were copied onto the post contrast maps with minor adjustments to avoid artefact. 
These values were then used to calculate extracellular volume fraction (ECV%, 
Chapter 3).  
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Figure 2.2: T1 mapping analysis using CVI42 software 
 
 
Analysis of short-axis T1 maps was performed by contouring the endocardial (red) 
and epicardial (green) borders. A 10% contour offset was then applied (white 
contours), and the right ventricle insertion points marked (blue and purple circles) 
resulting in automatic segmentation into 6 myocardial segments). The average T1 
value from 6 segments (Chapter 4) or 1 segment (segment 9, blue area, Chapter 5) 
was used for reporting native and post-contrast T1 values and for calculation of 
ECV% and iECV. 4-chamber T1 maps were analysed by drawing a manual region of 
interest (ROI) in the septal myocardium taking care to avoid partial volume effects 
(blue oval, Chapter 6). In both cases, blood pool T1 was taken as the average of a 





All statistical analyses were performed using GraphPad Prism Version 7.0 and 
SPSS Version 23.  A two-sided P<0.05 was considered statistically significant. 
The distribution of all continuous variables using the Shapiro-Wilk test and 
visual analysis of histograms. Data was then presented as mean ± standard 
deviation or median [interquartile range].  Comparisons were made using the 
2-sample t-test and the Mann-Whitney test (or for paired data, the paired t-test 
or Wilcoxon matched pairs signed-rank test) where appropriate. Annualised 
change in Chapter 4 was assessed using a one sample t-test or Wilcoxon 
signed-rank test where appropriate to compare with a hypothetical mean (or 
median) of zero. Comparisons between three or more groups were made 
using the one-way analysis of variance (ANOVA) or Kruskal-Wallis tests where 
appropriate. 
 
We presented all categorical variables as percentages and used the χ2 test 
for comparison. The relationship between two continuous variables was 
assessed using either Pearson’s r or Spearman’s r, as appropriate.  Potential 
confounders were adjusted using multivariable linear regression analyses. 
Time-to-first event survival curves were estimated using the Kaplan-Meier 
method and compared with the log-rank test. Univariable and multivariable 
Cox regression models were used to determine clinical and imaging factors 
associated with events. Further details regarding specific statistical methods 
are found in the corresponding results chapter. 
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Chapter 3: Myocardial Fibrosis and Cardiac 
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We used cardiovascular magnetic resonance (CMR), to investigate the 
extracellular compartment and myocardial fibrosis in patients with aortic 
stenosis and their association with other measures of left ventricular 
decompensation and mortality. 
   
Background 
Progressive myocardial fibrosis drives the transition from hypertrophy to heart 
failure in aortic stenosis. Diffuse fibrosis is associated with extracellular 
volume expansion detectable using T1-mapping, whilst late gadolinium 
enhancement (LGE) detects replacement fibrosis.  
 
Methods 
In a prospective observational cohort study, 203 subjects (166 with aortic 
stenosis [69 years, 69% male]; 37 healthy volunteers [68 years, 65% male]) 
underwent comprehensive phenotypic characterisation with clinical, imaging 
and biomarker evaluation. On CMR we quantified the total extracellular 
volume of the myocardium indexed to body surface area (iECV). The iECV 
upper limit of normal from the control group (22.5 mL/m2) was used to define 
extracellular compartment expansion. Areas of replacement mid-wall LGE 
were also identified. All-cause mortality was determined over 2.9±0.8 years of 




iECV demonstrated a good correlation with diffuse histological fibrosis on 
myocardial biopsies (r=0.87, P<0.001, n=11) and was increased in patients 
with aortic stenosis (23.6±7.2 versus 16.1±3.2 mL/m2 in control subjects, 
P<0.001). iECV was used alongside LGE to categorize patients: normal 
myocardium (iECV <22.5 mL/m2, 51% of patients), extracellular expansion 
(iECV ≥22.5 mL/m2, 22%) and replacement fibrosis (presence of mid-wall 
LGE, 27%). Across these groups, there was evidence of increasing 
hypertrophy, myocardial injury, diastolic dysfunction and longitudinal systolic 
dysfunction consistent with progressive left ventricular decompensation (all 
P<0.05). Moreover this categorisation was of prognostic value with step-wise 
increases in unadjusted all-cause mortality (8 versus 36 versus 71 
deaths/1000 patient-years respectively, P=0.009).  
 
Conclusion 
CMR detects ventricular decompensation in aortic stenosis through the 
identification of myocardial extracellular expansion and replacement fibrosis. 
This holds major promise in tracking myocardial health in valve disease and 





Calcific aortic stenosis is the most common valvular heart condition in the 
western world and a major public health burden (135). In recent years, the role 
of left ventricular (LV) remodelling in disease progression, symptom 
development and adverse cardiovascular events in aortic stenosis has been 
increasingly appreciated (6). In the initial phases, the increased afterload 
imposed by aortic valve narrowing induces adaptive LV hypertrophy that acts 
to maintain wall stress and cardiac output. Ultimately, this process 
decompensates and patients transition from hypertrophy to heart failure and 
the development of symptoms and adverse cardiovascular events (6,136). 
This transition often correlates poorly with the severity of aortic valve 
narrowing and is predominantly driven by myocardial fibrosis and myocyte cell 
death (8) perhaps as a consequence of supply-demand mismatch and 
myocardial ischemia in the hypertrophied myocardium (6). There is therefore 
considerable interest in developing novel biomarkers to detect the early signs 
of left ventricular decompensation. 
 
Cardiovascular magnetic resonance imaging (CMR) provides the non-invasive 
gold standard method for measuring left ventricular wall thickness, mass, 
volumes, and ejection fraction.  Moreover, it is able to detect structural 
changes in the left ventricular myocardium including replacement fibrosis with 
the late gadolinium technique and expansion of the extracellular volume using 
T1 mapping (85). The latter in part reflects increases in diffuse myocardial 
fibrosis (a reversible early form of fibrosis) (137) and potentially changes in the 
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intravascular compartment. Early studies have suggested that CMR-derived 
measures of LV mass and replacement myocardial fibrosis are of prognostic 
significance (46,49). However, these studies have largely been conducted in 
small cohorts of patients with end-stage aortic stenosis referred for CMR on 
clinical grounds. Findings may therefore have been confounded by referral 
bias, limiting their applicability and generalizability to the broad population of 
patients with aortic stenosis. Moreover comparisons with age- and sex-
matched control populations and prognostic T1 mapping studies have been 
lacking.  
 
We here report the largest prospective study to evaluate systematically the 
utility of CMR in patients with aortic stenosis. In particular, we investigated its 
ability to detect expansion of the extracellular volume and replacement 
myocardial fibrosis, and how these are related to other markers of left 







All stable patients with at least mild aortic stenosis (aortic jet velocity ≥2 m/s) 
attending the Edinburgh Heart Centre between March 2012 and August 2014 
were invited to participate in this prospective observational cohort study. The 
exclusion criteria were other forms of valvular heart disease (≥moderate 
severity), significant co-morbidities with limited life expectancy, 
contraindications to gadolinium-enhanced CMR, and acquired or inherited 
non-ischaemic cardiomyopathies (assessed by clinical history or ultimately on 
CMR). In addition, we recruited healthy volunteers from the community with a 
similar demographic profile in terms of age and sex but no history or clinical 
features consistent with current cardiovascular disease. The study was 
conducted in accordance with the Declaration of Helsinki and approved by the 




All subjects underwent detailed clinical evaluation including history, physical 
examination and electrocardiogram. In addition, venous blood samples were 






Plasma cardiac troponin I concentrations (cTnI) were determined by the 
ARCHITECT STAT high-sensitivity cTnI assay (Abbot Laboratories, Abbott 
Park, Il, USA) (54). The brain natriuretic peptide (BNP) concentration was 
determined with Triage BNP assay (Biosite Inc., San Diego, CA, USA).  
 
Six-Minute Walk Test 
A six-minute walk test was performed in 156 (94%) patients as an objective 
measure of functional capacity in our predominantly elderly cohort many of 
whom could not perform an exercise tolerance test. Explicit instructions were 
given to patients asking them to walk as far as possible for six minutes.  
 
Echocardiography 
Comprehensive transthoracic echocardiography was performed in all patients 
(iE33, Philips Medical Systems, The Netherlands) by a dedicated research 
ultrasonographer (ACW) and a cardiologist certified in echocardiography 
(CWLC). The severity of aortic stenosis and diastolic function were assessed 
according to American Society of Echocardiography (ASE) guidelines.  
 
Cardiovascular Magnetic Resonance  
Cardiovascular magnetic resonance was performed using a 3T scanner 
(MAGNETOM Verio, Siemens AG, Erlangen, Germany). Short-axis cine 
images were acquired and used to calculate ventricular volumes, mass and 
function. Left ventricular hypertrophy (LVH) was defined as left ventricular 
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mass (indexed to body surface area, using the Du Bois formula) >95th centile 
using age- and sex-specific reference ranges (138). Left ventricular 
longitudinal function was determined by measuring the difference in mitral 
annular displacement between end-systole and end-diastole. 
 
Focal replacement fibrosis and extracellular volume (ECV) expansion were 
assessed in all patients using late gadolinium enhancement and myocardial 
T1 mapping respectively.  Late gadolinium enhancement was performed 15 
min following 0.1 mmol/kg of gadobutrol (Gadovist, Bayer Pharma AG, 
Germany). The presence of mid-wall myocardial fibrosis was determined 
qualitatively by two independent and experienced operators (MRD and CWLC) 
and its distribution recorded (46,54). 
 
T1 mapping was performed using the Modified Look-Locker Inversion-
recovery (116) and a standardised image analysis approach (82). In the short-
axis mid-cavity myocardium, 6 standard segments were defined on native T1 
maps and these regions were then copied onto the corresponding 20-min 
post-contrast maps (OsiriX version 4.1.1, Geneva, Switzerland). Analysis of 
mid-ventricle segments has been shown to correlate well with analysis of all 
17 myocardial segments, is simpler to perform and avoids partial volume 
effects in apical segments (82). Segments with mid-wall LGE present were 
included in this analysis whereas segments containing subendocardial, infarct-
pattern LGE were excluded. Four commonly used T1 approaches were 
assessed: native and post-contrast myocardial T1, partition coefficient (l) and 
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extracellular volume (ECV) fraction. We have recently reported the 
reproducibility of these measures at 3T (82).  
 
We also investigated a novel marker, the indexed extracellular volume (iECV) 
that modifies the ECV fraction to act as a measure of the total volume of the 
extracellular compartment in the left ventricle. It was derived using the formula: 
ECV fraction x left ventricular end-diastolic myocardial volume normalised to 
body surface area.  
 
Histological Validation of Myocardial Fibrosis 
 
All patients who underwent surgical aortic valve replacement were 
approached regarding intra-operative myocardial biopsy at the time of surgery. 
Biopsies were obtained from the basal muscular septum 2 cm below the 
outflow tract using a Tru-Cut needle, stained with picrosirius red and analysed 
using an automated segmentation tool. Two blinded and independent 
observers (ATV and GE) analysed all the specimens, and the inter-observer 




We examined the prognostic value of the different patterns of fibrosis on all-
cause mortality as our primary outcome. Patients were followed between 
March 2012 and September 2015. All deaths were identified through the 
General Register of Scotland. We also assessed AS-related mortality. This 
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was established from the official death certificate and defined as any death 
where aortic stenosis was listed as either the primary cause or a contributing 




We assessed the distribution of all continuous variables using the Shapiro-
Wilk test, and presented them as mean ± standard deviation or median 
[interquartile range].  Comparisons were made using the 2-sample t-test and 
the Mann-Whitney test where appropriate.  We presented all categorical 
variables as percentages and used the χ2 test for comparison. The relationship 
between two continuous variables was assessed using either Pearson’s r or 
Spearman’s r, as appropriate.  Potential confounders were adjusted using 
multivariable linear regression analyses. Time-to-first event survival curves 
associated with the categories of LV decompensation were estimated using 
the Kaplan-Meier method and compared with the log-rank test. All statistical 
analyses were performed using SPSS Version 20 and GraphPad Prism 






A total of 203 subjects were recruited: 166 patients with aortic stenosis (peak 
aortic valve velocity 3.8±0.90 m/s) and 37 healthy volunteers. These two 
groups were well matched for age, sex, chronic renal impairment and 
diabetes. Although a history of hypertension was more common in the AS 
group, blood pressure was well-controlled and similar between the two groups 















Clinical Characteristics  
Age, years 68 [63, 74] 69 [63,75] 0.44 
Males, n (%) 24 (65) 115 (69) 0.57 
Hypertension, n (%) 10 (27) 112 (67) <0.001 
Diabetes Mellitus, n (%) 0 25 (15) - 
Coronary artery disease, n (%) 3 (8) 62 (37) - 
- CCTA assessment, n (%) 13 (35) 21 (13) - 
- Invasive coronary 
angiography, n (%) 3 (8) 78 (47) - 
- Previous PCI, n (%) 2 (5) 11 (6) - 
- Previous CABG, n (%) 0  8 (5) - 
Atrial fibrillation, n (%) 0 4 (2) - 
Body mass index, kg/m2 27.0±3.6 28.9±4.8 0.02 
Body surface area (m2) 1.86±0.16 1.88±0.19 0.54 
NYHA Class, n (%)    
I 36 (97) 74 (45)  
II 1 (3) 56 (34) <0.001 
III - 32 (19)  
IV - 4 (2)  
Six-minute walk test, m 430 [400,475] 400 [340, 450] 0.001 
Systolic blood pressure, mmHg 148±16 151±21 0.53 
Biomarkers  
High sensitivity troponin I 
concentration, ng/L 3.1 [1.2, 7.1] 6.6 [3.8, 12.4] <0.001 
Brain natriuretic peptide concentration, 
pg/mL 9.5 [5.1, 20.6] 26.1 [10.7, 54.3] 0.001 
Echocardiography  
Aortic valve area, cm2 2.4±0.6 1.0±0.4 <0.001 
Peak aortic jet velocity, m/s 1.4±0.2 3.8±0.9 <0.001 
Mean pressure gradient, mmHg 4.2±1.4 35±19 <0.001 
Dimensionless index 0.71 [0.67, 0.81] 0.26 [0.22, 0.32] <0.001 
Valvulo-arterial impedance, 
mmHg/ml/m2 4.0 [3.6, 4.7] 4.3 [3.6, 5.1] 0.38 
Mean e’, cm/s 7.3 [6.2, 8.1] 5.9 [4.9, 7.5] <0.001 
Mean E/e’ ratio 8.5 [7.0, 10.4] 12.6 [10.3, 16.9] <0.001 
Mean diastolic dysfunction grade 0.5±0.8 2.0±0.9 <0.001 
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Cardiovascular Magnetic Resonance  
End-diastolic volume (indexed) (EDVi), 
mL/m2 66 [60, 80] 69 [61, 78] 0.52 
End-systolic volume (indexed), mL/m2 23 [19, 29] 23 [18, 27] 0.40 
Stroke volume (indexed), mL/m2 44 [40, 50] 47 [40, 54] 0.16 
Systolic ejection fraction, % 65 [62, 68] 67 [63, 71] 0.02 
Longitudinal function, mm 14.8±2.7 12.2±2.9 <0.001 
Left ventricular mass (indexed) (LVMi), 
g/m2 62 [54, 71] 88 [73, 99] <0.001 
LVMi/EDVi, g/mL 0.92 [0.84, 0.99] 1.24 [1.04, 1.44] <0.001 
Maximal myocardial wall thickness, 
mm 7.5 [6.8, 8.7] 11.4 [8.8, 14.2] <0.001 
Mean myocardial wall thickness, mm 5.6 [5.0, 6.3] 7.4 [6.3, 9.0] <0.001 
Indexed left atrial volume, ml/m2 28±11 36±15 0.01 
Mid-wall late gadolinium enhancement, 
n (%) 0 44 (27) - 
Native myocardial T1, ms 1166±27 1184±42 0.02 
20-min post-contrast myocardial T1, 
ms 645±51 638±46 0.47 
Partition coefficient 0.45±0.02 0.46±0.04 0.06 
Extracellular volume (ECV) fraction, % 26.5±1.3 27.7±2.6 0.005 
Extracellular volume, mL 29.9±7.3 44.4±15.1 <0.0001 
Indexed extracellular volume (iECV), 
mL/m2 16.1±3.2 23.6±7.2 <0.0001 
  
CCTA: coronary computed tomography angiography, PCI: percutaneous coronary 
intervention, CABG: coronary artery bypass graft, NYHA: New York Heart Association,  
Coronary artery disease was defined by previous myocardial infarction, clinical symptoms of 
angina with documented evidence of myocardial ischemia in the absence of severe aortic 
stenosis, a >50 % luminal stenosis in a major epicardial coronary artery or previous coronary 




Left Ventricular Hypertrophy  
Although the severity of aortic stenosis correlated positively with left ventricular 
hypertrophy (left ventricular mass index r=0.48, P<0.001), it accounted for less 
than a quarter (r2=0.23) of the variance observed (Figure 3.1). Male sex and 
aortic stenosis severity were the only independent predictors of left ventricular 
mass (P<0.001 for both), independent of systolic blood pressure, age and 
coronary artery disease status.  
  
 115 
Figure 3.1: Factors Governing the Magnitude of the Hypertrophic 
Response in Aortic Stenosis. 
 
Only a modest correlation between the severity of valve narrowing and the 
magnitude of the hypertrophic response was observed. The other predictor of left 
ventricular mass index on multivariate analysis was sex with males having more 






T1 Mapping and Extracellular Expansion 
Myocardial biopsies were obtained in 11 out of 37 patients who underwent 
surgical aortic valve replacement. Strong correlations were observed between 
the amount of myocardial fibrosis on histology and T1 mapping parameters 
(native T1 r=0.76, P=0.007; l r=0.82, P=0.002; ECV fraction r=0.70, P=0.016; 
iECV r=0.87, P<0.001; Figure 3.2) with the exception of post-contrast 
myocardial T1 (r=0.01, P=0.98). Indexed LV mass also correlated well with 
histological fibrosis (r=0.83, P<0.001). 
 
Compared to the healthy volunteers, patients with aortic stenosis had 
increased diffuse myocardial fibrosis with iECV providing the best 
discrimination between cases and controls (23.6±7.2 versus 16.1±3.2 mL/m2, 
P<0.0001; Table 3.1, Figure 3.2). Moreover, of all the T1-measures, only the 
iECV demonstrated a progressive increase across patients with mild, 
moderate and severe aortic stenosis (19.6±4.6 versus 22.9±5.4 versus 
25.5±8.1 mL/m2 respectively, P<0.001; Table 3.2). Notably ECV fraction did 
not vary with aortic stenosis severity (as measured by AV Vmax, P=0.30, 
Table 3.2) and showed a high degree of overlap between cases and controls 
(26.5±1.4% versus 27.7±2.6%, P=0.007).  
 
We explored iECV in greater detail, dividing our entire patient cohort into 
tertiles of iECV (Table 3.3). Using this approach, a steady increase across the 
tertiles was observed for each of the following markers of disease severity and 
LV decompensation: indexed LV mass, peak aortic valve velocity, plasma high 
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sensitivity cardiac troponin I concentrations, serum BNP concentrations, 
diastolic dysfunction, longitudinal systolic dysfunction and the proportion of 
patients with mid-wall fibrosis (P<0.05 for all). Similar results were obtained 
using tertiles of ECV fraction (Table 3.4) but by comparison, tertiles of LV mass 
index were less discriminatory with no differences in diastolic function nor 
serum BNP concentrations across these groups (both P>0.05, Table 3.5).  
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Figure 3.2: Indexed Extracellular Volume (iECV) as a Marker of 
Extracellular Expansion in the Myocardium  
 
A. Regions of interest manually drawn onto native and post-contrast T1 maps are 
used to calculate iECV. B. Histology from a patient with aortic stenosis with areas of 
diffuse fibrosis stained with picrosirus red. C. Excellent correlation between iECV 
and diffuse myocardial fibrosis on histology. D. iECV provided good discrimination 
between disease states. E. iECV values were higher in patients with replacement 
fibrosis than patients with normal myocardium or extracellular expansion.  
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Table 3.2:  Cardiovascular Magnetic Resonance Measures of 









(n=87) P value 
Age 67 [56, 75] 72 [66, 77] 71 [65, 76] 0.048 
Male gender (%) 20 (59) 32 (71) 63 (72) 0.33 
     
End-diastolic volume (indexed) 
(EDVi), mL/m2 69 [60, 77] 68 [64, 81] 69 [61, 79] 0.72 
End-systolic volume (indexed), 
mL/m2 24 [19, 26] 23 [20, 27] 22 [17, 27] 0.87 
Stroke volume (indexed), mL/m2 47 [39, 52] 47 [42, 56] 47 [40, 54] 0.56 
Systolic ejection fraction, % 67 [63, 69] 66 [63, 70] 67 [63, 72] 0.65 
Longitudinal function, mm 13.6±2.4 13.2±2.9 11.2±2.8 <0.001 
     
Left ventricular mass (indexed) 
(LVMi), g/m2 71 [61. 86] 87 [74, 98] 93 [80, 104] <0.001 
LVMi/EDVi, g/mL 1.08±0.20 1.21±0.23 1.36±0.28 <0.001 
Maximal myocardial wall 
thickness, mm 8.2±2.1 11.1±3.3 13.4±3.4 <0.001 
Mean myocardial wall thickness, 
mm 5.9±1.1 7.3±1.6 8.7±1.9 <0.001 
Number of patients with LVH, (%) 6 (17) 24 (53) 59 (68) <0.001 
     
Native myocardial T1, ms 1170±30 1180±37 1192±46 0.02 
20-min post-contrast myocardial 
T1, ms 637±45 643±48 636±45 0.73 
Partition coefficient 0.466±0.03 0.466±0.04 0.466±0.05 0.07 
Extracellular volume (ECV) 
fraction, % 27.8±2.5 27.5±2.0 27.8±3.0 0.79 
Indexed extracellular volume 
(iECV), mL/m2 19.6±4.6 22.9±5.4 25.5±8.1 <0.001 
Extracellular expansion 
(iECV>22.5 mL/m2, %) 9 (26) 23 (51) 47 (54) 0.021 
Mid-wall late gadolinium 
enhancement, n (%) 2 (5.9) 14 (31) 28 (32) 0.008 
     
















Table 3.3: Progressive increase in markers of LV hypertrophy and 
decompensation with increasing Indexed Extracellular Volume (iECV) 
stratified in to tertiles 
 
5 patients had insufficient data to calculate iECV  
AV; Aortic valve, BNP; Brain natriuretic peptide 







Age 70 [63, 75] 70 [65, 70] 72 [64, 78] 0.30 
Male gender, n (%) 27 (50) 42 (78) 43 (81) 0.0006 
Echo     
Peak aortic jet velocity, m/s 3.45±0.78 3.77±0.81 4.25±0.96 <0.0001 
Aortic valve area, cm2 1.01±0.37 0.95±0.36 0.90±0.35 0.32 
Mean AV pressure gradient, mmHg 27.6 ±12.7 32.7±15.0 42.6±23.7 <0.0001 
   - Mild aortic stenosis, n 19 12 3  
   - Moderate aortic stenosis, n 13 17 15  
   - Severe aortic stenosis, n 22 25 35  
Valvulo-arterial impedance, 
mmHg/ml/m2 4.4±1.1 4.0±1.0 3.8±1.0 0.019 
Mean e’ (cm/s) 6.9±2.0 6.4±1.7 5.4±1.8 <0.0001 





Mean diastolic dysfunction grade 1.5±1.0 2.0±0.8 2.5±0.7 <0.0001 
CMR     
Left ventricular mass (indexed), g/m2 68±9 88±9 110±19 <0.0001 
Ejection fraction, % 68  [63, 71] 67 [64, 73] 66 [61, 71] 0.44 
Longitudinal function, mm 13.0±2.7 12.8±2.7 11.0±3.0 0.0004 
Mid wall fibrosis, n (%) 2 (4) 6 (11) 36 (68) 0.0001 
Indexed left atrial volume, ml/m2 29±13 36±14 38±13 0.004 
Biomarkers     
Natural log (hs troponin I) 1.3 [0.8, 1.6] 2.1 [1.5, 2.4] 2.5 [1.9, 3.3] <0.0001 
Natural log (BNP) 2.8 [1.9, 3.5] 3.1 [2.4, 3.9] 4.0 [2.8, 4.7] <0.0001 
Functional Status     





NYHA class (%)     
1 27 (50) 23 (43) 24 (45)  
2 20 (37) 19 (35) 15 (28)  
3 6 (11) 12 (22) 11 (21)  
4 1 (2) 0 (0) 3 (6)  
OUTCOMES     
All-cause mortality, n 2 2 10 - 
Mortality rate (per 1000 patient-
years) 12 12 72 0.005 
Aortic-stenosis related mortality, n 0 2 8 - 
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Table 3.4. Aortic stenosis population stratified into tertiles of ECV 
fraction. 
Although significant differences exist across the tertiles for most measures, 
ECV fraction was unrelated to aortic stenosis severity. 
 







Age 68 [61, 72] 71 [65, 75] 73 [66, 78] 0.025 
Male gender, n (%) 43 (80) 37 (70) 32 (60) 0.07 
Echo     
Peak aortic jet 
velocity, m/s 3.74±0.84 3.73±0.77 3.98±1.1 0.30 
Aortic valve area, 
cm2 0.96±0.35 1.00±0.41 0.91±0.31 0.58 
Mean AV pressure 
gradient, mmHg 33±15 32±14 38±25 0.29 
   - Mild aortic 
stenosis, n 11 12 11  
   - Moderate aortic 
stenosis, n 14 17 14  
   - Severe aortic 
stenosis, n 29 24 29  
Mean E/e’ ratio 12.2±4.7 13.7±5.5 17.8±10.3 0.0003 
CMR     
Longitudinal function, 
mm 12.7±2.8 12.7±2.8 11.4±3.1 0.025 
Ejection fraction, % 67 [63, 71] 68 [63, 72] 67 [63, 71] 0.87 
Left ventricular mass 
(indexed), g/m2 82±14 87±20 97±26 0.002 
Mid wall fibrosis, n 
(%) 1 (2) 13 (25) 30 (56) <0.0001 
Biomarkers     
Natural log (hs 
troponin I) 1.6 [1.3, 2.2] 1.7 [1.3, 2.3] 2.4 [1.4, 3.4] 0.002 
Natural log (BNP) 2.7 [1.6, 3.7] 3.3 [2.4, 3.8] 4.0 [2.9, 4.8] <0.0001 
Functional Status     
Six-minute walk test, 
m 420 [360, 455] 390 [340, 450] 
380 [290, 
430] 0.02 
OUTCOMES     
All-cause mortality, n 2 1 11 - 
Mortality rate (per 
1000 patient-years) 12 6 78 0.0006 
Aortic stenosis-
related mortality, n 0 1 9 - 
AV; Aortic valve, BNP; Brain natriuretic peptide, hs; high sensitivity 
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Table 3.5. Aortic stenosis population stratified into tertiles of LV mass 
index. 
Unlike the tertiles of iECV there was no significant differences in diastolic 
function, BNP or all-cause mortality across these groups 
 







Age 70 [63, 77] 70 [65, 74] 71 [63, 77] 0.44 
Male gender, n (%) 25 (45) 43 (77) 47 (85) <0.0001 
Echo     
Peak aortic jet velocity, m/s 3.39±0.77 3.77±0.74 4.35±0.92 <0.001 
Aortic valve area, cm2 1.02±0.37 0.95±0.36 0.88±0.33 0.12 
Mean AV pressure gradient, 
mmHg 26.8 ±13.6 32.3±13.0 44.8±23.1 <0.0001 
   - Mild aortic stenosis, n 23 8 3  
   - Moderate aortic stenosis, n 14 19 12  
   - Severe aortic stenosis, n 18 29 40  
Mean E/e’ ratio 12.2 [10.1, 15.0] 12.6 [9.5, 17.0] 
13.6 [10.8, 
18.0] 0.28 
CMR     
Longitudinal function, mm 13.1±2.9 12.1±3.1 11.5±2.6 0.016 
Ejection fraction, % 68 [63, 71] 66 [63, 70] 66 [62, 71] 0.54 
Extracellular volume (ECV) 
fraction, % 27.3±2.0 27.1±2.3 28.8±3.1 0.0008 
Mid wall fibrosis, n (%) 4 (7) 10 (18) 30 (55) <0.0001 
Biomarkers     
Natural log (hs troponin I) 1.3 [0.7, 1.6] 2.2 [1.5, 2.5] 2.3 [1.8, 3.1] <0.0001 
Natural log (BNP) 3.1 [2.1, 3.7] 3.1 [2.5, 4.0] 3.8 [2.6, 4.5] 0.060 
Functional Status     
Six-minute walk test, m 400 [340, 440] 390 [340, 430] 400 [320, 460] 0.74 
OUTCOMES     
All-cause mortality, n 2 5 7 - 
Mortality rate (per 1000 patient-
years) 12 32 47 0.23 
Aortic stenosis-related mortality, 
n 0 5 5 - 
AV; Aortic valve, BNP; Brain natriuretic peptide, hs; high sensitivity 
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Replacement Myocardial Fibrosis  
Replacement mid-wall fibrosis assessed by late gadolinium enhancement was 
present in 44 (27%) patients with aortic stenosis but none of the healthy 
volunteers. We examined the association between mid-wall myocardial 
fibrosis and the severity of aortic stenosis (Table 3.2). Although patients with 
mid-wall fibrosis had more severe aortic stenosis compared to those without 
(AV Vmax 4.1 [3.7, 4.6] versus 3.8 [3.4, 4.6] m/s respectively, P=0.001), this 
difference was small and unlikely to be of any clinical significance.  By contrast, 
patients with mid-wall fibrosis demonstrated a marked 30% increase in left 
ventricular mass indicative of an advanced hypertrophic response (left 
ventricular mass index 107±24 versus 82±16 g/m2 respectively; P<0.001).  
Indeed, left ventricular mass index was independently associated with mid-
wall myocardial fibrosis in those with hypertrophy (odds ratio 1.09, 95% 
confidence interval 1.04 to 1.14; P<0.001) after adjusting for aortic stenosis 
severity, age, sex and systolic blood pressure.  
 
Relationship Between Myocardial Extracellular Volume and 
Replacement Fibrosis 
It has been suggested that replacement fibrosis represents the irreversible 
final stage of diffuse interstitial fibrosis and extracellular expansion.  
Consistent with this hypothesis, patients with replacement mid-wall fibrosis 
had evidence of increased extracellular volume on T1 mapping compared to 
patients without (iECV 32.0 [29.1 34.9] versus 21.5 [20.6 22.4] mL/m2, 
P<0.0001; ECV fraction 29.1±2.4 versus 26.9±2.1 %, P<0.001).  Indeed, the 
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iECV was independently associated with mid-wall fibrosis after adjusting for 
age, sex, severity of aortic stenosis and even left ventricular mass (odds ratio 
1.22; 95% confidence interval 1.11 to 1.35; P<0.001). Similar associations 
were observed using ECV fraction.  
 
Categorisation of Left Ventricular Decompensation 
We proceeded to categorise patients into three groups according to our CMR 
measures of myocardial fibrosis: normal myocardium, extracellular expansion 
and replacement mid-wall fibrosis (Figure 3.3). The upper limit of normal for 
iECV in the healthy volunteers (defined by two standard deviations above the 
mean, 22.5 mL/m2) was used to define expansion of the extracellular 
myocardium. Values below this threshold defined normal myocardium. This 
categorisation was then validated in the 11 patients who underwent 
myocardial biopsy, with the percentage fibrosis on histology increasing 
progressively across the three groups (normal myocardium 8.9%±4.0 vs. 
extracellular expansion 12.4±2.5% vs replacement fibrosis 22.4±4.9%, 
P<0.004; Table 3.6).  
 
In the larger imaging cohort of patients with aortic stenosis (after exclusion of 
patients with an infarct pattern of LGE n=22, or incomplete T1 mapping data 
n=5), 71 patients had normal myocardium (iECV <22.5 mL/m2). These patients 
had largely mild-to-moderate aortic stenosis, a mild hypertrophic response, 
minimal cardiac injury and good left ventricular performance (Table 3.6, 
Figures 3.3 & 3.4). Thirty-one patients had extracellular expansion (iECV 
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≥22.5 mL/m2) with values for aortic stenosis severity, left ventricular mass, 
myocardial injury, diastolic function, and longitudinal systolic function that were 
intermediate between patients with normal myocardium and replacement 
fibrosis. Finally, 37 patients had evidence of replacement myocardial fibrosis 
on late gadolinium enhancement. These patients were confirmed as having 
the most severe aortic stenosis, left ventricular hypertrophy, myocardial injury 
and impairment in left ventricular performance (Table 3.6). Compared to 
patients with extracellular expansion, they had even greater iECV values 
(30.4±8.2 versus 25.4±3.1 mL/m2, P<0.0001, Figure 3.2) whilst compared to 
patients with normal myocardium they had increased serum BNP 
concentrations (16.7 [6.1, 36.0] versus 34.4 [10.5, 76.2] pg/mL respectively, 
P=0.026) and impaired functional capacity (6-minute walk test 405±74 versus 
359±138 m respectively, P=0.03). Indeed, both mid-wall fibrosis and ECV 
fraction were predictors of functional capacity independent of age, gender, LV 
mass and peak velocity (Table 3.7). These findings were unchanged when 
patients with mild aortic stenosis were excluded from the analysis (Table 3.8). 
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Figure 3.3: CMR Categorisation of Myocardial Fibrosis in Aortic 
Stenosis 
 
Patients with aortic stenosis were categorized into three groups based upon CMR 






Table 3.6: Characteristics of Patients Stratified According to Indexed 












Age 70 [63, 75] 70 [63, 75] 71 [65, 78] 0.59 
Gender (male=1) 0.56 [0.44, 0.68] 0.81 [0.67, 0.96] 
0.76 [0.62, 
0.90] 0.023 
Hypertension (%) 48 (68) 20 (65) 22 (59) 0.70 
Diabetes (%) 8 (11) 7 (23) 2 (5) 0.09 
Body mass index, kg/m2 28.2±4.5 28.9±4.6 29.3±4.3 0.44 
Echo     
Peak aortic jet velocity, m/s 3.53±0.82 3.79±1.0 4.23±0.92 <0.001 
Aortic valve area, cm2 0.98 [0.73, 1.18] 0.88 [1.2, 0.7] 
0.83 [0.73, 
0.91] 0.049 
Mean AV pressure gradient, 
mmHg 29.1±14.2 34.8±21.1 41.1±23.5 0.007 
- Mild aortic stenosis, n 24 7 2  
- Moderate aortic 
stenosis, n 18 10 11  
- Severe aortic stenosis, n 29 14 24  
Valvulo-arterial impedance, 
mmHg/ml/m2 4.1±1.0 3.9±0.9 4.0±1.0 0.46 
Mean e’ (cm/s) 6.7±2.0 6.5±1.8 5.2±1.4 0.0004 
Mean E/e’ ratio 13.1±7.7 13.2±4.8 16.5±6.5 0.04 
Mean diastolic dysfunction 
grade 1.5±0.9 2.0±0.9 2.7±0.5 <0.0001 
CMR      
Left ventricular mass 
(indexed), g/m2 73±11 96±11 107±25 <0.0001 
Relative wall thickness 0.60±0.12 0.61±0.09 0.67±0.11 0.018 
Indexed extracellular volume, 
mL/m2 18.3±2.5 25.4±3.1 30.4±8.2 <0.0001 
Ejection fraction, % 68 [63, 71] 66 [64, 71] 67 [64, 72] 0.94 
Longitudinal systolic function, 
mm 13.2±2.6 12.5±2.4 11.2±3.1 0.002 
Indexed left atrial volume, 
ml/m2  31±13 37±11 38±15 0.027 
Biomarkers     
Natural log (hs troponin I) 1.43±0.96 2.02±0.93 2.60±0.90 <0.0001 
Natural log (BNP) 2.95±1.00 3.06±0.96 3.41±1.10 0.12 
Functional Status     
Six minute walk test, m 406±74 385±95 359±138 0.08 
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NYHA class (%)     
1 33 (46) 18 (58) 17 (46)  
2 27 (38) 6 (19) 12 (32)  
3 11 (15) 7 (23) 5 (14)  
4 0 (0) 0 (0) 3 (8)  
     
OUTCOMES     
All-cause mortality, n 2 4 8 - 
All-cause mortality rate (per 
1000 patient-years) 8 36 71 0.009 
Aortic stenosis-related 
mortality, n 0 4 6 - 
AS-related mortality rate (per 
















Histological fibrosis (%) 8.9±4.0 12.4±2.5 22.4±4.9 0.004 
Aortic valve area, cm2 0.57±0.10 0.94±0.29 0.81±0.44 0.29 
Peak aortic jet velocity, m/s 4.6 [4.4, 5.1] 4.5 [4.0, 5.9] 4.9 [4.1, 8.0] 0.63 
     
Left ventricular mass 
(indexed), g/m2 76±15 98±4 162±6 <0.0001 
Native myocardial T1, ms 1189±23 1183±16 1277±15 0.0002 
Post-contrast myocardial T1, 
ms 676±45 615±24 672±84 0.22 
Partition coefficient 0.43±.0.05 0.47±0.02 0.55±0.02 0.008 
Extracellular volume (ECV) 
fraction, % 25.3±3.1 27.3±1.4 32.2±1.9 0.019 
Indexed extracellular 
volume (iECV), mL/m2 18.8±1.9 25.6±0.7 49.6±4.8 <0.0001 
     
 
AS; aortic stenosis, AV; aortic valve, BNP; brain natriuretic peptide, CMR; cardiac magnetic 




Table 3.7:  Univariable and Multivariable Linear Regression Analysis to 




 Univariable Analysis Multivariable Analysis 
   Model 1 (ECV fraction) Model 2 (mid-wall fibrosis) 
 Relative 
















Age ≥70, years - 50.3 [- 83.0 to -17.6] 0.003 
- 41.4 
[- 74.5 to - 8.36] 
0.01 
- 50.3 
[- 83.0 to – 17.7] 0.003 
Sex, males - 0.81 [- 37.7 to 36.1] 0.97 
- 19.9 
[- 61.3 to 21.6] 
0.35 
- 8.88 
[- 48.5 to 30.7] 
0.66 
Peak aortic jet 
velocity, m/s 
- 12.25 
[- 30.6 to 6.14] 0.19 
- 14.9 
[- 35.4 to 5.73] 
0.16 
- 11.9 






[- 1.00 to 0.56] 0.57 
0.62 
[- 0.44 to 1.68] 
0.25 
0.45 






[-15.4 to -2.81] 
0.005 - 9.77 
[- 17.0 to - 2.58] 





[- 78.5 to - 3.24] 0.03 - - 
-45.6 
[- 89.1 to - 2.11] 0.04 
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Table 3.8.  Characteristics of Patients with Moderate and Severe Aortic 
Stenosis Only (Mild Aortic Stenosis Excluded) Stratified According to 
Indexed Extracellular Volume Thresholds and Presence of Mid-Wall 












Age 71 [66, 75] 71 [66, 75] 71 [65, 78] 0.94 
Male gender, n (%) 27 (57) 19 (79) 28 (80) 0.047 
Echo     
Peak aortic jet velocity, m/s 3.99±0.59 4.17±0.80 4.31±0.88 0.17 
Mean AV pressure gradient, 
mmHg 
36.6±11.2 41.0±20.0 42.4±23.4 0.32 
Aortic valve area, cm2 0.82±0.21 0.85±0.21 0.83±0.22 0.90 
- Moderate aortic stenosis, n 18 10 11   
- Severe aortic stenosis, n 29 14 24  
Mean E/e’ ratio 14.1±9.0  14.1±4.6 16.3±6.5 0.37 
CMR     
Left ventricular mass 
(indexed), g/m2 
76±12 97±12 108±24 <0.0001 
Ejection fraction (%) 68 [64, 72] 66 [63, 74] 67 [64, 72] 0.49 
Longitudinal systolic function, 
mm 
12.9±3.0 12.1±2.0 11.3±3.1 0.042 
Indexed extracellular volume 
(iECV), mL/m2 
18.7±2.3 25.7±3.3 30.5±8.3 <0.0001 
Biomarkers     
Natural log (hs troponin I) 1.68±1.03 2.00±0.81 2.58±0.90 0.0003 
Natural log (BNP) 3.08±1.07 3.15±0.84 3.42±1.11 0.39 
Functional Status     
Six-minute walk test, m 400±77 383±104 356±142 0.23 
NYHA class (%)     
1  17 (36) 11 (46) 15 (43)  
2 21 (45) 6 (25) 12 (34)  
3 9 (19) 7 (29) 5 (14)  
4 0 (0) 0 (0) 3 (9)  
OUTCOMES     
All-cause mortality, n 2 4 8 - 
Mortality rate (per 1000 
patient-years) 12 46 76 0.047 
Aortic-stenosis related 
mortality, n 0 4 6 - 
AS-related mortality rate (per 
1000 patient-years) 0 46 57 0.017 
AV; Aortic valve, BNP; Brain natriuretic peptide, NYHA; New York Heart Association 
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Clinical Outcomes 
Participants were followed up for an average of 2.9±0.8 years during which a 
total of 14 patients with aortic stenosis died: 2 with normal myocardium, 4 with 
extracellular expansion and 8 with replacement fibrosis. Unadjusted all-cause 
mortality rates rose progressively across the groups (8 versus 36 versus 71 
deaths/1000 patient-years, log-rank test P=0.009; Table 3.6, Figure 3.4). AS-
related mortality also increased in a stepwise fashion (0 versus 36 versus 52 
deaths/1000 patient-years, P=0.0045) with no AS-related deaths in the normal 
myocardium group. Tertiles of ECV fraction (P=0.0006, Table 3.4) and iECV 
(P=0.005, Table 3.3) also displayed prognostic ability in this unadjusted 
analysis but no difference in mortality was observed across tertiles of the 
indexed LV mass (P=0.23, Table 3.5).   
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Figure 3.4: Progressive Left Ventricular Decompensation on moving 
from Normal Myocardium to Extracellular Expansion to Replacement 
Fibrosis 
On moving from normal myocardium to extracellular expansion and then 
replacement fibrosis there was a step-wise increase in the following measures: the 
severity of valve narrowing (A); the degree of hypertrophy (B); myocardial injury (C); 
left ventricular performance (D) and all-cause-mortality (E). 





This is the largest prospective CMR study to evaluate systematically both 
extracellular expansion and replacement fibrosis in the myocardium of patients 
with aortic stenosis and healthy control subjects. Both measures are increased 
in aortic stenosis but are only weakly associated with the severity of valve 
narrowing. In contrast, they demonstrate a close association with the 
magnitude of the hypertrophic response, the presence of left ventricular 
dysfunction, the functional capacity of the patient and clinical outcome. We 
believe these findings demonstrate that the structural changes in the left 
ventricular myocardium are as important a consideration as the severity of the 
valvular disease itself. Based on these results, we propose that patients with 
aortic stenosis be categorised into three groups: those with normal 
myocardium, extracellular expansion and replacement myocardial fibrosis. We 
believe this classification has major potential in the early detection of 
subclinical ventricular decompensation in aortic stenosis and ultimately may 
be able to guide decisions regarding the timing of aortic valve replacement.  
 
As one would expect, our data have demonstrated an association between the 
severity of valve narrowing and the degree of hypertrophy in aortic stenosis. 
However, this only explained approximately a quarter of the observed variance 
in LV mass, confirming that the hypertrophic response in aortic stenosis 
cannot be accurately predicted from the degree of valve narrowing alone and 
should be assessed independently.  
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T1 mapping techniques (ECV fraction and iECV) can provide an assessment 
of myocardial extracellular volume expansion. Potentially this can reflect 
increased myocardial fibrosis, myocardial infiltration or expansion in the 
intravascular compartment (132). In aortic stenosis myocardial fibrosis has 
been established pathologically as a key process driving the transition from 
hypertrophy to heart failure (8). Moreover we and others have observed a 
close correlation between these parameters and histological assessments of 
myocardial fibrosis (78,79,85,87). However, there is now some debate as to 
whether T1 mapping can provide direct assessment of myocardial fibrosis with 
recent evidence indicating that increased intravascular volume may also 
influence native T1 values (67),(139). Pressure overload conditions such as 
aortic stenosis are associated with reduced capillary density (75) and 
myocardial ischemia (77). Mahmod et al recently suggested that this ischemia 
may result in coronary vasodilatation and increased intravascular volume 
potentially contributing to increased native T1. Whilst confirmation of this 
interesting hypothesis is required it may be that T1 values also relate to the 
closely related myocardial ischemia that is believed to trigger fibrosis and the 
transition from hypertrophy to heart failure. Regardless, T1 mapping remains 
at the very least a useful surrogate of myocardial fibrosis and LV 
decompensation in aortic stenosis.   
 
Controversy remains as to the optimal T1 image analysis strategy 
(82,132,140). Consistent with previous research (82), both native T1 and ECV 
fraction demonstrated major overlap with values in control groups and little 
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difference between patients with mild, moderate and severe aortic stenosis. 
We sought to tackle this issue by developing a novel parameter, the iECV that 
provides an assessment of the total extracellular volume in the myocardium. 
This effectively combines the prognostic information provided by ECV fraction 
with the improved discrimination between groups associated with indexed LV 
mass into a single measure.  
 
iECV demonstrated good correlation with histological assessment of fibrosis 
burden. Moreover, across tertiles of iECV there was a clear step-wise increase 
in each of the different clinical and imaging measures of LV decompensation 
as well as clinical outcomes, supporting iECV as a marker of decompensation. 
Finally, iECV provided the best discrimination between disease states, being 
the only T1 measure to differentiate between patients with mild, moderate and 
severe aortic stenosis. In combination iECV would therefore appear to provide 
the most useful marker of left ventricular decompensation in aortic stenosis 
with advantages compared to both ECV fraction and LV mass in isolation.  
 
How do extracellular expansion and diffuse fibrosis relate to the development 
of replacement fibrosis as detected using mid-wall LGE? In agreement with 
previous studies (46,49), regions of mid-wall LGE were observed in 27% of 
our patients, with roughly two-thirds having severe aortic stenosis and one-
third moderate. Importantly patients with mid-wall replacement fibrosis also 
had marked increases in iECV, as a surrogate for diffuse fibrosis, in their 
remote myocardium. Indeed, iECV was an independent predictor of the 
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presence of mid-wall LGE. This was confirmed by our histological data and 
suggests that replacement fibrosis does not occur until the end stages of 
myocardial matrix remodelling and is preceded by an intermediate stage of 
extracellular expansion reflecting increasing diffuse fibrosis. Longitudinal 
studies using serial CMR imaging are required to confirm this hypothesis.  
 
Using our CMR assessments of myocardial structure, we categorised our 
patients into three stages of left ventricular decompensation. We used iECV 
to differentiate patients with normal myocardium from those with extracellular 
expansion and then late gadolinium enhancement to define replacement 
fibrosis (Figure 3.3). On moving across these groups, patients had advancing 
left ventricular hypertrophy, histological fibrosis, myocyte cell injury, diastolic 
dysfunction and longitudinal systolic dysfunction, suggesting progressive, 
subclinical LV decompensation. Most importantly there was a steady decline 
in prognosis with unadjusted all-cause mortality rates quadrupling on moving 
from normal myocardium to the extracellular expansion groups and more than 
doubling again in those with replacement fibrosis. Moreover these groups also 
predicted AS-related deaths on unadjusted analysis, with no AS-related 
deaths occurring in the normal myocardium group. More simple categorisation 
using LV mass was less discriminatory and not of prognostic value. 
 
Our categorisation holds promise as a mean of monitoring the development of 
LV decompensation, and helping to optimise the timing of aortic valve 
replacement. Currently the development of symptoms guides the need for 
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surgery. However symptoms are frequently difficult to assess in elderly 
patients with multiple co-morbidities. Objective imaging assessments that 
monitor the changes in myocardial structure that are themselves responsible 
for progressive LV decompensation are therefore potentially attractive (6,136). 
This is the first study to describe iECV in aortic stenosis, so that confirmation 
of our findings in larger studies with longer follow-up is required. However we 
here present the fourth separate cohort to demonstrate the adverse prognosis 
associated with mid-wall LGE in aortic stenosis (19,46,49) as well as 
demonstrating its association with patient functional capacity, left ventricular 
performance and multiple other parameters of LV decompensation. This data 
has now led to the Early Valve Replacement guided by Biomarkers of Left 
Ventricular Decompensation in Asymptomatic Patients with Advanced Aortic 
Stenosis (EVoLVeD) study. This multicentre randomised controlled trial will 
begin enrolment next year and assess whether early valve intervention in 
patients with asymptomatic advanced aortic stenosis and mid-wall fibrosis on 






There were insufficient deaths to perform multivariate analysis. Studies with 
longer follow up are required to confirm whether iECV is of independent 
prognostic value and assess the contribution of the intravascular volume to T1 
mapping values. Finally, although similar to previous studies (78,79,87), the 
number of patients agreeing to intraoperative myocardial biopsy was modest 







CMR can detect progressive fibrosis in aortic stenosis and can be used to 
categorise patients as having normal myocardium, extracellular expansion or 
replacement fibrosis. On moving across these groups, there was a step-wise 
increase in myocardial injury, fibrosis, left ventricular dysfunction and 
unadjusted mortality consistent with progressive ventricular decompensation. 
This categorisation may be able to track the transition of hypertrophy to heart 









Chapter 4: Progression of Hypertrophy and 
Myocardial Fibrosis in Aortic Stenosis: A 
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Aortic stenosis (AS) is accompanied by progressive left ventricular 
hypertrophy and fibrosis. We investigated the natural history of these 
processes in asymptomatic patients and their potential reversal post-aortic 
valve replacement (AVR). 
 
Methods  
Asymptomatic and symptomatic patients with AS underwent repeat 
echocardiography and magnetic resonance imaging. Changes in peak aortic-
jet velocity, left ventricular mass index (LVMi), diffuse fibrosis (indexed 
extracellular volume [iECV]) and replacement fibrosis (late gadolinium 
enhancement [LGE]) were quantified.  
 
Results 
In 61 asymptomatic patients (43% mild, 34% moderate, 23% severe AS) 
significant increases in peak aortic-jet velocity, LVMi, iECV and LGE mass 
were observed after 2.1±0.7 years, with the most rapid progression observed 
in patients with most severe stenosis.  Patients with baseline mid-wall LGE 
(n=16 (26%); LGE mass 2.5 [0.8 - 4.8] g) demonstrated particularly rapid 
increases in scar burden (78 [50 -158] % increase in LGE mass per year).  
  
In 38 symptomatic patients (age 66±8 years, 76% male) who underwent AVR 
there was a 19 [11 - 25] % reduction in LVMi (P<0.0001) and an 11 [4 - 16] % 
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reduction in iECV (P=0.003) 0.9±0.3 years following surgery. By contrast mid-
wall LGE (n=10 (26%); mass 3.3 [2.6 - 8.0] g) did not change post-AVR (n=10; 
3.5 [2.1 - 8.0] g, P=0.23), with no evidence of regression even out to 2 years.   
 
Conclusion  
In patients with AS, cellular hypertrophy and diffuse fibrosis progress in a rapid 
and balanced manner but are reversible following AVR. Once established, 
mid-wall LGE also accumulates rapidly but is irreversible post-valve 
replacement.  Given its adverse long-term prognosis, prompt AVR when mid-
wall LGE is first identified may improve clinical outcomes.  
 
Clinical Trial Registration 







Aortic stenosis is the most common valve disease requiring operative 
intervention in high-income countries (1). Traditional assessments of aortic 
stenosis severity focus on the degree of hemodynamic obstruction in the 
valve. However the importance of the myocardial response to pressure 
overload has been increasingly appreciated, especially when considering the 
development of symptoms and long-term prognosis following valve 
intervention (6). Left ventricular hypertrophy (LVH) initially normalises wall 
stress and maintains cardiac output for many years, if not decades. However, 
with time, the left ventricle decompensates and the patient transitions towards 
heart failure, symptoms and adverse events.  
 
Pathological studies have suggested that this transition from hypertrophy to 
heart failure is driven by a combination of myocyte cell death and myocardial 
fibrosis (8). Magnetic resonance imaging can detect focal myocardial fibrosis 
using late gadolinium enhancement (LGE) and estimates diffuse interstitial 
fibrosis with T1 mapping. A mid-wall pattern of LGE observed in aortic stenosis 
acts as a marker of left ventricular decompensation and is associated with an 
adverse prognosis following surgery (7,19,46,49,141). However, to date, we 
have lacked longitudinal studies to assess how left ventricular hypertrophy and 
fibrosis progress with time, and how aortic valve replacement (AVR) affects 
these processes. The aims of this prospective multicentre study were to 
assess the time course of left ventricular hypertrophy and fibrosis in patients 
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with asymptomatic aortic stenosis, and to determine how they are affected in 






Patients were recruited from two large prospective observational magnetic 
resonance imaging studies investigating the natural history of aortic stenosis 
(NCT01755936; Edinburgh Heart Centre, United Kingdom (7), and 
NCT01679431; Quebec Heart and Lung Institute, Canada (142)). In both 
studies, patients underwent comprehensive clinical and echocardiographic 
assessment including repeat magnetic resonance imaging. Eligible 
participants had undergone at least two serial magnetic resonance imaging 
scans. Symptomatic patients had AVR shortly after baseline magnetic 
resonance imaging allowing us to assess the reverse remodelling effect of 
surgery on repeat scans. The study was conducted in accordance with the 
Declaration of Helsinki and approved by the local research committees.  
Written informed consent was obtained from all participants. Study data can 




Comprehensive transthoracic echocardiography was performed in all patients 





Cardiac Magnetic Resonance  
Magnetic resonance imaging was performed using both 1.5T and 3T scanners 
and standard cine images of the left ventricle were acquired. Late gadolinium 
enhancement was performed 15 minutes following administration of 
gadobutrol. T1 mapping was performed using the Modified Look-Locker 
Inversion-recovery sequence (116) before and 15-20 minutes following 
gadolinium contrast administration. Although there was variation in the 
scanners used at the different centres all patients underwent standardised 
baseline and repeat imaging within their respective institutions (see Appendix). 
To account for potential inter-scanner variation in T1 measurements (143), 
extracellular volume (ECV)-derived T1 mapping measures were obtained to 
normalise myocardial T1 values to blood-pool measurements.  
 
Image analysis 
Analysis of all magnetic resonance imaging scans from both centres was 
performed at the Edinburgh Core Lab using CVI42 (Circle Cardiovascular 
Imaging Inc., Calgary, Canada) by a single reporter (RJE) blinded to the scan 
time-point (see Appendix). Short-axis cine images were used to calculate 
ventricular volumes, mass and function. The presence of mid-wall late 
gadolinium enhancement was determined both qualitatively and quantitatively 
by two experienced operators (RJE and MRD), and its distribution recorded. 
LGE was quantified in a semi-automated manner using a signal intensity 
threshold of >3 standard deviations above the mean value in a region of 
normal myocardium (130).  Whilst segments with mid-wall late enhancement 
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were included in the overall T1 calculation, segments with subendocardial 
infarct pattern LGE were excluded. Extracellular volume fraction (ECV%) and 
indexed extracellular volume (iECV: ECV% x left ventricular end-diastolic 
myocardial volume normalised to body surface area) were calculated using 
the motion-corrected native and post-contrast T1 maps (see Appendix). We 
have previously reported the reproducibility of these measures at 3T (82), and 
demonstrated that iECV acts as a marker of left ventricular decompensation 
in aortic stenosis, correlates with the burden of diffuse fibrosis on histology, 
and is associated with future clinical events (7). Other groups have also 
recently used the same parameter (144).  
 
Statistical analysis 
All statistical analyses were performed using GraphPad Prism Version 7.0 and 
SPSS Version 23.  A two-sided P<0.05 was considered statistically significant. 
Given heterogeneity in timing of follow-up imaging, changes in the left 
ventricular remodelling variables were annualised. Annualised change was 
calculated as the difference between the baseline and final follow-up magnetic 
resonance imaging scans, divided by the number of days in between time 
points and multiplied by 365. This approach assumes that progression is 
linear. In a sensitivity analysis we restricted analysis of progression and 
reverse remodelling in those patients who had repeat imaging at the same 
time interval (2 years in the natural history cohort and 1 year in the AVR cohort) 
and examined absolute change in the left ventricular remodelling variables.  
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We assessed the distribution of all continuous variables using the Shapiro-
Wilk test, and presented them as appropriate using mean ± standard deviation 
or median [interquartile range].  Annualised change was assessed using a one 
sample t-test or Wilcoxon signed-rank test where appropriate to compare with 
a hypothetical mean (or median) of zero. Other comparisons were made using 
the Kruskal-Wallis test where appropriate. We presented all categorical 
variables as percentages and used the χ2 test for comparison. Absolute 
change in the sensitivity analysis was analysed using the paired t-test or 
Wilcoxon matched pairs signed-rank test. Univariate linear regression was 
performed on both cohorts to investigate the change in indexed LV mass using 
variables known or suspected to influence LV mass change (including age, 
gender, history of hypertension and valvulo-arterial impedance). Multivariable 
linear regression analysis was then performed with change in indexed LV 
mass as the dependent variable and the same relevant clinical variables 
included as covariates. RJE had full access to study data and is responsible 







Repeat magnetic resonance imaging was performed in a total of 99 patients 
(n=63 from UK, n=36 from Canada; Table 4.1), 38 underwent AVR (AVR 
Cohort: age 66±8 years, 76% male, peak aortic-jet velocity 4.70±0.83 m/s) and 
61 remained under medical surveillance without intervention (Natural History 




Table 4.1: Baseline characteristics of Patients in the Natural History 
and AVR Cohorts 
 





Age, years 61±12 66±8 
Male gender n (%) 40 (66) 29 (76) 
Body mass index (kg/m2) 28.3±5.6 27.3±3.6 
Body surface area (m2) 1.88±0.21 1.86±0.16 
Past medical history   
Hypertension, n (%) 35 (58) 23 (61) 
Diabetes mellitus, n (%) 21 (34) 6 (16) 
Hyperlipidemia, n (%) 17 (28) 19 (50) 
Obstructive coronary artery disease, 
n (%) 
15 (25) 16 (42) 
Previous percutaneous coronary 
intervention, n (%) 
9 (15) 6 (16) 
Previous coronary artery bypass 
graft, n (%) 
3 (5) 0 (0) 
Systolic blood pressure, mmHg 139±22 146±22 
Diastolic blood pressure, mmHg 82±11 85±13 
Echocardiography   
Aortic stenosis severity, n (%)   
- Mild 26 (43) 0 
- Moderate 21 (34) 0 
- Asymptomatic severe 14 (23) 0 




Natural History Cohort (LV Remodelling) 
At baseline, aortic stenosis was graded as mild in half of the cohort, with the 
remainder split between moderate (34%) and severe (23%, Table 4.1). No 
patient had symptoms attributable to valve disease. Follow-up magnetic 
resonance imaging was performed at 2.1±0.7 years following baseline scan.  
 
As expected, aortic stenosis severity increased (peak aortic-jet velocity 0.15 
[0 to 0.29] m/s/yr; mean gradient 3 [1 to 5] mmHg/yr; AVA: -0.05 [-0.08 to -
0.01] cm2/yr; P<0.001 for all, Table 4.2) with concurrent increases in both left 
ventricular mass index (3 [1 to 5] g/m2/yr, P<0.001) and maximum left 
ventricular wall thickness (0.5 [0 to 1] mm/yr, P<0.001). These changes were 
accompanied by a reduction in longitudinal systolic function (-0.5 [-1.5 to 0.3] 
mm/yr, P=0.003) and an increase in left ventricular filling pressures (E/e’ 0.6 
[-0.4 to 1.3] /yr, P=0.006, Table 4.2). There was no significant change in left 
ventricular stroke volume or ejection fraction over time (both P≥0.20). 
 
When classified by baseline aortic stenosis severity, there was a stepwise 
increase in the progression of both the valve stenosis severity (change in peak 
aortic-jet velocity: mild aortic stenosis 0.05 [-0.03 to 0.20], moderate aortic 
stenosis 0.16 [-0.04 to 0.29], and severe aortic stenosis 0.33 [0.16 to 0.42] 
m/s/yr, P=0.002) and the hypertrophic response (change in left ventricular 
mass index: mild aortic stenosis 2 [1 to 4], moderate aortic stenosis 3 [2 to 5], 
and severe aortic stenosis 5 [2 to 9] g/m2/yr, P=0.07; Table 4.3, Figure 4.1). 
Indeed, a moderate correlation was observed between the rate of peak aortic-
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jet velocity progression and the rate of LVMi progression (r=0.41, P=0.001) 
with both baseline and annualised peak aortic-jet velocity change being 
predictors of the rate of left ventricular mass index progression on univariable 
analysis. Annualised change in peak aortic-jet velocity was the only 
independent predictor of left ventricular mass index progression on 
multivariable analysis (P=0.02, Table 4.4).  
 
Myocardial Fibrosis 
Indexed extracellular volume (iECV) increased over time (0.5 [0 to 2.3] 
mL/m2/yr; P<0.0001, Table 4.2, Figure 4.1), with progression again appearing 
to increase in a step-wise manner across patients with mild (0.3 [-0.1 to 0.6] 
mL/m2), moderate (0.8 [-0.1 to 2.9] mL/m2) and severe (2.0 [0.2 to 2.9] mL/m2) 
aortic stenosis (P=0.07, Table 4.3). Indeed, iECV increased almost 7-fold 
faster in those with severe versus mild aortic stenosis (p=0.01, Figure 4.1). By 
contrast, no progression in ECV% was observed over time either across the 
cohort as a whole (0 [-1 to 1] %, P=0.80) or within severity subgroups (P=0.61). 
 
Mid-wall LGE was present at baseline in 16 patients (26%) and progressed 
rapidly with time (change in LGE mass 1.6 [0.4 to 4.1] g/yr, P<0.0001; Table 
4.2), equivalent to a relative annual progression of 78 [50 to 158] %. This 
occurred both at the sites of existing LGE and, in a quarter of patients, at 
remote sites with the development of new areas of mid-wall LGE (Figures 4.2 
and 4.3). Again faster rates of progression were observed in patients with more 
advanced valve stenosis (P=0.02) and greater levels of diffuse fibrosis 
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(P=0.019, by tertiles of iECV, Figure 4.2). Moreover patients with the most 
mid-wall LGE at baseline demonstrated the fastest subsequent progression 
(tertile 1 baseline LGE: 0.3 [0.1 to 0.9], tertile 2: 1.6 [1.0 to 3.8] and tertile 3: 
4.1 [3.4 to 7.2] g/yr, P=0.007; Figure 4.2). Eight patients (13%) had a 
subendocardial pattern of LGE at baseline. On repeat magnetic resonance 
imaging there were no new areas of subendocardial LGE and no change in 
the subendocardial LGE mass (P=0.56, Table 4.2), consistent with these 




Figure 4.1: Annualised Changes in Aortic Valve Obstruction, Left 
Ventricular Hypertrophy and Diffuse Fibrosis in the Natural History and 
AVR Groups.   
 
Annualised progression in peak aortic-jet velocity (A), left ventricular mass (B) and 
diffuse fibrosis (iECV, C) increased in a step-wise fashion with severity of aortic 
stenosis. The slowest progression for each parameter was observed in patients with 
mild aortic stenosis and the fastest progression in those with severe stenosis. ECV% 
did not change (D) suggesting balanced progression in cellular hypertrophy and 
interstitial fibrosis. 
Following AVR there was significant regression in valve obstruction (A), LVMi (B) and 
iECV (diffuse fibrosis, C). ECV% increased (D) suggesting more rapid regression in 
cellular hypertrophy than interstitial diffuse fibrosis (all P values <0.005). 
AVR; aortic valve replacement, ECV; extracellular volume, iECV; indexed 






Figure 4.2: Serial Magnetic Resonance Images in a Patient with Severe 
Aortic Stenosis and Progression of Replacement Fibrosis. 
 
Top Row: Mid-wall LGE is present baseline magnetic resonance imaging (white 
arrow, baseline image). New areas of LGE can be seen on follow-up magnetic 
resonance imaging after one year (red arrows). The patient subsequently developed 
exertional breathlessness and underwent AVR. Repeat imaging 1 year after AVR 
demonstrated no change in the pattern or volume of LGE.   
In patients with established mid-wall LGE, rapid accumulation of further LGE was 
observed with the fastest progression in those with the most severe aortic stenosis 
(A), the highest baseline burden of LGE (B) and the most advanced iECV (C). 




Figure 4.3: Changes in Left Ventricular Mass, Diffuse Fibrosis and 
Replacement Fibrosis in Aortic Stenosis Before and After Valve 
Replacement  
 
Longitudinal changes in left ventricular mass (LVMi), diffuse fibrosis (iECV) and 
replacement fibrosis (LGE) before and after valve replacement (AVR) are illustrated 
with two example patients (A and B). All three measures increase exponentially as 
stenosis severity increases (patient A, natural history cohort) and new areas of LGE 
are seen on follow-up imaging (red arrows). However following AVR, cellular 
hypertrophy regresses more quickly than diffuse fibrosis and replacement fibrosis 







Table 4.2: Baseline and Annualised Change in Markers of Left 
Ventricular Remodelling Amongst Patients in the Natural History Group  
 
 
Variables are expressed as mean ± standard deviation or median [IQR] as appropriate 
For the annualised changes, the unit is the unit mentioned after the name of the variable per 
year: e.g. for indexed left ventricular volumes (mL/m2), the unit for the annualised change is 
mL/m2/yr. 
  
 NATURAL HISTORY GROUP (N = 61) 










Indexed left ventricular-end diastolic volume, 
mL/m2 70±12 -1 [-4, 2] 0.015 
Indexed left ventricular-end systolic volume, 
mL/m2 18±7 -1 [-3, 1] 0.03 
Indexed stroke volume, mL/m2 52±9 0 [-3, 2] 0.31 
Ejection fraction, % 75±8 0 [-2, 4] 0.23 
Left ventricular mass index, g/m2 75±20 3 [1, 5] <0.0001 
Maximum left ventricular wall thickness, mm 12±3 0.5 [0, 1] <0.0001 
Mass/volume, g/mL 1.09±0.28 0.08 [0.02, 0.14] <0.0001 
Longitudinal systolic function, mm 14±3 -0.5 [-1.5, 0.3] 0.0003 
Indexed left atrial volume, mL/m2 37±12 0 [-3, 3] 0.99 
Infarct late gadolinium enhancement, n (%) 8 (13) - - 
Infarct late gadolinium enhancement mass, g 7.6±4.5 -0.1 [-1.4, 0.7] 0.56 
Mid-wall late gadolinium enhancement, n (%) 16 (26) - - 
Mid-wall late gadolinium enhancement mass, g 2.5 [0.8, 4.8] 1.6 [0.4, 4.1] <0.0001 
T1 mapping measures    
Extracellular volume fraction, % 26.6±3.1 0 [-1, 1] 0.80 
Total extracellular volume, mL 40±13 0.8 [0.1, 4.0] <0.0001 
Indexed extracellular volume, mL/m2  21±6 0.5 [0, 2.3] <0.0001 
Echocardiography    
Peak aortic-jet velocity, m/s 3.24±0.76 0.15 [0, 0.29] <0.0001 
Mean aortic valve gradient, mmHg 24±12 3 [1, 5] <0.0001 
Aortic valve area, cm2 1.08±0.31 -0.05 [-0.08, -0.01] <0.0001 
Indexed stroke volume, mL/m2 42±7 0 [-1, 2] 0.31 
Mean systolic blood pressure, mmHg 139±22 -1 [-6, 2] 0.011 
Valvuloarterial impedance (Zva), mmHg/mL/m2 4.06±0.99 -0.01 [-0.15, 0.20] 0.86 
E/A ratio 1.1±0.3 0 [-0.1, 0.1] 0.71 
Mean e’, cm/s 7.47±2.34 -0.10 [-0.59, 0.42] 0.20 
E/e’ ratio 10.9 [8.7, 12.8] 0.6 [-0.4, 1.3] 0.006 
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Table 4.3: Annualised Change in Markers of Progression and Left 
Ventricular Remodelling According to Aortic Stenosis Severity in the 
Natural History Group 
Results expressed as median [IQR] 
 Aortic Valve Stenosis severity  
LV assessment Mild N = 26 
Moderate 
N = 21 
Severe 
N = 14 
P 
value 
Indexed left ventricular-end 
diastolic volume, mL/m2/yr -1 [-5, 3] -1 [-4, 2] -2 [-5, 3] 0.93 
Indexed left ventricular-end 
systolic volume, mL/m2/yr -1 [-5, 4] -1 [-7, 2] -3 [-5, 3] 0.43 
Indexed stroke volume, mL/m2/yr -1 [-3, 1] 0 [-3, 3] 0 [-3, 2] 0.55 
Ejection fraction, %/yr 0 [-3, 2] 0 [-1, 4] 2 [-2, 4] 0.26 
Left ventricular mass index, 
g/m2/yr 2 [1, 4] 3 [2, 5] 5 [2, 9] 0.07 
Maximum left ventricular wall 
thickness, mm/yr 0.5 [0.0, 1.0] 0.5 [-0.3, 1.2] 0.5 [0.0, 1.0] 0.91 
Mass/volume, g/mL/yr 0.06 [-0.01, 0.11] 0.06 [0.02, 0.12] 
0.14 [0.08, 
0.27] 0.01 
Longitudinal systolic function, 
mm/yr -0.5 [-1.1, 0.3] -1.2 [-2.0, -0.3] -0.1 [-1.5, 0.5] 0.08 
Indexed left atrial volume, 
mL/m2/yr -1 [-3, 2] 1 [-2, 5] 0 [-5, 2] 0.30 
Infarct late gadolinium 
enhancement, n (%) 2 (8) 3 (14) 3 (21) - 
Mid-wall late gadolinium 
enhancement, n (%) 1 (4) 10 (48) 5 (36) - 
Mid wall late gadolinium 
enhancement mass, g/yr 0 1.2 [0.3, 2.4] 4.1 [2.8, 7.2] 0.02* 
T1 mapping measures     
Extracellular volume fraction, %/yr 0 [-1.9, 0.8] 0 [-0.8. 1.7] 0 [0.5, 0.9] 0.61 
Total extracellular volume, mL/yr 0.7 [0.0, 1.0] 1.5 [-0.2, 6.8] 3.7 [0.4, 6.0] 0.08 
Indexed extracellular volume, 
mL/m2/yr 0.3 [-0.1, 0.6] 0.8 [-0.1, 2.9] 2.0 [0.2, 2.9] 0.07 
Echocardiography     
Peak aortic-jet velocity, m/s/yr 0.05 [-0.03, 0.20] 0.16 [-0.04, 0.29] 
0.33 [0.16, 
0.42] 0.002 
Mean aortic valve gradient, 
mmHg/yr 2 [0, 3] 2 [0, 5] 7 [3, 10] <0.001 





Indexed stroke volume, mL/m2/yr -1 [-2, 1] 0 [-1, 2] 3 [-2, 5] 0.06 
Mean systolic blood pressure, 
mmHg/yr -2 [-6, 1] -1 [-7, 3] -5 [-15, 1] 0.65 
Valvuloarterial impedance (Zva), 
mmHg/mL/m2/yr 0 [-0.15, 0.28] 0 [-0.15, 0.49] 
0.36 [-0.32, 
1.19] 0.50 
E/A ratio 0 [-0.1, 0.1] 0 [-0.1, 0.2] 0 [-0.2, 0.1] 0.91 





E/e’ ratio 0.6 [-0.4, 1.2] -0.1 [-0.9, 1.1] 1.6 [0.9, 2.3] <0.001 
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Table 4.4: Univariable and Multivariable Linear Regression Analysis to 
Examine the Predictors of Annualised Progression of Left Ventricular 
Mass Over Time in the Natural History Group.  
 
 Univariable analysis Multivariable analysis 
 Change in left 
ventricular mass 
index, b (95% CI) 
(g/m2/yr) 
P value Change in left 
ventricular mass 




Age, years 0.03 (-0.05 to 0.10) 0.50 0.05 (-0.04 to 0.13) 0.30 
Men 0.66 (-1.33 to 2.64) 0.51 0.95 (-1.16 to 3.05) 0.37 
Hypertension -1.38 (-3.25 to 0.49) 0.14 -1.75 (-3.95 to 0.44) 0.12 
Valvuloarterial 














0.45 (-1.67 to 2.56) 0.68 -0.17 (-2.28 to 1.95) 0.88 
 






AVR Cohort (Reverse Remodelling) 
Patients underwent AVR for a guideline-based indication 32 [13 to 66] days 
after baseline imaging with repeat imaging performed 0.9±0.3 years after AVR. 
Twenty-nine patients received a bioprosthetic AVR and in 9 patients a 
mechanical prosthesis was utilized. No patient underwent transcatheter valve 
replacement (TAVR). As expected, echocardiographic assessments of aortic 
valve obstruction improved after surgery (change in peak aortic-jet velocity -
2.05 [-2.70 to 1.56] m/s, change in mean gradient: -32 [-44 to -26] mmHg, 
change in AVA 0.73 [0.46 to 0.91] cm2, change in valvulo-arterial impedance 
ZVa -0.60 [-1.19 to 0.08], all P<0.0001; Table 4.5).  
 
There was a 19% reduction in left ventricular mass index (-10 [-19 to -5] 
g/m2/yr, P<0.0001, Table 4.5) following AVR, accompanied by a 
corresponding reduction in maximal left ventricular wall thickness (-2 [-2 to -1] 
mm/yr, P<0.0001). A moderate correlation was observed between the 
magnitude of left ventricular mass regression and the reduction in peak aortic-
jet velocity following valve intervention (r=0.35, P=0.03). On multivariable 
regression analysis, a high pre-AVR left ventricular mass index and the 
absence of hypertension were both associated with greater left ventricular 
mass regression (Table 4.6) as was a lower post-AVR Vmax, although this 




Measures of left ventricular relaxation and filling pressure improved following 
AVR (mean e’ 1.35 [0.26 to 2.91], P=0.0004; E/e’ -1.3 [-4.3 to 1.1], P=0.02) 
and there was an apparent trend towards improved longitudinal left ventricular 
systolic function (1 [-1 to 3] mm/yr, P=0.10). No change in ejection fraction was 
observed (P=0.78) although the indexed end-diastolic left ventricular volume 
did decrease modestly (-3 [-9 to 2] mL/m2/yr, P=0.009).  
 
Myocardial Fibrosis 
There was a 11% reduction in indexed extracellular volume (iECV) on repeat 
imaging following AVR (-2 [-3 to -1] mL/m2/yr, P<0.001; Table 4.5, Figure 4.1). 
In contrast, the ECV% increased (1.2 [0.4 to 2.2] %/yr, P=0.003; Figure 4.1) 
consistent with faster regression of left ventricular mass than diffuse fibrosis. 
The type of replacement valve implanted did not influence the degree of LV 
mass (P=0.61) or iECV (P=0.97) regression.  
 
Upon visual assessment, mid-wall LGE was present in 10 patients (26%) at 
baseline. No patient went on to develop new areas of LGE on repeat imaging, 
nor did any patient with existing LGE demonstrate resolution of any 
established areas post-AVR (Figure 4.3). Quantitatively there was no 
significant change in LGE mass following AVR (P=0.22, Table 4.5), even in 
patients rescanned after 2 years. Infarct pattern LGE was observed at baseline 
in 5 patients (13%). One new infarct was detected on repeat imaging but 
overall no change was observed in LGE mass in these patients (P=0.72). 
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Sensitivity analysis was performed in patients who underwent repeat imaging 
at the same time interval (2 years in the natural history cohort, n=50, 1 year in 
the AVR cohort, n=27). Our findings were unchanged from those made across 
the cohort as a whole (Figure 4.4 and Tables 4.7 and 4.8).  
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Figure 4.4: Absolute Changes in Aortic Valve Obstruction, Left 
Ventricular Hypertrophy and Diffuse Fibrosis in the Natural History and 
AVR Groups.   
 
Absolute change in measures was assessed at the time-point with the majority of 
patient follow-up in the Natural History (2 years, N=50) and the AVR (1 year, N=27) 
groups. As in the annualised change analysis, there is an increase in rate of 
progression of aortic-jet velocity, LVMi and iECV with increasing AS severity in the 
Natural History group. However, ECV fraction does not change at 2 years. Following 
AVR, there is regression of both LVMi and iECV, and again consistent with the 
annualised change analysis, we see an increase in ECV fraction, suggesting that 





Table 4.5: Baseline and Annualised Change in Markers of Left 
Ventricular Remodelling Amongst Patients in the AVR Group  
 AVR GROUP (N = 38) 













Indexed left ventricular-end 
diastolic volume, mL/m2 67±15 - -3 [-9, 2] 0.009 
Indexed left ventricular-end systolic 
volume, mL/m2 19±13 - -2 [-5, 1] 0.19 
Indexed stroke volume, mL/m2 49±8 - -3 [-7, 1] 0.009 
Ejection fraction, % 74±8 - 0 [-4, 4] 0.78 
Left ventricular mass index, g/m2 93±21 - -10 [-19, -5] <0.0001 
Maximum left ventricular wall 
thickness, mm 15±3 - -2 [-2, -1] <0.0001 
Mass/volume, g/mL 1.43±0.32 - -0.08 [-0.19, 0.02] 0.003 
Longitudinal systolic function, mm 12±3 - 1 [-1, 3] 0.10 
Indexed left atrial volume, mL/m2 37±11 - -1 [-8, 4] 0.33 
Infarct late gadolinium 
enhancement, n (%) 5 (13) - - - 
Infarct late gadolinium 
enhancement mass, g 4.8±2.8 - 0 [-0.7, 1.7] 0.72 
Mid-wall late gadolinium 
enhancement, n (%) 10 (26) - - - 
Mid-wall late gadolinium 





T1 mapping measures     
Extracellular volume fraction, % 27.2±2.8 - 1.2 [0.4, 2.2] 0.003 
Total extracellular volume, mL 47±18 - -3 [-12, -1] <0.0001 
Indexed extracellular volume, 
mL/m2  25±8 - -2 [-3, -1] <0.0001 
Echocardiography     
Peak aortic-jet velocity, m/s 4.70±0.83 -2.05 [-2.70, 1.56] - <0.0001 
Mean aortic valve gradient, mmHg 52±22 -32 [-44, -26] - <0.0001 
Aortic valve area, cm2 0.79±0.20 0.73 [0.46, 0.91] - <0.0001 
Indexed stroke volume, mL/m2 48±10 - -1 [-9, 4] 0.13 
Mean systolic blood pressure, 
mmHg 146±22 - -2 [-22, 11] 0.46 
Valvuloarterial impedance (Zva), 
mmHg/mL/m2 4.29±1.05 
-0.60 [-1.19, 
0.08] - <0.0001 
E/A ratio 1.0±0.3 - 0.16 [-0.06, 0.42] 0.004 
Mean e’, cm/s 6.15±2.04 - 1.35 [0.26, 2.91] 0.0004 





Table 4.6: Univariable and Multivariable Linear Regression Analysis to 
Examine the Predictors of Annualised Regression of Left Ventricular 
Mass Over Time in the AVR Group.  
 
 Univariable analysis Multivariable analysis 
 
Change in left 
ventricular mass 
index, b (95% CI) 
(g/m2/yr) 
P value 
Change in left 
ventricular mass 
index, b (95% CI) 
(g/m2/yr) 
P value 
Age, years 0.45(0.01 to 0.90) 0.047 -0.11(-0.46 to 0.24) 0.53 
Men -3.0(-12.1 to 6.1) 0.50 5.23(-1.10 to 11.55) 0.10 














velocity at 1 
year post-AVR, 
m/s 





-9.3(-17.5 to -1.1) 0.027 -4.7(-10.5 to 1.12) 0.11 
 
CI; confidence interval 
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Table 4.7: Baseline and Absolute Change in Markers of Left Ventricular 
Remodelling at 2 Years in the Natural History Group  
 
 NATURAL HISTORY GROUP 
N = 50 
LV assessment Baseline values 
2-year absolute 
change P value 
Indexed left ventricular-end diastolic 
volume, mL/m2 69±11 -2 [-8, 5] 0.058 
Indexed left ventricular-end systolic 
volume, mL/m2 15 [13, 22] -2 [-5, 3] 0.07 
Indexed stroke volume, mL/m2 52±9 -1 [-6, 4] 0.47 
Ejection fraction, % 75±9 0 [-4, 8] 0.15 
Left ventricular mass index, g/m2 72±17 5 [2, 12] <0.0001 
Maximum left ventricular wall thickness, 
mm 12±3 1 [0, 2] <0.0001 
Mass/volume 1.06±0.28 0.15 [0.02, 0.29] <0.0001 
Longitudinal systolic function, mm 14±3 -1 [-3, 0.5] 0.0005 
Indexed left atrial volume, mL/m2 37±11 -1 [-7, 5] 0.79 
Infarct late gadolinium enhancement, n 
(%) 4 (8) 4 (8) - 
Infarct late gadolinium enhancement 
mass, g 8.2±4.9 0.6 [-1.8, 1.4] 0.94 
Mid-wall late gadolinium enhancement, n 
(%) 10 (20) 10 (20) - 
Mid-wall late gadolinium enhancement 
mass, g 1.2 [0.5, 4.5] 2.6 [0.7, 6.0] 0.002 
T1 mapping measures    
Extracellular volume fraction, % 26.6±3.4 0.1 [-1.0, 1.5] 0.89 
Total extracellular volume, mL 38±11  2 [4, 1] 0.001 
Indexed extracellular volume, mL/m2  20±5 1 [0, 4] 0.001 
Echocardiography    
Peak aortic-jet velocity, m/s 3.13±0.73 0.25 [-0.05, 0.51] <0.0001 
Mean aortic valve gradient, mmHg 23±12 4 [1, 9] <0.0001 
Aortic valve area, cm2 1.12±0.31 -0.09 [-0.16, -0.02] <0.0001 
Indexed stroke volume, mL/m2 42±7 -1 [-3, 3] 0.73 
Mean systolic blood pressure, mmHg 138±20 -3 [-12, 5] 0.06 
Valvuloarterial impedance (Zva), 
mmHg/mL/m2 3.99±0.97 0.02 [-0.28, 0.44] 0.26 
Mean e’, cm/s 7.58±2.07 -0.10 [-1.17, 0.96] 0.33 






Table 4.8: Baseline and Absolute Change in Markers of Left Ventricular 




 AVR GROUP 
N=27 





Indexed left ventricular-end diastolic volume, 
mL/m2 68±16 -4 [-18, 6] 0.047 
Indexed left ventricular-end systolic volume, 
mL/m2 19 [13, 25] -3 [-8, 4] 0.22 
Indexed stroke volume, mL/m2 48±9 -3 [-14, 4] 0.08 
Ejection fraction, % 73±9 1 [-5, 7] 0.77 
Left ventricular mass index, g/m2 97±23 -18 [-26, -7] <0.0001 
Maximum left ventricular wall thickness, mm 15±3 -2 [-4, -2] <0.0001 
Mass/volume 1.50±0.35 -0.17 [-0.34, -0.07] 0.02 
Longitudinal systolic function, mm 11±3 3 [-1, 5] 0.003 
Indexed left atrial volume, mL/m2 36±11 -12 [-26, 0] 0.08 
Infarct late gadolinium enhancement, n (%) 3 (11) 4 (15) - 
Infarct late gadolinium enhancement mass, g 4.8±2.8 0 [-0.8, 1.7] 0.72 
Mid-wall late gadolinium enhancement, n (%) 10 (37) 10 (37) - 
Mid-wall late gadolinium enhancement mass, g 3.6 [2.6, 9.6] -1 [-1.4, 0] 0.14 
T1 mapping measures    
Extracellular volume fraction, % 26.9±2.5 1.4 [0.8, 4.0] <0.0001 
Total extracellular volume, mL 50±20 -4 [-12, -1] <0.0001 
Indexed extracellular volume, mL/m2  27±9 -2 [-7, -1] <0.0001 
Echocardiography    
Peak aortic-jet velocity, m/s 4.73±0.91 -2.15 [-2.78, -1.60] <0.0001 
Mean aortic valve gradient, mmHg 54±25 -32 [-48, -26] <0.0001 
Aortic valve area, cm2 0.79±0.22 0.70 [0.49, 1.06] <0.0001 
Indexed stroke volume, mL/m2 47±10 -2 [-8, 3] 0.028 
Mean systolic blood pressure, mmHg 143±21 -4 [-17, 12] 0.15 
Valvuloarterial impedance (Zva), mmHg/mL/m2 4.33±1.14 -0.56 [-1.39, -0.05] 0.0004 
Mean e’, cm/s 6.05±2.01 1.38 [-0.12, 3.37] 0.003 




This is the first study to characterise how left ventricular hypertrophy and 
fibrosis progress in aortic stenosis and how these processes then reverse 
remodel following AVR. Using a multicentre multi-modality imaging approach 
with serial echocardiography and magnetic resonance imaging, we have 
demonstrated that both hypertrophy and fibrosis progress in an increasingly 
rapid manner as aortic stenosis severity advances. Once mid-wall patterns of 
replacement fibrosis (LGE) have become established, further scarring appears 
to accumulate rapidly. Whilst left ventricular hypertrophy and diffuse fibrosis 
reverse following AVR, mid-wall LGE does not and appears to be irreversible. 
Given the adverse prognosis associated with mid-wall fibrosis burden, our 
data suggest prompt AVR at the first sign of mid-wall LGE or just before its 
development might improve long-term patient outcomes.  
 
In the Natural History Cohort we observed a slow and steady progression in 
each of the echocardiographic measures of valvular stenosis as 
anticipated.(14) This valve progression was strongly influenced by baseline 
aortic stenosis severity, with the slowest progression in patients with mild 
stenosis and the most rapid progression in those with severe obstruction. This 
was mirrored by a similar pattern of increasing left ventricular mass 
progression. Indeed a moderate correlation was observed between valve 
stenosis progression and left ventricular mass progression, with the 
annualised increase in peak aortic-jet velocity the only independent predictor 
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of left ventricular mass progression on multi-variable analysis. Consistent with 
this, AVR resulted in a substantial reduction in aortic valve obstruction that 
was accompanied by a ~20% reduction in the left ventricular mass. Again 
there was a strong correlation between the reduction in trans-valvular gradient 
and left ventricular mass regression, with the former emerging as an 
independent predictor of reverse remodelling on multivariable analysis. One 
surprising finding was a small but significant reduction in stroke volume 
following AVR. This may relate to accompanying reductions in LV end-diastolic 
volume but requires further study. 
 
What about myocardial fibrosis? Magnetic resonance imaging is the only non-
invasive imaging technique capable of assessing both diffuse interstitial (T1 
mapping techniques) and replacement fibrosis (LGE). T1 mapping provides 
multiple different measurements that demonstrate close agreement with 
collagen volume fraction on histology and therefore act as surrogates of 
interstitial myocardial fibrosis.(7,85) We here investigated the ECV% and iECV 
because of the advantages these measures hold when comparing values 
acquired in a multi-centre setting on different scanners and at different field 
strengths. Whilst ECV% gives an indication of the proportion of the 
myocardium made up of fibrosis, iECV is a surrogate of the total fibrosis 
burden in the left ventricle. Together these two measures can provide unique 
insights into how the extracellular and intracellular compartments of the 
myocardium change in aortic stenosis and in response to AVR. Like peak 
aortic-jet velocity and left ventricular mass index, the iECV increased with time 
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suggesting progressive expansion of the extracellular compartment and 
diffuse interstitial fibrosis. Once again this progression appeared to occur 
quickest in those with the most advanced valvular stenosis. By comparison, 
ECV% did not demonstrate any evidence of progression suggesting balanced 
increases in the size of the cellular and extracellular compartments as left 
ventricular remodelling advances.  
 
Following AVR, reductions in iECV were observed similar to those observed 
in peak aortic-jet velocity and left ventricular mass, confirming that diffuse 
interstitial fibrosis is indeed reversible. However the accompanying rise in 
ECV% suggests that regression in cellular hypertrophy occurs faster and to a 
greater degree than this reduction in diffuse fibrosis. These novel imaging 
findings are in keeping with historical data from myocardial biopsies performed 
following AVR showing an initial increase of percentage interstitial fibrosis on 
histology at 18 months.(137)  
  
Mid-wall LGE represents a more advanced stage of focal replacement 
fibrosis(55) in the myocardium and has been described in numerous aortic 
stenosis populations.(46,49,66) Mid-wall LGE is a marker of left ventricular 
decompensation demonstrating a close association with myocardial injury, left 
ventricular diastolic function, left ventricular systolic function and exercise 
capacity.(7) Moreover multiple different studies from multiple centres have 
confirmed mid-wall LGE as a powerful prognostic marker of long-term all-
cause and cardiovascular mortality.(7,19,46,49) Most of these adverse events 
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occur after AVR(145) and there appears to be a proportionate relationship: the 
more myocardial LGE, the worse the clinical outcomes.(19,46)  
 
For the first time, we have demonstrated that the burden of mid-wall LGE 
increases whilst asymptomatic patients are being monitored in the clinic. 
Indeed, once mid-wall LGE has become established then further accumulation 
of such scarring is relatively rapid, increasing on average by 75% each year 
especially in patients with a high baseline fibrosis burden. Importantly, we go 
on to demonstrate that whilst this progressive scarring is arrested by AVR, it 
does not reverse even out to 2 years after AVR. This is consistent with smaller 
short-term studies and implies that the scar patients develop whilst waiting for 
surgery remains with them for the rest of their life, contributing to their poorer 
long-term prognosis. These findings could have important clinical implications 
for optimising patient care and the timing of aortic valve replacement. For 
example, based on our data, prompt AVR could be undertaken when mid-wall 
LGE is first identified, in order to prevent the accumulation of further scarring 
and to improve long-term patient outcomes. This strategy requires prospective 
confirmation and is currently being tested in the Early Valve Replacement 
guided by Biomarkers of Left Ventricular Decompensation in Asymptomatic 
Patients with Severe Aortic Stenosis (EVOLVED) randomised controlled trial 
(NCT03094143).  
 
Our study does have some limitations. Given the heterogeneity in the timing 
of follow-up imaging we used annualised change for our primary analysis. This 
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assumes linear progression or regression of variables which may not be the 
case. In the sensitivity analysis, we repeated our analysis of the data using 
absolute change in the subgroup of patients who underwent repeat imaging 
after the same time interval (2 years in the natural history cohort (n=50) and 1 
year in the AVR cohort (n=27)). Our results were consistent with the 
annualised analysis. Further studies are still required to investigate how LV 
remodelling and reverse remodelling progress over multiple time points in 
individual patients. The ECV measurements (ECV%, iECV) reflect the size of 
the extracellular compartment and therefore potentially represent multiple 
different factors including the intravascular space and myocardial infiltration. 
However, in patients with aortic stenosis (and in the absence of associated 
cardiac amyloidosis), there is a close association between these ECV 
measurements and histological markers of interstitial fibrosis, confirming that 







We have used echocardiography and magnetic resonance imaging to 
characterise the structural changes in the myocardium that occur in patients 
with aortic stenosis both during routine surveillance and following AVR. In 
patients with aortic stenosis, cellular hypertrophy and diffuse interstitial fibrosis 
increase in a balanced and exponential manner before reversing at different 
rates following AVR. Once established, mid-wall replacement fibrosis 
accumulates rapidly but appears irreversible following AVR. The myocardial 
scar burden that patients develop whilst waiting for surgery therefore persists 
into the long-term along with prognostic implications that this entails. Prompt 
valve replacement as soon as mid-wall fibrosis develops holds promise in 




Chapter 5: Myocardial Extracellular Volume in 
Patients with Aortic Stenosis Undergoing 









Myocardial fibrosis is a key mechanism of left ventricular decompensation in 
advanced aortic stenosis and can be quantified using cardiac magnetic 
resonance (CMR) imaging T1 mapping techniques. We assessed T1 mapping 
measures of fibrosis in patients with severe aortic stenosis referred for aortic 
valve intervention, and determined their associations with clinical 
characteristics, disease severity and long-term clinical outcome.  
 
Methods 
In this international prospective cohort study, patients with severe aortic 
stenosis underwent CMR with T1 mapping prior to aortic valve intervention. 
Image analysis was performed by a single core laboratory and three T1 
mapping measures (native T1, extracellular volume fraction [ECV%] and 
indexed extracellular volume [iECV]) were determined.  
 
Results 
Four-hundred patients (70±10 years, 60% male) from nine international 
centres were enrolled. Native T1 was higher in patients imaged at 3 T 
compared to 1.5 T (1213±57 versus 1050±48 ms, P<0.001), whereas ECV% 
did not vary by CMR scanner manufacturer, magnetic field strength or T1 
mapping sequence (all P>0.30).  
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Unadjusted native T1 did not show clear associations with clinical or imaging 
variables. ECV% correlated with increasing age, Society of Thoracic Surgeons 
Predicted Risk of Mortality score, known coronary artery disease, reduced 
peak velocity, increasing left ventricular mass, presence of late gadolinium 
enhancement and reduced ejection fraction (P<0.05 for all). Following 
adjustment for all clinical variables, ECV% remained associated with both left 
ventricular ejection fraction (P<0.001) and mass index (P=0.043). Similar 
associations were seen with iECV.  
 
Aortic valve intervention was performed 19 [4, 61] days following CMR 
imaging, with median of 3.8 [1.7, 4.5] years follow-up in 391 patients and 40 
deaths recorded. No prognostic association for native T1 was observed, even 
after adjustment for magnetic field strength. A progressive increase in all-
cause mortality was seen across tertiles of ECV% (14.0, 28.5 and 53.7 deaths 
per 1000 patient-years; log-rank test, P=0.003). ECV% was independently 
associated with all-cause mortality following adjustment for age, sex, peak 
velocity, impaired ejection fraction and presence of late gadolinium 
enhancement (hazard ratio per unit increase in ECV%: 1.13, 95%, (1.04 to 
1.24), P=0.006). iECV was associated with all-cause mortality following 
adjustment for age and sex (hazard ratio 1.03 [1.00 to 1.06], P=0.04) but not 






In patients with severe aortic stenosis scheduled for aortic valve intervention, 
extracellular volume-based T1 mapping measures are robust, track with left 






Aortic stenosis is a disease of both valve and myocardium. Progressive 
myocardial hypertrophy occurs over time in response to sustained pressure 
overload restoring wall stress and maintaining cardiac performance. However, 
this hypertrophic response eventually decompensates, and patients transition 
to heart failure, symptoms and adverse events.  
 
Myocardial fibrosis is a key pathological process driving left ventricular 
decompensation (8). Two patterns of fibrosis are observed; focal replacement 
fibrosis and diffuse interstitial fibrosis (55). Both forms of fibrosis can be 
detected non-invasively using cardiac magnetic resonance (CMR) imaging; 
replacement fibrosis with the late gadolinium enhancement (LGE) technique 
and diffuse interstitial fibrosis with newer T1 mapping approaches. While 
replacement fibrosis appears irreversible, regression of diffuse fibrosis is 
observed following relief of pressure overload with aortic valve intervention 
(137,144,146). Accurate and robust assessment of diffuse fibrosis burden is 
therefore desirable to identify early left ventricular decompensation at a stage 
where pathological left ventricular changes are largely reversible and targeted 
early valve intervention may improve patient outcomes.  
 
Several T1 mapping measures have been proposed to date. Native T1 
mapping produces a voxel-based map of the myocardium which estimates 
absolute myocardial T1 values (70). Extracellular volume (ECV)-based 
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measures utilise gadolinium contrast to calculate the relative (extracellular 
volume fraction [ECV%]) or absolute (indexed extracellular volume [iECV]) 
extracellular volume of the myocardium (7,85). Although these measures have 
been validated against histology (7,78-81,84-86,147), the optimal T1 mapping 
approach in aortic stenosis remains unclear and robust multicentre outcome 
data are lacking. 
 
In the present study, we investigated T1 mapping in a large international 
multicentre study of patients with severe aortic stenosis scheduled for aortic 
valve intervention. In particular, we analysed the technical factors affecting 
measurement variability and explored the association of native T1, ECV% and 








Patients with AHA/ACC/ESC criteria (5,148) for severe aortic stenosis who 
were awaiting aortic valve intervention were recruited as part of prospective 
observational cohorts from several centres across Europe, North America and 
Asia: the UK (Edinburgh, Leeds, Leicester, Oxford, Barts Heart Centre - 
London), Germany (Berlin), U.S.A. (Pittsburgh), Canada (Quebec) and South 
Korea (Table 5.1). All patients underwent CMR with T1 mapping performed 
both prior to and following intravenous gadolinium contrast administration. 
Exclusion criteria were the presence of an implantable cardiac device, major 
renal dysfunction (estimated glomerular filtration rate <30 mL/min/1.73m2) and 
presence of another co-existent myocardial pathology such as cardiac 
amyloidosis, hypertrophic cardiomyopathy or myocarditis. The study was 
conducted according to the Declaration of Helsinki and approved by local 
research ethics committees. Written informed consent was obtained from all 
participants. All patients underwent comprehensive medical history and 
physical examination. Transthoracic echocardiography was performed 
according to international clinical guidelines and within accredited tertiary 
echocardiographic units. Particular focus was placed upon measurement of 
aortic stenosis severity, which was assessed on the basis of the peak velocity, 
mean gradient and aortic valve area (149).  
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Table 5.1: Cardiac magnetic resonance technical details and T1 

















































































































































































































77 1232±47 28.3±3.6 
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Cardiac magnetic resonance  
CMR was performed on local platforms employing a range of different 
scanners, T1 mapping sequences and field strengths (Table 5.1). Standard 
long-axis cine images were acquired as well as a short-axis cine stack of the 
left ventricle. LGE imaging with both a short-axis left ventricular stack and 
standard long-axis views was performed 10-15 min following gadolinium 
contrast medium administration. T1 mapping data were acquired in a short-
axis mid-ventricular view of the left ventricle both prior and 10-20 min following 
gadolinium contrast medium administration.  
 
Image post-processing and analysis 
CMR image analysis was performed by a core lab according to a standardized 
analysis protocol (see appendix) using CVI42 software (Circle Cardiovascular 
Imaging Inc., Calgary, Canada). Patients with CMR features consistent with a 
diagnosis of an alternative myocardial pathology were excluded from the final 
analysis. Body surface area was calculated using the Mosteller formula. The 
short-axis stack was contoured to calculate left and right ventricular volumes, 
ejection fraction and left ventricular mass which were indexed to body surface 
area. Values were compared to age and sex specific normal ranges in order 
to define the presence of left ventricular hypertrophy (138). Left ventricular 
trabeculations and papillary muscles were included in the myocardial mass 
and excluded from the cavity volumes as per Society of Cardiovascular 
Magnetic Resonance (SCMR) recommendations(128). Left atrial volume was 
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calculated via the biplane area-length method and indexed to body surface 
area (129). 
 
The presence of non-infarct (mid-wall) and infarct patterns of LGE were 
recorded together and quantitative analysis performed using the full-width-at-
half-maximum technique (128), with the extent of LGE expressed as a 
percentage of total left ventricular mass. Areas of inversion artefact or signal 
contamination by epicardial fat or blood pool were manually excluded. 
 
Core lab T1 mapping analysis was performed using a standardized pre-
specified analysis protocol. Epicardial and endocardial contours were 
manually drawn in the mid-inferoseptum (segment 9 of the standard 17-
segment model (131) on scanner-generated, short-axis, native and post-
contrast T1 maps at the mid-ventricular level. A 10% offset was applied to 
minimize the influence of signal from the adjacent blood pool and epicardial 
fat. A septal segment was chosen because improved reproducibility has 
previously been demonstrated using septal regions of interest compared with 
analysis of all mid-ventricular segments on short-axis images (150). Segments 
containing non-infarct LGE were included in the T1 mapping analysis whereas 
those with infarct LGE were excluded according to SCMR guidelines (132). 
Extracellular volume fraction (ECV%) and indexed extracellular volume (iECV) 
were then calculated (see appendix). Interobserver reproducibility of each of 
the T1 mapping measures was determined from independent analysis of 15 
randomly selected scans. ECV% and iECV were pre-specified as the 
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predominant T1 mapping measures for comparison because of the potential 
advantages these measures offer when comparing values acquired at different 
magnetic field strengths (151) and with different pulse sequences (84). The 
variability of native T1, ECV% and iECV were investigated to explore the effect 
of imaging centre, scanner manufacturer, magnetic field strength and pulse 
sequence (Shortened [ShMOLLI] versus standard MOdified Look-Locker 
Inversion-recovery [MOLLI]).  
 
Longitudinal follow-up and clinical events 
The primary outcome measure was all-cause mortality. The secondary 
outcome measure was cardiovascular mortality, which was defined as death 
attributable to myocardial ischaemia or infarction, heart failure, cardiac arrest 
(due to arrhythmia or unknown cause) or cerebrovascular accident. Cause of 
death was adjudicated by three observers (PB, JPG, MRD). Amongst the 
centres in the United Kingdom, official death certificates were available in all 
patients. Deaths occurring at international sites outside of the United Kingdom 
were adjudicated using a combination of medical record review, reports from 
family members and death certificates where available.  
 
Statistical analysis 
The distribution of all continuous variables was assessed using the Shapiro-
Wilk test, which were presented using mean ± standard deviation or median 
[interquartile range]. Comparisons between groups were performed using the 
independent two-sample t-test or Mann-Whitney test as appropriate. We 
presented all categorical variables as counts and percentages and used the 
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Fishers exact test or χ2 test for comparison. The relationship between two 
continuous variables were assessed using Pearson’s r and Spearman’s rho 
as appropriate. Comparisons between ECV% and iECV tertiles were 
performed with one-way analysis of variance (ANOVA) or Kruskal-Wallis test 
as appropriate.  
 
The influence of imaging centre, CMR scanner manufacturer, magnetic field 
strength and pulse sequence on T1 mapping values was analysed using 
independent two-sample t-tests and linear regression analysis. Univariable 
linear regression was also performed to determine associations between 
clinical and imaging variables with T1 mapping measures. Multivariable linear 
regression was then performed using variables significantly associated with 
T1 measures as well as important variables (e.g. age and sex) regardless of 
strength of univariable association. Univariable Cox-regression analysis was 
performed to determine which variables were associated with the primary 
outcome measure (all-cause mortality). Time to event or final status check was 
taken from the date of valve intervention. Variables with a significant 
association, as well as any variables not significantly associated but thought 
to potentially have an effect on outcome were included in the multivariable Cox 
regression model. The hazard ratio (HR) per unit increase in the variable of 
interest and 95% confidence intervals (CI) were expressed as HR, 95% CI. 
 
All statistical analyses were performed using SPSS Version 23 and GraphPad 




A total of 400 patients across 9 sites in 5 countries were included in the final 
analysis (70±10 years, 60% male; Figure 5.1) with a large proportion having 
hypertension (65%), diabetes mellitus (20%), and coronary heart disease 
(40%) (Table 5.2 and Table 5.3). Overall 237 (59%) patients were imaged on 









CMR; cardiovascular magnetic resonance, SAVR; surgical aortic valve replacement, 
TAVI; transcatheter aortic valve insertion  
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Table 5.2: Baseline characteristics, echocardiography and cardiac 
magnetic resonance imaging results by centre 
 






































































































69±7 2 (100) 0 (0) 2.76 5.04  ±0.81 
0.34 




















































Table 5.3: Baseline characteristics and imaging results in all study 
participants and by ECV% tertile 
 
  Extracellular volume fraction (ECV%)  












Age, years 70±10 69±9 70±10 71±10 0.28 
Male sex, n (%) 240 (60) 81 (61) 82 (61) 77 (58) 0.83 
Body mass index, kg/m2 27.9±5.1 28.2±5.1 28.1±5.6 27.4±4.6 0.45 
Body surface area, m2 1.87±0.23 1.86±0.26 1.86±0.25 1.83±0.26 0.41 
Past medical history      
Hypertension, n (%) 258 (65) 83 (62) 84 (63) 91 (70) 0.42 
Diabetes mellitus, n (%) 81 (20) 21 (16) 23 (17) 36 (28) 0.04 
Atrial fibrillation, n (%) 46 (12) 9 (7) 13 (10) 24 (18) 0.01 
Previous myocardial 
infarction, n (%) 
38 (10) 4 (3) 13 (10) 21 (16) 0.002 
Known coronary artery 
disease*, n (%) 
159 (40) 42 (32) 47 (35) 70 (53) 0.001 
Clinical factors      
NYHA functional class III or 
IV, n (%) 
143 (36) 29 (25) 54 (48) 60 (54) <0.001 
Systolic blood pressure, 
mmHg 
132±19 133±17 135±21 129±18 0.04 
Diastolic blood pressure, 
mmHg 
73±12 73±12 73±11 72±14 0.75 






[1.17, 3.33] <0.001 









     
Peak aortic-jet velocity, m/s 4.41±0.78 4.42±0.65 4.50±0.75 4.30±0.91 0.13 
Peak aortic valve gradient, 
mmHg 
80±28 80±23 83±27 77±33 0.25 
Mean aortic valve gradient, 
mmHg 
49±18 49±16 50±17 47±21 0.39 
Aortic valve area, cm2 0.74±0.25 0.74±0.19 0.77±0.31 0.72±0.24 0.21 
Indexed aortic valve area, 
cm2/m2 
0.40±0.13 0.40±0.11 0.41±0.16 0.40±0.13 0.38 
Valvuloarterial impedance, 
mmHg/mL/m2 
3.93±1.11 3.93±1.14 3.96±1.18 3.92±1.02 0.96 
Bicuspid aortic valve, n (%) 129 (32) 41 (33) 43 (35) 45 (36) 0.82 
Cardiac magnetic 
resonance      
Indexed left ventricular end-
diastolic volume, mL/m2 77±27 68±19 77±26 86±31 <0.001 
Indexed left ventricular end-
systolic volume, mL/m2 24 [14, 43] 19 [11, 33] 20 [12, 43] 34 [21, 55] <0.001 
Indexed left ventricular 
stroke volume, mL/m2 48±13 48±11 50±14 47±13 0.26 
Left ventricular ejection 
fraction, % 66±16 72±12 68±15 59±17 <0.001 
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Left ventricular ejection 
fraction <50%, n (%) 60 (15) 8 (6) 18 (13) 34 (26) <0.001 
Left ventricular mass index, 
g/m2 92±31 84±24 91±29 100±36 0.001 
Maximum left ventricular 
wall thickness, mm 15±3 15±3 15±3 15±3 0.42 
Mass/volume, g/mL 1.26±0.40 1.28±0.36 1.26±0.48 1.22±0.36 0.51 
Indexed right ventricular 
end-diastolic volume 65±17 63±14 64±15 68±20 0.067 
Indexed right ventricular 
end-systolic volume, mL/m2 21 [15, 29] 20 [15, 25] 20 [14, 28] 25 [17, 31] 0.15 
Indexed right ventricular 
stroke volume, mL/m2 41±10 41±10 41±10 41±10 >0.99 
Right ventricular ejection 
fraction, % 64±11 66±9 65±10 62±13 0.019 
Indexed left atrial volume, 
mL/m2 53±22 46±16 54±22 59±25 <0.001 
Late gadolinium 
enhancement, n (%) 208 (52) 53 (40) 68 (51) 87 (66) <0.001 












Extracellular volume fraction 
(ECV%), % 27.8±3.7 23.9±1.6 27.5±1.0 31.9±2.4 - 
Indexed extracellular 









Clinical events      
All-cause mortality, rate / 
1000 patient years  - 14.0 28.5 53.7 0.003 
 
LGE; late gadolinium enhancement, NYHA; New York Heart Association, STS-PROM; Society 
of Thoracic Surgeons Predicted Risk of Mortality 
 
*known coronary artery disease defined as history of previous myocardial infarction, 
obstructive disease on angiography (stenosis >50% left main stem or >70% proximal 
epicardial coronary artery) or previous coronary intervention 
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Consistency of T1 Mapping  
In keeping with previous work (151,152), substantial variation in native T1 
values was observed between the different centres (Figure 5.2). In particular, 
native T1 values were higher in patients imaged at 3 T compared to 1.5 T 
(1213±57 versus 1050±48 ms, P<0.001). However, there was no association 
between native T1 and either scanner manufacturer or the pulse sequence 
used (such as ShMOLLI or MOLLI) when adjusted for magnetic field strength 
(model 1, Table 5.4). In contrast, ECV% values were relatively consistent 
across the different centres (Figure 5.2), with no differences between ECV% 
values in patients imaged at 1.5 T and 3 T (27.9±3.9% versus 27.7±3.5%, 
P=0.55). On univariable linear regression analysis, there was no association 
between ECV% values and either magnetic field strength (P=0.571), scanner 




Figure 5.2: Multiparametric cardiac magnetic resonance assessment  
 
Cardiac magnetic resonance (CMR) short axis cine images were contoured to provide 
ventricular volume, mass and ejection fraction measurements (A). Areas of late 
gadolinium enhancement (LGE, B, red arrows) were quantified using the 5-standard-
deviation technique. Native (C) and post-contrast (D) T1 maps were analysed and 
the mean value from segment 9 (shaded blue) and blood pool (orange contour) were 
used to calculate the extracellular volume fraction (ECV%). Native T1 values varied 
significantly by centre (G) mainly due to the effect of magnetic field strength (black = 
1.5T, blue = 3T). Less variation was observed with ECV% values (H) which did not 
vary by field strength (P=0.55, F). 
 
EDI; Edinburgh, LGI; Leeds, GLE; Leicester, BHC; Barts Heart Centre, ORH; 
Oxford, BER; Berlin, UPMC; Pittsburgh, QUE; Quebec, SNUH; Seoul, Sh; ShMOLLI 
T1 mapping sequence used  
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T1 Mapping and Clinical Factors 
Native T1 displayed good interobserver reproducibility (1.5±1.4%, intraclass 
correlation coefficient = 0.923). After adjustment for magnetic field strength on 
multivariable analysis, higher native T1 values were associated with female 
sex, presence of coronary artery disease, reduced left ventricular ejection 
fraction, higher peak aortic valve velocity and presence of LGE (Tables 5.4 
and 5.5).  
 
The mean ECV% was 27.8±3.7, with low interobserver variability for this 
measurement (4.4±3.4%, intraclass correlation coefficient = 0.961). To 
explore associations between ECV% and clinical variables further, the total 
cohort was divided into tertiles (tertile 1: <25.9%, tertile 2: 25.9-29.3%, tertile 
3: >29.3%; Figure 5.3 and Table 5.3). Across the tertiles, there was a 
progressive increase in patients with established coronary heart disease 
(P<0.05), and both Society of Thoracic Surgeons Predicted Risk of Mortality 
(STS-PROM) and EuroSCORE II risk scores (both P<0.001). More patients 
were classified as NYHA functional status III or IV (P<0.001), and both indexed 
left ventricular volumes and mass increased progressively (all P£0.001; Table 
5.3) as did the proportion of patients with LGE (P<0.001). In contrast, there 
was a fall in both left and right ventricular ejection fraction across the tertiles, 
albeit largely within the normal range (both P<0.001; Table 5.3). Although 
similar associations with ECV% were observed in the univariable analysis 
(Table 5.6), only lower left ventricular ejection fraction (P<0.001) and greater 
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left ventricular mass index (P=0.043) remained independently associated with 
ECV% on multivariable analysis.  
 
Median iECV was 22.5 [18.0 to 29.1] mL/m2. Analysis by iECV tertile (tertile 1, 
<19.3 mL/m2; tertile 2, 19.3-26.5 mL/m2; tertile 3, >26.5 mL/m2; Table 5.7) 
demonstrated a progressive increase in the proportion of males, subjects with 
known coronary heart disease and surgical risk scores (EuroSCORE II; 
P<0.01 for all). Similar to ECV%, imaging markers of left ventricular 
decompensation (LV mass, LV volumes, presence of LGE, reduction in 
ejection fraction) also progressed across the tertiles (Table 5.7). Associations 
with iECV on univariable analysis were similar to the tertiles analysis (Table 
5.8). On multivariable analysis, clinical measures independently associated 
with iECV were age, male sex, known coronary heart disease, presence of 





Figure 5.3: Progression of clinical and imaging variables across ECV% 
and iECV tertiles 
 
When comparing clinical and imaging variables across ECV% tertiles, there was a 
progressive increase in left ventricular mass (A), left ventricular end-diastolic volume 
(C) and proportion of patients with late gadolinium enhancement (E), with a reduction 
in left ventricular ejection fraction (G). A similar pattern was seen when comparing 
across iECV tertiles (B,D,F,H). 
EDVi; indexed end-diastolic volume, LGE; late gadolinium enhancement, LV; left 
ventricle, LVEF; left ventricular ejection fraction 
  
 199 
Table 5.4: Baseline characteristics and imaging results by native T1 
tertile  
 










Age, years 71±10 71±11 70±8 0.53 
Male sex, n (%) 78 (59) 74 (55) 88 (66) 0.18 
Body mass index, kg/m2 29.1±5.0 28.5±5.7 26.2±4.0 <0.001 
Body surface area, m2 1.94±0.22 1.88±0.24 1.79±0.22 <0.001 
Past medical history     
Hypertension, n (%) 89 (67) 95 (72) 74 (56) 0.016 
Diabetes mellitus, n (%) 30 (23) 24 (18) 26 (20) 0.66 
Atrial fibrillation, n (%) 19 (14) 20 (15) 7 (5) 0.022 
Previous myocardial 
infarction, n (%) 11 (8) 23 (17) 4 (3) <0.001 
Known coronary artery 
disease*, n (%) 61 (46) 61 (46) 37 (28) 0.003 
Clinical factors     
NYHA functional class III or 
IV, n (%) 48 (36) 63 (49) 32 (40) 0.092 
Systolic blood pressure, 
mmHg 132±18 132±19 132±20 0.99 
Diastolic blood pressure, 
mmHg 73±12 73±13 73±13 0.83 




[0.93, 2.20] 0.009 




[0.87, 1.83] <0.001 
Echocardiographic 
measures     
Peak aortic-jet velocity, m/s 4.19±0.68 4.42±0.71 4.63±0.89 <0.001 
Peak aortic valve gradient, 
mmHg 72±22 80±25 89±34 <0.001 
Mean aortic valve gradient, 
mmHg 45±15 48±17 53±21 0.001 
Aortic valve area, cm2 0.75±0.27 0.72±0.23 0.76±0.27 0.31 
Indexed aortic valve area, 
cm2/m2 0.39±0.12 0.38±0.11 0.43±0.16 0.004 
Valvuloarterial impedance, 
mmHg/mL/m2 3.98±1.08 4.05±1.02 3.77±1.21 0.095 
Bicuspid aortic valve, n (%) 33 (25) 41 (32) 55 (50) <0.001 
Cardiac magnetic 
resonance     
Indexed left ventricular end-
diastolic volume, mL/m2 70±25 82±26 80±29 <0.001 
Indexed left ventricular end-
systolic volume, mL/m2 18 [11, 26] 30 [16, 52] 20 [12, 33] <0.001 
Indexed left ventricular stroke 
volume, mL/m2 46±11 46±10 53±15 <0.001 
Left ventricular ejection 
fraction, % 70±14 60±17 70±15 <0.001 
Left ventricular ejection 
fraction <50%, n (%) 13 (10) 34 (25) 13 (10) <0.001 
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Left ventricular mass index, 
g/m2 82±24 92±27 102±37 <0.001 
Maximum left ventricular wall 
thickness, mm 14±2 15±3 16±3 <0.001 
Mass/volume, g/mL 1.23±0.32 1.19±0.44 1.34±0.42 0.006 
Indexed right ventricular end-
diastolic volume 64±18 66±17 65±15 0.35 
Indexed right ventricular end-
systolic volume, mL/m2 22 [16, 27] 21 [15, 30] 22 [16, 28] 0.75 
Indexed right ventricular 
stroke volume, mL/m2 40±10 42±10 41±10 0.52 
Right ventricular ejection 
fraction, % 64±10 64±11 64±12 0.90 
Indexed left atrial volume, 
mL/m2 50±21 57±26 52±16 0.04 
Late gadolinium 
enhancement, n (%) 66 (50) 79 (59) 63 (48) 0.15 
LGE as a percentage of 
myocardial mass (full-width-






[2.21, 7.87] 0.22 
Extracellular volume fraction, 
% 26.3±3.5 28.9±3.8 28.3±3.3 <0.001 







[19.6, 33.3] <0.001 
Clinical events     
All-cause mortality, rate / 
1000 patient years  28.6 35.6 30.9 0.85 
 
LGE; late gadolinium enhancement, NYHA; New York Heart Association, STS-PROM; Society 
of Thoracic Surgeons Predicted Risk of Mortality 
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Table 5.5: Univariable and multivariable associations with native T1  
 
  Analysis of associations with native T1  





 Univariable analysis B SE Beta P value 
Technical 
factors 
Magnetic field strength (3 T v 
1.5 T) 163.0 5.308 0.839 <0.001 
 T1 mapping sequence 
(ShMOLLI v MOLLI) 98.83 14.17 0.330 <0.001 
 Scanner vendor (Phillips v 
Siemens) -48.48 16.77 -0.143 0.004 
      
Clinical 
factors 
Age -0.683 0.494 -0.069 0.167 
 Male sex 9.302 9.762 0.048 0.341 
 Hypertension -19.36 10.06 -0.096 0.055 
 Diabetes mellitus 4.802 12.00 0.020 0.689 
 Atrial fibrillation -36.34 14.90 -0.121 0.015 
 STS-PROM score -4.108 2.927 -0.074 0.161 
 EuroSCORE II -5.736 1.738 -0.171 0.001 
 Known coronary disease -26.75 9.691 -0.137 0.006 
 NYHA functional class III or IV 5.221 9.513 0.030 0.584 
 Peak aortic-jet velocity, m/s 24.89 6.023 0.204 <0.001 
 Indexed aortic valve area, 
cm2/m2 100.4 35.72 0.142 0.005 
 Left ventricular ejection 
fraction, % 0.019 0.301 0.003 0.950 
 Indexed left atrial volume, 
mL/m2 0.117 0.219 0.027 0.595 
 Right ventricular ejection 
fraction, % 0.061 0.438 0.007 0.888 
 Presence of LGE -1.911 9.585 -0.010 0.842 
 LGE as a percentage of 
myocardial mass (full-width-at-
half-maximum method), % 
2.340 1.600 0.104 0.145 
 Multivariable analysis     
Model 1  Magnetic field strength (3 T v 
1.5 T) 163.6 5.852 0.841 <0.001 
 T1 mapping sequence 
(ShMOLLI v MOLLI) 9.48 9.443 0.028 0.316 
 Scanner vendor (Phillips v 
Siemens) 2.33 8.882 0.008 0.793 
      
Model 2 Magnetic field strength (3 T v 
1.5 T) 169.5 5.518 0.871 <0.001 
 Age -0.205 0.276 -0.021 0.457 
 Male sex -14.23 5.322 -0.073 0.008 
 Atrial fibrillation 5.816 8.418 0.019 0.490 
 Known coronary disease 11.04 5.559 0.057 0.048 
 Peak aortic-jet velocity, m/s 8.55 3.360 0.070 0.011 
 Left ventricular ejection 
fraction, % -0.75 0.170 -0.126 <0.001 
 Presence of LGE 11.38 5.486 0.060 0.039 
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Table 5.6: Univariable and multivariable associations with ECV%  
 
LGE; late gadolinium enhancement, LV; left ventricle, NYHA; New York Heart Association, 
STS-PROM; Society of Thoracic Surgeons Predicted Risk of Mortality 
  
  Analysis of associations with ECV%  





 Univariable analysis B SE Beta P value 
Scanning 
factors 
Magnetic field strength (3 T v 1.5 
T) -0.213 0.376 -0.028 0.571 
 T1 mapping sequence (ShMOLLI 
v MOLLI) 0.511 0.579 0.044 0.379 
 Scanner vendor (Phillips v 
Siemens) -0.669 0.654 -0.051 0.307 
      
Clinical 
factors 
Age, per 10 years 0.430 0.190 1.120 0.025 
 Male sex -0.198 0.378 -0.026 0.601 
 Hypertension 0.222 0.389 0.029 0.570 
 Diabetes mellitus 1.039 0.460 0.113 0.024 
 Atrial fibrillation 1.537 0.575 0.133 0.008 
 STS-PROM score 0.622 0.111 0.283 <0.001 
 EuroSCORE II 0.427 0.066 0.323 <0.001 
 Known coronary disease 0.990 0.375 0.131 0.009 
 NYHA functional class III or IV 1.609 0.396 0.216 <0.001 
 Peak aortic-jet velocity, m/s -0.521 0.237 -0.110 0.029 
 Indexed aortic valve area, cm2/m2 0.921 1.403 0.033 0.512 
 Left ventricular ejection fraction, % -0.080 0.011 -0.345 <0.001 
 Left ventricular mass index, g/m2 0.030 0.006 0.247 <0.001 
 Indexed left atrial volume, mL/m2 0.040 0.008 0.238 <0.001 
 Right ventricular ejection fraction, 
% -0.037 0.017 -0.112 0.027 
 Presence of LGE 1.681 0.360 0.228 <0.001 
 LGE as a percentage of 
myocardial mass (full-width-at-
half-maximum method), % 
0.135 0.062 0.154 0.031 
      
 Multivariable analysis     
Model 1 Age, per 10 years 0.290 0.210 0.790 0.171 
 Male sex -0.746 0.415 -0.100 0.073 
 Diabetes mellitus 0.459 0.469 0.050 0.329 
 Atrial fibrillation 0.633 0.637 0.058 0.321 
 Known coronary disease 0.473 0.404 0.064 0.242 
 NYHA functional class III or IV 0.660 0.400 0.089 0.100 
 Peak aortic-jet velocity, m/s -0.243 0.268 -0.050 0.364 
 Left ventricular ejection fraction, % -0.064 0.015 -0.281 <0.001 
 Left ventricular mass index, g/m2 0.018 0.009 0.125 0.043 
 Indexed left atrial volume, mL/m2 0.014 0.011 0.082 0.199 
 Right ventricular ejection fraction, 
% 0.022 0.022 0.065 0.308 
 Presence of LGE 0.666 0.403 0.091 0.099 
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Table 5.7: Baseline characteristics and imaging results by iECV tertile  
 











Age, years 70±9 71±10 70±10 0.41 
Male sex, n (%) 57 (43) 85 (63) 98 (74) <0.001 
Body mass index, kg/m2 28.7±5.2 28.2±4.4 26.8±5.4 0.10 
Body surface area, m2 1.87±0.21 1.88±0.23 1.85±0.26 0.53 
Past medical history     
Hypertension, n (%) 89 (67) 88 (66) 81 (62) 0.65 
Diabetes mellitus, n (%) 22 (17) 29 (22) 29 (22) 0.46 
Atrial fibrillation, n (%) 14 (11) 15 (11) 17 (13) 0.84 
Previous myocardial infarction, n 
(%) 10 (8) 11 (8) 17 (13) 0.30 
Known coronary artery disease*, n 
(%) 45 (34) 49 (37) 65 (49) 0.028 
Clinical factors     
NYHA functional class III or IV, n 
(%) 49 (39) 43 (38) 51 (50) 0.18 
Systolic blood pressure, mmHg 135±17 134±19 128±20 0.006 
Diastolic blood pressure, mmHg 75±11 74±13 70±13 0.016 
STS-PROM score, % 1.42 [0.98, 2.28] 1.62 [1.07, 2.62] 
1.80 [0.98, 
2.76] 0.075 
EuroSCORE II, % 1.29 [0.87, 2.00] 1.64 [0.96, 2.79] 
1.88 [1.00, 
3.53] 0.001 
Echocardiographic measures     
Peak aortic-jet velocity, m/s 4.26±0.62 4.50±0.68 4.46±0.99 0.03 
Peak aortic valve gradient, mmHg 74±21 83±25 83±36 0.012 
Mean aortic valve gradient, mmHg 45±14 50±16 50±23 0.015 
Aortic valve area, cm2 0.77±0.24 0.73±0.23 0.74±0.29 0.47 
Indexed aortic valve area, cm2/m2 0.41±0.12 0.39±0.12 0.40±0.16 0.40 
Valvuloarterial impedance, 
mmHg/mL/m2 4.22±1.16 3.95±0.99 3.63±1.10 <0.001 
Bicuspid aortic valve, n (%) 40 (32) 42 (34) 47 (38) 0.55 
Cardiac magnetic resonance     
Indexed left ventricular end-
diastolic volume, mL/m2 61±14 73±19 97±32 <0.001 
Indexed left ventricular end-
systolic volume, mL/m2 17 [10, 23] 23 [15, 35] 39 [21, 66] <0.001 
Indexed left ventricular stroke 
volume, mL/m2 44±9 49±10 52±16 <0.001 
Left ventricular ejection fraction, % 72±11 69±13 58±19 <0.001 
Left ventricular ejection fraction 
<50%, n (%) 6 (5) 11 (8) 43 (32) <0.001 
Left ventricular mass index, g/m2 65±11 86±11 124±29 - 
Maximum left ventricular wall 
thickness, mm 13±2 15±2 17±3 <0.001 
Mass/volume, g/mL 1.11±0.28 1.25±0.33 1.40±0.51 <0.001 
Indexed right ventricular end-
diastolic volume 60±13 64±15 71±20 <0.001 
Indexed right ventricular end-
systolic volume, mL/m2 18 [14, 25] 21 [15, 28] 24 [18, 33] <0.001 
Indexed right ventricular stroke 
volume, mL/m2 39±9 42±10 43±12 0.009 
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Right ventricular ejection fraction, 
% 65±9 66±8 61±14 <0.001 
Indexed left atrial volume, mL/m2 45±17 53±25 64±27 <0.001 
Late gadolinium enhancement, n 
(%) 48 (36) 70 (53) 90 (68) <0.001 
LGE as a percentage of 
myocardial mass (full-width-at-
half-maximum method), % 
2.21 [1.19, 
3.95] 3.74 [2.21, 7.02] 
5.47 [2.23, 
8.12] 0.001 
Extracellular volume fraction, % 25.6±2.9 27.8±3.1 30.0±3.7 <0.001 
Indexed extracellular volume 
(iECV), mL/m2 
16.4 [14.0, 
18.0] 22.3 [20.6, 24.1] 
32.7 [28.9, 
39.5] - 
Clinical events     
All-cause mortality, rate / 1000 
patient years  22.9 36.0 36.0 0.34 
 
LGE; late gadolinium enhancement, NYHA; New York Heart Association, STS-PROM; Society 
of Thoracic Surgeons Predicted Risk of Mortality 
 
*known coronary artery disease defined as history of previous myocardial infarction, 
obstructive disease on angiography (stenosis >50% left main stem or >70% proximal 




Table 5.8: Univariable and multivariable associations with iECV  
 
LGE; late gadolinium enhancement, NYHA; New York Heart Association, STS-PROM; Society 
of Thoracic Surgeons Predicted Risk of Mortality 
 
  
  Analysis of associations with iECV  





 Univariable analysis B SE Beta P value 
Clinical factors Age, per 10 years -0.570 0.510 -0.550 0.269 
 Male sex 5.523 0.977 0.273 <0.001 
 Hypertension -0.746 1.043 -0.036 0.475 
 Diabetes mellitus 2.376 1.234 0.096 0.055 
 Atrial fibrillation 0.430 1.560 0.014 0.783 
 STS-PROM score 1.118 0.311 0.186 <0.001 
 EuroSCORE II 0.971 0.183 0.268 <0.001 
 Known coronary disease 2.287 1.010 0.113 0.024 
 NYHA functional class III or IV 2.085 0.945 0.119 0.028 
 Peak aortic-jet velocity, m/s 0.930 0.638 0.073 0.145 
 Indexed aortic valve area, 
cm2/m2 2.022 3.776 0.027 0.593 
 Left ventricular ejection 
fraction, % -0.222 0.029 -0.356 <0.001 
 Indexed left atrial volume, 
mL/m2 0.132 0.022 0.297 <0.001 
 Right ventricular ejection 
fraction, % -0.214 0.043 -0.242 <0.001 
 Presence of LGE 5.126 0.965 0.258 <0.001 
 LGE as a percentage of 
myocardial mass (full-width-at-
half-maximum method), % 
0.409 0.170 0.170 0.017 
      
 Multivariable analysis     
Model 1 Age, per 10 years -2.540 0.460 -3.050 <0.001 
 Male sex 4.620 0.826 0.270 <0.001 
 Diabetes mellitus 0.502 0.975 0.024 0.607 
 Known coronary disease 1.496 0.285 0.313 <0.001 
 NYHA functional class III or IV 1.132 0.839 0.066 0.179 
 Peak aortic-jet velocity, m/s 0.361 0.822 0.021 0.661 
 Left ventricular ejection 
fraction, % -0.160 0.030 -0.305 <0.001 
 Indexed left atrial volume, 
mL/m2 0.086 0.020 0.224 <0.001 
 Right ventricular ejection 
fraction, % 0.064 0.042 0.084 0.130 
 Presence of LGE 2.020 0.814 0.120 0.014 
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Clinical Outcomes 
Aortic valve intervention was performed in all patients 19 [4 to 61] days 
following magnetic resonance imaging. This was either isolated surgical aortic 
valve replacement (n=283, 71%), combined coronary artery bypass grafting 
with surgical aortic valve replacement (n=59, 15%), or transcatheter aortic 
valve insertion (n=58, 14%). Clinical outcome data were collected from 391 
patients after a median of 3.8 [1.7 to 4.5] years (9 patients were lost to follow-
up). Over this time, 40 deaths were observed (10%), of which five occurred 
within 30 days of valve intervention. No information on cause of death was 
available at the time of thesis writing for 19 individuals. Of the 21 deaths where 
the cause of death was established, 12 (57%) were classified as cardiac 
deaths.  Secondary analysis of associations with cardiovascular death was 
therefore not performed due to missing data, although these data should be 
available shortly.   
 
Similar rates of all-cause mortality were observed across native T1 tertiles 
(P=0.85, Table 5.9) and native T1 showed no association with all-cause 
mortality on univariable Cox regression analysis (P=0.74). Similarly, no 
association with the primary outcome measure was seen when native T1 
values were adjusted for differences in scanner magnetic field strength 
(P=0.88) or when additional correction for age, sex, peak aortic-jet velocity and 
presence of LGE was performed (P=0.84, model 2, Table 5.9). 
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All-cause mortality progressively increased across the ECV% tertiles, being 
nearly 4 times higher in the top versus the bottom tertile (tertile 1, 14.0; tertile 
2, 28.5; tertile 3, 53.7 deaths per 1000 patient-years log-rank test, P=0.003; 
Figure 5.4). Univariable Cox regression analysis showed a positive 
association between ECV% and mortality (hazard ratio 1.18, 95% confidence 
interval 1.09 to 1.28, P<0.0001); other univariate predictors included age, male 
sex, STS-PROM score, EuroSCORE II, atrial fibrillation, indexed left atrial 
volume, and established coronary heart disease (all P<0.05, Table 5.10). 
Whilst there was an apparent trend for LGE to be associated with mortality, 
this did not reach statistical significance (hazard ratio 1.60, 95% confidence 
interval 0.84 to 3.03, P=0.15). Inclusion of variables in the multivariable models 
was limited to prevent overfitting. In the first model, ECV% remained predictive 
of the primary outcome independent of age and sex. In the second model, it 
remained predictive independent of age, sex, LGE, peak velocity, and left 
ventricular ejection fraction (hazard ratio 1.13, 95% confidence interval 1.04 to 
1.24, P=0.006; Figure 5.4 and Table 5.11). In the third model, ECV% was 
predictive of outcome independent of age, sex and STS-PROM risk score 
(hazard ratio 1.12, 95% confidence interval 1.03 to 1.23, P=0.013). 
 
There was no difference between all-cause mortality rates when the cohort 
was analysed by iECV tertile (P=0.34, Figure 5.4). However, univariable Cox 
regression analysis demonstrated a positive association between iECV and 
all-cause mortality (hazard ratio 1.03, 95% confidence interval 1.01 to 1.06, 
P=0.018). Multivariable cox-regression analysis was then performed using the 
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same models as employed for ECV% (Table 5.11). iECV remained associated 
with the primary outcome when adjusted for age and sex (model 1: hazard 
ratio 1.03, 95% confidence interval 1.00 to 1.06, P=0.033) but was no longer 
an independent predictor when adjusted for age, sex, peak aortic valve 
velocity, impaired left ventricular ejection fraction and presence of LGE (model 
2, P=0.092, Figure 5.4) or in the final model adjusting for age, sex and STS-




Figure 5.4: Distribution of ECV fraction and iECV values and 
relationship with clinical events 
 
Extracellular volume fraction (ECV%) is normally distributed (A). When divided into 
tertiles, the all-cause mortality rate progressively increased across the tertiles (red 
squares). Indexed extracellular volume (iECV) presents with a positively skewed 
distribution (B). All-cause mortality similarly increases across tertiles of iECV (red 
squares, B). When the cohort was divided into tertiles of ECV% a progressive 
worsening of prognosis was seen across the tertiles (C). Greater overlap was seen 
between tertiles of iECV (D, P=0.34). ECV% remained an independent predictor of 
adverse outcome on multivariable analysis (E, hazard ratio: 1.13, P=0.006) however 





Table 5.9: Univariable and multivariable cox regression analysis of 
associations between native T1 value and all-cause mortality 
 
      95% CI for HR 
 Variable b SE P value HR Lower Upper 
Univariable Native T1 -0.0001 0.002 0.743 0.999 0.996 1.003 
        
Model 1 Native T1 0.000 0.003 0.876 1.000 0.994 1.006 
 Magnetic field 
strength (3 T 
v 1.5 T) 
-0.019 0.599 0.975 0.982 0.304 3.175 
        
Model 2 Native T1 0.001 0.003 0.837 1.001 0.995 1.006 
 Magnetic field 
strength (3 T 
v 1.5 T) 
-0.139 0.641 0.828 0.870 0.248 3.054 
 Age, yrs 0.088 0.022 <0.001 1.092 1.046 1.141 




-0.651 0.219 0.003 0.522 0.340 0.801 
 Presence of 
LGE 0.164 0.352 0.642 1.178 0.591 2.348 
 
CI; confidence interval, HR; hazard ratio, LGE; late gadolinium enhancement, SE; standard 
error  
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Table 5.10: Univariable cox regression analysis for all-cause mortality 
 
 Univariable analysis 
Variable Hazard ratio (95% CI) P value 
Age, years 1.08 (1.04 to 1.13) <0.001 
Male sex 2.73 (1.26 to 5.92) 0.011 
STS-PROM Score, % 1.35 (1.19 to 1.53) <0.001 
EuroSCORE II, % 1.14 (1.08 to 1.20) <0.001 
Known coronary disease 2.25 (1.20 to 4.22) 0.011 
NYHA functional class III or IV 2.46 (1.24 to 4.88) 0.01 
Atrial fibrillation 4.20 (2.13 to 8.28) <0.001 
Peak aortic-jet velocity, m/s 0.55 (0.37 to 0.82) 0.003 
Mean aortic valve gradient, 
mmHg 0.97 (0.95 to 0.99) 0.002 
Indexed aortic valve area, 
cm2/m2 1.67 (0.20 to 14.24) 0.64 
Bicuspid aortic valve 0.63 (0.31 to 1.30) 0.21 
LV ejection fraction < 50% 1.73 (0.85 to 3.56) 0.27 
Indexed LV end-diastolic 
volume, mL/m2 1.00 (1.00 to 1.01) 0.57 
Indexed LV stroke volume, 
mL/m2 0.98 (0.95 to 1.00) 0.078 
Indexed LV mass, g/m2 1.00 (1.00 to 1.01) 0.39 
Indexed left atrial volume, mL/m2 1.02 (1.00 to 1.03) 0.007 
Valvuloarterial impedance  1.04 (0.79 to 1.37) 0.78 
Late gadolinium enhancement 1.60 (0.84 to 3.03) 0.15 
Right ventricular ejection 
fraction, % 0.98 (0.95 to 1.00) 0.052 
Native T1 (per 10 ms change) 0.99 (0.96 to 1.03) 0.74 
ECV%, % 1.18 (1.09 to 1.28) <0.001 
iECV, mL/m2 1.03 (1.01 to 1.06) 0.018 
 
CI; confidence interval, ECV; extracellular volume, iECV; indexed extracellular volume, LV; 
left ventricular, NYHA; New York Heart Association, STS-PROM; Society of Thoracic 




Table 5.11: Multivariable cox regression analysis of association between ECV% and iECV and predictors of all-cause 
mortality 
 
 Extracellular volume fraction (ECV%) Indexed extracellular volume (iECV) 
      95% CI for HR     95% CI for HR 
 Variable b SE P value HR Lower Upper b SE Sig. HR Lower Upper 
Univariable ECV% 0.168 0.042 <0.001 1.183 1.091 1.284 - - - - - - 
 iECV, mL/m2 - - - - - - 0.029 0.013 0.021 1.030 1.004 1.056 
              
Model 1 ECV% 0.149 0.041 <0.001 1.161 1.072 1.257 - - - - - - 
 iECV, mL/m2 - - - - - - 0.029 0.014 0.038 1.029 1.002 1.058 
 Age, yrs 0.074 0.020 <0.001 1.077 1.036 1.120 0.089 0.021 <0.001 1.093 1.049 1.138 
 Male sex 1.203 0.399 0.003 3.331 1.524 7.283 1.002 0.405 0.013 2.721 1.231 6.029 
              
Model 2 ECV% 0.123 0.045 0.006 1.131 1.035 1.236 - - - - - - 
 iECV, mL/m2 - - - - - - 0.027 0.017 0.103 1.028 0.995 1.062 
 Age, yrs 0.076 0.022 <0.001 1.079 1.034 1.126 0.089 0.021 <0.001 1.093 1.049 1.140 
 Male sex 1.157 0.411 0.005 3.182 1.422 7.120 1.014 0.414 0.014 2.755 1.223 6.205 
 Peak aortic-jet 
velocity, m/s -0.492 0.227 0.030 0.611 0.392 0.954 -0.629 0.224 0.005 0.533 0.343 0.827 
 Presence of LGE -0.035 0.369 0.925 0.966 0.468 1.992 -0.009 0.369 0.981 .991 0.481 2.044 
 LVEF <50% 0.054 0.430 0.901 1.055 0.455 2.449 0.051 0.465 0.912 1.053 0.423 2.621 
              
Model 3 ECV% 0.114 0.046 0.013 1.120 1.025 1.225 - - - - - - 
 iECV, mL/m2 - - - - - - 0.015 0.016 0.354 1.015 0.984 1.047 
 Age, yrs 0.063 0.023 0.007 1.065 1.018 1.115 0.065 0.024 0.007 1.067 1.018 1.119 
 Male sex 1.425 0.431 0.001 4.157 1.786 9.677 1.334 0.447 0.003 3.797 1.581 9.119 
 STS-PROM 
score, % .141 0.097 0.149 1.151 0.951 1.393 0.205 0.097 0.035 1.227 1.015 1.484 
CI; confidence interval, SE; standard error, HR; hazard ratio, LVEF; left ventricular ejection fraction, LGE; late gadolinium enhancement; STS-PROM; 










We present the largest T1 mapping study in aortic stenosis and the first to 
adopt a pragmatic multicentre protocol using a range of different magnetic 
resonance imaging scanners, pulse sequences and magnetic field strengths. 
We have demonstrated the feasibility of this generalisable approach and that, 
in this setting, ECV-based T1 mapping measures are robust across centres, 
scanner manufacturers and field strengths. Moreover, we have shown that 
both ECV% and iECV demonstrate clear associations with multiple different 
clinical and imaging measures of left ventricular decompensation, and that 
ECV% in particular provides powerful and independent long-term prognostic 
information. ECV-based T1 mapping indices hold major promise as fully 
quantitative markers of myocardial fibrosis and left ventricular 
decompensation in aortic stenosis.  
 
Native T1 has some considerable advantages as a marker of diffuse 
myocardial fibrosis. In particular, it requires only a single measurement and 
avoids the need for gadolinium-based contrast medium administration. 
However, in this pragmatic multicentre setting, native T1 was hampered by the 
considerable variation in values at different field strengths and was not of 
prognostic value. Recent studies have demonstrated that standardisation of 
native T1 values acquired in different centres at different field strengths can 
be achieved with phantom testing (153). This was not performed in our study 







The ECV-based techniques explored in our study offer important advantages 
over native T1 mapping. First, gadolinium chelates do not cross cell 
membranes, and therefore distribute throughout the extracellular space 
following intravenous administration. Whereas native T1 combines signal from 
both intra and extracellular compartments, the potent T1-shortening effect of 
gadolinium allows the myocardial extracellular space to be specifically 
interrogated (85). Second, the calculation of ECV% corrects myocardial T1 for 
values in the blood pool on the same scan thereby potentially correcting for 
many between scanner differences (84,151) and enabling comparison 
between ECV% values across centres. Accordingly, we observed no 
difference in ECV% values between patients imaged on Siemens or Phillips 
platforms, at 1.5 or 3 T, or using different pulse sequences (shortened versus 
standard Modified Look-Locker Inversion-recovery).  
 
The two ECV-based measures examined in this study provide complementary 
information regarding diffuse myocardial fibrosis in the left ventricle. The 
ECV% provides an assessment of relative diffuse fibrosis burden and has 
been extensively validated against histological fibrosis (84-86,147). Our 
experience to date suggests that whilst ECV% offers an accurate point 
assessment of diffuse fibrosis in aortic stenosis, serial ECV% measurements 
are less sensitive in detecting alterations in fibrosis content over short-term 
follow-up due to balanced increases in myocyte mass and extracellular 






measure of absolute fibrosis burden, indexed to body surface area (7) that can 
better track changes in diffuse fibrosis over time and in response to 
intervention such as valve replacement (146). In our cohort, both greater 
ECV% and iECV were associated with multiple features of a decompensating 
ventricle; higher left ventricular mass, volumes, left atrial volumes, atrial 
fibrillation, surgical risk scores, presence and amount of LGE and worsening 
left ventricular ejection fraction. As such both measures hold great promise as 
fully quantitative markers of left ventricular decompensation in aortic stenosis. 
 
Prognostic data on T1 mapping in aortic stenosis has been limited to date, with 
preliminary data only available from small single centre studies.(7,83) For the 
first time, we have shown a strong association between ECV% and all-cause 
mortality in patients with aortic stenosis on both univariable and multivariable 
models. Indeed, after correction for a variety of other well-established 
prognostic markers, a 14% increase in risk of all-cause mortality was seen for 
every 1% increase in ECV%. iECV performed less well in the multivariable 
models compared with ECV%, predicting adverse outcome independent of 
age and sex but not when adjusted for other imaging findings. This is an 
interesting observation. iECV relates not only to the percentage fibrosis but 
also the volume (and therefore mass) of the left ventricle. The more powerful 
association of outcomes with ECV% than iECV suggests that fibrosis is more 







One unexpected finding was the lack of an association between late 
gadolinium enhancement and the primary outcome in this cohort. A positive 
association between LGE and all-cause mortality has been repeatedly 
demonstrated in multiple observational studies (7,19,46,49) including the 
recent large AS700 multicentre study (69). The hazard ratio associated with 
the presence of LGE in our study was 1.60 (95% confidence interval 0.84 to 
3.03), which is in fact similar to that previously reported in AS700 (e.g. AS700 
(HR 2.21 (95% CI 1.34 to 3.36), P=0.002 (69)) although this particular study 
resulted in twice the number of deaths. This apparent discrepancy is therefore 
most likely to reflect insufficient statistical power, although it is of interest that 
ECV% was able to demonstrate a clear independent association in the same 
data set. Further data comparing the prognostic value of LGE and ECV% is 
warranted in aortic stenosis and indeed other cardiovascular conditions.   
 
Limitations 
We observed no prognostic utility of native T1 in this cohort. Whilst we 
performed a simple statistical adjustment to account for differences in 
magnetic field strength, it is possible that more complex statistical modelling 
may yet alter this finding. Whilst we demonstrated no effect of T1 mapping 
pulse sequence on ECV%, this result cannot be extrapolated to saturation 
recovery-based T1 mapping techniques, which were not examined and may 
produce a lower ECV% value compared to inversion recovery sequences 
(154). In addition, analysis of associations with cardiovascular mortality was 








Extracellular volume-based T1 mapping measures in aortic stenosis are 
comparable across different magnetic resonance imaging scanners, pulse 
sequences and magnetic field strengths, and associated with multiple 
measures of left ventricular decompensation. ECV% is a strong independent 
predictor of long-term adverse events in patients scheduled for aortic valve 
replacement, with further work now required to determine how these measures 








Chapter 6: Combined Magnetic Resonance / 











Hybrid magnetic resonance / positron emission tomography (MR/PET) offers 
combined functional metabolic imaging with advanced tissue characterisation. 
This technique has not yet been investigated in aortic stenosis (AS). In 
addition, the radiotracer 18F sodium fluoride (18F-NaF) may be able to detect 
co-existent cardiac transthyretin (TTR) amyloidosis.   
 
Methods 
Patients with severe AS awaiting aortic valve replacement (AVR) and age and 
sex matched healthy volunteers underwent hybrid MR/PET imaging using 18F-
NaF. Multiparametric MR examination included late gadolinium enhancement 
and T1 mapping sequences. Magnetic resonance attenuation correction 
(MRAC) maps were acquired using both standard Dixon and free breathing 
radial gradient echo (GRE) sequences and used to reconstruct the list-mode 
PET data, which were then fused with a novel non-contrast image navigator 
(iNAV) based coronary magnetic resonance angiography (CMRA) sequence 
with inline motion correction (MC). Aortic valve and septal myocardial 
radiotracer uptake were analysed using standardised uptake values (SUV) 
and target-to-background ratios (TBR). Septal myocardial biopsy was 










Sixteen patients with severe AS were recruited (80±5 years, 63% male) along 
with six healthy volunteers (78±5 years, 66% male). Overall the scan was well 
tolerated, with 95% of participants completing the full imaging protocol. MRAC 
using radial GRE sequence was superior to the Dixon method with significant 
reduction in bright artefact. Analysis of valvular and myocardial 18F-NaF 
uptake was possible in all patients, with significantly greater radiotracer activity 
in the aortic valve in AS patients compared with controls (SUVmax: 2.57±0.60 
versus 1.32±0.18, P<0.0001). No increased septal myocardial 18F-NaF uptake 
or MR evidence of cardiac amyloidosis was seen in any patient, with no 
evidence of TTR deposition on any myocardial biopsy specimen (n=7). MR 
image quality allowed for detailed assessment of the aortic valve and annulus 
in 82% of participants. The iNAV MC CMRA sequence provided good views 
of the proximal coronary arteries in most participants (64%) and an excellent 
anatomical reference for fusion with PET data, with minor adjustments 
required to coregistration in only three (14%) participants.   
 
Conclusion 
MR/PET is feasible and well-tolerated in AS populations and can provide a 
comprehensive “one stop” assessment of valve, annulus, myocardium and 
coronary arteries. Future work should concentrate on improved motion 
correction of both PET and MR datasets. Further studies are required to 










Aortic stenosis (AS) is a major public health burden with an increasing 
prevalence linked to the aging population. Current management involves 
watchful waiting for patient-reported symptoms or the detection of a reduction 
in left ventricular ejection fraction (LVEF) which is a late and often irreversible 
finding (9). There is therefore considerable interest in novel methods of 
assessment of both the LV myocardium and aortic valve that could more 
accurately stage disease progression, plan interventional valve strategies and 
be used to monitor response to novel therapies.  
 
Positron emission tomography (PET) offers functional metabolic imaging 
allowing the activity of specific disease processes to be assessed in-vivo. 
Radiolabelled 18F-sodium fluoride (18F-NaF) binds preferentially to newly 
developing regions of microcalcification (92) and has therefore been used as 
a marker of calcification activity in the aortic valve using PET/CT imaging (4). 
Greater aortic valve tracer uptake is seen in more advanced AS (6) and 
appears to predict both disease progression and future clinical events (93). In 
addition, recent work suggests that 18F-NaF PET may be able to detect cardiac 
transthyretin (TTR) amyloidosis (112), which is observed in up to 16% of 
patients being considered for transcatheter aortic valve implantation (TAVI) 







Cardiac magnetic resonance imaging (MRI) has to date been used primarily 
in a research capacity in aortic stenosis patients. It not only provides more 
accurate estimates of LV volume, mass and ejection fraction (155) but also 
offers non-invasive tissue characterisation, being able to detect both focal 
replacement and diffuse interstitial myocardial fibrosis using late gadolinium 
enhancement (LGE) and T1 mapping techniques respectively. Mid-wall late 
enhancement is a common finding in advanced aortic stenosis (29-62% 
depending on the population studied) and is well established as a strong 
independent predictor of adverse clinical outcomes (7,19,46,49,69). 
Importantly mid-wall fibrosis appears to accumulate rapidly prior to valve 
replacement in some individuals and is irreversible following valve intervention 
(144,146). T1 mapping methods still require further investigation and 
optimisation however both native T1 (83) and extracellular volume (ECV)-
based measures (7) have shown a close association with histological fibrosis 
assessments and other markers of LV decompensation in patients with aortic 
stenosis. Importantly, both of these techniques may be able to identify early 
evidence of LV decompensation and therefore help optimise the timing of 
valve intervention. 
 
Hybrid MR/PET technology is now available potentially combining the 
strengths of these two imaging modalities. Moreover MR/PET holds important 
advantages over PET/CT including reduced radiation exposure, advanced 
myocardial tissue characterisation and improved co-registration and motion 






modality that can assess multiple aspects of the disease process in both the 
valve and myocardium in a single scan is potentially attractive. To our 
knowledge, only a single case using MR/PET in aortic stenosis has been 
published to date (156). We here report our early experience with combined 
MR/PET in the assessment of patients with severe AS, providing 
comprehensive single stop imaging of the valve and myocardium as well as 











Patients with severe aortic stenosis referred for valve intervention were 
recruited from cardiology and cardiothoracic clinics at a single centre between 
September 2017 and August 2018. Healthy volunteers with no history or 
symptomatology to suggest current cardiovascular disease were also 
recruited. The study was approved by South East Scotland Research Ethics 
Committee 01 (17/SS/0066) and was conducted in accordance with the 
Declaration of Helsinki. All participants provided written consent prior to 
participation. Patients underwent comprehensive clinical assessment 
including 12-lead electrocardiogram and blood sampling for haematocrit and 
renal function. Participants with severe aortic stenosis underwent clinical 
transthoracic echocardiography at an accredited department with 
comprehensive assessment of aortic valve haemodynamics. 
 
MR/PET 
All participants underwent simultaneous 18F-NaF PET and MR imaging using 
a hybrid MR/PET system (Biograph mMR, Siemens, Erlangen, Germany). In 
the aortic stenosis group this occurred within 4 weeks prior to a planned date 
of valve intervention. PET data was acquired for 50 min in list-mode, starting 
60 min after intravenous injection of 250 MBq of 18F-NaF. Both 3D Dixon VIBE 
(124) and free-breathing radial gradient echo (GRE, Siemens work-in-
progress #793F) sequences were acquired for MR attenuation correction 






et al (98). protocol included standard long- and short-axis cine imaging. 
Coronary magnetic resonance angiography (CMRA) was performed using a 
non-contrast ECG-gated image-navigator (iNAV) based motion corrected 
(MC) proprietary sequence with 100% respiratory scan efficiency (iNAV-based 
CMRA with in-line 2D translational motion correction, Kings College London, 
UK (125)) to achieve a high-resolution isotropic 3D data volume 
encompassing proximal coronary arteries, aortic valve and left ventricular 
myocardium which could be fused with the PET dataset. T1 mapping was 
performed using MOLLI (native 5(3)-3, post contrast 4(1)-3(1)-2, MyoMaps 
product, Siemens) on a single 4-chamber slice both before and 15-20 minutes 
after 0.1 mmol/kg of intravenous gadobutrol contrast (Gadovist, Bayer Pharma 
AG, Germany). Late gadolinium enhancement (LGE) was performed 
approximately 10 minutes following contrast injection using phase-sensitive 
inversion recovery sequences (2D short-axis, 10 slices). The total MRI scan 
duration was approximately 60 minutes. 
   
MR post-processing and analysis 
Image analysis was performed by a single reporter (RE) using CVI42 (Circle 
Cardiovascular Imaging Inc., Calgary, Canada). Short-axis cine images were 
used to calculate ventricular volumes, mass and function as per SCMR 
guidelines (128). Longitudinal systolic function was assessed as previously 
described (146). The presence of mid-wall LGE was determined both 
qualitatively and quantitatively in a semi-automated manner using signal 






in a region of normal myocardium (130). Native and post-contrast T1 mapping 
analysis was performed using manually drawn regions of interest in the basal 
septum on the motion corrected scanner-generated T1 maps and used to 
calculate both extracellular volume fraction (ECV%) and indexed extracellular 
volume (iECV: ECV% x left ventricular end-diastolic myocardial volume 
normalised to body surface area). Whilst segments with mid-wall late 
enhancement were included in the overall T1 calculation, segments with 
subendocardial infarct pattern LGE were excluded (132). Aortic valve annulus 
and coronary height measurements were performed using OsiriX software 
(Pixemo, Bernex, Switzerland).  
 
PET post-processing and analysis 
Off-line PET reconstructions were carried out using e7tools (Siemens 
Healthcare). The full list mode acquisition was reconstructed using an Ordered 
Subsets Expectation Maximization (OSEM) algorithm with the following 
parameters: 256x256 field of view, 4 iterations, 21 subsets, 5mm Gaussian 
filter, zoom 1. No ECG gating was applied. PET data was first reconstructed 
applying the standard 3D Dixon VIBE MRAC method (4 tissue class 
segmentation; air, lung, soft tissue and fat). PET data was also reconstructed 
when applying a custom MRAC map derived from the free-breathing radial 
GRE sequence (2 tissue classes: background [air and lung] and soft tissue 
[soft tissue and fat] (98)). PET reconstructions were fused with the iNAV-based 
MC CMRA sequence (125). As the MR and PET data is acquired 






However, all images were reviewed for discrepancies and in cases where co-
registration was imperfect, small manual corrections were performed by 
aligning PET uptake in the ventricular cavities, aorta and aortic valve with 
these structures on the MR angiogram.  
 
PET image analysis was performed using FusionQuant software (Cedars-
Sinai Medical Center, Los Angeles, U.S.A). Radiotracer uptake was analysed 
using a standardised protocol (see appendix). In brief, regions of interest (ROI) 
were drawn on the co-registered image around the perimeter of the aortic 
valve on co-axial short-axis views. Standardised uptake values (SUV, mean 
and maximum) were then calculated for these ROIs and were corrected for 
blood pool activity (measured in the right atrium (134)) to generate tissue-to-
background ratios (TBR). Myocardial SUV values were also measured in the 
septal myocardium at mid cavity level.  
 
Myocardial biopsies and histological analysis 
All patients undergoing surgical aortic valve replacement consented to 
intraoperative septal myocardial biopsy which was performed under direct 
vision by the surgical team using a 14-gauge coaxial needle (BD Carefusion, 
Tru-cut needle) from the basal interventricular septum 2 cm below the left 
ventricular outflow tract (LVOT). Samples were then fixed in 10%-buffered 
formalin and embedded in paraffin. The presence of cardiac amyloidosis was 
assessed using Congo red staining and both bright field and cross-polarised 






birefringence under cross-polarised light, immunohistochemistry was to be 
performed using a TTR antibody. 
 
Statistical Analysis 
All statistical analyses were performed using GraphPad Prism Version 7.0 and 
SPSS Version 23. A two-sided P<0.05 was considered statistically significant. 
The distribution of all continuous variables was assessed using the Shapiro-
Wilk test, which were presented using mean ± standard deviation or median 
[interquartile range]. Comparisons between groups were performed using the 
two-sample t-test or Mann-Whitney test as appropriate. We presented all 
categorical variables as percentages and used the Fishers exact test or χ2 
test for comparison. The relationship between two continuous variables were 









In total, 16 patients with severe aortic stenosis (80±5 years, 63% male) and 6 
healthy volunteers (78±5 years, 66% male) were recruited to the study. 
Patients and healthy volunteers were well matched for age and sex with similar 
prevalence of non-cardiac comorbidities (Table 6.1). Recorded blood 
















Age, years 78±5 80±5 0.59 
Male gender, n (%) 4 (66) 10 (63) >0.99 
Hypertension, n (%) 2 (33) 10 (63) 0.35 
Hypercholesterolaemia, n (%) 3 (50) 7 (44) >0.99 
Diabetes mellitus, n (%) 1 (17) 3 (19) >0.99 
Cerebrovascular accident, n (%) 0 (0) 2 (13) >0.99 
Previous myocardial infarction, n 
(%) 
- 2 (13) - 
Percutaneous coronary 
intervention, n (%) 
- 2 (13) - 
Coronary artery bypass grafting, n 
(%) 
- 1 (6) - 
Known coronary artery disease*, n 
(%) 

















Body mass index, kg/m2 25.7±3.0 28.6±4.9 0.18 
Body surface area, m2 1.90±0.21 1.95±0.18 0.54 
Systolic blood pressure, mmHg 147±7 144±20 0.71 
Diastolic blood pressure, mmHg 77±6 74±8 0.35 
ECG 
Atrial fibrillation, n (%) 0 (0) 1 (6) - 
Heart rate, bpm 63±9 66±10 0.59 
QRS duration, ms 99±31 103±18 0.69 
ECG criteria for left ventricular 
hypertrophy, n (%) 
1 (17) 13 (81) 0.01 
ECG strain pattern, n (%) 0 (0) 9 (56) 0.046 
 
 
*known coronary artery disease defined as history of previous myocardial infarction, 
obstructive disease on angiography (stenosis >50% left main stem or >70% proximal 











All volunteers completed the study protocol uneventfully. None had symptoms 
suggestive of cardiac disease. One patient had an incidental finding of right 
bundle branch block and another thin patient had ECG criteria for left 
ventricular hypertrophy. Neither patient had a detectable cardiac structural 
abnormality on MRI.  
 
Aortic stenosis patients 
All patients had severe AS on echocardiography (peak aortic-jet velocity 
4.63±0.60 m/s, mean gradient 52±15 mmHg, aortic valve area 0.78±0.27 cm2). 
Most patients (n=14) had high-gradient severe AS, with two patients exhibiting 
low-gradient subtypes (Table 6.2). All valves were tricuspid in morphology 
when assessed using MRI, although this was indeterminate on 
echocardiography in 3 (19%) patients.  
 
All but one patient was symptomatic awaiting valve intervention at enrolment. 
One patient was asymptomatic but was due to undergo early surgery as part 
of the EVOLVED randomised controlled (NCT03094143). Most patients had 
ECG criteria for LVH and half had the LV strain pattern (Table 6.1). One AS 
patient (age 89, scheduled for TAVI) requested early termination of the scan 
due to general discomfort just prior to gadolinium contrast administration. In 
this case, all acquired MRI data (including approximately 30 minutes of PET 
acquisition) were included in the analysis. All other participants completed the 






Table 6.2: Echocardiographic characteristics of the aortic stenosis 
group 
 
 Severe aortic stenosis 
N=16 
Peak aortic-jet velocity, m/s 4.63±0.60 
Mean aortic valve gradient, mmHg 53±15 
Aortic valve area, cm2 0.80±0.25 
Indexed aortic valve area, cm2/m2 0.40±0.10 
Left ventricular outflow tract area, cm2 3.32±0.47 
Left ventricular outflow tract area (planimetered 
on CMRA), cm2 
4.57±0.78 
Aortic valve area (continuity equation using 
planimetered MRI LVOT area), cm2 
1.01±0.30 
Indexed aortic valve area (continuity equation 
using planimetered MRI LVOT area), cm2/m2 
0.52±0.16 
Aortic regurgitation, n (%) 
• None 
• Trivial or mild 





Indexed stroke volume (SVi), mL/m2 44±12 
Low flow state (SVi £35mL/m2), n (%) 4 (25) 
Left ventricular systolic function, n (%) 
• Normal 
• Mild impairment 
• Moderate impairment 






Aortic stenosis subtype, n (%)  
• High-gradient 14 
• Low-flow low-gradient impaired EF 1 
• Low-flow low-gradient preserved EF 1 
E/A ratio 1.03±0.66 
Mean e’, cm/s 6.3±1.6 
E/e’ ratio 14.8 [9.5, 18.9] 
Deceleration time, ms 251±80 
 
EF; ejection fraction, LVOT; left ventricular outflow tract, CMRA; coronary magnetic 







Technical aspects of MR/PET 
The average administered dose of 18F-NaF was 239±12 MBq. Upon review of 
the fused PET reconstructions with the iNAV-based MC CMRA sequence, 
minor manual adjustments to registration were only required in 3 patients. 
Significant artefacts affecting image interpretation were present in all study 
participants when the images were reconstructed using the standard Dixon 
MRAC. This consisted of increased tracer activity around the heart-lung and 
liver-lung borders and also in the bronchial tree (due to mis-segmentation of 
bronchi as soft tissue). In two participants, there was reduced activity in both 
lung bases. Artefact was successfully eliminated in all patient images when 
the PET data was reconstructed using the free-breathing radial GRE MRAC 
rather than the 3D Dixon VIBE MRAC (Figure 6.1). Subsequent quantification 
of PET uptake was therefore performed on the free-breathing radial GRE PET 
reconstruction. Detailed analysis of PET uptake in the valve, and myocardium 
was possible in all patients. Analysis of coronary PET uptake was possible in 








Figure 6.1: Magnetic resonance attenuation correction using free-
breathing radial gradient echo reconstruction reduces artefact. 
 
Positron emission tomography (PET) reconstructions in the coronal plane 
fused with the non-contrast angiogram sequence are shown in three patients 
(A, C and D). The left-hand column applied the MR attenuation correction 
(MRAC) map derived from the standard 3D Dixon VIBE MRAC and the right 
column applied the MRAC map from the radial gradient echo (GRE) 
acquisition. Examples of the MRAC maps for each sequence are shown (B). 
The radial GRE improves the segmentation of tissues along the heart-lung 
borders and bronchial tree (blue arrows) compared with the Dixon attenuation 
correction map. Bright artefacts are seen around the heart-lung and liver-lung 
borders (red arrows) as well as the main bronchi (white arrows) in the Dixon 
reconstruction but these artefacts are eliminated using the radial GRE map to 













Table 6.3: Quality of hybrid magnetic resonance imaging / positron 
emission tomography assessments 
 
Number of participants with diagnostic 








Valve morphology  6 (100) 16 (100) 
Annulus measurements 6 (100) 12 (75) 
18F-NaF uptake 6 (100) 16 (100) 
Myocardium 
LV volumes, mass and ejection fraction 6 (100) 16 (100) 
Late gadolinium enhancement 6 (100) 16 (100) 
T1 mapping 6 (100) 16 (100) 
18F-NaF uptake 6 (100) 16 (100) 
Coronary arteries 
Proximal arteries visualised 5 (83) 9 (56) 
Mid arteries visualised 5 (83) 4 (25) 
Distal arteries visualised 5 (83) 1 (6) 
Coronary ostia height 6 (100) 12 (75) 








Aortic valve measurements 
High intensity 18F-fluoride was observed in the aortic valves of all the aortic 
stenosis patients. AS patients had greater 18F-fluoride uptake in the aortic 
valve compared with controls whether defined using SUVmax (2.57±0.60 
versus 1.32±0.18, P<0.0001) or TBRmax (2.57±0.62 versus 1.66±0.23, 
P<0.0001, Figure 6.2 and Table 6.4). No correlation was observed between 
SUVmax and aortic valve peak jet velocity (r=0.05, P=0.86).  
 
CMRA image quality was considered sufficient to measure aortic annulus / 
LVOT dimensions in 18 (82%) participants. Two patients underwent TAVI and 
had a pre-procedure cardiac CT available for comparison. Measurements 
were similar on CMRA and CT in these patients for aortic annulus area (mean 
absolute and percentage difference between measurements = 0.2 cm2, 4%), 
annular perimeter (1.2 mm, 1%)), circular diameter (0.5 mm, 2%), maximum 
annular diameter (0.7 mm, 3%) and minimum annular diameter (1.75 mm, 
8%). In the AS cohort, LVOT measurements were greater when using 
planimetered values from the CMRA compared with standard 
echocardiographic assessment (CMRA LVOT area: 4.57±0.78 cm2, echo 
LVOT area: 3.32±0.47 cm2, P<0.0001, Table 6.2). This resulted in increased 
AVA valve using the continuity equation when the CMRA LVOT area was 









Figure 6.2: 18F-sodium fluoride uptake in the aortic valve in a patient 
with severe aortic stenosis 
 
Aortic valve leaflet thickening is clearly visualised on the non-contrast iNAV-
based motion-corrected coronary magnetic resonance angiogram sequence 
(orthogonal views a, b and c). 18F-sodium fluoride (18F-NaF) activity localises 
to all three valve leaflets (orthogonal view d, e and f). Aortic valve SUVmax was 
2.01 and TBRmax was 3.35. Overall, both aortic valve SUVmax (g) and TBRmax 
(h) were greater in aortic stenosis patients compared with healthy volunteers 
(both P<0.003). 














Table 6.4: Hybrid magnetic resonance imaging / positron emission 










Indexed left ventricular-end diastolic 
volume, mL/m2 72±20 74±26 0.88 
Indexed left ventricular-end systolic 
volume, mL/m2 20 [13, 21] 17 [10, 31] 0.76 
Indexed stroke volume, mL/m2 55±17 51±12 0.56 
Ejection fraction, % 75±6 73±16 0.72 
Ejection fraction < 50%, n (%) 0(0) 1 (6) - 
Left ventricular mass index, g/m2 64±8 105±27 0.002 
Maximum left ventricular wall 
thickness, mm 11±1 17±3 0.0007 
Mass/volume, g/mL 0.9 [0.7, 1.1] 1.3 [1.1, 1.6] 0.008 
Myocardial contraction fraction, % 84±17 52±20 0.002 
Longitudinal systolic function, mm 15.3±3.3 8.3±3.6 0.0005 
Indexed left atrial volume, mL/m2 38±3 51±16 0.13 
Infarct late gadolinium enhancement, n 
(%) 0 (0) 1 (6) - 
Mid-wall late gadolinium 
enhancement, n (%) 0 (0) 8 (50) - 
Mid-wall late gadolinium enhancement 
mass (3 standard deviation method), g - 8.2±5.2 - 
Mid-wall late gadolinium enhancement 
mass (5 standard deviation method), g - 1.5±1.3 - 
T1 mapping 
Native T1 (mid-inferoseptum), ms 1241±39 1285±49 0.06 
Post-contrast T1 (mid-inferoseptum), 
ms 656±45 654±30 0.92 
Extracellular volume fraction, % 27.6±2.4 27.5±2.0 0.94 
Indexed extracellular volume, mL/m2  17±2 28±8 0.003 
Standardised uptake values (SUV) 
Aortic valve SUVmax 1.32+0.18 2.57±0.60 <0.0001 
Aortic valve SUVmean 1.07±0.16 1.81±0.35 <0.0001 
Septal myocardium SUVmax 0.86±0.13 0.92±0.23 0.53 
Septal myocardium SUVmean 0.74±0.09 0.78±0.21 0.61 
Right atrium SUVmean 0.81±0.18 1.05±0.32 0.10 
Tissue-to-Background Ratio (TBR)* 
Aortic valve TBRmax  1.66±0.23 2.57±0.62 0.003 
Aortic valve TBRmean 1.34±0.14 1.80±0.34 0.005 
Septal myocardium TBRmax  1.08±0.19 0.90±0.13 0.014 
Septal myocardium TBRmean 0.93±0.15 0.76±0.12 0.01 
 







Myocardial assessment  
Assessment of left ventricular volumes and ejection fraction was possible in 
all participants and values were similar between AS patients and controls 
(Table 6.3). Most AS patients (n=15) had preserved LVEF as measured on 
MRI with one patient found to have an ejection fraction less than 50%. This 
patient (81-year-old, male) was assessed as moderate LV dysfunction on 
echocardiography but had a severely reduced LVEF (30%) on MRI in the 
context of previous myocardial infarction. One further patient (89-year-old, 
female, atrial fibrillation, TAVI referral) had suboptimal image quality on 
transthoracic echocardiography with moderate LV systolic impairment by 
visual assessment but an MRI LVEF measured above 50%.  
 
Indexed left ventricular mass was greater in AS patients compared to controls 
(105±27 g/m2 versus 64±8 g/m2, P=0.02) as was maximum left ventricular wall 
thickness (17±3 mm versus 11±1 mm, P=0.0007, Table 6.4). Myocardial 
contraction fraction was significantly reduced in AS patients compared with 
controls (52±20% versus 84±17%, P=0.002) as was longitudinal systolic 
function (8.3±3.6 mm versus 15.3±3.3 mm, P=0.0005). Although the mean 
indexed LV stroke volume was similar between modality (MR: 51±12 mL/m2, 
echo: 43±12 mL/m2, P=0.08), echocardiography consistently underestimated 
indexed stroke volume compared with MR (Bland-Altman analysis; bias -7.4 







Mid-wall late gadolinium enhancement was seen in eight AS patients (50%) 
and none of the healthy volunteers (Figure 6.4). One AS patient had 
subendocardial late enhancement consistent with previous anteroapical 
myocardial infarction. No patient had echocardiographic or MRI features 
suggestive of a diagnosis of cardiac amyloidosis. Of interest, there was a trend 
towards greater septal native T1 between AS patients compared with controls 
(1285±49 ms versus 1241±39 ms) but this did not reach statistical significance 
(P=0.06, Table 6.4). ECV% was similar between groups (patients with AS: 
27.5±2.0%, control subjects: 27.6±2.4%, P=0.94) but iECV was greater in 
patients with AS (28±8 mL/m2 versus 17±2 mL/m2, P=0.003).  
 
No 18F-NaF uptake in the myocardium was observed in any patient on visual 
analysis (Figure 6.4). There was no difference in SUVmax of the septal 
myocardium between patients with AS and control subjects (P=0.53). Across 
all participants, 18F-NaF septal myocardial uptake did not correlate with native 
T1 (SUVmax: r=0.37, P=0.09) or ECV% (SUVmax: r=-0.28, P=0.22). 
 
All patients who underwent surgical aortic valve replacement consented to 
intraoperative myocardial biopsy (n=14) from the interventricular septum. At 
the time of writing, nine biopsy samples had been collected and analysed. 
Samples were not collected from patients who underwent TAVI (n=2) or 
surgical AVR via mini-sternotomy (n=1), and in one patient the sample was 
not sufficient for analysis. No complications from biopsy collection were 






Hospital, London, UK); Congo red staining was negative for the presence of 









Figure 6.3: Bland-Altman analysis of echocardiography and magnetic 










Figure 6.4: Multiparametric assessment of the left ventricular 
myocardium using hybrid magnetic resonance imaging / positron 
emission tomography 
 
Late gadolinium enhancement imaging (a and phase-swap, b) can detect focal 
replacement fibrosis (red arrow). Cine imaging (c) provides gold-standard 
assessment of LV volumes, mass, stroke volume and ejection fraction. Both 
native T1 mapping (d) and extracellular volume fraction (ECV%, combination 
of native and post-contrast (e) T1 mapping) can detect and quantify diffuse 
fibrosis and look for the presence of cardiac amyloidosis. The absolute fibrosis 
burden can be quantified with the indexed extracellular volume (iECV) by 
combining ECV% and left ventricular mass (c). Myocardial 18F-sodium fluoride 
activity can be assessed using a region of interest in the interventricular 














The coronary ostia height could be measured in 18 (81%) participants. There 
was reasonable agreement in measurements between MR/PET and CT in the 
two patients who underwent pre-operative CT TAVI (mean absolute and 
percentage difference in left coronary ostia height: 1.1 mm, 7%), right coronary 
ostia height: 1.6 mm, 8%).  
 
Excellent resolution of the proximal coronary arteries was possible with the 
iNAV-based MC CMRA sequence in 14 (64%) of participants. In 9 individuals, 
good image quality was also available of the mid-vessels, with the lumen of 
more distal vessels such as the posterior descending artery clearly seen in 
four participants (Table 6.3 and Figure 6.5). Detailed analysis of the CMRA for 
presence and degree of coronary stenosis was not performed, as the 
sequence was not optimised for this purpose in these scans. 
 
Coronary 18F-NaF uptake could be assessed in 21 individuals (95%), with 
uptake noted in 3 participants (all with aortic stenosis, Figure 6.5). In total, five 
high-uptake areas were identified (3 left anterior descending artery, 2 left 








Figure 6.5: Hybrid magnetic resonance imaging / positron emission 
tomography of the coronary arteries 
 
Excellent resolution of the proximal coronary arteries was possible with the 
iNAV-based motion-corrected coronary magnetic resonance angiogram 
sequence in most participants. The left anterior descending (LAD, white 
arrows), left circumflex (green arrows) and right coronary (blue arrow) arteries 
are clearly visible in one of the healthy volunteers (a-e). In a separate patient 
with aortic stenosis, a lesion is seen (red arrows) in the proximal LAD (f). There 
is co-localised 18F-sodium fluoride activity (g) was an SUVmax of 1.85. The 
corresponding invasive angiogram confirmed an obstructive proximal LAD 
stenosis in the same location (red arrows) 










This is the first description of cardiac MR/PET imaging in a cohort of patients 
with severe aortic stenosis with age and gender-matched healthy volunteers. 
We have demonstrated that MR/PET imaging is feasible and well tolerated in 
these cohorts, and offers a multiparametric assessment of the valve, 
myocardium and coronary arteries. In particular, we have shown that MRAC 
with a free-breathing radial GRE sequence is superior to the standard Dixon 
approach, and that novel non-contrast iNAV-based MC CMRA with 100% 
respiratory scan efficiency provides excellent visualisation of the valve, 
myocardium and proximal coronary arteries in the majority of imaged patients. 
 
Hybrid MR/PET platforms offer considerable advantages over PET/CT in that 
functional metabolic information can be acquired with considerable reduction 
in radiation exposure whilst simultaneously offering high resolution functional 
assessment of both the valve and myocardium with added myocardial tissue 
characterisation. Two specific technical issues related to MR/PET imaging that 
require further optimisation are attenuation correction and motion correction.  
 
Accurate quantification and localisation of PET activity requires application of 
attenuation correction maps (MRAC map) to account for the radiodensity of 
tissues that PET photons must traverse from their source at an annihilation 
event to the PET detector. In PET/CT, the CT source can be used to generate 






alternative approaches use MRI sequences to segment the acquired volume 
into different tissue types. A correction factor (or linear attenuation coefficient, 
LAC) unique to each tissue type is then applied to the PET data (124). The 
standard Dixon MRAC map provides poor resolution particularly along the 
heart-lung and liver-lung interfaces which are subject to respiratory motion and 
usually mis-segments the bronchi as soft tissue, leading to significant artefact 
due to inaccurate correction of the PET counts. MRAC using a novel free-
breathing radial GRE sequence has been shown to reduce these artefacts in 
a coronary disease population (98). We have here confirmed the superiority of 
this method of attenuation correction for cardiac purposes demonstrating that 
it eliminates these reported artefacts. 
 
Regional analysis of PET data in different structures within the heart requires 
fusion with a 3D anatomical MR dataset. In our study, this was provided by a 
novel non-contrast CMRA sequence. This ECG-gated and respiratory 
translational motion corrected sequence produces a high-resolution isotropic 
volume encompassing LV, aortic valve and proximal coronary arteries without 
the need for gadolinium contrast administration and in a predictable scan time. 
This meant that only a single bolus dose of gadolinium was required for late 
enhancement imaging, avoiding staggered contrast doses which might 
confound image interpretation. Whilst co-registration of PET and MRI datasets 
is generally good as they are acquired simultaneously, manual registration 
adjustment was sometimes required in this study and enabled by the 






CMRA approach has been recently proposed to correct for both PET and 
CMRA data leading to co-registered MRAC, PET and CMRA images. This 
approach has been demonstrated in a small cohort of patients with total 
coronary occlusion (157) and will be investigated in patients with severe aortic 
stenosis in future work.  
  
The valve 
Hybrid MR/PET imaging allowed detailed anatomical assessment of the aortic 
valve in most participants. As previously noted using PET/CT (6), intense 
aortic valve uptake was noted in all the aortic stenosis patients. Previous 
studies have established that this activity indicates increased calcification 
activity within the valve and serves as a method to predict future valve disease 
progression and when patients are likely to require valve replacement. Aortic 
annulus measurements could also be performed showing good agreement 
with CT in two cases where both modalities were available for comparison. 
Accurate annulus area measurements are of potential utility in valve sizing 
prior to TAVI, and also for more accurate estimation of the aortic valve area 
(AVA) using the continuity equation. Indeed, substantial underestimation of 
the annulus / LVOT area and therefore the AVA was observed with 
echocardiographic measurements compared with MR. Substituting MR 
measurements in deriving AVA has previously been shown to reduce the 
inconsistency in the relationship between mean gradient and AVA, and the 
number of patients with discordant haemodynamic assessments of disease 






LV volumes, including LV stroke volume (155). We showed a systematic 
underestimation and poor agreement between echocardiography and MR in 
LV stroke volume assessment, which not only influenced calculation of aortic 
valve area but also assessment of flow status. Using MR in the assessment of 
both AS severity and flow status may therefore prove useful to confirm AS 
severity and subtype (e.g. low-flow low-gradient) in borderline cases, 
particularly when considering high-risk intervention.  
 
The myocardium  
We have shown that comprehensive multiparametric assessment of the 
myocardium is feasible within a single scan. T1 mapping and LGE assessment 
can detect and quantify diffuse and replacement myocardial fibrosis 
respectively, both of which are associated with an adverse prognosis and have 
been proposed as early markers of LV decompensation (7,46,49,83). There is 
considerable interest in using these as objective markers of LV 
decompensation prior to the development of symptoms or impaired ejection 
fraction in order to optimise the timing of valve intervention. Whether a strategy 
of targeted early valve replacement in asymptomatic patients with preserved 
LVEF but evidence of mid-wall LGE on MR imaging can improve long-term 
clinical outcomes is being tested in the Early Valve Replacement guided by 
Biomarkers Of LV Decompensation in Asymptomatic Patients with Severe 







One further advantage of hybrid techniques is the identification and 
characterisation of co-existent pathology. Transthyretin (TTR) cardiac 
amyloidosis is an increasingly recognised condition in the elderly but given 
that the imaging features on transthoracic echocardiography are similar to 
those seen in advanced AS, a diagnosis of concomitant amyloidosis is often 
not considered. In fact, the prevalence of coexistent myocardial TTR amyloid 
deposition has been estimated at between 6 and 16% of severe AS 
populations (104,111) and up to 25% in the general population over 85 (100). 
Not only can MRI identify overt cardiac amyloidosis using LGE and T1 
mapping, but early studies show that the addition of 18F-NaF PET may be able 
to discriminate between TTR and AL subtypes without the need for further 
investigations (112). This is important as patients with co-existent TTR 
amyloidosis have a mortality rate approaching 50% regardless of 
interventional strategy (104,159) and this diagnostic information could be used 
to inform decision making about approach or even appropriateness of valve 
intervention.  
 
In spite of recruiting an elderly cohort (mean age 80 years), no patient in our 
study had typical MRI imaging features of cardiac amyloidosis. Septal 
myocardial SUVmax values in our cohort were consistently less than blood pool, 
as described in the control patients of the previous report by Trivieri et al (112). 
Importantly, cardiac amyloid deposition was excluded in all patients where 
myocardial biopsy samples were available for histological analysis. The 






population therefore remains unproven and requires a study with a larger 
sample size.   
 
Coronary imaging 
Coronary imaging using MRI has traditionally been challenging given the small 
size and complex motion of the coronary arteries. We have demonstrated that 
novel ECG-gated, free-breathing MR sequences with inline 2D translational 
respiratory motion correction can provide high quality imaging of the proximal 
coronary arteries in most cases, without the need for contrast administration 
and in a predictable scan time (no data rejection due to respiratory motion). 
Whilst detailed coronary analysis remains challenging scan quality was 
sufficient for localisation of coronary PET data to the coronary vasculature and 
also for accurate and detailed measurement of the height of the coronary 
arteries above the plane of the aortic valve: another key measurement used 
in the work up of patients being considered for TAVI. Further improvements in 
motion correction, including non-rigid respiratory motion compensation, have 
been shown to lead to better visualization of the coronaries (160) and will be 
investigated as future work. 
 
Where might this hybrid MR/PET technique find future clinical use in aortic 
stenosis? Undoubtedly for the foreseeable future MR/PET will remain a 
research tool but in time may become attractive as a “one-stop” assessment 
of valve, myocardium and coronary arteries prior to considering an 






CT can be replicated using MRI, which might be particularly useful in patients 
with renal impairment or proven contrast allergy where non-contrast MR 
angiography sequences could be used. Whilst not performed in this study MR 
also provides excellent assessment of the peripheral vasculature. MR 
assessment of LVOT area and stroke volume may be able to clarify AS 
severity in borderline case and to more accurately identify reductions in 
ejection fraction. Moreover, the ability of MR/PET to detect presence of mid-
wall LGE and co-existent cardiomyopathy such as TTR amyloidosis may play 
a future role in deciding on when best to replace the valve, although further 
work in this area is required.  
 
Further improvements to this technique are possible, particularly in the area of 
motion correction. MR allows for monitoring of both cardiac and respiratory 
motion which can be used to apply non-rigid motion correction to both the MR 
and PET data as shown in recent studies (125,157). This results in a reduced 
acquisition time, increased visible length and sharpness of coronary arteries 
and improved PET signal-to-noise ratio. In addition, ultrashort echo time MR 
imaging could potentially be used to detect vascular and valvular calcification 











Hybrid MR/PET imaging in aortic stenosis is feasible and well-tolerated, 
offering a multiparametric assessment of aortic valve, LV myocardium and 
coronary arteries. Compared with PET/CT, advantages include reduced 
radiation dose, simultaneous acquisition of PET and MR data, added 
myocardial tissue characterisation and potential avoidance of intravenous 
iodinated contrast. Further research is required to optimise motion correction 
techniques and assess the ability of 18F-NaF to detect co-existent TTR 




We would like to thank Siemens Healthcare for allowing us to use their Radial 
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SUMMARY OF FINDINGS  
Aortic stenosis is a condition of both valve and myocardium. Cardiac magnetic 
resonance assessment of the left ventricular myocardium can detect both 
diffuse and replacement myocardial fibrosis. In this thesis, I have applied a 
novel T1 mapping marker of diffuse fibrosis, the indexed extracellular volume 
(iECV) and shown that patients with aortic stenosis can be classified into three 
groups depending on the amount and type of myocardial fibrosis. In addition, 
this classification is able to detect early evidence of decompensation of the LV 
hypertrophic response. I have also characterised the progression and 
regression of cellular hypertrophy and different types of myocardial fibrosis 
over time using cardiac magnetic resonance. I then proceeded to further 
demonstrate the association of extracellular-volume based measures with 
various measures of LV decompensation and adverse clinical outcomes 
following aortic valve intervention in a large multicentre cohort. Finally, I 
explored the utility of novel hybrid positron emission tomography / magnetic 






Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis 
 
Aortic stenosis is now well-recognised as a disease both of the valve and the 
myocardium (6). Cardiac magnetic resonance (CMR) offers distinct and 
complementary advantages to echocardiographic assessment: namely gold 
standard assessments of ventricular volumes, mass and ejection fraction 
(161) but also tissue characterisation and the detection and quantification of 
myocardial fibrosis. Focal replacement fibrosis is detected using late 
gadolinium enhancement techniques and has been shown to be a powerful 
independent predictor of adverse prognosis in several cohorts (19,46,49,141). 
Newer T1 mapping methods can identify extracellular volume expansion and 
diffuse fibrosis (85) which appear to be an early, reversible form of fibrosis 
(137). The utility of T1 mapping in the assessment of patients with aortic 
stenosis requires further study. 
 
Using CMR assessment of myocardial fibrosis, I have shown that patients with 
aortic stenosis can be classified into three groups depending on the amount 
and type of fibrosis - normal ventricle, extracellular volume expansion (diffuse 
fibrosis) and mid-wall late gadolinium enhancement (replacement fibrosis). I 
found that a novel marker, the indexed extracellular volume (or iECV), an 
absolute marker of burden of diffuse fibrosis, was better able to differentiate 
patients according to AS severity and correlated well with collagen volume 
fraction on myocardial biopsy. Markers of both systolic and diastolic LV 
function, as well as cardiac biomarkers worsened across these three groups 






decompensation of the LV hypertrophic response. More importantly there was 
a stepwise worsening of both all-cause and aortic stenosis related mortality 
across the three groups. This is the first study showing the potential prognostic 






Progression and Regression of Hypertrophy and Fibrosis in Aortic 
Stenosis 
Although cardiovascular magnetic resonance can accurately assess both 
cellular hypertrophy and extracellular volume (a widely used surrogate 
measure of diffuse myocardial fibrosis), how these processes change over 
time both in the natural history of aortic stenosis and in response to relief of 
pressure overload following aortic valve intervention has not been described. 
In addition, although focal replacement fibrosis is thought to be irreversible 
following valve replacement (68), how this process evolves over time in the 
natural history of AS is unknown. 
 
In order to further investigate longitudinal changes in these processes, I have 
analysed a multicentre cohort of almost 100 patients who underwent serial 
echocardiography and CMR imaging at multiple time points. By examining the 
novel marker iECV, along with ECV% and LV mass I was able to provide a 
comprehensive assessment of both myocardial intra and extracellular 
compartments. Whilst some patients underwent valve replacement surgery 
during the interval between imaging timepoints, others did not, allowing me to 
study both the natural history of hypertrophy and fibrosis in AS and also how 
these processes remodel following valve intervention. In the natural history 
group, there was steady progression in both myocyte volume and diffuse 
fibrosis / extracellular volume over time, resulting in no change in the relative 






rapid accumulation over time with new areas visible in remote myocardial 
segments in several patients.  
 
Following valve replacement, there was regression of diffuse fibrosis but much 
faster fall in myocyte volume, leading to an initial increase in ECV%. I also 
confirmed findings in previous studies that replacement fibrosis (mid-wall LGE) 
is irreversible and although valve replacement appeared to arrest progression, 
no regression of replacement fibrosis was seen during the study follow-up. 
This provides insights into the rapid progression of replacement fibrosis in the 
natural history of AS, which appears to confer a worse prognosis the more 
fibrosis is present (46) and suggests that valve replacement limits further 
scarring from forming. Thus, a strategy of early valve replacement when 
replacement fibrosis is detected might lead to improved clinical outcomes 








Myocardial Extracellular Volume in Patients with Aortic Stenosis 
Undergoing Valve Intervention  
 
Further investigation of the utility of T1 mapping assessments of diffuse 
fibrosis in aortic stenosis requires larger multicentre studies for adequate 
statistical power and to demonstrate the feasibility of techniques over multiple 
vendor platforms and sequences.  
 
Gathering patient data internationally from 400 individuals enrolled in 
prospective observational cohort studies I analysed the largest cohort to date 
of severe aortic stenosis patients scheduled for valve replacement surgery 
who underwent T1 mapping CMR prior to their procedures. As expected, there 
was significant variation in native T1 values across different centres, mainly 
related to differing magnetic field strength. In contrast, I showed that 
extracellular volume-based measures did not significantly vary with the above 
technical factors.  
 
Native T1 was not clearly associated with measures of disease severity. In 
particular, native T1 did not predict clinical outcomes, even after adjusting for 
technical factors. However, both ECV% and the novel marker iECV were 
associated with several markers of LV decompensation and more importantly 
with patient outcomes. I observed a 14% increase in all-cause mortality for 
every 1% rise in ECV% independent of age, sex, peak velocity, presence of 






mortality independent of age and sex but not when other clinical factors were 
considered.   
 
In patients with severe aortic stenosis awaiting valve replacement, I have 
demonstrated that ECV-based T1 mapping techniques are robust across 
different scanner platforms and field strengths, correlate well with measures 






Feasibility and Utility of Hybrid Magnetic Resonance Imaging / Positron 
Emission Tomography in Aortic Stenosis 
 
Positron emission tomography (PET) offers functional metabolic imaging 
allowing the activity of specific disease processes to be measured in vivo. 
Previous work has demonstrated that 18F-sodium fluoride (18F-NaF) 
radiotracer binds to hydroxyapatite in newly developing areas of calcification 
in the aortic valve is activity appears to predict valve disease progression and 
future clinical events when combined with computed tomography (PET/CT) 
(6,93). Hybrid MR/PET technology offers significant advantages; reduced 
overall radiation dose and improved tissue characterisation, co-registration 
and motion correction.  
 
I investigated the novel use MR/PET in aortic stenosis in 16 patients scheduled 
for valve replacement procedures and 6 healthy volunteers. I showed that 
MR/PET is feasible and well-tolerated in this patient group and offered 
excellent image quality in the majority of patients. In particular, detailed 
assessments of the aortic valve, annulus, proximal coronary arteries and LV 
myocardium were possible. I also investigated the use of novel methods of 
attenuation correction and motion correction, which allow simultaneous 
assessment of calcification activity in the aortic valve along with CMR 








Investigating the clinical utility of CMR mid-wall fibrosis assessment  
There is now a significant body of observational evidence identifying mid-wall 
replacement myocardial fibrosis as a marker of early LV decompensation in 
aortic stenosis. Multiple single centre observational studies (19,46,49) as well 
as a large multicentre study (69) have found the presence of mid-wall LGE to 
be a strong independent risk factor for adverse outcomes. I have shown that 
once present in AS patients, mid-wall fibrosis accumulates rapidly (146) and 
previous work suggests that increasing LGE mass is associated with a higher 
risk of adverse events (46). In addition, although valve replacement arrests 
further LGE development (146), no regression of existing LGE is seen out to 
two years following intervention (68,144,146) indicating that this type of 
fibrosis is permanent and once developed patients are left with poor long-term 
outcomes with conventional management strategies (48). Given the 
accumulated evidence it is now time for a randomised controlled trial to 
determine if an early valve replacement procedure in patients without 
conventional indication for surgery but with evidence of mid-wall fibrosis could 
improve clinical outcomes. 
 
To that end, we have designed and implemented the Early Valve Replacement 
guided by Biomarkers of Left Ventricular Decompensation in Asymptomatic 
Patients with Severe Aortic Stenosis (EVOLVED, NCT03094143) clinical trial. 






blinded endpoint (PROBE) controlled trial of early aortic valve intervention in 
asymptomatic patients with severe AS and evidence of LV decompensation 
(mid-wall fibrosis) on CMR imaging. There is an additional observation arm of 
patients without evidence of LV decompensation on cardiac MRI. During my 
PhD I was instrumental in designing and writing the study protocol, acted as 
Principal Investigator in Edinburgh and was responsible for setting up remote 
study sites along with the EVOLVED trial manager.  
 
Patients with severe aortic stenosis (aortic valve peak velocity ≥4.0 m/s, or 
aortic valve area indexed to body surface area <0.6 cm2/m2 with aortic valve 
peak velocity ≥3.5 m/s) are eligible to be enrolled if they are asymptomatic. 
This is a pragmatic definition, that requires the treating cardiologist to 
determine they have no symptoms that would warrant consideration of aortic 
valve intervention. Key exclusion criteria are 1) planned cardiac surgery or 
previous valve replacement, 2) co-existent severe valvular regurgitation, 3) LV 
ejection fraction <50%, 4) any contraindication to MRI scanning (e.g. 
pacemaker), 5) any contraindication to gadolinium contrast (e.g. egfr 
<30mL/min/1.73m2) and 6) patient deemed unfit to be considered for valve 
intervention. Full exclusion criteria are listed in the appendix (EVOLVED study 
protocol). 
 
Patients meeting the inclusion criteria are initially screened with high sensitivity 
troponin (if Abbott architect high sensitivity assay available locally) and 12-






ng/L or ECG left ventricular hypertrophy plus strain pattern (≥1mm concave 
downsloping ST segment depression with asymmetrical T wave inversion in 
at least two contiguous lateral leads). In the ECG-only sites (where the Abbott 
troponin assay is not available) patients are considered higher risk if they meet 
ECG criteria for left ventricular hypertrophy, regardless of presence of the 
strain pattern.  
 
Patients who are lower risk are not eligible for further study participation. 
Those deemed higher risk are invited back for a baseline assessment (see 
study protocol in Appendix for further details). This includes a CMR scan with 
gadolinium contrast and late gadolinium enhancement imaging. Several LGE 
sequences are performed (short-axis stack, phase swap stack and long-axis 
views) to optimise the ability to interpret the images for the presence of mid-
wall fibrosis.  
 
Following CMR, final eligibility check is performed. If patients meet all criteria, 
they are randomised using a web-based system with minimisation criteria. If 
mid-wall fibrosis is present patients undergo randomisation 1 (1:1 between 
early valve intervention and routine clinical care, Figure 7.1). If mid-wall 
fibrosis is not present, patients undergo randomisation 2 (1:2 randomisation 
between routine clinical care with study follow-up and routine clinical care 



















If randomised to early valve intervention this should be performed as per local 
NHS processes. The trial protocol does not mandate an interventional strategy 
(AVR versus TAVI) and concomitant coronary bypass grafting or aortic root 
surgery may also be performed. If possible, intervention should be performed 
within 2 months of randomisation. Patients randomised to routine clinical care 
will have any decisions about timing of future valve intervention made by their 
usual cardiologist.  
 
Study follow-up is annual, with a telephone call and medical records check. 
The primary outcome is a composite of all-cause mortality and unplanned 
aortic stenosis related hospitalisation. The study end-point is event driven with 
an expected mean follow-up time of 2-3 years. 
 
In total across the sites we plan to screen approximately 1600 patients of 
whom approximately 1000 higher risk patients will be invited to attend baseline 
visit including CMR imaging. We expect this to identify 400 patients with mid-
wall fibrosis for the primary study randomisation. The study has a 90% power 
at the 5% significance level once 88 events are reached assuming an event 
rate of 25% in the routine care arm and 13.4% in the early intervention arm.   
 
One key aspect of the study design was introducing blinding of the CMR result 
to patients, clinicians and the study investigators. This is to avoid bias that 
might be introduced by patients randomised to routine care being aware they 






fibrosis will also receive study follow-up, and the cohort of patients receiving 
routine care with study follow-up will contain patients both with and without 
mid-wall fibrosis and will appear as a single group to all those except the CMR 
reviewers (Figure 7.2). The CMR review result (presence of absence of mid-
wall fibrosis) is logged in the trial database so that the appropriate 
randomisation step and group allocation is performed if a patient meets 













Patients, researchers and clinicians are blinded to the results of the CMR 
review (A). As a result, patients are placed into one of three groups as a result 
of the two randomisation processes depending on the presence of mid-wall 
fibrosis on CMR review. The middle group has a mixture of patients with and 
without mid-wall fibrosis. However, to blinded individuals this appears as a 








Research ethics committee approval was obtained on 12th May 2017 
(17/SS/0052) and recruitment in Edinburgh commenced on 27th July 2017. To 
date, 12 sites are open to recruitment with another 12 planned to open (Figure 
7.3). Provisional end-date for recruitment is August 2020.  
 
It is hoped that the strategy explored in EVOLVED will target valve intervention 
to those patients who will derive greatest benefit and we await the trial results 









Figure 7.3: EVOLVED study sites 
 
Sites in green are open to recruitment, yellow; awaiting sponsors authorisation 






Diffuse fibrosis as a marker of risk / threshold for intervention 
Although mid-wall fibrosis is now well established as a marker of early LV 
decompensation it appears to be permanent (68,144,146) meaning that such 
patients are still left with an elevated risk of adverse events following valve 
replacement (48). It would clearly be advantageous to utilise an earlier 
reversible marker of LV decompensation, such as T1 mapping assessments 
of diffuse fibrosis (137,144,146), in future decision-making pathways. I have 
demonstrated the prognostic importance of ECV-based T1 mapping measures 
in patients with severe aortic stenosis undergoing valve replacement and the 
feasibility of conducting multicentre studies using this technique. As such, 
future research should concentrate on developing and validating thresholds 
for abnormal diffuse fibrosis that could be investigated in randomised 









MR/PET in aortic stenosis 
I have demonstrated that MR/PET is feasible as a one-stop assessment of 
aortic valve, myocardium and coronary arteries in AS patients. Excellent 
image quality was obtained in most patients but could potentially be improved 
upon. For example, further application of advanced motion correction 
techniques for both MRA and PET datasets may significantly improve image 
clarity, PET signal-to-noise ratio and reduce acquisition time (125). With novel 
therapies for TTR amyloidosis now becoming available (101), MR/PET could 









Aortic stenosis is the most common valve disease requiring intervention in the 
developed world however no randomised evidence exists to help determine 
treatment decisions. Clinical guidelines currently recommend valve 
intervention for severe aortic stenosis in the presence of classical symptoms 
or findings of an impaired ejection fraction (5,148). However, improvements in 
surgical technique, peri-operative care, replacement valve technology and the 
advent of transcatheter procedures, along with a not insignificant rate of 
sudden death (approximately 1-1.5% per year whilst symptom free (41-43)) 
mean that the balance of risks and benefits is likely shifting towards offering 
earlier valve intervention in the asymptomatic phase. How we as doctors are 
able to identify those patients who will benefit most from an earlier procedure 
is critical. Although many novel biomarkers such as troponin, diastolic 
dysfunction and assessments of myocardial strain may be able to identify 
earlier evidence of decompensation, assessments of myocardial fibrosis 
appear the most promising. 
 
Myocardial fibrosis appears to be a consequence of direct pressure-overload 
and repeated myocardial ischaemia (8). Although the mechanism of sudden 
cardiac death in aortic stenosis is poorly understood it is likely that myocardial 
fibrosis may contribute as a substrate for life-threatening arrhythmia. Offering 
early valve replacement to those with evidence of replacement myocardial 






which will be the first randomised controlled trial of targeted early intervention 
in asymptomatic patients with severe aortic stenosis.  
 
Furthermore, advanced imaging techniques such as T1 mapping are able to 
detect and quantify diffuse fibrosis, a precursor to replacement fibrosis which 
is reversible following valve intervention (144,146). Further work to identify 
clinically relevant thresholds for abnormal levels of diffuse fibrosis which could 
then be examined as triggers for valve intervention in prospective randomised 
trials is warranted. In addition, T1 mapping provides fully quantitative, accurate 
and reproducible assessment of whole-heart fibrosis, meaning this technique 
may be used as an end-point for future clinical trials assessing novel anti-
fibrotic therapies. 
 
Finally, as decision-making surrounding intervention becomes more complex, 
“one-stop” multiparametric imaging using MR/PET to assess the aortic valve, 
ventricular myocardium, coronary arteries and aorta is attractive. Such an 
assessment could provide information on activity of calcification in the valve, 
presence and extent of myocardial fibrosis and identify co-existent amyloidosis 
that enables clinicians to make a fully informed decision about the method or 
even appropriateness of valve intervention. In addition, this assessment could 
provide valuable technical information about the aortic annulus, aorta, 
coronary arteries and peripheral vasculature to determine the optimum 
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Chapter 4: Progression of Hypertrophy and Myocardial 





A comprehensive transthoracic echocardiographic assessment was performed in all 
patients (Edinburgh: iE33, Philips Medical Systems, The Netherlands. Quebec: iE33 
or EPIQ, Philips Healthcare, Ontario, Canada) by dedicated research 
ultrasonographers. Careful attention was given in the assessment of aortic stenosis 
severity.  The left ventricular (LV) outflow tract diameter was measured in the 
parasternal long-axis view, at the insertion of the aortic cusps from the inner edge of 
the septal endocardium to the inner edge of the anterior mitral leaflet in mid-systole.  
Left ventricular outflow tract velocity-time integral was measured in the apical 5-
chamber view using pulsed-wave Doppler just proximal to the aortic valve, with care 
taken to obtain a laminar spectral tracing.  The peak aortic jet velocity and mean 
transvalvular gradient were derived from the aortic valve velocity-time integral, using 
continuous-wave Doppler. The highest aortic jet velocity and mean transvalvular 
gradient were determined in multiple acoustic windows using both standard S51 and 
D2cwc probes (Philips Medical Systems, Best, the Netherlands). The mean of 3 
readings (5 if the patient had atrial fibrillation) was recorded.  Aortic valve area was 
calculated using the continuity equation.  The severity of aortic stenosis was 
assessed and classified according to the European Association of 
Echocardiography/American Society of Echocardiography guidelines.1  
 
Trans-mitral early (E) and late diastolic velocities, as well as, deceleration time of 
early filling velocity were measured at the tips of the mitral valve leaflets using pulsed-
wave Doppler.  The mean early diastolic velocities of the medial and lateral mitral 
annulus (e’) were measured using pulsed-wave tissue Doppler imaging. Diastolic 




Magnetic resonance imaging 
Magnetic resonance imaging was performed using both 1.5 and 3T scanners 
(Edinburgh: MAGNETOM Verio, Siemens AG, Erlangen, Germany; Quebec: 
ACHIEVA and INGENIA, Philips Healthcare, Best, the Netherlands or, Erlangen, 
Germany). Repeat imaging was performed using the same standardized protocols at 
each site. Short-axis cine images extending from the mitral valve to the left ventricular 
apex were obtained using a balanced steady-state free precession sequence 
(Edinburgh: 8-mm parallel slices with 2-mm spacing; temporal resolution £45ms. 
Quebec: 8 mm parallel slices with no gap). Typical parameters at 1.5T were FOV 380 
mm, TR/TE 3.2/1.6 ms, flip angle 60º and NEX of 1, in-plane spatial resolution of 1.6 
x 2 mm. Equivalent acquisition parameters at 3T were FOV 380 mm, TR/TE 2.8/1.3 
ms, flip angle 45º, and NEX of 1, in-plane spatial resolution of 1.7 mm x 2 mm, 7-mm 
slice thickness, 0-mm gap.  
 
Focal replacement and diffuse interstitial myocardial fibrosis was assessed in all 
patients using late gadolinium enhancement (LGE) and myocardial T1 mapping, 
respectively.  Late gadolinium enhancement was performed 15 min following 
gadobutrol (Gadovist, Bayer Pharma AG, Germany, 0.1 mmol/kg [Edinburgh], 0.2 
mmol/kg [Quebec]) using an inversion-recovery fast gradient-echo sequence 
performed in two phase-encoding directions to differentiate true late enhancement 
from artefact. The LGE imaging parameters at 1.5T were FOV 350 mm, TR/TE 4.5/1.3 
ms, flip angle 15 º, 8-mm slice thickness, in-plane resolution of 1.9 mm x 3.1 mm with 
an inversion time of 200 to 300 ms adjusted to null normal myocardium following 
gadolinium contrast administration. Equivalent acquisition parameters at 3T were 
FOV 350 mm, TR/TE 6.1/3 ms, flip angle 25 º, 8 mm slice thickness, in-plane 
resolution of 1.6 mm x 2 mm. The inversion time was optimized to achieve satisfactory 
nulling of the myocardium.  
 
Diffuse myocardial fibrosis was assessed using Modified Look-Locker Inversion-
recovery with built-in motion correction. A heart beat acquisition scheme of 3(3)-3(3)-
5 was used in Edinburgh (flip angle 35°; minimum TI 100 ms; TI increment of 80 ms; 
time delay of 150 ms)3,4,5 whilst an acquisition scheme of 5(3)-3 was used in Quebec 
(with a post-contrast acquisition scheme of 4(1)3(1)2 used in patients scanned at 
3T).6 A gradient echo field map and associated shim were performed to minimize off-
frequency artefact.   
 
Image analysis 
Ventricular volumes, mass and function were quantified using dedicated software 
(CVI42 (Circle Cardiovascular Imaging Inc., Calgary, Canada) by a single reporter 
(RJE) blinded to the scan time-point.  Basal ventricular slices were included if >50% 
of the LV blood pool was surrounded by myocardium. Papillary muscles and minor 
trabeculations were included in the left ventricular mass measurements and excluded 
from the intracavity volume measurements as per Society for Cardiovascular 
Magnetic Resonance guidelines.7  
 
The left ventricular wall thickness was measured in each of the 16 myocardial 
segments (excluding the LV apex) and the maximum value recorded. Left ventricular 
longitudinal function was determined by measuring the difference in the distance 
between the mitral valve plane and the epicardial left ventricular apex in end-systole 
and end-diastole. The final value was calculated as the mean value of the recorded 
measurements in both 4-chamber and 2-chamber views. Left atrial volume was 
calculated using the bi-plane area-length method by tracing the endocardial LA 
contour in end-ventricular systole in both 2 and 4 chamber long-axis views. 
 
The presence of mid-wall myocardial fibrosis was determined qualitatively by two 
independent and experienced operators (MRD and RJE).  The distribution of mid-wall 
fibrosis was described according to the standard 17-segment model recommended 
by the American College of Cardiology/American Heart Association.8 LGE was 
quantified in a semi-automated manner using a signal intensity threshold of >3 
standard deviations above the mean value in a region of normal myocardium.9 Areas 
of inversion artefact, infarct pattern LGE or signal contamination by epicardial fat or 
blood pool were manually excluded. Sub-endocardial LGE was also identified and 
quantified using the same analysis technique. 
 
T1 mapping analysis was performed using CVI42 (Circle Cardiovascular Imaging Inc., 
Calgary, Canada). Endocardial and epicardial contours were manually contoured on 
the native motion-corrected myocardial T1 maps with manual offsetting of the 
contours to avoid partial volume effects. The right ventricular insertion points were 
identified leading to automatic segmentation of the basal and mid-ventricular slices. 
No analysis was performed on the apical myocardial segments as these are most 
susceptible to partial volume effects. These contours were subsequently copied onto 
corresponding 20-minute post-contrast maps with minor adjustments made to avoid 
partial volume effects and artefact. Segments demonstrating mid-wall late 
enhancement were included in the overall T1 analysis whereas those containing 
infarct pattern LGE were excluded as per recent post-processing guidelines.10 The 
extracellular volume fraction (ECV%) was calculated according to: ECV% = partition 
coefficient x [1-haematocrit], where partition coefficient = [∆R1myocardium/∆R1blood-pool] 
and ∆R1 = (1/post-contrast T1-1/pre-contrast T1). This was calculated based on the 
average of the values obtained from the basal and mid ventricular segments. 
Hematocrit was sampled at the time of cardiovascular magnetic resonance imaging.  
The indexed extracellular volume (iECV) in each patient was derived using the 
following: ECV% x left ventricular end-diastolic myocardial volume indexed to body 
surface area (using the Dubois formula), where left ventricular myocardial volume = 
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ECV400: Image analysis protocol 
 
(adapted from BSCMR valve consortium guidance for AS700 study, Musa, 
Treibel et al, Circulation 2018) 
 
 
1. Left and right ventricular volume and mass quantification 
a. The left ventricle 
b. The right ventricle 
2. Left atrial volume  
3. Late gadolinium enhancement 
4. T1 mapping 
 
1. Left and right ventricular volume and mass quantification 
(adapted from Schulz-Menger et al. Journal of Cardiovascular Magnetic Resonance 2013, 
15:35) 
 
- For each study, LV and RV volumes and LV mass are to be contoured by the 
same one individual using the dedicated LV short axis cine stack.  
- If no intra- or extracardiac shunts are present, the RV and LV stroke volumes 
should be nearly equal (small differences are seen as a result of bronchial artery 
supply). Since the LV stroke volume is more reliably determined than the RV 
stroke volume, the LV data can be used to validate RV data. 
- Manual contouring performed in cvi42 using the Bezier tool is the suggested 
method of analysis; the fully automated contour detection option is to be avoided.  
 
 
1a. The left ventricle 
 
- The LV end-diastolic and end-systolic image should be chosen as the images 
with the largest and smallest LV blood volumes respectively (for their 
identification, the full image stack should be evaluated). 
- Deviations may occur, and extra care should be taken in the setting of LV 
dyssynchrony or severe mitral regurgitation. Aortic valve closure defines end-
systole. 
- If a slice is uninterpretable (e.g. degraded by triggering/breathing artefact) it 
should be excluded from systolic and diastolic measurements of both the LV and 
RV. 
- The LV outflow tract is included as part of the LV blood volume. When aortic valve 
cusps are identified on the basal slice(s) the contour is drawn to include the 
outflow tract to the level of the aortic valve cusps. 
- Care must be taken with the one or two most basal slices. A slice that contains 
blood volume at end-diastole may include only left atrium (LA) without LV blood 
volume at end-systole. The LA can be identified when less than 50% of the blood 
volume is surrounded by myocardium and the blood volume cavity is seen to be 
expanding during systole. 
- Papillary muscles are to be EXCLUDED from the LV cavity for the purpose of 
analysis and INCLUDED within the LV mass (thus do require specific 
delineation). 
- Epicardial borders should be drawn on the middle of the chemical shift artefact 
line (when present). 
- Absolute LV mass is derived from diastolic epicardial and endocardial 
delineation; systolic epicardial contours are NOT required. 
- Maximal LV wall thickness is measured as the thickest portion of the 
interventricular septum in short axis at end diastole (mm) 
- When the most basal slice contains only a small crescent of basal lateral 
myocardium and no discernible ventricular blood pool, an epicardial contour for 
the visible myocardium is included for LV mass only. 
- Similarly, when the most apical slice contains only a circle of myocardium without 
cavity blood pool, an epicardial contour without an endocardial contour should be 




Left ventricular (LV) chamber quantification. For LV chamber quantification, the 
endocardial (blue) and epicardial (yellow) contours are delineated in diastole in a 
stack of short axis slices that cover the whole left ventricle. c) illustrates the 
approach with Exclusion of the papillary muscles as part of the LV volume. 
 
 
1b. The right ventricle 
 
 
- As for the LV, it may be necessary to review all image slices in the stack to define 
end-diastole and end-systole for the RV. 
- Trabeculations of the RV should be ignored, and a smooth endocardial border 
drawn to improve reader reproducibility (RV trabeculae and papillary muscles are 
typically included in RV volumes). 
- Again, if no intra- or extracardiac shunts are present, the RV and LV stroke 
volumes should be nearly equal (small differences are seen as a result of 
bronchial artery supply). 
- Since the LV stroke volume is more reliably determined than the RV stroke 
volume, the LV data can be used to validate RV data. 
- The pulmonary valve may be visualized, and contours are included just up to, but 
not superior to this level. 
 
 
Right ventricular (RV) chamber quantification. For RV volume quantification, the 
endocardial (red) contours are delineated in diastole (top) and systole (bottom) or 




2. Left atrial volume quantification 
-  
- Measurement of left atrial (LA) volume is by the biplane area–length method.  
- Images are analysed in the viewer module of cvi42 with a dual panel display 
selected to permit synchronisation of HLA and VLA by phase. 
- All measurements are taken from the two-chamber (A) and four-chamber (B) 
views at end-ventricular systole, ensuring maximal LA size.  
- The atrial endocardial border is traced to determine LA area with exclusion of the 
pulmonary veins, LA appendage, and mitral valve recess.  
- LA length is measured from the midpoint of the mitral annulus plane to the 
posterior aspect of the left atrium. Left atrial volume (LAV) was calculated using 
the formula: 
 
LAV = 8 x (A2Ch) x (A4Ch) / 3πL 
 
- where A2Ch and A4Ch refer to the LA area in the two-chamber and four-chamber 
views, 
respectively, and L is the shorter of the two LA length measurements (L2Ch, 
L4Ch) from these views. 
 
 




3. Late gadolinium enhancement quantification 
 
- All images are to be quantified using CVI 42.  
- The short axis LV stack acquired 10-15 minutes following gadolinium contrast 
administration is used for the purposes of late gadolinium quantification. 
- Each slice is visually inspected by an experienced CMR reader for the presence 
or absence of gadolinium enhancement. Phase swap and other geometry images 
were used in order to assist in decision making where required.  
- In only those slices deemed to have LGE present, epi and endocardial contours 
should be manually drawn, with care take to exclude artefact, blood pool, fat and 
pericardium. 
- The auto-identification tool is then applied, and an area of normal remote 
myocardium defined alongside identification of areas with increased signal 
intensity.  
- Any hyperintense regions felt to be related to artefact are manually excluded.  
- The 5SD technique should be used to determined LGE mass.  
- LGE mass is then divided by absolute LV mass as determined from the SA cine 




4. T1 mapping analysis 
- All T1 mapping analysis should be performed using the T1 mapping module of 
CVI42 
- The mid-ventricular short axis native T1 map should be loaded into the viewer 
(scanner generated motion-corrected T1 maps are preferred). 
- The endocardial and epicardial contours should be drawn using the Bezier tool 
(‘click-draw’ icon displayed). 
 
 
- Anterior and posterior RV insertion points should be marked with the appropriate 
tool. 
- The manual epicardial and epicardial offsets should both be set to “10%” and the 
number of segments per slice changed to “6”. This should result in automatic 
segmentation in the right-hand display into the 6 mid-ventricular myocardial 
segments (segments 7-12 of the AHA/ACC model). 
- The blood pool contour should be drawn in the centre of visible blood pool with 
care taken to avoid papillary muscles within the region of interest. 
- The above process should be repeated using the post-contrast T1 map at the 
same slice position (again, scanner-generated map is preferred). The blood pool 
contour should be copied from the native T1 map with adjustments applied as 
needed to avoid papillary muscles or artefact. 
- The mean native and post-contrast T1 values for segment 9 are then recorded 
along with the mean blood pool native and post-contrast T1 values. If mid-wall 
LGE is present in segment 9 this is included in the analysis, however if 
subendocardial infarct LGE is present then this area is manually excluded (as per 
SCMR post-processing guidance). In the case of extensive infarction LGE in 
segment 9, a separate unaffected mid-ventricular myocardial segment may be 
selected for T1 analysis. 
 
- Extracellular volume fraction (ECV%) is then calculated using the following 
equations: 
o ECV% = partition coefficient x [1-hematocrit] x 100    
    (to give a percentage value from 0-100) 
o Partition coefficient = [∆R1myocardium / ∆R1blood-pool]  
o ∆R1 = (1 / post-contrast T1) - (1 / native T1) 
 
- Indexed extracellular volume (iECV) is calculated using the following equation: 
o iECV = (ECV% x indexed LV mass) / (myocardial density x 100) 
o Myocardial density = 1.05 g/mL 
 
  
PET/MRI in Aortic Stenosis (PASS) – PET Analysis Protocol 
Version 1.0, January 2018 
 
Open FusionQuant software 
Load caspr motion- corrected non-contrast angiogram sequence as “background” 
 
Load MRAC-corrected PET data as “overlay”: 
- Gate 1: Siemens 3D Dixon VIBE  
- Gate 2: NYC radial GRE VIBE 
 
1. Find aortic valve plane (CT method) 
Draw polygon ROI in short axis view 
Depth 6mm (similar to CT method) centred on valve 
Record: 
- AV SUV max  
- AV SUV mean 
 
2. Reorientate views to show 4Ch, 2Ch and short axis at mid-ventricle level, centre 
image on LV cavity 
Draw cylinder ROI (3mm radius x 15mm depth) at mid-myocardial level parallel 
to LV long axis. Ensure ROI is as far away from endo / epicardial surface as 
possible 
Record  
- Septal Myo SUV max 
- Septal Myo SUV mean 
 
3. Keeping with same SA plane: 
Draw spherical ROI in middle of LV cavity (6mm radius, approx. 1cm3 volume) 
Record  
- LV background SUV mean 
 
Draw spherical ROI in middle of RV cavity (6mm radius, approx. 1cm3 volume) 
Record  
- RV background SUV mean 
 
4. Keeping in same 4Ch plane: 
Draw spherical ROI in middle of LA cavity (6mm radius, approx. 1cm3 volume) 
Record  
- LA background SUV mean 
 
Draw spherical ROI in middle of RV cavity (6mm radius, approx. 1cm3 volume) 
Record  
- RA background SUV mean 
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12 May 2017 
 
 Dr Marc Dweck 
University of Edinburgh, Centre for Cardiovascular Sciences 
Chancellors Building 




Dear Dr Dweck  
 
Study title: Early Valve Replacement guided by Biomarkers of Left 
Ventricular Decompensation in Asymptomatic Patients with 
Severe Aortic Stenosis 
REC reference: 17/SS/0052 
Protocol number: AC17024 
IRAS project ID: 196827 
 
Thank you for your letter of 11th May 2017, responding to the Committee’s request for further information on 
the above research. 
 
The further information has been considered on behalf of the Committee by the Chair.  
 
We plan to publish your research summary wording for the above study on the HRA website, together with 
your contact details. Publication will be no earlier than three months from the date of this opinion letter.  
Should you wish to provide a substitute contact point, require further information, or wish to make a request 
to postpone publication, please contact hra.studyregistration@nhs.net outlining the reasons for your request. 
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Design: A parallel-group multicentre prospective randomised open-label blinded 
endpoint (PROBE) controlled trial of early aortic valve intervention in asymptomatic 
patients with severe aortic stenosis (AS) and evidence of left ventricular (LV) 
decompensation (mid-wall fibrosis) on cardiac magnetic resonance imaging (MRI), 
with an observation arm of patients without evidence of LV decompensation on cardiac 
MRI. 
Setting: Hospitals in Scotland and England. 
Target Population: 
Inclusion criteria: 1. Severe aortic stenosis (aortic valve peak velocity ≥4.0 
m/s, or aortic valve area indexed to body surface area <0.6cm2/m2 with aortic 
valve peak velocity ≥3.5m/s) 2. Age over 18 years 3. No symptoms attributable 
to aortic stenosis that require aortic valve replacement 
Exclusion criteria: 1. Deemed lower risk for mid-wall fibrosis on screening 
2. Planned cardiac surgery 3. Previous valve replacement 4. Severe 
hypertension (systolic >180 or diastolic >110 mmHg) 5. Acute pulmonary 
oedema or cardiogenic shock 6. Left ventricular ejection fraction <50% on 
cardiac MRI 7. Significant abnormalities on cardiac MRI that would prevent 
enrolment 8. Coexistent severe aortic regurgitation or mitral regurgitation 
9. Coexistent mitral stenosis greater than mild in severity 10. Coexistent 
hypertrophic cardiomyopathy or cardiac amyloidosis 11. Any contraindication 
to MRI scanning 12. Advanced renal impairment 13. Pregnancy or breast 
feeding 14. Patient judged to be unfit to be considered for aortic valve 
replacement or transcatheter aortic valve implantation 15. Patient declines to 
consider undergoing valve replacement surgery or transcatheter aortic valve 
implantation 16. Inability to give informed consent 17. Previous randomisation 
into this study 
Health technologies being assessed: Use of aortic valve intervention (surgical aortic 
valve replacement or transcatheter aortic valve implantation) in patients with 
asymptomatic severe aortic stenosis with evidence of LV decompensation. 
Measurement of outcome 
Primary outcome: Composite of all-cause mortality or unplanned aortic 
stenosis-related hospitalisation between randomisation and final follow up visit 
for study participants with mid-wall fibrosis. 
Secondary outcomes: 1. Mortality: all-cause, cardiovascular, AS-related, and 
sudden cardiac death. 2. Unplanned aortic-stenosis related hospitalisation. 3. 
Symptomatic status as assessed by NYHA functional classification. 4. Health 
and disability status as assessed by the WHODAS 2.0. 5. The development of 
systolic LV dysfunction. 6. Stroke 7. Permanent pacemaker insertion, cardiac 
resynchronisation therapy or automated implantable cardioverter defibrillator. 
8. Endocarditis 9. 30 day post-operative complications following aortic valve 
intervention 
Sample size: We expect the proportion of primary outcome events (all-cause mortality 
or unplanned AS-related hospitalisation) to be 25% in the routine care arm of the study, 
and 13.4% in the early intervention arm (a hazard ratio of 2), over 2 years of follow up 
(Dweck et al 2011, RBH cohort).  We aim to recruit 1000 participants with evidence of 
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decompensation on screening (ECG and/or troponin) who will then be imaged with 
cardiac MRI for evidence of LV decompensation (mid-wall fibrosis). We would expect 
this to result in 400 patients with mid-wall fibrosis being randomised (1:1). Using a 
logrank approach, we will need to observe 88 primary outcome events to give us 90% 
power at 5% significance level.  We will follow participants up for as long as possible 
before the end of study, and thus participants will have between 2 and 3.5 years of 
follow up. We expect mean follow up to be 2.75 years.  We are likely to reach 88 events 
when we have recruited 356 participants (slightly more allowing for drop-out). 
 
Lay Summary 
The aortic valve can be thought of as a one-way door through which blood leaves the 
heart to enter the body. It has to be able to open well to allow blood out and close 
properly to stop blood leaking back and overloading the heart. 
 
Aortic stenosis is a condition where the aortic valve becomes progressively narrowed 
(stenosed; i.e. the door doesn’t open very well) usually over a number of years or 
decades. This is usually caused by hardening and thickening of the valve so that it 
becomes less flexible. This puts a strain on the heart muscle as it has to work harder 
to “open the door” and pump blood through the narrowed valve. For many years the 
heart adapts and copes with this increased pressure but eventually it is no longer able 
to cope and patients develop symptoms (chest pain, breathlessness, collapse) and an 
increased risk of heart failure and dying. The only treatment currently available for 
severe aortic stenosis is surgery to replace the narrowed valve. The timing is key: 
replace the valve too early and patients are put through surgery and the risk of a 
replacement valve without reason; too late and patients may be left with irreversible 
symptoms and heart failure. At the moment we replace the valve when patients first 
develop symptoms but these can be tricky to assess in patients with lots of other health 
conditions or in those that are inactive. As a consequence the timing of aortic valve 
operations is often suboptimal.  
 
Fibrosis or scarring of the heart is one of the key processes that causes the heart to 
fail in this condition. Scarring once formed does not appear reversible, so any scar that 
forms prior to valve replacement will remain with the patient even after surgery. Using 
cardiac MRI (a completely safe method of scanning the heart involving strong magnetic 
fields and lying in a tunnel) we are able to detect the earliest stages of this scarring. 
We believe this will identify patients whose hearts are starting to fail (even before they 
develop symptoms) and who therefore need prompt replacement of their valves.  
 
In our study we will use cardiac MRI to look for heart scarring in patients with severe 
aortic stenosis but no symptoms. Patients with confirmed heart scarring will then be 
randomised to either early valve replacement surgery or to the current treatment 
strategy. This consists of continued monitoring of the valve over time waiting for 
patients to develop symptoms.  
 
We believe that performing aortic valve replacement on patients with severe aortic 
stenosis with no symptoms but who have evidence of early scarring on cardiac MRI 
will prevent further scarring from forming, reduce subsequent heart failure and lead to 
improved long-term symptoms following surgery (e.g. breathlessness) and a reduced 
chance of dying. The aim of this trial is to find out whether this is correct. 
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Aortic stenosis is the most common form of valve disease in the western world. It is 
already a major health care burden 1,2 but, with an ageing population, is set to treble 
by the year 2050. In the initial phases, the increased afterload imposed by aortic valve 
narrowing induces adaptive LV hypertrophy that acts to maintain wall stress and 
cardiac output. Ultimately, this process decompensates and patients transition from 
hypertrophy to heart failure and the development of symptoms and adverse 
cardiovascular events 3-5.  
Yet despite the prevalence of aortic stenosis, we lack effective medical therapies. 
Indeed, the only treatment option available is replacement of the valve using either 
surgical or percutaneous techniques. Judicious timing of aortic valve replacement 
(AVR) is crucial. Too early and patients are exposed unnecessarily to the significant 
morbidity and mortality associated with prosthetic heart valve replacement surgery. 
Too late and patients will sustain irreversible damage to their heart muscle that 
translates in to an increase in post-operative complications, the development of heart 
failure and an adverse long-term prognosis. Current guidelines recommend AVR in 
patients with severe stenosis and evidence of left ventricular decompensation. 
Traditionally the latter is defined by the development of symptoms and/or a fall in 
ejection fraction. However, both of these criteria are outdated and have major 
limitations. Symptoms are subjective and frequently difficult to interpret in elderly 
patients, whilst a reduction in ejection fraction is often a late and irreversible 
phenomenon 6.  
There is therefore a major unmet clinical need for more objective and specific markers 
of LV decompensation that can more accurately define the optimum timing of AVR. 
The purpose of this study is to address these key issues and ultimately to improve the 
care of patients with aortic stenosis.  
1.2 RATIONALE FOR STUDY 
The development of symptoms and adverse events in aortic stenosis relates to how 
the left ventricle adapts to the associated increases in afterload. Indeed aortic stenosis 
triggers a hypertrophic response in the myocardium that initially restores wall stress 
and maintains cardiac performance, but eventually leads to decompensation, driving 
the transition to heart failure, symptoms and ultimately death (Figure 1—1). Importantly 
only a weak association exists between the magnitude of the hypertrophic response 
and the severity of valve obstruction, making it important that both processes are 
considered independently. 
In conditions associated with left ventricular pressure overload such as aortic stenosis 
and hypertension, myocyte size and myocardial wall thickness increase to restore wall 
stress. This hypertrophic response is initially adaptive maintaining cardiac output and 
systolic function. However as hypertrophy increases, the left ventricle ultimately 
decompensates, leading to progressive impairment in ventricular performance and the 
development of symptoms and adverse cardiovascular events. Histological studies 
have indicated that this pathologic transition from ventricular adaptation to 
decompensation is driven primarily by two processes: myocyte death and myocardial 
fibrosis. Myocyte death takes the form of apoptosis and necrosis (cell swelling and loss 
of membrane integrity sometimes referred to as oncosis in this context), and is 
accompanied by signs of cellular stress manifest as increased autophagy. 
 
EVoLVeD (IRAS Project ID 196827) 
Version 4.0 01/05/2018 
 
12 of 38 
 
Figure 1—1: Progressive Changes in the Left Ventricle in Aortic Stenosis 
 
Replacement myocardial fibrosis is believed to occur in response to cell death and the 
ensuing inflammation. Such fibrosis is irreversible and its accumulation in the ventricle 
leads to progressive impairment of myocardial relaxation (diastolic dysfunction) and 
contraction (systolic dysfunction), driving the clinical progression to heart failure. 
The presence of myocardial fibrosis can be assessed non-invasively using cardiac MRI 
and the late gadolinium enhancement (LGE) technique. Following an intravenous 
bolus, gadolinium partitions and accumulates within the extra-cellular volume. This is 
particularly prominent where the extracellular volume has expanded, such as areas of 
replacement myocardial fibrosis, and is detectable on T1-weighted cardiac MRI. 
Studies examining myocardial biopsy samples have shown a good correlation between 
histological myocardial fibrosis and LGE on cardiac MRI 7. Importantly, the presence 
of LGE in patients with severe aortic stenosis is an independent predictor of all-cause 
mortality 7-9.  
Although cardiac MRI is non-invasive and safe, it is time consuming, expensive and 
access is still limited in many centres across the United Kingdom. We have recently 
demonstrated that two routinely used markers, plasma high sensitivity cardiac troponin 
I (hsTnI) concentration and the ECG (presence of voltage criteria for left ventricular 
hypertrophy [ECG-LVH] and the ECG-strain pattern) are independently associated 
with mid-wall myocardial fibrosis on cardiac MRI and adverse cardiovascular events 
10,11. 
We therefore propose that in a population with severe asymptomatic aortic stenosis, 
(who currently do not meet guideline indications for surgery) that screening with the 
ECG and hsTnI will identify patients with an increased probability of mid-wall 
myocardial fibrosis and LV decompensation as identified on subsequent cardiac MRI. 
With current management strategies, these patients are at increased risk of adverse 
cardiovascular events and all-cause mortality. We hypothesise that early aortic valve 
intervention in this group will limit progression of myocardial fibrosis, halt the transition 
to heart failure and lead to improved patient outcomes compared to routine clinical 
management. 
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2 STUDY OBJECTIVES 
2.1 OBJECTIVES 
2.1.1 Primary Objective 
• To determine whether early aortic valve replacement can reduce death and 
unplanned AS-related hospital admissions in patients with asymptomatic 
severe aortic stenosis who have subclinical but objective evidence of LV 
decompensation. 
 
2.1.2 Secondary Objectives 
• To determine whether early aortic valve replacement in patients with 
asymptomatic severe aortic stenosis who have subclinical but objective 
evidence of LV decompensation improves other clinical outcomes (see section 
2.2.2) including death and unplanned AS considered separately, long-term 
symptomatic status, post-operative outcomes and reduce the development of 
LV dysfunction.  
• To determine whether amongst patients receiving routine care, those with mid-
wall fibrosis develop symptoms more quickly or have worse clinical outcomes 
compared to those without fibrosis. 
2.1.3 Exploratory Objectives 
• To explore the association between clinical factors, cardiac biomarkers and 
cardiac MRI characteristics in patients with aortic stenosis. 
 
2.2 ENDPOINTS 
2.2.1 Primary Endpoint 
• Composite of all-cause mortality or unplanned aortic stenosis-related 
hospitalisation between randomisation and final follow up visit for study 
participants with mid-wall fibrosis. 
 
Unplanned aortic stenosis-related hospitalisation is defined as an unplanned 
admission with syncope, heart failure, chest pain or arrhythmia (ventricular arrhythmia 
or second or third degree heart block) attributed to aortic stenosis. This endpoint will 
be adjudicated by two independent investigators blinded to the details of randomisation 
(see section 10.5).  
2.2.2 Secondary Endpoints 
 
• Mortality: all-cause, cardiovascular, AS related, and sudden cardiac death 
between randomisation and final follow up visit 
• Unplanned aortic-stenosis related hospitalisation between randomisation and 
final follow up visit 
• Health and disability as assessed by the 12-item WHO Disability Assessment 
Schedule 2.0 (WHODAS) at the final follow up visit. 
• The development of LV systolic dysfunction (ejection fraction <45% 
quantitatively or at least moderate LV dysfunction qualitatively) between 
randomisation and final follow up visit.  
• Symptomatic status as assessed by NYHA functional classification at the final 
follow up visit. 
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• Permanent pacemaker insertion, cardiac resynchronisation therapy or 
automated implantable cardioverter defibrillator between randomisation and 
final follow up visit 
• Stroke between randomisation and final follow up visit 
• Endocarditis between randomisation and final follow up visit  
• 30 day post-operative complications following aortic valve intervention (safety 
end-point, appendix A). 
 
Cardiovascular mortality is defined as death due to myocardial infarction, sudden 
cardiac death, heart failure, stroke, or other cardiovascular causes, death related to 
cardiovascular procedures, and death due to other cardiovascular causes. 
AS-related death is a death where aortic stenosis has been listed as a contributory 
cause by the clinical care team on the patient’s official death certificate. 
Sudden cardiac death is defined as any death that occurs unexpectedly and not within 
30 days of acute myocardial infarction (MI). This includes unsuccessful resuscitation 
following an arrhythmia. (see appendix B for full list 12). 
Stroke is defined as any new rapid-onset focal or global neurological deficit (change in 
conscious level, hemiplegia, hemiparesis, numbness or sensory loss affecting one side 
of the body, dysphasia, visual loss, or any other sign consistent with a stroke) persisting 
greater than 24 hours or with brain imaging compatible with new infarction or 
haemorrhage. 
Endocarditis is defined as a clinical diagnosis of endocarditis by the treating physician 
and have at least one positive blood culture for a typical endocarditis organism (e.g. 
staphylococcus or streptococcus species). 
Secondary endpoints will be analysed in groups A, B and C. 
2.2.3 Exploratory Endpoints 
Blood samples will be obtained and stored from consented participants to gain a 
greater understanding of the pathophysiology of aortic stenosis. These will be used to 
analyse biochemical markers associated with cardiac disease (e.g. Brain Natriuretic 
Peptide (BNP), hsTnI). Cardiac MRI parameters (such as LV mass, ejection fraction 
and T1 mapping measures) and their relationship with clinical factors and other 
biomarkers will also be analysed. In addition, genetic analysis will be performed to 
assess for gene associations with myocardial fibrosis / LV decompensation. 
3 STUDY DESIGN 
This will be a parallel-group multi-centre prospective randomised open label blinded 
endpoint (PROBE) controlled trial with an additional observational arm. Randomisation 
will be 1: 1 among those with mid-wall fibrosis being randomised into the two arms of 
the full study, and will use a flexible, adaptive randomisation ratio among those without 
mid-wall fibrosis being randomised into the observational arm or no further follow up. 
Patients with severe aortic stenosis attending outpatient clinics or echocardiogram 
appointments will be identified and assessed for eligibility.  Participants may also be 
identified by participating centres from local databases – these participants can be 
invited to take part by sending a letter from their normal care team. Potential 
participants meeting the inclusion criteria and demonstrating normal left ventricular 
ejection fraction (LVEF) on routine echocardiography can be approached about 
participating in study.  
Potential participants will undergo an initial screening assessment based upon troponin 
I measurements and/or the ECG.  This will determine whether potential participants 
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are considered lower-risk or higher-risk for the presence of mid-wall myocardial fibrosis 
on cardiac MRI. At sites where the Abbott high sensitivity troponin I assay is available 
patients will be considered at higher risk if they demonstrate ECG-LVH with strain 
and/or elevated troponin levels (≥6ng/L). At sites where the Abbott high sensitivity 
troponin I assay is not available then patients at that site will be screened using the 
ECG only (ECG only sites).  At these sites the presence of voltage criteria for LVH on 
the ECG (ECG-LVH) with or without strain will be used to define patients at higher risk. 
Patients at lower-risk (without ECG-LVH with strain and troponin levels <6ng/L; or at 
the ECG only sites patients without ECG-LVH) will be considered to have a healthy 
myocardium and no suggestion of LV decompensation. These patients will take no 
further part in the study but their details will be retained by the research team for future 
record linkage. 
Patients at higher-risk will undergo baseline assessments including cardiac MRI.  
If a participant is still eligible following baseline assessment and no other exclusion 
criteria are identified on central cardiac MRI review (see section 5.5.4), then the 
participant can be enrolled into the study.  If the central cardiac MRI review 
demonstrated mid-wall myocardial fibrosis then the participant will be randomised 1:1 
to early treatment or routine care. These patients will be followed up in the study 
annually. 
If no mid-wall fibrosis is detected on central cardiac MRI review then participants will 
be entered into an observational arm using a flexible, adaptive randomisation ratio, 
aimed at balancing those in the observational arm and the routine care arm. Those 
who do not enter the observational arm will have no further study follow up but their 
data will be retained for future data linkage.  Those entered into the observational arm 
will have the same study follow up schedule to those participants with mid-wall fibrosis. 
As well as providing key mechanistic insight this approach will also maintain the patient 
and physician blinding as to the presence or absence of mid-wall fibrosis on cardiac 
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Figure 3—1: Study Design Overview (screening with ECG and hsTnI) 
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Figure 3—2: Study Design Overview (screening with ECG only) 
  
EVoLVeD (IRAS Project ID 196827) 
Version 4.0 01/05/2018 
 
18 of 38 
 
4 STUDY POPULATION 
4.1 NUMBER OF PARTICIPANTS 
 
The sites taking part in this study are listed in the Participating Sites document. 
 
We aim to screen patients with asymptomatic severe aortic stenosis (aortic valve peak 
velocity ≥4.0 m/s on Doppler echocardiography or aortic valve area indexed to body 
surface area <0.6cm2/m2 with aortic valve peak velocity ≥3.5 m/s) and preserved LV 
systolic function to identify approximately 1000 patients with evidence of LV 
decompensation to proceed to cardiac MRI.  Those meeting the eligibility criteria will 
be enrolled into the study. 400 participants with mid-wall fibrosis will be randomized 
1:1 to receive early valve intervention or routine care.  Amongst those without mid-wall 
fibrosis (approximately 600), 200 participants will enter an observation arm and 400 
will not be followed up but their data will be retained for future data linkage. The 
planned recruitment period is 18 months. 
4.2 INCLUSION CRITERIA 
 
For inclusion in the study, participants should fulfil the following criteria: 
 
1. Severe aortic stenosis (aortic valve peak velocity ≥4.0 m/s, or aortic valve area 
indexed to body surface area <0.6cm2/m2 with aortic valve peak velocity 
≥3.5m/s)  
2. Age over 18 years  
3. No symptoms attributable to aortic stenosis that require aortic valve 
replacement 
4.3 EXCLUSION CRITERIA 
 
Participants cannot be enrolled into the study if any of the following criteria are fulfilled: 
 
1. Deemed lower risk for mid-wall fibrosis on screening 
2. Planned cardiac surgery  
3. Previous valve replacement 
4. Severe hypertension (systolic >180 or diastolic >110 mmHg)  
5. Acute pulmonary oedema or cardiogenic shock 
6. Left ventricular ejection fraction <50% on cardiac MRI  
7. Significant abnormalities on cardiac MRI that would prevent enrolment (see 
section 5.5.4) 
8. Coexistent severe aortic regurgitation or mitral regurgitation  
9. Coexistent mitral stenosis greater than mild in severity  
10. Coexistent hypertrophic cardiomyopathy or cardiac amyloidosis 
11. Any contraindication to MRI scanning (such as permanent pacemaker) 
12. Advanced renal impairment (glomerular filtration rate <30 mL/min/1.73 m2) 
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13. Pregnancy or breast feeding 
14. Patient judged to be unfit to be considered for aortic valve replacement or 
transcatheter aortic valve implantation 
15. Patient declines to consider undergoing valve replacement surgery or 
transcatheter aortic valve implantation 
16. Inability to give informed consent 




Co-enrolment will be considered on a case-by-case basis and will consider the extra 
burden being placed on the study participants and the likelihood of study assessments 
or interventions influencing the outcomes of either study. The Sponsor’s 
representatives require Investigators from all studies involved in co-enrolment to be 
aware of the co-enrolment plans and provide documented permission for co-enrolment 
to be undertaken in their study. 
 
The acceptability of co-enrolment with some specific trials are now considered: 
• SALTIRE 2 (a randomised controlled trial of bisphosphonates/denosumab 
versus placebo on the progression of mild to moderate aortic stenosis) – co-
enrolment will not be permitted as both studies could directly affect outcome 
measures of the other. No wash out time is required following the end of a 
participant’s involvement in SALTIRE 2. 
• MODE-AS (observational study of patients undergoing AVR with intraoperative 
myocardial biopsy) – co-enrolment is permitted as there is significant overlap 
in study assessments leading to minimal extra burden on patients. 
• COMPASS (observational study of patients with asymptomatic moderate to 
severe aortic stenosis) – co-enrolment will be permitted on a case-by-case 
basis following discussion between investigators. 
 
5 PARTICIPANT SELECTION AND ENROLMENT 
5.1 IDENTIFYING PARTICIPANTS 
Participants will be identified and recruited from the cardiology outpatient clinics or 
echocardiogram lists at participating centres with the aid of local databases 
(participants can be invited by sending a letter from their normal care team). When 
identifying potential participants for screening an echocardiogram demonstrating 
severe aortic stenosis performed within the previous three years is acceptable. 
However, if a patient proceeds to baseline assessment and no echocardiogram result 
is available dated within the previous 6 months, an echocardiogram should be 
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5.2 CONSENTING PARTICIPANTS 
 
Potential participants will be approached for consent by the site Principal Investigator 
or appropriate qualified individual to whom this task has been delegated.  This will 
include research nurses and practitioners if compatible with local policy.  Once 
participants have had adequate time to consider the information and ask questions 
written consent will be sought.  Potential participants can be consented on the same 
day for screening, but should be given at least 24 hours to consider entering the main 
trial. 
 
The consent process will vary depending on access to the Abbott high sensitivity 
troponin I assay.  When screening with ECG and the Abbott high sensitivity troponin I 
assay there will be two-step consenting process:  
 
• Consent to screening for risk of mid-wall fibrosis 
Potential participants who meet the inclusion criteria and have preserved LV 
systolic function will be supplied with the Screening Participant Information 
Sheet (Part A) and Consent Form.  If consent is given, this will allow for 
demographic data to be collected and screening procedures including 
venepuncture to take place to determine risk of mid-wall fibrosis (see section 
5.3). 
 
• Consent to Baseline, Cardiac MRI and trial entry 
Those patients deemed to be at higher-risk for mid-wall myocardial fibrosis 
following screening will be invited to attend for baseline assessment. Written 
informed consent will be obtained before any study related procedures are 
performed. Details of the baseline assessments can be found in section 6.2. 
 
This 2-step consent process will allow us to screen patients with troponin quickly and 
efficiently in the clinic. In those found to be eligible, a more detailed second stage 
consent process will then ensue before participation in the main part of the clinical trial. 
 
When screening without the Abbott high sensitivity troponin I assay (i.e. ECG only), 
consent will be simplified to a single step and any study-specific activities will be carried 
out after this consent. 
 
5.3 SCREENING FOR MID-WALL FIBROSIS RISK 
The following investigations will be carried out for screening: 
1. A standard 12-lead electrocardiogram (ECG),  
• If the participant’s most recent ECG is within 6 months of screening and 
is interpretable then there is no requirement to repeat the ECG at 
screening. 
2. Blood high sensitivity troponin I (hsTnI) concentration 
• This is a marker of myocardial injury using the Abbott 
ARCHITECTSTAT assay. The level of detection of this assay is 1.2 ng/L 
and the coefficient of variation is <10% at 4.7 ng/L. 
• When screening without the Abbott high sensitivity troponin I assay (i.e. 
at ECG only sites), a serum sample should still be collected for storage 
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at ≤-700C to enable retrospective evaluation of baseline hsTnI 
concentration.  This storage sample can be performed at the baseline 
assessment. 
3. A blood sample will be taken according to local policy to determine eGFR.  This 
is to check suitability for cardiac MRI scanning if the participant proceeds to 
baseline assessment.  If the participant’s most recent eGFR result is ≥30 
mL/min/1.73 m2 and within 12 months of screening then there is no requirement 
to repeat eGFR at screening unless the investigator makes a clinical judgment 
that a more contemporary result is needed. 
The screening process will allow us to stratify patients as lower risk or higher risk of 
mid-wall myocardial fibrosis which is defined as the presence of mid-wall late 
gadolinium enhancement on cardiac MRI. Importantly, there are two methods of 
screening depending on local availability of the Abbott hsTnI assay. Consequently 
some sites will screen with troponin/ECG whilst others will screen with the ECG only. 
In centres screening with both hsTnI and ECG, patients will be deemed at higher-risk 
in the presence of either: 
• A high-sensitivity troponin I concentration of ≥6 ng/L 
• LV hypertrophy and LV strain pattern on 12-lead electrocardiogram. LVH 
will be defined according to standard ECG criteria (including but not limited to 
the Peguero-Lo Presti criteria [SD+SV4 ≥2.8 mV in males, ≥2.3 mV in females]13; 
Sokolow-Lyon index; Cornell voltage criteria; and Romhilt-Estes point score 
system).  Patients with left bundle branch block, in whom these criteria cannot 
be applied, will be assumed to meet ECG criteria for LVH. LV strain will be 
defined by the presence of LVH with ≥1mm concave downsloping ST segment 
depression with asymmetrical T wave inversion in at least two contiguous 
lateral leads. 
In centres where local hsTnI testing is not available and screening is performed 
using ECG only, higher-risk will be defined as: 
• LV hypertrophy pattern on 12-lead electrocardiogram, as determined using 
standard ECG criteria for LVH with or without the strain pattern (see above). 
Patients with left bundle branch block, in whom these criteria cannot be applied, 
will be assumed to meet ECG criteria for LVH. 
Patients at higher-risk for mid-wall myocardial fibrosis and with eGFR ≥30 mL/min/1.73 
m2 will be invited to have baseline assessments and undergo cardiac MRI imaging (see 
section 6.2). 
If the patient does not meet the above higher-risk criteria they will be considered lower-
risk for mid-wall myocardial fibrosis and will not take further part in the study. Their 
personal information will be retained for potential future data linkage on the outcomes 
of those who are considered lower-risk for mid-wall myocardial fibrosis. 
If for any reason the screening investigations do not provide a result but the participant 
is still considered at higher-risk for mid-wall myocardial fibrosis then they can proceed 
to baseline assessments.  Missing results should be repeated at the baseline visit, 
noting that an eGFR result is needed prior to cardiac MRI. 
 
EVoLVeD (IRAS Project ID 196827) 
Version 4.0 01/05/2018 
 
22 of 38 
 
5.4 INELIGIBLE AND NON-RECRUITED PARTICIPANTS 
Potential participants meeting the inclusion criteria and demonstrating normal LVEF 
on routine echocardiography but who do not consent to any part of the study will be 
recorded on the study screening log. All patients who consent to any part of the study 
will be entered into the study database.  Ineligible and non-recruited patients will 
continue to be seen by their cardiologist as part of standard clinical care. 
 
5.5 ENROLMENT AND RANDOMISATION 
5.5.1 Enrolment and Randomisation Procedures 
Following completion of baseline assessments, cardiac MRI and central MRI review, 
patients that meet all inclusion/exclusion criteria will be enrolled into the study. A web-
based computer-generated randomisation process will be employed.  There are two 
separate randomisations, one for patients with mid-wall fibrosis (Randomisation 1) and 
another for those without mid-wall fibrosis (Randomisation 2).  
5.5.2 Randomisation 1 – Patients with Mid-Wall Fibrosis 
We will randomise patients in a 1:1 ratio to either early intervention (group A) or routine 
clinical care (group B). Minimisation techniques will be employed to ensure balancing 
of key variables: age, sex, aortic valve peak velocity, ischaemic heart disease and 
screening method (ECG and hsTnI or ECG only). 
 
Group A: Early intervention (200 patients) 
 
Patients will be referred immediately for aortic valve intervention. The choice of 
either surgical aortic valve replacement or transcatheter aortic valve 
implantation (TAVI) will be made by the local clinical team according to local 
policies. In patients undergoing surgical replacement the choice of surgical 
technique and type of valve replacement used will be at the discretion of the 
operating surgeon and the patient. Patients found to have significant coronary 
artery disease requiring concomitant coronary artery bypass surgery will not be 
excluded. Similarly the choice of TAVI valve and need for percutaneous 
coronary intervention will be made by the TAVI heart team. The procedure 
should be performed as soon as possible and ideally within two months of 
randomisation and allocation to group A. Participants will be followed up in the 
study as described in section 6.3. 
 
Group B: Routine care (200 patients) 
 
Patients will be invited back for clinical follow up according to local policy. 
Decision-making regarding future aortic valve intervention will be taken by the 
participant’s clinical team (cardiologist and cardiac surgeon). Participants will 
be followed up in the study as described in section 6.3. 
 
5.5.3 Randomisation 2 – Patients without Mid-Wall Fibrosis 
We will randomise patients using a flexible, adaptive ratio to either routine clinical care 
(group C) or no further study follow up (group D).  The aim of the randomisation ratio 
is to balance the number of participants in group C and group B.  This will be a simple 
randomisation.  Details of the randomisation ratio value, and dates of change will be 
recorded. 
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Group C: Routine care (approximately 200 patients) 
 
Patients will be invited back for clinical follow up according to local policy. 
Decision-making regarding future aortic valve intervention will be taken by the 
patient’s clinical team (cardiologist and cardiac surgeon).  Participants will be 
followed up in the study as described in section 6.3. Group C will appear 
identical to Group B (see section 5.5.4). 
 
Group D: No further study follow up (approximately 400 patients) 
 
Patients will be invited back for clinical follow up according to local policy. 
Decision-making regarding future aortic valve intervention will be taken by the 
patient’s clinical team (cardiologist and cardiac surgeon).  No further study 
follow up will take place but personal data will be retained for future data 
linkage. 
 
5.5.4 Blinding of the Routine Care Group and Cardiac MRI Result 
The patient and clinical team will be blinded to the central cardiac MRI review and 
result. This is to ensure that this does not influence future treatment for participants 
with mid-wall fibrosis who are allocated routine care.  If mid-wall fibrosis is present, the 
patient will undergo Randomisation 1. If randomised to early intervention (Group A), 
the patient will be aware they have mid-wall fibrosis as they will be referred to a 
surgeon for consideration of valve replacement.  
If mid-wall fibrosis is not present, the patient will undergo Randomisation 2. If 
randomised to no study follow up (Group D), the patient will be aware they do not have 
mid-wall fibrosis and will have no further follow up in the study. 
However if patients are allocated to routine care groups (B or C) the patient and clinical 
team will simply be told that they have been allocated routine care and not informed if 
they are in group B or C. Groups A, B and C will have the same follow up which will 
maintain patient blinding in groups B and C.  
The clinical care team will also remain blinded to the cardiac MRI result and allocation 
to routine care groups ensuring that the presence or absence of fibrosis does not 
influence clinical decision-making. The cardiac MRI scans will be reviewed centrally 
prior to enrolment.  Any clinically significant cardiac findings that would prevent 
enrolment or influence patient management will be made available to the clinical team.  
This includes but is not limited to: 
• Impaired LV ejection fraction <50% 
• Intracardiac thrombus 
• Intracardiac or extracardiac malignancy 
• Significant valve disease not appreciated on echocardiography (e.g. severe 
eccentric aortic regurgitation) 
• Significant aortic pathology likely to require surgical repair. 
Any local reporting of the cardiac MRI back to the clinical care team should be limited 
to non-cardiac findings and should specifically not report on the presence or absence 
of mid-wall fibrosis.  
 
5.5.5 Withdrawal of Study Participants 
Participants are free to withdraw from the study at any point or a participant can be 
withdrawn by the investigator, but participants are not required to withdraw solely 
because they have been non-adherent with the randomised treatment or follow up 
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plan. If withdrawal occurs, the nature and reason for withdrawal will be documented on 
a change of status form. Any data collected until this point will be retained and analysed 
unless the participant specifically withdraws consent for this. Participants will be 
followed up for the primary outcome according to group allocation regardless of their 
adherence to treatment strategy, unless they withdraw their consent for this. 
 
If a participant, who has given informed consent, loses capacity to consent during the 
study they should be withdrawn. Identifiable data or tissue already collected with 
consent can be retained and used in the study. No further data or tissue should be 
collected or any other research procedures carried out on or in relation to the 
participant. 
 
Projected dropout of participants is accounted for in the sample size calculation and 
therefore withdrawn participants will not be replaced. 
6 STUDY ASSESSMENTS 
6.1 SCREENING ASSESSMENTS 
See section 5.3 for details of screening. 
6.2 BASELINE ASSESSMENTS  
Patients at higher-risk of mid-wall myocardial fibrosis on screening tests will be invited 
back to attend for baseline assessments, where the following investigations will then 
take place. At ECG-only sites the screening and baseline assessments may be 
performed at the same visit. 
1. Relevant medical history  
• Data on medical history, risk factors and current medication will be 
collected. 
2. Height and weight 
• The patient’s height and weight will be recorded. 
3. Blood pressure measurement  
• This should be taken using an appropriately sized arm cuff and 
performed and recorded three times, with the average of the final two 
readings used to determine eligibility. If the 1st reading shows severe 
hypertension (systolic BP >180 mmHg or diastolic BP >110 mmHg) the 
patient should be instructed to lie down in a quiet room for 5 minutes 
before the 2nd and 3rd BP measurements are performed. 
4. Urine pregnancy test 
• This is only required if the participant thinks there is a chance they could 
be pregnant.  Given the age of the study population it is unlikely that 
this will be required. 
5. Edmonton Frail Scale (EFS) 
• The Edmonton Frail Scale is a brief, valid and reliable tool for measuring 
frailty, consisting of nine domains and eleven items. 
6. New York Heart Association Functional Classification 
7. WHODAS, 12-item version 
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8. Phlebotomy  
• Approximately 20 ml of venous blood will be taken using standard 
venepuncture equipment (optional). This sample will be spun and 
processed locally for both serum and plasma then frozen below -70°C 
for future analysis. 
• In addition, 10ml venous blood will be taken and stored below -70oC for 
future genetic analysis (optional).  
• Explicit informed consent will be sought for these samples. Provision 
and/or collection of these samples are optional at both a site and patient 
level.  
• If a site is acquiring the optional T1 mapping cardiac MRI sequences 
then a further 4.9ml EDTA sample is required to perform haematocrit 
measurements. This is required in the calculation of the extracellular 
volume fraction. This sample should be taken on the same day as the 
cardiac MRI scan. 
9. Echocardiogram  
• If a clinical echocardiogram report is available from within the previous 
6 months then this result can be used for the trial. If not, a standard 
transthoracic echocardiogram will be performed.  The minimum 
requirement for reporting is: 
i. Aortic valve peak velocity (continuous wave Doppler) 
ii. Mean aortic valve gradient 
iii. Aortic valve area (calculated using continuity equation) 
iv. An assessment of LV systolic function (visual estimation or 
Simpson’s biplane calculation if available) 
 
 
10. Cardiac Magnetic Resonance Imaging 
• Either a 1.5 or 3 tesla (T) MRI scanner will be used according to local 
availability at the research site. More details regarding technical aspects 
of the scan are contained within the standardised cardiac MRI scanning 
guidance. Sites should ensure that there are no absolute 
contraindications to cardiac MRI before proceeding. 
• The cardiac MRI will include late gadolinium enhancement imaging, 
performed 10-15 min following the administration of gadolinium based 
contrast agent. Full details can be found in the cardiac MRI scanning 
guidance. 
• The cardiac MRI scan will usually take place at the same time as 
baseline assessment but can take place on a separate visit if necessary. 
If the optional T1 mapping sequences are being acquired then a plasma 
EDTA sample is required on the day of the scan to enable calculation 
of T1 mapping measures. 
• Should the cardiac MRI scan be non-diagnostic then it can be repeated 
at the investigator’s discretion. 
6.3 FOLLOW UP ASSESSMENT 
Participants in Groups A, B and C will have annual study follow up (linked to the date 
of randomisation). This will consist of:  
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1. Annual contact with patient 
Participants will be contacted by telephone annually to assess for symptoms or 
events. At each annual contact NYHA functional classification will be assessed and 
the WHODAS 2.0 (12-item version) completed. If telephone follow up is 
unsuccessful, other methods of collecting this information (such as routine clinic 
appointment, post, email) are acceptable. 
 
2. Medical record review 
Participant medical records should be reviewed at least annually to check for study 
events that require central reporting, however if research teams become aware of 
an event it should be reported contemporaneously.  The following events should 
be reported until completion of study follow up: 
• Death 
• Hospitalisation for syncope, heart failure, chest pain or arrhythmia 
(ventricular arrhythmia or second or third degree heart block) 
• Routine echocardiograms 
• Stroke 
• Insertion of a permanent pacemaker, cardiac resynchronisation 
therapy device or an automated implantable cardioverter defibrillator 
• Endocarditis 
It is anticipated that annual follow up will be conducted until 2020.  If the event rate is 
lower or the study needs to be extended then participants will be asked if they are 
happy to be contacted beyond this date.  This will be discussed when the participant 
consents to take part in the study so written informed consent will not be required to 
extend follow up. 
Long-term follow up of participants will be facilitated by data linkage. Consent will be 
sought for this. 
6.4 AORTIC VALVE INTERVENTION 
Patients undergoing aortic valve intervention (regardless of treatment group allocation) 
will have data collected on post-operative complications within 30 days of surgery. This 
will be achieved by retrospective examination of participant records. 
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Table 6—1: Schedule of Assessments 
 Screening1 Baseline Surgery Annually 
Informed consent - screening2 X    
hsTnI X3    
ECG X4    
eGFR X5    
Demographics X6    
Informed consent – study2   X   
Relevant medical history   X   
Height and weight  X   
BP measurement  X   
Urine pregnancy test  X7   
Edmonton Frail Scale  X   
NYHA classification  X  X 
WHODAS 2.0  X  X 
Phlebotomy  X   
Echocardiogram  X8   
Cardiac MRI  X   
Inclusion/exclusion criteria  X   
Surgery details & post-operative 
complications 
  X  
Annual participant contact    X 
Medical record review    X 
 
  
                                               
1 When screening with ECG only, the screening and baseline assessments may be performed at the 
same visit 
2 When screening with ECG only, the consent process is simplified to a single consent step 
3 Using Abbott ARCHITECTSTAT platform. When screening at ECG only sites, a serum blood sample 
should be taken and frozen to allow for a retrospective analysis of hsTnI centrally. 
4 If the participant’s most recent ECG is within 6 months of screening and is interpretable then there is 
no requirement to repeat this 
5 If the participant’s most recent eGFR result is ≥30 mL/min/1.73 m2 and within 12 months of screening 
then there is no requirement to repeat this unless the investigator makes a clinical judgment that a 
more contemporary result is needed 
6 Demographic data will include a unique identifying number (i.e. CHI or NHS number) for future record 
linkage 
7 This is only required if the participant thinks there is a chance they could be pregnant. 
8 If the participant’s most recent echocardiogram is within 6 months of baseline and the minimum 
reporting criteria have all been measured then is no requirement to repeat this 
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7 DATA COLLECTION 
Data will be collected from consent until final follow up visit.  Site-specific source data 
plans will be created to indicate where protocol required information will be originally 
documented. Source data worksheets created by the Edinburgh Clinical Trials Unit 
(ECTU) will be made available but their use is optional. 
 
Study data will be entered onto an eCRF (case report form) developed by ECTU.  Data 
collected as part of the central cardiac MRI review and endpoint adjudication will be 
entered directly onto the eCRF. 
8 STATISTICS AND DATA ANALYSIS 
8.1 SAMPLE SIZE CALCULATION 
We expect the proportion of primary outcome events (all-cause mortality or unplanned 
AS-related hospitalisation) to be 25% in the routine care arm of the study, and 13.4% 
in the early intervention arm (a hazard ratio of 2), over 2 years of follow up (Dweck et 
al 2011, RBH cohort). We aim to recruit 1000 participants to be screened with cardiac 
MRI for evidence of LV decompensation (mid-wall fibrosis). We would expect this to 
result in 400 patients with mid-wall fibrosis being randomised (1:1). Using a logrank 
approach, we will need to observe 88 primary outcome events to give us 90% power 
at 5% significance level. We will follow participants up for as long as possible before 
the end of study, and thus participants will have between 2 and 3.5 years of follow up, 
and we expect mean follow up to be 2.75 years. We are likely to reach 88 events when 
we have recruited 356 participants (slightly more allowing for drop-out). 
For further calculations we have assumed that our optimal hsTnI threshold will be ~6 
ng/L. This is based upon our preliminary troponin data to date, which demonstrated 
that 62% of patients with an aortic valve peak velocity ≥4.0 m/s had a troponin >6.0 
ng/L. Of these patients, 42% had mid-wall fibrosis on cardiac MRI. On this basis, we 
will therefore need to screen approximately 1600 patients to identify 1000 patients for 
cardiac MRI in order to recruit our target of 400 patients with mid-wall fibrosis. 
At the time that the required amount of data for the primary analysis of the 2 groups 
with mid-wall fibrosis has accrued, we should have 90% power to detect a difference 
in the all-cause mortality between the 2 groups who do not receive early surgery of 
15% vs 29% (log rank test, p=0.05, 2 sided test) 
8.2 PROPOSED ANALYSES 
The primary outcome is defined as first event of all-cause mortality or unplanned AS-
related hospital admission, and the primary comparison will be between group A and 
group B. Time to primary outcome is defined as time from randomisation to primary 
outcome. Patients withdrawing consent for their data to be collected prospectively prior 
to reaching primary outcome will have their time to primary outcome censored at the 
last contact date. The relationship between intervention and the primary outcome will 
be analysed using Cox proportional hazard regression adjusted for the minimisation 
variables used in the randomisation algorithm. The results will be expressed as a 
hazard ratio with the corresponding 95% confidence intervals and 2-sided p-value 
(which will be considered statistically significant if it is ≤0.05). The individual elements 
of the composite primary outcome will be reported separately.  There are no planned 
subgroup analyses.   
Secondary outcomes will be analysed using appropriate methods: Cox proportional 
hazards regression for time-to-event outcomes, logistic regression for binary outcomes 
and linear regression for normally distributed continuous outcomes, adjusted as 
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described above. Continuous outcomes that are not normally distributed will be 
analysed using appropriate nonparametric techniques. Secondary outcomes will be 
presented for groups A, B and C.  A first set of secondary analyses will compare groups 
A and B, and a second set of secondary analyses will compare groups B and C. 
For the purpose of analysis, we will retain participants in the treatment groups to which 
they were originally assigned irrespective of the treatment actually received. Every 
effort will be made to minimise missing data, analysis will be a complete case analysis. 
If there is a sufficient level of missing data for it to affect our conclusions, a multiple 
imputation analysis will be undertaken, using clinically appropriate variables, as a 
sensitivity analysis. A full statistical analysis plan will be written during the trial, and 
finalised prior to database lock.   
9 ADVERSE EVENTS 
The Investigator, or a delegated researcher, is responsible for the detection and 
documentation of adverse events that may be related to participating in the study and 
that meet the criteria and definitions detailed below. 
9.1 DEFINITIONS 
An adverse event (AE) is an untoward medical occurrence in a study participant. 
An adverse reaction (AR), in the context of this study, is any untoward and unintended 
response which is related to any dose of gadolinium based contrast agent administered 
to that participant.  
A serious adverse reaction (SAR) is any AR that: 
• results in death of the clinical trial participant; is life threatening*; 
• requires in-patient hospitalisation^ or prolongation of existing hospitalisation; 
• results in persistent or significant disability or incapacity; 
• consists of a congenital anomaly or birth defect; 
• results in any other significant medical event not meeting the criteria above. 
A suspected unexpected serious adverse reaction (SUSAR) is any AR that is 
classified as serious and is suspected to be caused by the gadolinium contrast agent, 
that it is not consistent with the information in the Summary of Product Characteristics 
(SPC). 
*Life-threatening in the definition of an SAE or SAR refers to an event where the 
participant was at risk of death at the time of the event. It does not refer to an event 
which hypothetically might have caused death if it were more severe. 
^Any hospitalisation that was planned prior to randomisation will not meet seriousness 
criteria. Any hospitalisation that is planned post randomisation will meet the 
seriousness criteria unless it does not constitute an untoward medical occurrence (e.g. 
cosmetic elective surgery, social and/or convenience admission, etc.). 
9.2 IDENTIFYING AEs AND ARs 
All AEs and ARs will be identified from the time a participant signs the consent form to 
take part in the study until the completion of study follow-up. 
9.3 RECORDING AEs AND ARs 
AEs, including post-operative complications, potential aortic stenosis related 
hospitalisations, and mortality, will be recorded as part of the outcome measures in the 
study CRF.  There is no requirement to complete an additional AE form. 
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When an AE occurs, it is the responsibility of the Investigator to review all 
documentation (e.g. hospital notes, laboratory and diagnostic reports) related to the 
event. To the extent the CRF permits, the Investigator will record relevant safety 
information in the CRF.   
Any adverse reaction (AR) to gadolinium contrast that meets seriousness criteria (see 
section 9.1) will be recorded and reported in the study CRF and will also be recorded 
on an ACCORD SAE form, which will then be sent to the Sponsor via email 
(safety@accord.scot).  
Pre-existing medical conditions (i.e. existed prior to informed consent) should be 
recorded as medical history and only recorded as AEs/ARs if medically judged to have 
unexpectedly worsened during the study. Events that are consistent with the expected 
progression of underlying disease should not be recorded as adverse events. 
9.4 ASSESSMENT OF AEs, SAEs, ARs, SARs and SUSARs 
Seriousness, causality, severity and expectedness will be assessed by the PI.  
The Investigator is responsible for assessing each adverse event. The CI may not 
downgrade an event that has been assessed by an Investigator as a SAR or SUSAR, 
but can upgrade an AR to a SAR or SUSAR if appropriate. 
9.4.1 Assessment of Causality 
The Investigator will make an assessment of whether an AE is likely to be related to 
the administration of gadolinium (and therefore be considered an AR) according to the 
definitions below. 
• Unrelated: Where an event is not considered to be related to the administration 
of gadolinium. 
• Possibly Related: The nature of the event, the underlying medical condition, 
concomitant medication or temporal relationship make it possible that the AE 
has a causal relationship to the administration of gadolinium in this study.  
9.4.2 Assessment of Seriousness 
Subsequent to the assessment causality, the Investigator will make an assessment of 
seriousness as defined in Section 9.1. 
9.4.3 Assessment of Severity 
The Investigator will make an assessment of severity for each SAR, and record this on 
the ACCORD SAE form according to one of the following categories: 
 Mild: an event that is easily tolerated by the participant, causing minimal 
discomfort and not interfering with every day activities. 
 Moderate: an event that is sufficiently discomforting to interfere with normal 
everyday activities. 
 Severe: an event that prevents normal everyday activities. 
Note: the term ‘severe’, used to describe the intensity, should not be confused with 
‘serious’ which is a regulatory definition based on participant/event outcome or action 
criteria. For example, a headache may be severe but not serious, while a minor stroke 
is serious but may not be severe. 
9.4.4 Assessment of Expectedness of SARs 
The Investigator will make an assessment of expectedness of any SARs identified 
following gadolinium administration. The assessment will be based upon the reference 
safety information available in the most current version of the Summary of Product 
Characteristics (SPC) for the gadolinium-based contrast agent dosed. 
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9.5 REPORTING OF SARs/SUSARs 
As this trial is a non-CTIMP and involves procedures and interventions that are very 
well established in the medical community, with extensive information available 
regarding risks, only serious adverse reactions (SARs) and Suspected Unexpected 
Serious Adverse Reactions (SUSARs) related to Gadolinium administration, will be 
onward reported to the Sponsor. 
Once the Investigator becomes aware that a gadolinium related SAR/SUSAR, has 
occurred in a study participant, the information will be reported to the ACCORD 
Research Governance & QA Office within 24 hours. If the Investigator does not have 
all information regarding an event, they should not wait for this additional information 
before notifying ACCORD. The ACCORD SAE report form will be used to submit the 
event report, and can be updated when the additional information is received. 
The SAE form will be transmitted by fax to ACCORD on +44 (0)131 242 9447 or may 
be submitted by hand to the office or sent via email to Safety.Accord@ed.ac.uk. Only 
forms in a pdf format will be accepted by ACCORD via email. 
Where missing information has not been sent to ACCORD after an initial report, 
ACCORD will contact the investigator and request the missing information.  
All reports sent to ACCORD and any follow up information will be retained by the 
Investigator in the Investigator Site File. 
9.6  REPORTING REQUIREMENTS 
The ACCORD Research Governance & QA Office is responsible for 
pharmacovigilance reporting on behalf of the co-sponsors (Edinburgh University and 
NHS Lothian). 
The Trial Manager will provide the ACCORD Research Governance & QA Office with 
quarterly safety reports based on the data collected on the CRF. 
9.7 FOLLOW-UP PROCEDURES 
After initially reporting a gadolinium related SAR/SUSAR, the Investigator will follow 
each participant until resolution or the completion of study follow-up. Follow-up 
information will be reported to the ACCORD office. 
10 TRIAL MANAGEMENT AND OVERSIGHT ARRANGEMENTS 
10.1 TRIAL MANAGEMENT GROUP 
ECTU will be responsible for trial management including: organisation of management 
group meetings, organisation of the steering committee, contracting with other 
organisations, preparation of REC and R&D applications, standard operating 
procedures, provision of the randomisation system, database development, data 
management, and data analysis.  
The trial will be led by Christopher Tuck and coordinated by ECTU. An informal project 
management group (PMG) comprising the Chief Investigator, Research Fellow and 
relevant members of the ECTU team will be formed. The Academic and Clinical Central 
Office for Research & Development (ACCORD) in Edinburgh will provide Sponsorship 
and monitoring oversight for the project and the trial will be conducted in line with the 
relevant Sponsor SOPs which are available on the Sponsor website. 
A Delegation Log will be prepared for each site, detailing the responsibilities of each 
member of staff working on the trial.   
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10.2 TRIAL STEERING COMMITTEE 
A Trial Steering Committee (TSC) will be established to oversee the conduct and 
progress of the study. The terms of reference of the Trial Steering Committee, and the 
names and contact details are detailed in the TSC charter. 
10.3 DATA MONITORING COMMITTEE 
As this trial involves procedures and interventions that are very well established in the 
medical community, with extensive information available regarding risks, it was felt that 
a Data Monitoring Committee is not required. 
10.4 INSPECTION OF RECORDS 
Investigators and institutions involved in the study will permit trial related monitoring 
and audits on behalf of the sponsor and REC review.  In the event of an audit or 
monitoring, the Investigator agrees to allow the representatives of the sponsor direct 
access to all study records and source documentation. 
10.5 ENDPOINT ADJUDICATION 
Two independent investigators who are blinded to randomisation details will be asked 
to adjudicate AS-related hospitalisation events from a review of the medical records 
(relevant sections of the medical records will be anonymized and uploaded to the study 
database). In the event of disagreement, the opinion of a third independent reviewer 
will be sought. Causes of death will be established from the death certificate. 
11 GOOD CLINICAL PRACTICE 
11.1 ETHICAL CONDUCT 
The study will be conducted in accordance with the principles of Good Clinical Practice 
(GCP). 
A favourable ethical opinion will be obtained from the appropriate REC and local R&D 
approval will be obtained prior to commencement of the study. 
11.2 INVESTIGATOR RESPONSIBILITIES 
The PI is responsible for the overall conduct of the study at the site and compliance 
with the protocol and any protocol amendments.  In accordance with the principles of 
GCP, the following areas listed in this section are also the responsibility of the 
PI.  Responsibilities may be delegated to an appropriate member of study site staff.  
11.2.1 Informed Consent 
The Investigator is responsible for ensuring informed consent is obtained before any 
protocol specific procedures are carried out.  The decision of a participant to participate 
in clinical research is voluntary and should be based on a clear understanding of what 
is involved. 
Participants must receive adequate oral and written information – appropriate 
Participant Information and Informed Consent Forms will be provided.  The oral 
explanation to the participant will be performed by the Investigator or qualified 
delegated person, and must cover all the elements specified in the Participant 
Information Sheet and Consent Form. 
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The participant must be given every opportunity to clarify any points they do not 
understand and, if necessary, ask for more information.  The participant must be given 
sufficient time to consider the information provided.  It should be emphasised that the 
participant may withdraw their consent to participate at any time without loss of benefits 
to which they otherwise would be entitled. 
The participant will be informed and agree to their medical records being inspected by 
representatives of the sponsor(s). 
The Investigator or delegated member of the trial team and the participant will sign and 
date the Informed Consent Form(s) to confirm that consent has been obtained.  The 
participant will receive a copy of this document, with the original filed in the Investigator 
Site File (ISF) and a copy in the participant’s medical notes. 
11.2.2 Study Site Staff 
The Investigator must be familiar with the intervention, protocol and the study 
requirements.  It is the Investigator’s responsibility to ensure that all staff assisting with 
the study are adequately informed about the intervention, protocol and their trial related 
duties.  
11.2.3 Data Recording 
The Principal Investigator is responsible for the quality of the data recorded in the CRF 
at each Investigator Site. The source data plan identifies which source data correspond 
to CRF data and states which data are recorded directly into the CRF. 
11.2.4 Investigator Documentation 
Prior to beginning the study, each Investigator will be asked to provide particular 
essential documents to the ACCORD Research Governance & QA Office, including 
but not limited to: 
• An original signed Investigator’s Declaration (as part of the Clinical Trial 
Agreement documents); 
• Curriculum vitae (CV) signed and dated by the Investigator indicating that it is 
accurate and current. 
The ACCORD Research Governance & QA Office will ensure all other documents 
required by ICH GCP are retained in a Trial Master File (TMF), where required, and 
that appropriate documentation is available in local ISFs. 
11.2.5 GCP Training 
All members of staff involved in study specific activities are strongly encouraged to 
undertake GCP training in order to understand the principles of GCP.   
11.2.6 Confidentiality 
All laboratory specimens, evaluation forms, reports, and other records must be 
identified in a manner designed to maintain participant confidentiality.  All records must 
be kept in a secure storage area with limited access.  Clinical information will not be 
released without the written permission of the participant.  The Investigator and study 
site staff involved with this study may not disclose or use for any purpose other than 
performance of the study, any data, record, or other unpublished, confidential 
information disclosed to those individuals for the purpose of the study.  Prior written 
agreement from the sponsor or its designee must be obtained for the disclosure of any 
said confidential information to other parties. 
11.2.7 Data Protection 
All Investigators and study site staff involved with this study must comply with the 
requirements of the Data Protection Act 1998 with regard to the collection, storage, 
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processing and disclosure of personal information and will uphold the Act’s core 
principles. 
Computers used to collate the data will have limited access measures via user names 
and passwords. 
Published results will not contain any personal data and be of a form where it does not 
identify individuals and re-identification is not likely to take place. 
12 STUDY CONDUCT RESPONSIBILITIES 
12.1 PROTOCOL AMENDMENTS 
Any changes in research activity, except those necessary to remove an apparent, 
immediate hazard to the participant in the case of an urgent safety measure, must be 
reviewed and approved by the Chief Investigator. 
Amendments to the protocol must be submitted in writing to the appropriate REC and 
local R&D for approval prior to participants being enrolled into an amended protocol. 
12.2 PROTOCOL VIOLATIONS AND DEVIATIONS 
Prospective protocol deviations, i.e. protocol waivers, will not be approved by the 
sponsors and therefore will not be implemented, except where necessary to eliminate 
an immediate hazard to study participants. If this necessitates a subsequent protocol 
amendment, this should be submitted to the REC and local R&D for review and 
approval if appropriate. 
Protocol deviations will be recorded in a protocol deviation log and logs will be 
submitted to the Sponsor every 3 months. Each protocol violation will be reported to 
the sponsor within 3 days of becoming aware of the violation.  All protocol deviation 
logs and violation forms should be emailed to QA@accord.scot. 
12.3 STUDY RECORD RETENTION 
All study documentation will be kept for a minimum of 3 years from the protocol defined 
end of study point. When the minimum retention period has elapsed, study 
documentation will not be destroyed without permission from the sponsor. 
12.4 END OF STUDY 
The end of study is defined as the time of database lock. 
The Investigators and/or the trial steering committee and/or the co-sponsor(s) have the 
right at any time to terminate the study for clinical or administrative reasons.  
The end of the study will be reported to the REC within 90 days, or 15 days if the study 
is terminated prematurely.  The Investigators will inform participants of the premature 
study closure and ensure that the appropriate follow up is arranged for all participants 
involved. 
A summary report of the study will be provided to the REC within 1 year of the end of 
the study. 
12.5 INSURANCE AND INDEMNITY 
The co-sponsors are responsible for ensuring proper provision has been made for 
insurance or indemnity to cover their liability and the liability of the Chief Investigator 
and staff. 
- The following arrangements are in place to fulfil the co-sponsors' 
responsibilities: 
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- The Protocol has been designed by the Chief Investigator and researchers 
employed by the University and collaborators.  The University has insurance in 
place (which includes no-fault compensation) for negligent harm caused by 
poor protocol design by the Chief Investigator and researchers employed by 
the University. 
- Sites participating in the study will be liable for clinical negligence and other 
negligent harm to individuals taking part in the study and covered by the duty 
of care owed to them by the sites concerned.  The co-sponsors require 
individual sites participating in the study to arrange for their own insurance or 
indemnity in respect of these liabilities. 
- Sites which are part of the United Kingdom's National Health Service will have 
the benefit of NHS Indemnity. 
13 REPORTING, PUBLICATIONS AND NOTIFICATION OF 
RESULTS 
The protocol for this trial will be submitted for publication and the trial results will be 
submitted for publication even if this trial stops early. If successfully completed the 
main paper from this project will be submitted for publication in a leading international 
general medical journal. 
  
The main outputs will be provided to guideline developing bodies (including NICE, 
SIGN and the European Society of Cardiology), key professional organisations (such 
as the College of Emergency Medicine) and patient representative organisations (such 
as the British Heart Foundation). 
 
13.1 AUTHORSHIP POLICY 
Ownership of the data arising from this study resides with the study team.  On 
completion of the study, the study data will be analysed and tabulated, and a study 
report will be prepared in accordance with the funders requirements. The authors for 
this project are listed in the trial’s writing committee and publication policy document. 
  
13.2 PUBLICATION 
The clinical study report will be used for publication and presentation at scientific 
meetings. Investigators have the right to publish orally or in writing the results of the 
study. 
Summaries of results will also be made available to Investigators for dissemination 
within their centres (where appropriate and according to their discretion). 
13.3 REPRODUCIBLE RESEARCH AND DATA SHARING 
Following publication of the primary paper, a deidentified individual participant data set 
will be submitted to a data archive for sharing purposes.  Access to the deidentified 
dataset will be under a controlled access model in line with ECTU policies at that time. 
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APPENDIX A 
Post-aortic valve intervention complications secondary 
endpoint 
 
The following post aortic valve intervention complications should be recorded if they 
occur within 30 days of surgery: 
 
• Death caused by an immediate complication of aortic valve intervention 
• Reoperation for any reason (e.g. redo valve replacement, pericardial collection) 
• Stroke 
• Myocardial infarction 
• Diagnosis of infective endocarditis 
• Severe paravalvular regurgitation 
• Valve thrombosis requiring treatment 
• Major vascular complication 
o Access site injury leading to life-threatening bleeding, visceral 
ischaemia or neurological impairment 
• Life threatening bleeding 
o Bleeding in a critical organ (e.g. intracranial, intraspinal, intraocular or 
intrapericardial requiring treatment) 
o Bleeding causing hypovolaemic shock 
o Drop in haemoglobin >5g/dL or ≥4 units blood transfused 
• Wound dehiscence 
• Permanent pacemaker implantation 
• Still requiring renal replacement therapy at 30 days post surgery 
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APPENDIX B  
Definition of Sudden Cardiac Death 
Death that occurs unexpectedly and not within 30 days of an acute myocardial 
infarction (MI).
Note: Sudden cardiac death includes the following scenarios:  
• Death witnessed and occurring without new or worsening symptoms  
• Death witnessed within 60 min of the onset of new or worsening cardiac 
symptoms unless the symptoms suggest acute MI  
• Death witnessed and attributed to an identified arrhythmia (e.g., captured on 
an electrocardiographic recording, witnessed on a monitor, or unwitnessed but 
found on ICD review)  
• Death after unsuccessful resuscitation from cardiac arrest (e.g., ICD 
unresponsive sudden cardiac death, pulseless electrical activity arrest)  
• Death after successful resuscitation from cardiac arrest and without 
identification of a specific cardiac or non-cardiac aetiology  
• Unwitnessed death in a subject seen alive and clinically stable 24 hours before 
being found dead without any evidence supporting a specific non- 
cardiovascular cause of death (information about the patient’s clinical status 
preceding death should be provided if available)  
• Unless additional information suggests an alternate specific cause of death, if 
a patient is seen alive 24 hours before being found dead, sudden cardiac death 
should be recorded. For patients who were not observed alive within 24 hours 
of death, sudden cardiac death should not be recorded. (e.g., a subject found 




Adapted from Hicks, K. A. et al. 2014 ACC/AHA Key Data Elements and Definitions 
for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College 
of Cardiology/American Heart Association Task Force on Clinical Data Standards 
(Writing Committee to Develop Cardiovascular Endpoints Data Standards). Journal of 
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Participant Information Sheet and Consent Form 
Part A (screening) 
 
The                               Trial 
 
 
(Early Valve Replacement guided by Biomarkers of Left Ventricular 
Decompensation in Asymptomatic Patients with Severe Aortic Stenosis) 
 
You are being invited to take part in screening for a research study.  Before 
you decide whether or not to take part, it is important for you to understand 
why the research is being done and what it will involve.  Please take time to 
read the following information carefully. Talk to others about the study if you 
wish.  Contact us if there is anything that is not clear or if you would like more 
information.  Take time to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
We are doing this study to find out if replacing heart valves earlier in patients with 
heart narrowing (severe aortic stenosis) reduces the chance of the heart failing in 
the future and helps people to live longer. 
 
Why have I been asked to take part? 
You have been asked to take part as you have been previously diagnosed with 
severe aortic stenosis but do not have symptoms (such as shortness of breath, chest 
pain or fainting) related to your narrowed valve.  At the moment, doctors aren’t sure 
when the best time to replace your valve is – normally we would wait until you have 
symptoms from your valve before sending you to a surgeon for a valve replacement.  
Having these symptoms suggests that the heart is struggling to cope with the valve 
narrowing, but it can be hard to know if these symptoms are from your valve or for 
another reason. 
 
Some doctors think we would get better results by operating earlier. By doing a heart 
scan (MRI) we can see if there is scarring in the heart, an early sign that the heart is 
struggling to work properly. Although we don’t know yet, replacing the valve when 
there is scarring but before symptoms develop could lower the chance of the heart 
failing in the future and help people to live longer. This trial will see which is better - 
replacing the valve when you have no symptoms but have heart scarring, or 
replacing the valve when you start to have symptoms. 
 
Before inviting you to take part in the main study and have the MRI scan we need to 
do some simple tests to see if you are suitable. 
 
Do I have to take part? 
No, it is up to you to decide whether or not to take part.  If you do decide to take part 
you will be given this information sheet to keep and be asked to sign a consent form.  
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a reason.  Deciding not to take part or withdrawing from the study will not affect the 
healthcare that you receive, or your legal rights. 
 
What will happen if I take part? 
If you decide to take part, you will be invited to confirm your consent in writing by a 
member of the research team and complete the following screening tests: 
 
Ø An ECG (electrical tracing of the heart using sticky pads).  You will only need to 
do this if you have not had one done in clinic recently. 
Ø A blood sample.  This will measure the amount of troponin, a protein found in 
heart muscle.  We will also use this sample to test your kidney function. This is 
checked in case you decide to proceed with the main trial as people with poor 
kidney function cannot receive a special injection that highlights heart scarring. 
 
We do these tests as we have found that a combination of troponin blood test and 
ECG is good at identifying people who are at lower risk of having heart scarring so 
we only have to invite those at higher risk of scarring to come back and have an MRI. 
 
What happens following the results of the screening tests? 
If the screening tests show you are at lower risk of having heart scarring you will not 
need any more tests as part of the study. We will contact you to let you know and 
you will continue to have your follow up with your cardiologist as you would normally. 
 
If the screening tests suggest you are at higher risk of having heart scarring, we will 
we will contact you to inform you of this. A second information sheet (Part B) 
containing further details regarding the EVoLVeD trial will have been given to you 
after your screening tests to read at your leisure. We will offer you an appointment to 
come and discuss these results in detail and take part in the EVoLVeD trial if you 
wish. 
 
Undertaking these screening tests may result in us noticing something that could be 
important to your health.  If so, we will contact you to explain what was noticed and 
support you with information regarding where to go for further advice. 
 
What if there is a problem?  
If you have a concern about any aspect of this study please contact Dr Russell 
Everett on his mobile phone (07736 927507) or via email (russell.everett@ed.ac.uk) 
who will do their best to answer your questions.  
 
In the unlikely event that something goes wrong and you are harmed during the 
research and this is due to someone‘s negligence then you may have grounds for a 
legal action for compensation against your hospital but you may have to pay your 
legal costs. The normal National Health Service complaints mechanisms will still be 
available to you (if appropriate). 
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Patient Experience Team, NHS Lothian 
2nd Floor, Waverley Gate, 2-4 Waterloo Place, Edinburgh, EH1 3EG 
Tel: 0131 536 3370             Email: feedback@nhslothian.scot.nhs.uk 
 
What happens when the study is finished? 
Your study data will be stored indefinitely in a secure manner with access restricted 
to the research team. With your consent, we will periodically ask central NHS 
registers to provide information on your health status (you will not be contacted 
directly for this). This is because it will enable us to find out about any longer-term 
consequences of aortic stenosis and heart scarring.  To help us identify you 
correctly, we will need to collect your unique patient identifier (CHI number or NHS 
number) and store it at the University of Edinburgh. 
 
At the end of the study we will make the study data available for other researchers to 
look at.  Before we make it available we will make sure it does not contain any of 
your personal data. 
 
What will happen to the results of the study? 
Once we have completed the study and analysed the results, we will write a paper, 
which will be submitted for publication in one of the medical journals. You will not be 
identifiable in any published results. We do not routinely contact participants to 
inform them of the outcome of the research but once the study has been published a 
summary of the findings will be available on the Edinburgh Clinical Trials website 
(http://www.ed.ac.uk/edinburgh-clinical-trials). 
 
Who is organising the research and why? 
The study is being sponsored by the University of Edinburgh and NHS Lothian and is 
being funded by the Sir Jules Thorn Charitable Trust.  Your doctors will not be paid 
for including you in this study. 
 
Who has reviewed the study? 
The study proposal has been reviewed by the funder and the Sponsor.  All research 
in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee. A favourable ethical opinion has been obtained from South East 
Scotland Research Ethics Committee. NHS management approval has also been 
obtained. 
 
Will my taking part in the study be kept confidential? 
All the information we collect during the course of the research will be kept 
confidential and there are strict laws which safeguard your privacy at every stage. In 
the unlikely event that you lose capacity and cannot continue to give consent, no new 
data would be collected but we would keep any data we have already. 
 
Study researchers will need access to your medical records and data to carry out this 
research. Information will be stored on secure university/NHS computers, or locked 
away in secure rooms with restricted access.  Access to personal identifiable 
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To ensure that the study is being run correctly, we will ask your consent for 
responsible representatives from the Sponsor and NHS Institution to access your 
medical records and data collected during the study, where it is relevant to you taking 
part in this research. The Sponsor is responsible for overall management of the study 
and providing insurance and indemnity. 
 
 
If you have any further questions about the study please contact Dr Russell 
Everett on his mobile (07736 927507) or via email (russell.everett@ed.ac.uk). 
 
Thank you for taking the time to read this information sheet. 
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Please initial 
each box 
SCREENING CONSENT FORM FOR THE EVOLVED TRIAL 
 
Name of Researcher (PI): Dr Russell Everett 
Site: Edinburgh (NHS Lothian) 




1. I confirm that I have read and understand the information sheet (as 
specified in this document header) for the above study and have had the 
opportunity to consider the information and ask questions. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. 
 
3. I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by individuals from the 
Sponsor, from the NHS organisation or other authorities, where it is 
relevant to my taking part in this research. I give permission for these 
individuals to have access to my records. 
 
4. I give permission for my Community Health Index (CHI) or NHS number 
to be collected and passed to the University of Edinburgh and its Clinical 
Trials Unit 
 
5. I understand that information held and managed by central UK NHS 
bodies and NHS Trusts may be used in order to provide information 
about my health status during and after the study. To do this, I 
understand that my information will be shared with those bodies. 
 
6. I agree to my data/tissue being used for future ethically approved studies 
 
 





     




     
Name of Person taking consent  Signature  Date 
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Participant Information Sheet and Consent Form 
Part B (main study) 
 
The                               Trial 
 
 
(Early Valve Replacement guided by Biomarkers of Left Ventricular 
Decompensation in Asymptomatic Patients with Severe Aortic Stenosis) 
 
You are being invited to take part in a research study.  Before you decide 
whether or not to take part, it is important for you to understand why the 
research is being done and what it will involve.  Please take time to read the 
following information carefully. Talk to others about the study if you wish.  
Contact us if there is anything that is not clear or if you would like more 
information.  Take time to decide whether or not you wish to take part. 
 
This section of the information sheet follows on from Part A and details what will 
happen if the screening tests were to find you to be at higher risk of having heart 
scarring. Just because you agreed to take part in the screening does not mean you 
have to take part in the main study. 
 
What will happen if I take part? 
If you decide to take part in the main study, you will be invited to confirm your 
consent in writing by a member of the research team and attend for the following 
baseline assessments. These assessments will take about 2 to 3 hours (including 
the MRI scan). 
 
Medical history. We will ask you about your medical history and any symptoms 
you have. We will also find out what medications you’re on. 
 
Blood pressure measurement. This will be performed three times with an 
automatic cuff. 
 
Questionnaire and Assessment. We will ask you to fill in a short questionnaire 
and do a 5 minute assessment to get an idea of any symptoms you may have and 
if you are limited in your day-to-day life. 
 
Blood tests. We will take up to approximately 40ml (8 teaspoons) of blood. We 
would like to freeze and store some of your blood for future research into heart 
disease, although you can decide that you would prefer us not to do this. 
 
Echocardiogram (heart ultrasound scan). This will need to be repeated if you 
have not had a recent scan in clinic.  
 
If you are safe to enter the study we will then perform a heart scan (MRI) to confirm 
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This will take place at Clinical Research Imaging Centre next to the Edinburgh 
Royal Infirmary. We will do our best to perform this scan when you attend for your 
baseline assessments however if the scanner is particularly busy we may have to 
invite you back on a separate day for this scan.  
 
The scanner itself involves a strong magnet and uses a combination of magnetic 
fields and radio waves to create extremely detailed pictures of the heart. No 
radiation is used and the scan is extremely safe. People who have certain types of 
metal in their bodies shouldn’t enter the magnetic field (e.g. if you have previously 
had metal fragments in your eyes). It may mean you cannot take part in the study. 
Most orthopaedic implants (such as hip and knee replacements) are completely 
safe as are heart artery stents if they were implanted more than 6 weeks before 
the scan date. It is however usually unsafe to scan patients with pacemakers. 
 
A small plastic tube (cannula) will be inserted into a vein in the arm and you will lie 
in the scanner for approximately 45 minutes. The scanning tunnel itself is relatively 
narrow, but you will be given headphones to listen to music during the scan if you 
wish, and you will also be able to directly speak to the radiographers performing 
the scan. If you suffer from sever claustrophobia you should discuss this with the 
research team before agreeing to take part. During the scan you will be asked to 
hold your breath for several seconds at a time in order to obtain better images. 
You will also receive an injection of a special dye (gadolinium contrast), which 
highlights if any heart scarring is present. The contrast itself is extremely safe.  
 




Example MRI scanner Heart MRI images with white area of heart 
scarring present (arrow) in the otherwise 
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Following the baseline assessments, you will be allocated to one of 3 options: 
 
Option 1: Early Valve Intervention 
 
You will be referred to a heart surgeon who will assess you for early valve 
replacement surgery. The surgeon will discuss in detail your options for surgery 
and any questions you may have. You will only be referred for early valve 
intervention if the MRI shows that you have heart scarring. 
 
We will also contact you annually as part of the study (see the How will I be 
followed up? section). 
 
Option 2: Routine Clinical Care (with study follow up) 
 
You will continue to undergo routine follow up with your regular cardiologist.  Any 
decision for heart valve surgery in the future will be based on normal NHS 
guidelines. This option will contain a mix of people – some will have heart scarring 
and others will not.  
 
We will also contact you annually as part of the study (see the How will I be 
followed up? section). 
 
Option 3: Routine Clinical Care (without study follow up) 
 
If allocated to this group, you will continue to be followed up by your regular 
clinical cardiology team as usual. However you will have no further follow up as 
part of the EVoLVeD study. Any decision for heart valve surgery in the future will 
be based on normal NHS guidelines. 
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How will my treatment be decided? 
Sometimes we don‘t know the best way to treat patients. To find out, we need to 
compare different treatments. We put people into groups and give each group a 
different treatment. The results are compared to see if one is better. To try to make 
sure the groups are the same to start with, each patient is put into a group by chance 
(randomly). 
 
In this study, if you have heart scarring you will be randomised to either option 1 or 2.  
You have an equal chance of getting either option. 
 
If you don’t have heart scarring you will be randomised to option 2 or 3.  You are 
twice as likely to be allocated option 3 as option 2. 
 
If you are allocated option 2, neither you nor your doctor will know if you have 
scarring on your heart.  This is known as blinding.  This is used in all randomised 
trials wherever possible to make sure the study is fair. 
 
 
How will I be followed up? 
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until the end of the study (approximately 3 years but a maximum of 5 years). This will 
involve a short discussion about your general health, any symptoms you may have 
had and we will complete a questionnaire with you. This should take about 10 
minutes in total. We will also check your health records for any hospital admissions 
or new medical problems you may have developed. 
 
If we have to contact you for more than 3 years we will discuss this at one of your 
study follow up visits and ask for your permission then. 
 
What are the possible benefits of taking part? 
You might benefit from the additional procedures and investigations that you will 
have as part of the study. This will include more contact with medical staff and heart 
imaging tests that might identify other important problems in the heart or outside the 
heart that were not previously known about. 
 
What are the possible disadvantages and risks of taking part? 
It is not thought that there are many disadvantages. The MRI scanner takes detailed 
images of a small area of your chest so there is a small chance that we will find 
another abnormality in this area. If these require further assessment we will let you 
and your GP know and arrange for you to see a specialist for any further tests that 
are required. Usually these abnormalities turn out to be of no significance to your 
health, but they may cause you stress and anxiety whilst they are being investigated.  
 
Valve surgery is generally very successful but, like any other surgery, it is not risk-
free. There is a small risk of having a heart attack or stroke, or dying, either during or 
soon after the operation. Your risk will depend on your age and your current state of 
health. There are also small risks of living with a replacement heart valve, such as 
infection, and some types of heart valve wear out gradually over time. Before you 
agree to take part in the study you should discuss with the research team the risks of 
surgery for you. These risks will not be increased by taking part in the study but will 
be brought forward if you enter the study and are selected to have early heart valve 
surgery. The risk of complications from surgery might be slightly lower if the 
operation is performed earlier when you and your heart are healthier.  
 
Taking part in a study might affect the insurance cover you get from your insurance 
provider. Always make sure you know what you need to tell your insurance company 
and what the insurance policy covers. 
 
Will any genetic research be done? 
With your permission, we may ask you to provide some blood for genetic research.  
This blood sample will be used to find out if certain genes are more common in 
people with aortic stenosis and for future research into heart disease. You will not 
know the type of future research your stored sample may be used for and you will not 
be told of the findings of this future research. You have the right to ask that your 
blood sample be destroyed at any time by contacting your study doctor. If you do not 
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What if there is a problem?  
If you have a concern about any aspect of this study please contact Dr Russell 
Everett on his mobile phone (07736 927507) or via email (russell.everett@ed.ac.uk) 
who will do their best to answer your questions.  
 
In the unlikely event that something goes wrong and you are harmed during the 
research and this is due to someone‘s negligence then you may have grounds for a 
legal action for compensation against your hospital but you may have to pay your 
legal costs. The normal National Health Service complaints mechanisms will still be 
available to you (if appropriate). 
 
What happens when the study is finished? 
If you have provided research blood samples we will continue to store these samples 
securely for up to 25 years.  When we test these samples in the future we may send 
them to other academic institutions or commercial companies to help us run those 
tests. 
 
Your study data will be stored indefinitely in a secure manner with access restricted 
to the research team. With your consent, we will periodically ask central NHS 
registers to provide information on your health status (you will not be contacted 
directly for this). This is because it will enable us to find out about any longer-term 
consequences of aortic stenosis and heart scarring.  To help us identify you 
correctly, we will need to collect your unique patient identifier (CHI number or NHS 
number) and store it at the University of Edinburgh. 
 
At the end of the study we will make the study data available for other researchers to 
look at.  Before we make it available we will make sure it does not contain any of 
your personal data. 
 
What will happen to the results of the study? 
Once we have completed the study and analysed the results, we will write a paper, 
which will be submitted for publication in one of the medical journals. You will not be 
identifiable in any published results. We do not routinely contact participants to 
inform them of the outcome of the research but once the study has been published a 
summary of the findings will be available on the Edinburgh Clinical Trials website 
(http://www.ed.ac.uk/edinburgh-clinical-trials). 
 
Who is organising the research and why? 
The study is being sponsored by the University of Edinburgh and NHS Lothian and is 
being funded by the Sir Jules Thorn Charitable Trust.  Your doctors will not be paid 
for including you in this study. 
 
Who has reviewed the study? 
The study proposal has been reviewed by the funder and the Sponsor.  All research 
in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee. A favourable ethical opinion has been obtained from South East 
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Will my taking part in the study be kept confidential? 
All the information we collect during the course of the research will be kept 
confidential and there are strict laws which safeguard your privacy at every stage. In 
the unlikely event that you lose capacity and cannot continue to give consent, no new 
data would be collected but we would keep any data we already have. 
 
Study researchers will need access to your medical records and data to carry out this 
research. Information will be stored on secure university/NHS computers, or locked 
away in secure rooms with restricted access.  Access to personal identifiable 
information will be restricted to the research team.  With your consent we will inform 
your GP that you are taking part. 
 
To ensure that the study is being run correctly, we will ask your consent for 
responsible representatives from the Sponsor and NHS Institution to access your 
medical records and data collected during the study, where it is relevant to you taking 
part in this research. The Sponsor is responsible for overall management of the study 
and providing insurance and indemnity. 
 
 
If you have any further questions about the study please contact Dr Russell 
Everett on his mobile (07736 927507) or via email (russell.everett@ed.ac.uk). 
 
If you would like to discuss this study with someone independent of the study 
please contact Dr Neil Grubb (please contact his secretary via the hospital 
switchboard: 0131 536 1000). 
 
If you wish to make a complaint about the study please contact NHS Lothian: 
 




2-4 Waterloo Place 
Edinburgh 
EH1 3EG 
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The study visit schedule at a glance 
 
Visit no. What will happen 
Screening ü The study team will ask for your consent to take a blood test 
(troponin) and perform an ECG (if you’ve not had one recently) 
ü These results will be used to work out your risk of having heart 
scarring 
ü Those who are at higher risk will be invited to attend a baseline 
visit 
Baseline ü You will be asked to give written consent to enter the study 
ü The study team will then ask you about your general health, ask 
you to complete a questionnaire and perform a brief assessment 
ü Your blood pressure will be taken. 
ü An echocardiogram heart scan may be repeated if you’ve not had 
one recently 
ü We will take some blood 
MRI scan ü The scan involves lying still inside a tunnel for approximately 45 
minutes 
ü A small tube will be inserted into the arm vein to deliver a small 
amount of contrast needed to highlight heart scarring on the scan 




ü If the MRI scan shows heart scarring you may be randomised to 
early surgery 
ü The type of surgery that you get will be agreed between you and 





ü If you are not randomised to early surgery you will continue to have 
follow up with your usual cardiology team 
ü You will be asked to tell your team if you get any symptoms and 
your heart will be checked periodically with ultrasound 
(echocardiogram) scans  




ü The study team will contact you annually to check how you are 
feeling and will also complete a questionnaire about your 
symptoms  
ü They will also review your health records to see if you have had 
any complications or admissions to hospital 
ü This will continue until the end of the study (approximately 3 years 
but a maximum of 5 years) 
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Please initial 
each box 
CONSENT FORM FOR THE EVOLVED TRIAL 
Name of Researcher (PI): Dr Russell Everett 
Site: Edinburgh (NHS Lothian) 
Patient Trial Number:  
 
 
1. I confirm that I have read and understand the information sheet (as 
specified in this document header) for the above study and have had the 
opportunity to consider the information and ask questions. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. 
 
3. I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by individuals from the 
Sponsor, from the NHS organisation or other authorities, where it is 
relevant to my taking part in this research. I give permission for these 
individuals to have access to my records. 
 
4. I understand that information held and managed by central UK NHS 
bodies and NHS Trusts may be used in order to provide information 
about my health status during and after the study. To do this, I 
understand that my information will be shared with those bodies. 
 
5. I agree to my data/tissue being used for future ethically approved studies  
 
 
6. I agree to my General Practitioner being informed of my participation in 
this study 
 
7. I agree to give a blood sample which will be frozen and stored for future 
use (optional – initial the Yes or No box) 
 
8. I agree to give a blood sample which will be used for genetic (DNA) 
analysis (optional – initial the Yes or No box) 
 
9. I understand my blood samples may be sent to other academic 
institutions or commercial companies for analysis 
 





     




     
Name of Person taking consent  Signature  Date 
 
Original – to Investigator Site File.      First Copy – to participant.      Second Copy – to hospital notes. 
Yes    No 
Yes    No 
EvoLVeD: Cardiac MRI Scanning Guidance 
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   Cardiac MRI Scanning Guidance 
 
The      Trial 
 
 
This guidance is designed to be used alongside local policies and procedures in the acquisition and 






• Either 1.5 or 3 Tesla (T) scanners may be used in image acquisition.  
• It is crucial to have a high quality ECG signal to ensure accurate cardiac triggering and optimal 






Patients should be imaged using either a dedicated phased array cardiac/body coil with anterior and 
posterior elements, or alternatively using elements of the spine coil posteriorly and a phased array 
body coil anteriorly. 
 
The patient should be positioned supine with the heart over the middle of the posterior coil elements 
being used for imaging. 
 
If the patient is male, the chest may need to be shaved prior to placement of ECG electrodes in order 
to establish optimal conduction of ECG-gating signal.  Electrodes should be placed according to 
scanner manufacturer specifications.  Only MRI-compatible ECG electrodes and gating equipment 
should be used.  Once the electrodes are in place, the technologist should view the ECG signal on the 
MR patient monitoring system and on the MR scanner console.  The technologist should check that 
the MR system is detecting a gating signal from the ECG.  If the MR system is gating reliably and 
correctly on the R-wave, the anterior cardiac or body coil should be placed over the patient chest, 
with the heart approximately in the middle of the coil. 
 
The patient should then be moved to the bore aperture and the ECG-gating signal checked again.  If 
the MR system is designed to run through a ‘learning’ phase for ECG-gating, this procedure should be 
followed at this stage. 
 
If the ECG-gating signal is still reliable, the middle of the imaging coil (and therefore patient heart) 
should be moved to magnet isocentre.  Once the patient is at isocentre, a final assessment of gating 
quality should be made.  If the MR system is not reliably gating to the patient R-wave, the patient 
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Structural imaging Late gadolinium 
enhancement 
T1 mapping (optional) 
Pulse 
sequence 
Cine MRI Fast IR-prepared gradient 
echo post contrast 
MOLLI pre and post contrast 
Typical 
images 
   
Rationale Quantify LV size, mass and 
systolic function 
Identify the presence of mid-
wall late gadolinium 
enhancement as a marker of 
LV decompensation 
To assess for extracellular 
volume expansion / diffuse 
myocardial fibrosis 
 
In brief the imaging protocol will consist of: 
 
1. Localiser sequences 
2. LV imaging I (4 chamber, 3 chamber and 2 chamber long axis cines + LV short axis stack) 
3. Native (pre-contrast) T1 measurements (optional) 
4. Gadolinium contrast administration 
5. LV imaging II (LVOT and aortic valve cines) 
6. Late gadolinium enhancement imaging  
7. Post-contrast T1 measurements (optional) 
 
 
1. Localiser sequences 
 
Note: all breath-holds should be acquired in expiration. 
 
1. Cardiac plane localization 
a) 3-plane localizer: run automatically, untriggered free breathing to localize heart centre 
position.   
b) 3-plane isocentre localizer: adjust heart to isocentre of bore (run this acquisition in 
ISOCENTRE mode).  Prescribe 3 axial, 3 coronal, 3 sagittal slices, single breath-hold, ECG-
trigger on every heartbeat, capture cardiac cycle for diastole. 
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c) Axial dark blood half-fourier localizer: 20 or more slices for coverage prescribed from 
sagittal and coronal 1b) views, cover from above aortic arch to below apex, multiple 
breath-holds if required by MR system, trigger on every second heartbeat, capture cycle 





d) 2 chamber localizer: prescribe 1 slice from axial view (1c) parallel to ventricular septum, 
bisect left ventricle through mitral valve and apex, single breath-hold, trigger on every 
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e) 4 chamber localizer: prescribe 1 slice from two chamber view (1d), bisect left ventricle 
through mitral valve and apex, single breath-hold, trigger on every heartbeat, capture 




f) Short-axis localizer: prescribe 3 slices from LVOT towards apex (whole stack is shown in 
image below) from 2 chamber (1d) and 4 chamber (1e) views, perpendicular to long axis 
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2. LV imaging I 
 
CMR cine imaging will be performed using steady state free-precession (SSFP), breath-hold cines. The 
following sequences should be acquired: 
 
a) 2-chamber cine: prescribe 1 slice, parallel to ventricular septum on a mid-ventricle short 
axis localiser (1f), bisect left ventricle through mitral valve and apex on four chamber 




b) 3-chamber cine: prescribe 1 slice, bisect the LVOT and posterolateral LV wall on the most 
basal short axis localiser (1f), and bisect the LV through the mitral valve and apex on a 4-





c) 4-chamber cine: prescribe 1 slice, bisect LV through the mitral valve and apex on 2-
chamber localiser (3a), bisect left and right ventricles on between anterior and posterior 
papillary muscle, mid-ventricle short axis localiser (1f), rotate FoV to avoid phase-wrap, 
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d) Short-axis cine stack: prescribe contiguous slices from 2-chamber cine diastolic view (2a) 
and 4-chamber cine (2c), perpendicular to long axis of LV, slices should be acquired with 
8mm slice thickness and no gap, with enough slices selected to cover from mitral valve 
to apex. Rotate FoV to avoid phase-wrap, multiple breath-holds (depending on parallel 
imaging factor used), retrospective gating. Checking each slice for gating artefacts and 
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3. Native (pre-contrast) T1 mapping (optional) 
 
If T1 mapping is performed a Modified Look Locker Inversion sequences should be used (3-3-5, start 
100ms, increment 80ms, and 160ms). 
 
Two T1 maps should be acquired which correspond to slice positions used during the short axis cine 
sequences. The two slices to be acquired are the basal-LV (the most basal slice with a full circle of 
myocardium that does not contain the LVOT in mid-diastole) and mid-LV (two slices more apically 
from the basal LV slice, approximately half way from mitral valve to LV apex). This aims to minimise 
scan time whilst maximising usable data. In our experience, T1 mapping analysis of apical slices is 
challenging due to partial voluming and therefore we do not intend to acquire T1 mapping images 
from this area. 
 
Selection of the basal slice is critical to enable image analysis. A complete ring of LV myocardium is 
necessary for accurate analysis. There should be no hint of LVOT visible on the septal wall to enable 





Incomplete ring of 
myocardium (portion of 
LVOT is visible). This 







First (most basal) slice 








Slice position chosen 
(from SA cine imaging) 2 
slices more apical than 
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4. Gadolinium contrast administration 
 
A non-linear gadolinium chelate with average (not high) relaxivity should be injected into a peripheral 
vein via an intravenous cannula. Ideally the cannula should be 20 gauge (pink) or above. The method 
of injection (power injector or by hand) should be as per local policy. Gadovist (gadobutrol) at a dose 
of 0.15 mmol/kg is the preferred contrast agent. If other agents are used the dose can be adjusted as 
per local policy. 
 
Other acceptable contrast agents are: 
• Prohance (gadoteridol) 
• Dotarem (gadoteric acid) 
 
A single scout image of the LV short axis should be acquired immediately following contrast injection. 
This image should be labelled as “contrast injection end” and will allow retrospective verification via 
the time stamps of the timing of the late gadolinium sequences with respect to contrast injection.  
 
 
5. LV imaging II (LV short axis cines) 
 
Further LV cine imaging will be performed post contrast injection to keep the total scan time as short 
as possible. 
 
a) LVOT cine (slice perpendicular to the three-chamber view) 
 
b) Aortic valve cross-section sequence (short-axis image of the valve perpendicular to the 
aortic valve leaflets tips observed on the 3-chamber and LVOT cine views). This should be 
gradient echo, with low flip angle and short TR (e.g. FLASH)  
 
 
6. Late gadolinium enhancement imaging 
 
The first images of the late gadolinium enhancement acquisition should be acquired 7 minutes after 
gadolinium infusion.  All late enhancement scans should be acquired with optimal TI selected to null 
normal myocardial signal as outlined below.  Please note that as time progresses TI may need to be 
adjusted to effectively null normal myocardium. 
 
a) TI scout: used to determine the optimal TI for nulling of normal myocardium in subsequent late 
gadolinium enhancement images. Prescribe as the mid ventricular short axis slice (copied from 
2d), rotate FoV to avoid phase-wrap, single breath-hold, trigger on every heartbeat, capture cycle 
for optimal acquisition window.  Please note that repeat T1 scouts should be considered if 
inadequate nulling it observed on later late gadolinium acquisitions. This should provide an 
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b) Short-axis gradient echo late gadolinium enhancement (GRE-LGE): prescribe slices of the breath 
hold segmented inversion recovery sequence. Copy the exact image position of short-axis cine 
slices (2d) so that these images can be directly compared to the LGE images. Adjust TI for nulling 
of normal myocardium (see image on right above), rotate FoV to avoid phase-wrap. Multiple 
breath-holds, trigger on every second heartbeat, capture cycle for diastolic imaging.  Slices should 
be acquired with 8mm slice width and no slice gap, copied to previously acquired short axis cine 




c) Phase swap short-axis GRE-LGE: the above (6b) should be repeated using identical settings but 
with phase swap in order to help distinguish artefact from true LGE.  
 
d) 4-chamber GRE-LGE: prescribe 1 slice, breath hold segmented inversion recovery sequence, copy 
slice position of 4 chamber cine (2c), adjust TI for nulling of normal myocardium, rotate FoV to 
avoid phase-wrap, single breath-hold, trigger on every second heartbeat, capture cycle for 
diastole. If regions of LGE are noticed on short-axis images the plane of this long axis image can 




e) 2 chamber late gadolinium enhancement: prescribe 1 slice, breath hold segmented inversion 
recovery sequence, copy slice position of 2 chamber cine (2a), adjust TI for nulling of normal 
myocardium, rotate FoV to avoid phase-wrap, single breath-hold, trigger on every second 
heartbeat, capture cycle for diastole. If regions of LGE are noticed on short-axis images the plane 
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NB. If poor quality GRE-LGE images despite best attempts to null normal myocardium and repeated 
T1 scouts please switch to phase sensitive inversion recovery (PSIR) imaging. 6abcd should be 
repeated using a phase sensitive inversion recovery turbo-FLASH technique (select both magnitude 







7. Post-contrast T1 measurements (optional) 
 
For post-contrast measurements, the same two slice locations should be used as the native T1 map. 
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8. Acceptable variation: 
 
a. Late gadolinium enhancement  
 
The preferred late gadolinium enhancement sequence is a breath-hold gradient echo as specified 
above (section 6b). Our primary goal is obtaining excellent image quality for the late enhancement 
imaging as this directly informs study randomisation. If a site has particular experience with other 
types of LGE sequences (e.g. free breathing PSIR) and these can be performed without sacrificing 
image quality these may be used instead. Please contact the EVoLVeD trial manager if there are any 
queries regarding this.  
 
 
b. Aortic valve cross section 
 
A single short axis cross section view is prescribed in the guidance above (section 5b). Sites that would 
prefer to perform additional images as part of a stack (e.g. 3 slices, 5mm slice thickness, no gap) may 
do so providing the quality of the late enhancement images is not compromised.  
 
 
c. Cross-cutting potential areas of LGE 
 
If areas of mid-wall LGE are observed during the short-axis LGE stack that would not be visible on the 
2, 3 or 4 chamber long-axis images, then a long-axis cross-cut view can be acquired. This should be 
planned on the relevant short axis slice so that the resulting long-axis image intersects both the centre 
of the LV cavity and the area thought to be LGE. This is useful for the image analysis team to confirm 
that enhancing areas are true LGE and not artefact. 
 
 
d. Repeat imaging 
 
In the event that repeat imaging is required, a reduced, targeted scan may be acceptable to minimise 
participant burden.  This would need to be approved by the study team in Edinburgh prior to any 
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Table of CMR sequences 
 






Position subject within scanner, ensure high quality 
ECG signal and IV cannula patency 
 5 mins  
Sequence    
Localiser 1   
Site specific method of localisers to derive 
appropriate cardiac planes 
1-5 1-3 mins  
4 chamber (horizontal long axis) cine 1 2 min  
2 chamber (vertical long axis) cine 1 2 min  
3 chamber cine 1 2 min  
LV short axis stack cine – 8mm slice thickness, no gap 14-15 6 mins  
MOLLI (basal and mid ventricle slices) - OPTIONAL 1 2 mins  
Inject contrast (0.15mmol/kg)    
Single scout – any image, localiser (labelled “contrast 
injection end” 
1 1 min 0-1 
LVOT cine (orthogonal to 3 chamber) 1 2 min 1-3 
Aortic valve FLASH 1 2 min 3-5 
Break – wait until 7 minutes post gadolinium  0-2 mins 5-7 
TI scout – to determine optimal TI 1 1 min 7-8 
GRE-T1 LGE LV short axis stack – 8mm slice thickness, 
no gap 
14-15 7 mins 8-15 
Phase swap GRE-T1 LGE LV short axis stack* 14-15 7 mins 15-22 
Long axis GRE-T1 LGE images 3 3 mins 24-27 
MOLLI (basal and mid ventricle slices) - OPTIONAL 1 2 mins 22-24 
Total scan time    
Standard protocol  45 mins  
Optional T1 mapping included  49 mins  
 
*PSIR LGE LV short axis stack to be performed instead of phase swap if initial GRE-T1 stack nulling is 
suboptimal  
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INTRODUCTION
Aortic stenosis (AS) is the most common valve 
disease requiring surgical intervention in high-in-
come countries.1 It is characterised by progressive 
thickening, fibrosis and calcification of the leaf-
lets leading to restriction and valve obstruction.2 
The consequent increase in left ventricular after-
load leads to a hypertrophic response of the left 
ventricle, normalising wall tension and maintaining 
cardiac output. However, with progressive valvular 
stenosis, this hypertrophic response eventually 
decompensates resulting in symptom development, 
heart failure and death.
With no medications proven to attenuate or 
reverse stenosis progression, the only available 
treatment is valve replacement. This should ideally 
be performed when the risks of the disease process 
(ie, sudden cardiac death, irreversible functional 
impairment and heart failure) outweigh those 
of intervention (ie, procedural risk, long-term 
complications and potential need for reoperation). 
However, we frequently lack robust evidence to 
make accurate assessments of such risk. Deciding 
on the timing of valvular intervention is therefore 
difficult in many patients, and contemporary clin-
ical guidelines are often underpinned by histor-
ical observational data rather than high-quality 
randomised controlled trials. This article will review 
our current understanding of the pathophysiology 
of AS, describe and examine the evidence behind 
current guideline recommendations and explore 
potential future strategies to optimise the timing of 
valve intervention.
PATHOPHYSIOLOGY OF VALVULAR STENOSIS 
AND THE HYPERTROPHIC RESPONSE
Since the original description of AS by Mönckeberg 
in 1904, the decline in rheumatic fever and ageing 
population have led to a demographic transition 
towards fibrocalcific disease. For many years, fibro-
calcific AS was viewed as a degenerative disease 
where progressive ‘wear and tear’ led to struc-
tural damage and passive valvular calcification. 
However, contemporary thinking is that fibrocal-
cific AS develops as part of a series of intricate and 
highly regulated inflammatory, fibrotic and osteo-
genic processes. The pathophysiological processes 
driving aortic valve stenosis can be divided into 
two phases.2 The initiation phase is characterised 
by endothelial injury accompanied by infiltration 
of lipids, lipid oxidation and proinflammatory 
response. Despite the clear similarities with athero-
sclerosis, three large randomised trials have failed 
to show any effect of statins on disease progression 
or clinical outcome. The propagation phase is char-
acterised by the appearance of osteoblast-like cells 
that coordinate progressive valvular calcium and 
bone matrix deposition. This osteogenic pheno-
type involves many signalling molecules involved in 
bone formation and is both self-perpetuating and 
highly regulated.2 Advances in imaging now allow 
for non-invasive assessment of both the burden and 
activity of calcification in the valve3 4; however, 
the severity of aortic valve obstruction is still best 
assessed using echocardiography.5
Myocardial response
The traditional focus of AS assessments has been on 
the valve. However, the left ventricular myocardial 
response to pressure overload is equally important,6 
particularly as the correlation between echocardio-
graphic measures of AS severity and the degree of 
myocardial hypertrophy is moderate at best.7 While 
left ventricular hypertrophy maintains wall stress 
and cardiac output for many years, it eventually 
decompensates, with cell death and myocardial 
fibrosis identified as key processes.8 Many imaging 
and biomarker surrogates of these processes have 
been investigated providing significant prog-
nostic information that will be discussed later in 
this article. Gender appears to have an important 
influence on both the LV remodelling response 
and patient outcomes,9 but detailed discussion is 
beyond the scope of this article.
CURRENT GUIDELINE-RECOMMENDED 
TREATMENT STRATEGIES AND THEIR 
LIMITATIONS
Broadly speaking, contemporary clinical guide-
lines recommend aortic valve intervention when 
stenosis severity is deemed severe and there is 
evidence of left ventricular decompensation, using 
either direct objective or surrogate symptomatic 
Learning objectives
 ► To review the pathophysiology of fibrocalcific 
aortic stenosis, the myocardial response to 
pressure overload and current clinical guidelines 
concerning the timing of valve intervention.
 ► To explore and to quantify the risks of earlier 
intervention in asymptomatic patients 
compared with the risks of a watchful waiting 
strategy.
 ► To detail future potential strategies for deciding 
on timing of aortic valve intervention and 
current ongoing randomised controlled trials.
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measures (figure 1 and table 1).10 11 Haemodynamic 
severity is best assessed using echocardiography but 
can be challenging when measures of severity are 
discordant or low-flow states exist. New recom-
mendations for confirming AS severity are given in 
the 2017 ESC/EACTS guideline update.5 Detailed 
discussion of low-flow states is beyond the scope of 
this article but can be found elsewhere.12
Presence of AS-related symptoms
It is universally accepted that the development of 
patient symptoms (exertional dyspnoea, angina 
or syncope; table 2) serves as an indicator of left 
ventricular decompensation and a dismal prognosis 
without intervention. This was first described in the 
seminal paper by Braunwald and Ross in 196813 and 
forms the underlying framework of how we manage 
patients today. However, this finding was based 
on retrospective data from just 12 patients with a 
mixture of bicuspid and rheumatic valve disease 
and a mean age of death of 63 years. The changing 
demographics of AS make it difficult to interpret 
the current relevance of these historical data to the 
patients seen in current practice who are frequently 
in their eighth or ninth decades. Symptom assess-
ment can be highly challenging in these patients due 
to the high prevalence of both comorbidity, which 
may cause symptoms to be falsely attributed to AS, 
and physical inactivity, which can conceal exer-
tion-related problems.
Exercise testing may help unmask symptoms in 
many patients and is safe when performed in stable 
patients.14 ESC guidelines recommend surgery in 
patients with severe ASand typical symptoms on 
exercise test (class I, level C) or a fall in systolic 
blood pressure at peak exercise (class IIa, level C). 
This recommendation is based largely on obser-
vational data demonstrating that a positive exer-
cise test is a strong predictor of sudden death or 
symptom development.15 However, these data are 
limited, consisting of a series of relatively small 
observational studies with inherent risk of bias and 
Figure 1 ESC/EACTS algorithm for management of severe AS (2017 guidelines). AS, aortic stenosis; LVEF, left ventricular ejection fraction; 
SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.
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heterogeneity as to what constituted an abnormal 
test. According to a recent meta-analysis, while 
the negative predictive value of stress testing for 
subsequent cardiac events is reasonable (79%), 
the positive predictive value is modest (66%).14 
Exercise testing has other major limitations; up 
to 20% of patients will be unable to perform the 
test due to poor mobility, while pre-existing ECG 
abnormalities are present in up to 50% of patients 
confounding test interpretation.16 It is worth noting 
that exercise testing may also detect abnormalities 
caused by coexistent coronary disease, which is an 
important determinant of both management and 
prognosis.17
Impaired left ventricular ejection fraction
Development of left ventricular systolic impairment, 
as identified by a reduced left ventricular ejection 
fraction, is an inevitable consequence of progressive 
and untreated valvular stenosis assuming sudden 
death does not occur. Although the risk of perioper-
ative mortality is elevated in the setting of reduced 
ejection fraction, these patients have a dismal prog-
nosis without intervention and improved long-term 
outcomes with valve replacement earning a class I, 
level C recommendation in clinical guidelines.10 11
In clinical practice, patients with AS can develop 
a reduction in ejection fraction for a variety of 
reasons, and it remains important to consider the 
mechanism of this reduction and whether it is 
reversible. Reductions in ejection fraction occur as 
a direct response to increases in afterload and will 
reverse following valve replacement. By contrast, 
the ejection fraction does not improve in approxi-
mately 25% of patients10 11 18 19 who are more likely 
to remain symptomatic and who have adverse long-
term outcomes (twice as likely to die over 5 years 
follow-up).20 In these patients, persistent systolic 
dysfunction appears related to the development of 
irreversible scar due to either myocardial infarction 
or decompensation of the hypertrophic response.21 
In sick, frail patients, such information may govern 
whether valve intervention is likely to be of benefit.
Reductions in ejection fraction are therefore a 
late, non-specific and often irreversible feature in 
AS, leading to interest in alternative methods for 
detecting left ventricular decompensation7 22–24 as 
will be discussed.
Very severe AS
Patients with critical AS appear to have a particu-
larly poor prognosis, similar to that of symptomatic 
Table 1 Recommendations for Intervention in patients with severe AS (ESC/EACTS guidelines 2017)
Symptomatic severe AS (surgical AVR or TAVI) Class Level
Indicated in severe high gradient AS (AV Vmax >4 m/s or mean gradient >40 mm Hg). I B
Indicated in patients with low-flow low-gradient severe AS with reduced ejection fraction and evidence of contractile reserve excluding pseudosevere 
AS.
I C
Should be considered in patients with low-flow low-gradient severe AS with preserved ejection fraction after careful confirmation of severe AS. IIa C
Should be considered in patients with low-flow low-gradient severe AS with reduced ejection fraction without evidence of contractile reserve 
especially where CT calcium scoring confirms severe AS.
IIa C
Should NOT be performed in patients with severe comorbidities where the intervention is unlikely to improve quality of life or survival. III C
Asymptomatic severe AS (surgical AVR only)
Indicated in patients with severe AS and left ventricular systolic dysfunction (LVEF <50%) not due to another cause. I C
Indicated in patients with abnormal exercise test showing symptoms on exercise clearly related to AS. I C
Should be considered in patients with abnormal exercise test showing a decrease in blood pressure below baseline. IIa C
Should be considered if the surgical risk is low and one of the following abnormalities is present:
 ► Very severe AS (AV Vmax >5.5 m/s).
 ► Severe valve calcification with a rate of progression ≥0.3 m/s/year.
 ► Markedly elevated BNP (>3-fold above age-corrected and sex-corrected normal range) confirmed by repeated measurements without other 
explanations.
 ► Severe pulmonary hypertension (systolic pulmonary artery pressure >60 mm Hg at rest confirmed by invasive measurement) without other 
explanation.
IIa C
AS, aortic stenosis; AV, aortic valve; BNP, B-type natriuretic peptide; LVEF, left ventricular ejection fraction; TAVI, transcatheter aortic valve implantation.
Table 2 Symptomatology of severe aortic stenosis
Symptom Aetiology Potential questions to ask:
Angina Supply–demand imbalance: coexistent coronary disease and fixed 
cardiac output versus hypertrophied myocardium.
‘Do you get chest pain or discomfort when walking or doing other 
activities?’
Breathlessness/reduced exercise capacity Reduced LV compliance, increased left ventricular end-diastolic and 
pulmonary capillary pressures.
‘Can you walk ask many stairs as this time last year?’
‘Can you keep up with your friends?’
Presyncope/syncope
(important to elicit any exertional 
component)
Fixed cardiac output, skeletal muscle vasodilation on exertion and 
resultant cerebral hypoperfusion.
‘Have you felt lightheaded like you might faint?’ 
‘Have you had any fainting or blackout episodes?’
Palpitations Development of atrial or ventricular arrhythmia, myocardial 
scarring.
‘Are you aware of your heart racing?’
LV, left ventricular.
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severe AS.25 Indeed patients with peak aortic jet 
velocities of >5.0 and >5.5 m/s demonstrate a 
2-year event-free survival of 43% and 25%, respec-
tively, compared with 70% in those with Vmax 
4.0–4.9 m/s.26 The ESC/EACTS guidelines there-
fore recommend consideration of aortic valve 
replacement in patients with Vmax >5.5 m/s if 
the estimated surgical risk is low (class IIa, level 
C). However, these observational studies mostly 
examined the composite endpoint of mortality and 
referral for aortic valve intervention with a strong 
risk of referral bias and event rates mainly driven by 
decisions to perform surgery.
Rapid haemodynamic progression
Although the average rate of progression (measured 
by peak aortic-jet velocity) is 0.24±0.30 m/s/
year, this rate is highly variable.27 Moreover, it is 
subject to scan–rescan variation in peak velocity 
measurements, which can be high in clinical prac-
tice. Patients with rapid progression (>0.3 m/s/
year) and significant valve calcification have a rate 
of symptom development or mortality of 79% at 2 
years.28 As a result, referral for surgical interven-
tion in these patients is given a class IIa, level C 
recommendation in the latest guidelines. However, 
again, this is based on limited observational data, 
and this strategy requires standardised high-quality 
echocardiography over several years to confidently 
determine rate of progression.
Elevation of B-type natriuretic peptide (BNP) 
levels
BNP is the first cardiac biomarker to be included 
in the decision-making algorithm for aortic valve 
replacement. Early studies investigating natri-
uretic peptides in AS showed promise but were 
criticised for their small size, observational nature 
and use of softer outcome endpoints.29 30 In 
addition, many patients were symptomatic, and 
the variation in normal BNP with age and sex 
were not accounted for. A more recent study of 
565 patients with asymptomatic moderate-to-se-
vere AS identified that a BNP ratio (measured 
BNP value divided by upper limit of normal for 
patient’s age and sex) of >1 was independently 
predictive of mortality and a ratio of >3 had an 
HR of 7.3 for survival in patients with asymp-
tomatic severe AS.31 As such, the latest clinical 
guidelines reflect these data with a level IIa, class 
C recommendation for aortic valve replacement if 
the BNP ratio is persistently above 3 and overall 
surgical risk is low. However, BNP is a non-spe-
cific marker of cardiac dysfunction, and its utility, 
like each of the other parameters, has yet to be 
tested in a randomised controlled trial.
The recently published ESC clinical guidelines 
also removed two previous IIb indications for AVR 
in asymptomatic patients: an increase in mean 
aortic gradient of >20 mm Hg with exercise, or the 
finding of excessive LV hypertrophy in the absence 
of hypertension.
BALANCING COMPETING RISKS
There are clear limitations with many of our 
guideline-advocated strategies. Most are based on 
limited observational data and supported by level 
C recommendations. There is therefore a need for 
randomised controlled trials assessing the optimal 
timing of surgery and novel objective methods to 
guide this major clinical decision. Ideally, interven-
tion would be performed in patients just as the left 
ventricle is starting to decompensate but before 
substantial irreversible damage has accrued and at 
a time when the short-term and long-term risks of 
the intervention are outweighed by the risks of not 
intervening (figure 2 and table 3). An understanding 
of these competing risks is therefore critical.
Figure 2 Optimising the timing of aortic valve intervention in progressive aortic stenosis. TAVI, transcatheter aortic valve insertion.
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Risks of valve intervention
Surgical aortic valve replacement remains the standard 
of care for valvular intervention, with improvements 
in surgical and postoperative care driving periopera-
tive mortality down to ~1%–3%. Other important 
perioperative complications include conduction 
disease requiring permanent pacemaker insertion 
(1.5%–8.6%32) and cerebrovascular accidents (2.4%–
8.1%33–35). There is also the risk of cognitive decline 
(due to perioperative cerebral hypoperfusion micro-
emboli or anaesthetic agent neurotoxicity35). An indi-
vidual’s risk of these complications can be estimated 
using surgical risk calculators such as EUROSCORE II 
and the Society of Thoracic Surgeons score. An argu-
ment in favour of early surgery is that operative risk 
is lower in younger patients that are asymptomatic, 
have less comorbidity and have normal left ventric-
ular function.
The emergence of minimally invasive transcath-
eter aortic valve insertion (TAVI) over the last 10 
years has completely changed the landscape for 
decision making regarding valve intervention in 
symptomatic patients. Current trials show non-in-
feriority of this percutaneous technique compared 
with surgical intervention in both high-risk and 
intermediate-risk patients,34 36–39 and procedural 
risk may further reduce with increasing clinical 
experience and advances in prosthesis design and 
delivery. Indeed, major vascular complications have 
decreased substantially (from >10% to <5%40) as 
have stroke rates, which are between 2% and 3% 
in contemporary cohorts.40 However, the require-
ment for permanent cardiac pacing postprocedure 
remains consistently higher than surgical interven-
tion at >10%40 and while TAVI allows for rapid 
patient recovery and mobilisation, the long-term 
durability of these bioprostheses has not been 
demonstrated.41 This will be key before their 
widespread use in younger or asymptomatic patient 
groups can be recommended.
Performing valve intervention introduces small 
but significant annual risks associated with the pres-
ence of a prosthetic valve. These risks are heavily 
influenced by valve type, with both anticoagulant 
related major bleeding (1.8%–2.6% per year) and 
thromboembolism (0.7%–1.0% per year) more 
frequent with mechanical valves.42 In addition, there 
is an increased risk of endocarditis (1%–3% during 
the first year then <0.5% per year43), which has a 
high associated morbidity and mortality. Whereas 
structural valve degeneration is exceedingly rare 
in mechanical valves, bioprosthetic valves have a 
limited lifespan which can be difficult to predict. 
In these patients, valve degeneration usually starts 
to occur 10 years following implantation44 and 
occurs more rapidly in younger patients.45 This is 
an extremely important issue if bioprosthetic valves 
are to be used in younger asymptomatic patients. 
Ongoing research into decellularisation techniques 
and tissue engineering may lead to improved 
bioprosthetic valve longevity, while advances in 
mechanical valve design might eventually elimi-
nate the need for anticoagulation and associated 
bleeding risk. In addition, the use of a transcatheter 
valve inside a surgical bioprosthetic valve (so called 
valve-in-valve TAVI) may reduce the risk of future 
procedures should valve degeneration occur.
Risks of not intervening
The risk of sudden cardiac death in patients with 
asymptomatic severe AS managed conservatively 
is ~1% per year and occurs without preceding symp-
toms in 70% of cases.46–48 Once symptoms develop, 
further clinical deterioration can be rapid with a 
significant risk of sudden death while awaiting inter-
vention (4% at 1 month, 12% at 6 months).49
Table 3 Estimates of clinical risks associated with watchful waiting or early intervention strategies 
Risks associated with watchful waiting Risk estimate Risks associated with early intervention Risk estimate
Sudden cardiac death 1.0%–1.5% per year
46–48
Perioperative mortality 1%–3%
(refine using validated risk calculator)
Death while awaiting elective intervention 
once symptoms develop




 ► Pacemaker requirement.
 ► Major bleeding.







 ► Impaired left ventricular function.
 ► No contractile reserve.





 ► Pacemaker requirement.
 ► Major vascular complications.
 ► Major bleeding.







Lack of improvement in ejection fraction 
following intervention
25%–50%10 11 Long-term prosthetic valve complications:
 ► Thromboembolism.




Incomplete resolution of symptoms Approximately 50%50 Prosthetic valve endocarditis 1%–3% in first year then <0.5% per year43
Increased late postintervention mortality:
 ► Impaired ejection fraction.
 ► Myocardial fibrosis.
HR 2.020
HR 1.25–5.2521 51 57
Reoperation for structural valve 
degeneration:
 ► <65 years of age.
 ► >65 years of age.
 
 
46%–55% at 20 years
8%–15% at 20 years45
SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.
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Delaying aortic valve intervention until there 
is evidence of advanced left ventricular decom-
pensation results in greater perioperative risks.48 
Observational studies have quoted increased 
perioperative mortality (9%–19%10 20 50) in patients 
who have developed left ventricular systolic impair-
ment and advanced myocardial fibrosis.51 Further 
risk stratification can be performed using stress 
echocardiography to assess myocardial contractile 
reserve, with lower perioperative risks if contractile 
reserve is present (5% vs 22%–32%11 52). However, 
given the dismal prognosis of untreated AS, even 
patients without contractile reserve have improved 
long-term survival if they survive the perioperative 
period.10 11
The highest burden in mortality and morbidity 
related to delaying valve intervention appears to 
occur in the months and years following AVR, 
particularly in those patients that have evidence 
of left ventricular decompensation. As discussed, 
patients with an impaired ejection fraction prior 
to AVR have a poor long-term prognosis,20 while 
in a recent study of AS patients with a high proba-
bility of LV decompensation, more than half were 
either dead or admitted to hospital with heart 
failure within 2 years.53 Both these observations 
may reflect the development of irreversible scarring 
in the myocardium while patients are waiting for 
surgery.
POSSIBLE FUTURE STRATEGIES
Several different strategies for optimising the timing 
of valve replacement in AS have been proposed, 
many of which are currently being evaluated within 
the context of randomised controlled trials (figure 3 
and table 4). Many of these target asymptomatic 
patients, and it should be recognised that many 
patients that feel otherwise fit and healthy might 
not want to undergo major heart surgery.
All-comers with severe AS
Historical teaching has been that ‘aortic valve 
replacement is the most common cause of death in 
patients with asymptomatic severe aortic stenosis’. 
However, improving outcomes following surgical 
and transcatheter valve replacement are challenging 
this doctrine. Performing valve intervention on all 
asymptomatic patients with severe AS is a simple 
and pragmatic solution that does not seek to iden-
tify the point at which left ventricular decompensa-
tion occurs. Although some patients will undergo 
intervention earlier than they may have required 
(and therefore be exposed unnecessarily to the 
problems associated with prosthetic valves), the 
risks associated with contemporary intervention 
techniques are low, and no patient should be left 
with irreversible left ventricular decompensation. 
This strategy is supported by evidence from the 
Japanese Contemporary outcomes after sURgery 
and medical tREatmeNT in patients with severe 
Aortic Stenosis (CURRENT AS) registry. Propensi-
ty-score matching was used to compare 291 asymp-
tomatic patients who underwent early surgery with 
291 patients who were managed conservatively. 
Those who received early AVR had a reduced 
all-cause mortality at 5 years (15%) compared 
Figure 3 Comparison of EARLY-TAVR and EVoLVeD randomised controlled trial designs. Currently, recruiting randomised controlled trials generally 
fall into two groups: those investigating valve intervention in all asymptomatic patients with severe AS (eg, EARLY-TAVR) and those looking to target 
intervention based on measures of left ventricular decompensation (eg, EVoLVeD). AS, aortic stenosis; CMR, cardiac magnetic resonance; EARLY-TAVR, 
Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients with AsYmptomatic Severe Aortic Stenosis; EVoLVeD, 
Early Valve Replacement Guided by Biomarkers of Left Ventricular Decompensation in Asymptomatic Patients with Severe AS; hs, high-sensitivity; LV, 
left ventricular; TAVI, transcatheter aortic valve insertion.
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with those who were initially managed conserva-
tively (26%). Heart failure hospitalisation was also 
reduced in the early intervention group (4% vs 
20%). However, propensity matching may not have 
accounted for all potential influences on outcomes 
and a significant proportion of the conservatively 
managed patients who developed symptoms were 
not referred for intervention, undoubtedly contrib-
uting to the worse observed survival in this group: 
confounding by indication. Three randomised 
controlled trials (AVATAR, ESTIMATE and EARLY-
TAVR; table 4) are currently recruiting, which will 
examine whether valve intervention in unselected 
asymptomatic patients with severe AS can improve 
clinical outcomes.
Refined assessment of valve structure and 
function
An alternative strategy is to operate only in asymp-
tomatic patients with very high peak aortic-jet 
velocities. Peak velocities >4.5 m/s are associated 
with increased referral for surgical intervention26 
but also increased rates of perioperative death 
and cardiac death in a prospective cohort study 
with propensity matching.47 The RECOVERY 
randomised controlled trial will examine whether 
early aortic valve replacement in asymptomatic 
patients with velocities >4.5 m/s and a negative 
exercise test leads to improved patient outcomes 
compared with watchful waiting (table 4).
The total haemodynamic load seen by the left 
ventricle can also be quantified by calculating the 
valvuloarterial impedence (ZVa=(systolic blood 
pressure+mean AV gradient)/indexed LV stroke 
volume). This measure has consistently been shown 
to be an independent marker of adverse outcome in 
asymptomatic patients54 and warrants further study 
for its use in determining the timing of intervention.
Another approach is to quantify valvular calcium 
burden using CT calcium scoring. Validated, 
sex-specific thresholds for severe AS have been 
proposed (2000 Agatston units (AU) for men, 
1200 AU for women),5 which provide powerful 
prediction of clinical events of incremental value to 
echocardiographic assessments.3 Performing valve 
intervention on the basis of severe valvular calcifi-
cation on CT might therefore represent an attrac-
tive alternative strategy.
Imaging and biomarkers of left ventricular 
decompensation
Simple cardiac biomarkers beyond BNP are being 
investigated in AS as markers of LV decompen-
sation. Cardiac troponin is a structural protein 
present in cardiomyocytes, which is released into 
the bloodstream during myocardial injury and can 
now be detected at very low plasma concentra-
tions using high-sensitivity assays. In AS, troponin I 
concentrations are associated with a more advanced 
left ventricular hypertrophic response, replace-
ment myocardial fibrosis and worse long-term 
patient outcomes in patients with AS.55 They are 
thought to reflect the cardiomyocyte death that 
drives progressive left ventricular decompensation 
alongside myocardial fibrosis.8 Elevation in cardiac 
troponin is not however specific to AS. By contrast, 
the presence of LVH and the strain pattern on the 
12-lead ECG demonstrate high specificity (but low 
sensitivity) for left ventricular hypertrophy and 
myocardial fibrosis, respectively, and also provides 
prognostic information.56 As will be discussed, 
there is interest in using these simple and cheap 
biomarkers as screening tools to aid the detection 
of LV decompensation (figure 4).
What about imaging assessment to detect left 
ventricular decompensation? Despite its limita-
tions, ejection fraction remains the current gold 
standard; however, several imaging techniques 
are under early investigation that can detect 
earlier abnormalities in left ventricular function. 
Table 4 Current and planned randomised controlled trials investigating timing of aortic valve intervention







Aortic Valve Replacement Versus 
Conservative Treatment in 
Asymptomatic Severe Aortic Stenosis 
(AVATAR)
312 patients with asymptomatic 
severe AS and STS score <8%.
SAVR or
routine care.





Early Surgery for Patients with 
Asymptomatic Aortic Stenosis 
(ESTIMATE)
360 patients with asymptomatic 









Evaluation of Transcatheter Aortic 
Valve Replacement Compared 
to SurveilLance for Patients with 
AsYmptomatic Severe Aortic 
Stenosis (EARLY-TAVR)
1109 patients aged >65 years with 
asymptomatic severe AS, trileaflet 






All-cause mortality, all stroke, 
and unplanned cardiovascular 






Refined assessment of 
valve function
– higher peak aortic-jet 
velocity threshold
Early Surgery Versus Conventional 
Treatment in Very Severe Aortic 
Stenosis (RECOVERY)
145 patients with very severe AS 









Assessment of myocardial 
decompensation




Early Valve Replacement Guided 
by Biomarkers of Left Ventricular 
Decompensation in Asymptomatic 
Patients with Severe AS (EVoLVeD)
400 patients with asymptomatic 
severe AS, normal LVEF and mid-wall 
fibrosis on cardiac MRI.
SAVR/TAVI or
routine care.
All-cause mortality and 
unplanned AS-related 




AS, aortic stenosis; ETT, exercise tolerance test; LVEF, left ventricular ejection fraction; MACE, major adverse cardiovascular events; SAVR, surgical aortic valve replacement; STS, Society of Thoracic Surgeons; 
TAVI, transcatheter aortic valve insertion.
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Echocardiography can detect alteration in various 
measures of diastolic and longitudinal systolic 
function in patients with AS, which appear related 
to the presence of myocardial fibrosis.7 Reduced 
left ventricular global longitudinal strain can be 
observed in asymptomatic patients with AS, acting as 
an independent predictor of mortality.23 However, 
several of these measures still require standardisa-
tion across vendor platforms and all suffer from 
significant overlap between results in healthy indi-
viduals and those with AS. Moreover, these imaging 
markers are not specific to valve heart disease and 
like symptoms might equally reflect comorbidity 
such as ischaemic heart disease.
Perhaps the most promising technique is cardiac 
MRI, which offers myocardial tissue characteri-
sation and can detect the myocardial fibrosis that 
drives the development of left ventricular decom-
pensation. Indeed, the late gadolinium enhance-
ment technique allows direct visualisation of this 
fibrosis in a midwall pattern that can easily be 
differentiated from prior myocardial infarction. 
Midwall fibrosis is a direct and specific marker of 
left ventricular decompensation with close asso-
ciation with measures of left ventricular func-
tion, myocardial injury and functional capacity.7 
Furthermore, multiple studies have confirmed 
that midwall fibrosis is a strong independent 
predictor of all-cause mortality and cardiovascular 
death.21 51 57 Increasing burden of midwall fibrosis 
correlates with a worse outcome,21 51 and this 
fibrosis appears irreversible following valve inter-
vention.58 Midwall fibrosis therefore appears as a 
useful tool to identify the early stages of irrevers-
ible left ventricular decompensation. T1 mapping 
is an alternative technique that might allow detec-
tion of the preceding stage of reversible diffuse 
interstitial fibrosis.59 At present, there are issues 
with variations in T1 values at different magnetic 
field strengths and on different scanners and prob-
lems caused by the overlap of T1 values between 
different disease states. Further work is required, 
although recent studies have shown promising early 
results for T1 parameters that seek to measure the 
overall myocardial fibrosis volume.7
It is possible that using a multibiomarker strategy 
to identify LV decompensation may prove superior 
to any single biomarker in isolation. For example, in 
the EVoLVeD randomised controlled trial (table 4), 
patients are initially screened with high sensitivity 
troponin I and an ECG. Patients with a normal 
troponin (<6 ng/L) are deemed to have a normal 
heart with no further imaging required. Patients 
with an elevated troponin or the ECG-strain 
pattern proceed to cardiac magnetic resonance 
(CMR) and those found to have midwall fibrosis 
then randomised to either early valve intervention 
or routine clinical care. It is hoped that this strategy 
will target valve intervention to those patients who 
will derive greatest benefit.
PRACTICAL RECOMMENDATIONS AND 
PROCESSES OF CARE
Care of the asymptomatic patient with AS can 
be complex and challenging. While additional 
evidence is awaited, we advise detailed clinical and 
Figure 4 Imaging and biomarker assessments of stage of valvular stenosis and myocardial response to increased afterload. Progressive 
haemodynamic obstruction as a result of aortic leaflet restriction is assessed using echocardiography. However, specific valvular pathologies such 
as fibrosis and calcification can be assessed using CT methods. Ejection fraction is a poorly sensitive marker of myocardial decompensation with 
abnormalities in Doppler measures, longitudinal strain and systolic function, which are all detectable prior to this. However, these measures, along 
with biomarkers such as troponin and B-type natriuretic peptide (BNP) are non-specific and may be abnormal as a result of coexistent myocardial 
pathology such as coronary heart disease. T1 mapping methods and late gadolinium enhancement are more specific for decompensation as a result of 
pressure overload.
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echocardiographic assessment with exercise testing 
and advanced imaging (eg, stress echocardiog-
raphy, TOE, CT and CMR) performed as indicated 
to clarify symptoms, severity of AS and myocar-
dial health. This should be performed by heart 
valve specialists working as part of a heart team.5 
Patient involvement in decision making is key 
where indications for intervention are borderline. 
Given delays between referral and procedure that 
are common in most healthcare systems, this could 
also be discussed with the patient and may inform 
decision making for earlier intervention. The recent 
ESC/EACTS guideline update also recommends the 
establishment of heart valve centres with access to 
advanced imaging modalities and contemporary 
interventional techniques supported by robust 
internal audit processes.5 Finally, patients managed 
conservatively should be educated as to the typical 
symptoms of AS (table 2) and the importance of 
prompt symptom reporting. Regular clinic surveil-
lance is essential, and current guidelines recom-
mend clinical assessment with echocardiography at 
least every 6 months.5
CONCLUSIONS
AS is a common condition; the only treatment 
for which is replacement of the aortic valve. The 
optimal timing of this valve intervention remains 
unclear with current guidelines based on obser-
vational data and expert opinion. However, 
multiple randomised controlled trials are currently 
underway investigating whether novel strategies 
might improve patient outcomes compared with 
current watchful waiting, heralding a new era of 
evidence-based medicine for patients with heart 
valve disease.
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Abstract
Purpose of Review Aortic valve disease is the most common
form of heart valve disease in developed countries. Imaging
remains central to the diagnosis and risk stratification of pa-
tients with both aortic stenosis and regurgitation and has tra-
ditionally been performed with echocardiography. Indeed,
echocardiography remains the cornerstone of aortic valve im-
aging as it is cheap, widely available and provides critical
information concerning valve hemodynamics and ventricular
function.
Recent Findings Whilst diagnostic in the vast majority of
patients, echocardiography has certain limitations including
operator variability, potential for measurement errors and
internal inconsistencies in severity grading. In particular,
low-gradient severe aortic stenosis is common and chal-
lenging to diagnose. Aortic valve imaging may therefore
be improved with alternative and complimentary
multimodality approaches.
Summary This review investigates established and novel tech-
niques for imaging both the aortic valve and the myocardial
remodelling response including echocardiography, computed
tomography, cardiovascular magnetic resonance and positron
emission tomography. Moreover, we examine how the
complementary information provided by each modality may
be used in both future clinical practice and the research arena.
Keywords Valve . Stenosis . Regurgitation .Magnetic
resonance imaging . Echocardiography . Computed
tomography . Positron emission tomography
Introduction
Aortic valve disease is the most common valvular heart dis-
ease in the developed world [1]. In particular, calcific aortic
stenosis is responsible for considerable morbidity and mortal-
ity [2]. Aortic stenosis (AS) was once thought to be related to
simple Bwear and tear^ as a result of advancing age but is
increasingly understood to be a highly regulated process with
some similarities to atherosclerosis. An initiating event is be-
lieved to cause endothelial damage, inflammatory cell infiltra-
tion and initiation of calcification. A progressive cycle of cal-
cium deposition in the valve leaflets then occurs leading to an
inexorable march towards severe aortic stenosis and the de-
velopment of symptoms and heart failure unless aortic valve
replacement (AVR) is performed [3]. Aortic regurgitation
(AR) is common in calcific aortic valve disease but may also
be caused by other pathology affecting the valve, such as
endocarditis, or the aortic root, causing functional regurgita-
tion as in hypertension, Marfan syndrome, annulo-aortic
ectasia, collagen vascular disease and aortic dissection.
In both aortic stenosis and regurgitation, imaging of the
aortic valve is critical in establishing a diagnosis, grading se-
verity and informing the timing of valvular intervention. In
addition, the importance of the myocardial remodelling re-
sponse to these forms of valve disease is increasingly appre-
ciated [4]. Aortic stenosis leads to a pressure-overloaded left
ventricle, resulting in the left ventricular hypertrophy (LVH),
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which normalises wall stress according to Laplace’s law. This
is initially adaptive, but decompensation eventually occurs
leading to the development of heart failure, symptoms and
adverse events. Current clinical guidelines suggest valvular
intervention in severe aortic stenosis when there is evidence
of LV decompensation as indicated by the development of
either symptoms or impaired LVejection fraction (EF) [5, 6].
However, assessment of symptoms in elderly patients who
often have multiple comorbidities can be challenging whilst
impairment of LV systolic function occurs late in the disease
process [7] and is often irreversible [8, 9]. There is therefore a
need for more objective assessments of the left ventricular
decompensation. Similarly, in aortic regurgitation, the left
ventricle dilates in response to chronic volume overload in
an eccentric hypertrophic response.With time, this decompen-
sation of this remodelling response also occurs, leading to
heart failure, symptoms and adverse events in the absence of
treatment. Current guidelines advocate valve replacement in
the presence of severe aortic regurgitation and symptoms or
when LV dilatation reaches certain thresholds.
In this review, we will describe how modern advances in
non-invasive imaging might optimise assessments of aortic
valve stenosis and regurgitation as well as how the left ven-
tricular remodels in response to those lesions. In particular, the
established role of echocardiography will be explored along-
side emergingmodalities such as computed tomography (CT),




Transthoracic echocardiography (TTE) is the clinical imaging
modality of choice for assessing aortic stenosis and has been
since in the 1980s when it supplanted invasive catheter-based
measurements. It is safe, non-invasive and widely available,
allowing direct visualisation of aortic valve anatomy (e.g. bi-
cuspid vs. trileaflet), function and hemodynamics whilst also
facilitating measurement of the left ventricular wall thickness,
cavity dimensions and both systolic and diastolic function.
Doppler echocardiography provides information on aortic
valve hemodynamics that is not readily available using other
imaging modalities. Simple assessments of both peak and
mean velocities through the aortic valve (Fig. 1) are used to
calculate peak andmean pressure gradients using the modified
Bernoulli formula as well as the aortic valve area (AVA) using
the continuity equation. The latter is flow independent and
therefore often essential for diagnostic accuracy particularly
in low-flow states [10]. Current guidelines recommend grad-
ing haemodynamic severity of aortic stenosis on the basis of
the combined information provided by the peak velocity (AV
Vmax), the mean gradient and the aortic valve area [5, 6].
Whilst this combined approach is effective in the majority
of patients, it leads to a wide spectrum of diagnostic categories
and the potential for clinical confusion. Other potential limita-
tions of echocardiography are also being increasingly appreci-
ated. Firstly, acquisition of diagnostic acoustic windows can be
impossible in certain patients as can perfect alignment of the
Doppler probe with the direction of maximal blood flow
through the valve. In both circumstances, measurement errors
will be introduced. Secondly, echocardiography may have dif-
ficulty in measuring the left ventricular outflow tract (LVOT)
diameter with accuracy: a key component when using the con-
tinuity equation to calculate the aortic valve area. Indeed, echo
often underestimates the LVOT diameter due to either calcifi-
cation or its elliptical shape, and as the measurement is
squared, even small errors become magnified substantially.
The continuity equation also relies on several geometric as-
sumptions that frequently do not hold true in aortic stenosis
(such as a circular outflow tract and laminar flow profile),
introducing further error. Finally, internal inconsistencies exist
in the severity thresholds established in the clinical guidelines.
An AVA of 1.0 cm2 is sensitive but less specific for severe
aortic stenosis and in fact corresponds to a mean pressure gra-
dient of 30–35 mmHg [11], rather than the 40 mmHg cut-off
recommended [5, 6]. This in part may explain why between 20
and 30 % of patients with moderate or severe aortic stenosis
have discrepant assessments of disease severity depending on
the echocardiographic marker assessed [4, 12].
Fig. 1 Echocardiographic assessment of a patient with severe aortic
stenosis. a Short axis view showing heavily calcified leaflets. b
Parasternal long axis view showing large calcium deposit on right
coronary cusp with restricted valve opening. c Right sternal edge
continuous-wave Doppler with aortic valve velocity >4 m/s,
corresponding with severe stenosis
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LV Function and Mass
Echocardiography-derived LVejection fraction is used in clin-
ical guidelines to reflect LV systolic function. Impairment in
the EF below 50 % is an indication for valve intervention as
these patients have a poor outcome without surgery [8, 13].
However, a fall in ejection fraction is an insensitive measure of
LV systolic dysfunction in the presence of concentric remod-
elling and hypertrophy. Indeed, approximately one third of
patients with aortic stenosis and a normal EF have significant
evidence of LV systolic impairment when assessed by other
methods [14]. These alternative markers include global longi-
tudinal strain measurements, which have been shown to be of
prognostic importance in patients with severe aortic stenosis
and a normal ejection fraction [15].
Patients with aortic stenosis invariably develop the left ven-
tricular hypertrophy as the LV remodels to normalise wall
stress. The degree to which this occurs is not well correlated
to the haemodynamic severity of stenosis and is an indepen-
dent predictor of outcomes [16, 17•]. The LV hypertrophic
response should therefore be assessed separately. Concentric
remodelling geometry [18] and severe LVH [19] have been
associated with mortality following valve replacement whilst
increased LV mass is associated with cardiovascular morbidity
and mortality in patients with asymptomatic severe AS [17•].
Importantly, recent evidence from 1656 patients in the SEAS
trial showed that LV mass index was an independent predictor
of cardiovascular events and all-cause mortality [20••].
Low-Flow Low-Gradient Subtypes
The most challenging patients are those with discordant pa-
rameters of severity, most commonly characterised by a low
AVA and low transvalvular gradient. As discussed, there are
several possible explanations for this including measurement
error and internal inconsistencies in guideline thresholds.
However, in many patients, the discrepancy will not be due
to error but instead reflect a low-flow status related to an array
of different factors. Low flow is usually defined by a stroke
volume (SV) index of <35 ml/m2 although this cut-off is
somewhat arbitrary.
Classical Low-Flow Low-Gradient AS
In patients with severe aortic stenosis and LV systolic dys-
function, the stroke volume is low due to reduced myocardial
contractility. As a consequence, the gradient generated over
the aortic valve is relatively low (mean gradient <40 mmHg)
but the valve area is small <1.0 cm2 (low-flow low gradient
with reduced EF severe AS). It is important to differentiate
this condition from Bpseudo-severe AS,^ where the ventricle
is severely impaired due to an alternative pathology to the
extent that it cannot generate sufficient flow to completely
open the aortic valve. Low-dose dobutamine stress echocardi-
ography (DSE), as recommended in clinical guidelines [5, 6],
can differentiate between these; if the mean valve gradient
increases to >40 mmHg (or AV Vmax >4 m/s) and valve area
remains <1.0 cm2 with dobutamine stress, then severe AS has
been identified. These patients have a relatively low operative
mortality (5–7 % [21, 22]) and benefit from AVR [23].
Flow Reserve
Those patients who fail to increase their gradient with stress
echocardiography likely have no or reduced Bflow reserve^
which is defined as an increase in stroke volume of less than
20 % [24]. This group of patients has significantly higher
operative mortality (22–30 % [13, 21]), but those who survive
AVR have outcomes (improvement in EF and mortality) sim-
ilar to those with flow reserve [13, 25] and an improved prog-
nosis compared to similar patients managed medically [13].
There may be an increased future role for transcatheter aortic
valve implantation (TAVI) in this group given their high op-
erative risk.
Paradoxical Low-Flow Low-Gradient AS
These patients have low flow in the context of preserved ejec-
tion fraction, again leading to a picture of a reduced AVA
(<1.0 cm2) and low mean gradient (<40 mmHg). It is often
referred to as low-flow low-gradient normal EF or paradoxical
low-flow low-gradient aortic stenosis andwas first identified in
2007 [26]. Commonly, these patients are female and elderly,
with a small hypertrophied LV cavity as the cause of their low
stroke volume. A recent meta-analysis of 7459 patients and
other studies have indicated that mortality is increased in this
group [26, 27••, 28, 29] and reduced by valve intervention
[28–31]. However, this has not been observed consistently in
all trials [32]. Stress echocardiography has not been shown to
be helpful in these patients as they often exhibit restrictive
physiology due to diastolic dysfunction limiting any increase
in SV; however, aortic valve CT calcium scoring may aid in
discrimination [12]. Current clinical guidelines recommend
aortic valve intervention in this group if the patient is symp-
tomatic and the clinician feels that valve obstruction is the most
likely cause of symptoms based on the above parameters [5, 6].
Normal-Flow Low-Gradient AS
Patients with both a low AVA and low mean gradient in the
context of preserved EF and normal flow are a common
[27••] but under recognised group who are not represented
in clinical guidelines. Although this is heterogeneous group
that encompasses measurement errors, small body size or
inconsistencies in clinical guidelines [11], a significant pro-
portion have severe AS [12] and AVR appears to improve
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survival [31]. A recent large meta-analysis has demonstrat-
ed that these patients have outcomes similar to high-
gradient severe AS which are improved by AVR [27••].
Further research in this area is required.
Dimensionless Index
The dimensionless velocity index is a flow-independent vari-
able calculated by dividing the LVOT velocity-time integral
(VTI, or Vmax) by the AV VTI (or Vmax) without a need to
measure the LVOT diameter. A ratio of <0.25 indicates severe
stenosis and is particularly useful where LVOT measurement
is difficult to perform or in cases of inconsistent grading [33].
Advanced Echocardiography
In addition to demonstrating flow reserve in low-flow low-
gradient severe AS with a reduced ejection fraction, stress
echocardiography has also been shown to improve prognosti-
cation in asymptomatic high-gradient severe AS where an
increase in mean gradient of >20 mmHg on exercise stress
predicts a greater risk of developing symptoms and adverse
events [34, 35].
Transoesophageal echocardiography (TOE) can be of
use in aortic stenosis with planimetry of the AVA used as
an alternative measure of aortic stenosis severity. Whilst
planimetry remains difficult on 2D imaging due to extensive
calcification and difficulty ensuring position at the leaflet
tips, it appears more readily feasible on 3D TOE. A study of
307 patients with severe aortic stenosis compared valve
planimetry using 3D TOE with TTE-derived aortic valve
area. They showed that valve planimetry was possible in
92 % of patients (in the 8 % where it was not possible, this
was due to severe calcification) and that the two measure-
ments showed a good correlation (r = 0.85). However,
planimetred AVA measurements were consistently higher
than those calculated with the continuity equation [36].
Adjudicating disease severity using planimetry can there-
fore be difficult although in that context, an AVA<1.0 cm2 is
a strong indication of severe aortic stenosis and a potentially
useful arbitrator in cases of diagnostic uncertainty.
TOE also offers accurate assessment of the aortic root and
annulus dimensions and is frequently performed preoperative-
ly before aortic valve surgery. Similar measurements can be
made with CT imaging and the modality used differs between
centres. The use of intraoperative TOE is routine in many
cardiothoracic centres where it allows accurate assessment of
anatomy and optimisation of hemodynamics before establish-
ing cardiopulmonary bypass. Post-procedure, TOE can con-
firm satisfactory valve function, stable hemodynamics and
exclude complications such as outflow tract obstruction. A
number of observational studies suggest that intraoperative
TOE changes management in 11–18 % of patients may
improve outcome [37, 38] and may be cost-effective [39].
Intraoperative TOE has a class lla recommendation from the
most recent CC/AHA/ASE 2003 Guideline Update for the
Clinical Application of Echocardiography.
Pre-procedural imaging (TOE or CT) is essential prior to
TAVI to ensure correct prosthesis sizing, and real-time intra-
procedural TOE is often used to aid in device sizing and po-
sitioning [40, 41], although this is limited to trans-apical and
aortic approaches where the patient is under general anaesthet-
ic. Studies are conflicting but suggest that there is overall a
slight overestimation of annulus area with CT and underesti-
mation with TOE [42, 43]. 3D TOE is superior to 2D TOE and
offers similar results to CT in some studies [44].
Valvular Calcification
Although the mechanisms underlying valvular calcification
remain incompletely determined [3], its importance to disease
progression and adverse events was first identified in the sem-
inal studies by Rosenhek and colleagues [45••, 46••]. One
hundred and twenty-six patients with asymptomatic severe
aortic stenosis were followed up for 22 ± 18 months. Aortic
valve calcification was measured on a four-point ordinal scale
with moderate or severe calcification (a score of 3 or 4) being
the only independent predictor of AVR or mortality,
outperforming haemodynamic measures of severity.
Significant valve calcification is also associated with faster
disease progression, need for AVR and all-cause mortality in
patients with mild to moderate stenosis [46••]. Whilst severe
aortic valve calcification is considered a lla indication for
AVR in asymptomatic patients with severe AS, this technique
is in practice difficult to apply because of poor intra-observer
agreement as to the severity of calcification [47].
CT
CT Calcium Scoring
Calcium burden in the aortic valve can be more accurately
quantified on electrographically gated non-contrast computed
tomography (CT). The aortic valve CTcalcium score can then
be measured using the Agatston score (AU), which accounts
for both the density and volume of CT measured calcium and
correlates closely with the weight of calcium in explanted
aortic valves [47]. Aortic valve CT calcium scoring has dem-
onstrated excellent intra- and inter-observer and scan-rescan
reproducibility [47, 48] and correlates closely with echocar-
diographic measures of haemodynamic severity [47–49].
Importantly, recent data has demonstrated that the aortic valve
CT calcium score provides powerful prediction of disease
progression and prognosis [50–52].
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Severity Cut-Offs
Thresholds in CT calcium score for differentiating moderate
from severe aortic stenosis have recently been proposed in a
study of 451 patients with concordant grading of AS severity
on echocardiography and preserved ejection fraction.
Interestingly, these were different for males and females
(≥2065 AU for men and ≥1274 AU for women) even after
indexing to the aortic annulus area (≥476 AU/cm2 for men and
≥292 AU/cm2 for women). These thresholds were then ap-
plied to a larger cohort of 794 patients and demonstrated a
strong predictive value for all-cause mortality of incremental
value to echocardiographic parameters of ejection fraction and
stenosis severity [53••] (Fig. 2).
Aortic valve calcium scoring may be of particular use in
cases of low-flow low gradient with reduced EF [49, 54],
especially in the absence of flow reserve [47] where it can
be challenging to determine severity by echocardiography
alone. Further work is required to assess the validity of these
thresholds in alternative patient populations and to confirm
their predictive value. If these prove confirmatory, then we
believe CT calcium scoring will emerge as a clinically useful
and flow-independent adjuvant to standard echocardiography.
Improved AVA Calculation
The increasing use of CTangiography for valve sizing prior to
TAVI procedures has demonstrated that the LVOT is often
eccentric not circular. Indeed, a recent study of 269 patients
with severe AS undergoing CT demonstrated that the LVOT is
eccentric in 93 % of patients [55]. As a consequence, TTE
measures of the LVOT diameter can frequently result in un-
derestimation of the true AVA [56]. Using CT, CMR or indeed
3D echo to planimeter the LVOTarea could therefore improve
the accuracy of AVA calculations.
PET
PET is a novel imaging technique, which allows the activity of
specific disease processes to be measured in vivo. Recently,
this technique has employed two tracers to measure inflam-
mation (18F-fluorodeoxyglucose (18F-FDG)) and calcification
activity (18F-fluoride) in the valves of patients with aortic ste-
nosis. Hybrid PET/CT scanners then allow the activity of
these two key processes to be compared with the presence of
established regions of macrocalcification on CT.
18F-Fluoride
18F-fluoride has been used as a bone tracer for 50 years binding
to hydroxyapatite crystal and detecting regions of increased
bone activity. In the vasculature, it binds preferentially to re-
gions of newly developing microcalcification because the sur-
face area of hydroxyapatite in these nanocrystalline regions is
at its highest. By contrast in regions of macrocalcification,
much of the hydroxyapatite is internalised and not available
for binding [57]. In aortic stenosis, 18F-fluoride acts as a mark-
er of calcification activity correlating with histological staining
for alkaline phosphatase (r = 0.65) and osteocalcin (r = 0.68)
[52] and predicts where novel regions of macroscopic calcium
are going to form (Fig. 3). Tracer uptake increases with more
advanced aortic stenosis [58], offers powerful prediction of
disease progression at 1 and 2 years, of small incremental value
to computed tomography [52, 59], and acts as an independent
predictor of adverse clinical events [59]. This technique holds
promise in better understanding the role of calcification in
aortic stenosis, for example, a recent PET study demonstrated
that whilst calcification activity in aortic stenosis is greater than
inflammation, the reverse is true in atherosclerosis, potentially
explaining the different effects of statins in these two condi-
tions [60]. With further improvement, 18F-fluoride PET may
Fig. 2 Survival of patients with aortic stenosis under medical treatment
according to valvular calcium score. Patients with severe absolute
calcification (a) or calcification indexed to body surface area (b) had
increased all-cause mortality compared to patients with non-severe
calcification. Indeed, severe aortic valve calcification (AVC) was an
independent predictor of survival following adjustment for age, sex,
presence of coronary artery disease or diabetes, indexed aortic valve area
and ejection fraction. Reproduced from Clavel et al. [53••] with
permission from Elsevier/Journal of the American College of Cardiology
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prove of clinical use in identifying patients likely to progress
rapidly towards surgery and as a marker of disease activity and
efficacy end point in clinical trials of novel therapies (e.g.
SALTIRE 2: NCT02132026).
18F-FDG
18F-FDG PET is widely used to image vascular inflammation.
This PET tracer is a glucose analogue, which accumulates in
metabolically active cells such as vascular macrophages.
Indeed, an excellent correlation between macrophage burden
on histology (CD68 staining on immunohistochemistry) in
carotid atheroma [61] and the 18F-FDG signal has been ob-
served. In aortic stenosis, 18F-FDG activity is higher in pa-
tients versus controls, demonstrating a modest correlation
with severity of valvular disease [58]. Of interest, no correla-
tion with CD68 staining of explanted valves was observed
suggesting that 18F-FDG uptake is occurring in other metabol-
ically active cells, although this study was limited by a low
sample size [52]. Perhaps, the biggest limitation of this tech-
nique is the effect of physiological myocardial 18F-FDG up-
take, which frequently contaminates signal originating from
the aortic valve.
CMR
Cardiac magnetic resonance is an emerging technology that
offers excellent spatial resolution, functional assessment and
the unique ability to provide myocardial tissue characterisa-
tion. However, it remains an expensive modality with limited
availability for cardiac patients in most centres,
LV Mass and Hypertrophy
CMR provides the gold-standard assessment of LV volumes
and mass and allows detailed investigation of both the degree
of hypertrophy and the different patterns of the left ventricular
adaption. Importantly, the myocardial hypertrophic response is
only weakly correlated with the hemodynamic severity of aor-
tic stenosis [16, 62, 63], with males generally display a greater
increase in LV mass even after correction for body size [16].
Classically, wall thickening occurs in a concentric pattern, but
recent studies have shown that asymmetrical patterns also exist
in around a quarter of patients assessed by CMR [16]. The
clinical importance of this observation remains unclear.
Myocardial Fibrosis
Myocardial fibrosis is a key mechanism driving the progres-
sion from the left ventricular hypertrophy to heart failure and
death in aortic stenosis [64]. Historically, it has only been
appreciated using invasive endomyocardial biopsy tech-
niques, but this carries a small but significant risk of compli-
cations [65] and is susceptible to sampling error. CMR pro-
vides a non-invasive assessment of whole-heart fibrosis using
two techniques: late gadolinium enhancement (LGE) and T1
mapping (Fig. 4).
LGE
This technique was first described in 1999 [66] and involves
the intravenous administration of gadolinium-based contrast
agents (GBCA). These agents alter myocardial T1 values and
enter healthy myocardium from the blood pool down a con-
centration gradient within 1–3 min (wash-in phase). Renal ex-
cretion of GBCA from the blood pool then produces a reverse
concentration gradient with myocardial GBCA concentrations
declining over the ensuing 10–30 min (wash-out phase). The
large molecular size of gadolinium stops GBCA from crossing
cell membranes, so that they effectively label the extracellular
space and accumulate in regions of replacement fibrosis due to
delayed wash-out [67]. These focal areas can then be detected
using T1-weighted sequences 15–20 min after contrast admin-
istration. In aortic stenosis, areas of replacement fibrosis appear
as bright areas in the mid-wall of the left ventricle in contrast to
surrounding healthymyocardium [68]. Areas of previousmyo-
cardial infarction, which are common in AS patients, are also
detected by this technique but can be differentiated from mid-
wall replacement fibrosis by their subendocardial/transmural
pattern and their coronary distribution.
Mid-wall replacement fibrosis as detected by LGE is com-
mon in aortic stenosis (29–62 % of patients depending on the
population studied [69, 70•, 71•]) and seems to be irreversible
following valve intervention [72]. The presence of LGE cor-
relates with histological fibrosis [73•] and evidence of
Fig. 3 18F-fluoride PET activity predicts the development of new
calcific deposits in the aortic valve on repeat CT imaging performed
after 1 year. Example imaging from two patients (a and b) are shown
below. Baseline non-contrast CT images (left) showed evidence of in-
creased 18F-Fluoride PET activity (middle) in areas where subsequent
calcification was observed on repeat CT scanning after 1 year (right).
Reproduced from Pawade et al. [3] with permission from Elsevier/
Journal of the American College of Cardiology
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myocardial injury (as measured by high sensitivity troponin I
concentrations) [74]. Advanced mid-wall fibrosis identifies
patients that do not gain improvement in LV systolic function
[73•] or overall functional status following AVR [72].
Importantly, three studies have confirmed that the presence
of LGE acts as an independent predictor of all-cause mortality
[70•, 71•, 73•], increasing the risk of death up to eightfold
[70•]. Mid-wall fibrosis therefore appears to be a direct marker
of the left ventricular decompensation in aortic stenosis and
may be of use in identifying patients whose ventricle are
starting to fail and who might benefit from prompt AVR.
Further research on this area is needed; indeed, EVoLVeD-
AS a multicentre randomised-controlled trial assessing the
benefit of early surgery in patients with advanced aortic ste-
nosis and mid-wall fibrosis on CMR is due to the start enroll-
ing patients next year.
Diffuse Fibrosis
The non-invasive assessment of diffuse fibrosis is more chal-
lenging. Its homogeneous nature means that it is missed on
LGE techniques, which rely on regions of normal myocardium
to generate contrast. However, the detection of diffuse fibrosis
is important because it is widely believed to be reversible [75]
and the precursor to irreversible forms of replacement fibrosis.
Myocardial T1 mapping techniques enable the calculation
of a specific T1 relaxation time (native T1) for each CMR
voxel which can then be displayed on a 2D map with colour
overlays applied for easier visual analysis. Multiple different
techniques have been developed (Table 1). Full examination
of these techniques is beyond the scope of this article, but
further information can be found in this recent review by
Moon et al. [76]. In brief, native T1 measurements can be
made without the need for contrast, an important potential
advantage especially in subjects with severe renal dysfunction
who are at risk of contrast-induced nephrogenic systemic fi-
brosis (NSF) [77]. GBCA can also be used to generate post-
contrast T1 maps as gadolinium shortens T1 relaxation times.
In principle, these images provide greater signal but they are
influenced by individual variation in gadolinium kinetics and
have suffered from poor reproducibility when studied in AS
populations [78•]. Importantly, these variations in kinetics can
be corrected using several approaches. The partition coeffi-
cient (λ) is calculated as a ratio of myocardial to blood post-
contrast T1 values, which improves reproducibility and cor-
rects for many confounders. At gadolinium contrast equilibri-
um, the contrast concentration in the blood and myocardium
should be equal. Calculating the blood volume of distribution
(1—haematocrit) enables the myocardial volume of distribu-
tion to be deduced, also termed the extracellular volume frac-
tion (ECV). Because ECV predominantly comprises collagen
and is increased in fibrotic states, it acts as a marker of myo-
cardial fibrosis, correlating closely with the collagen volume
fraction on histology [79–82].
Although native T1 and ECV have been extensively stud-
ied in the literature, results are mixed and interpretation is
confounded by heterogenous studied populations, variations
in T1 mapping sequence, CMR scanner, magnetic field
strength and analytical technique (e.g. inclusion or exclusion
of areas of LGE).
Native T1 values appear to correlate with histological myo-
cardial fibrosis [83, 84] as well as global longitudinal strain
Fig. 4 Cardiac magnetic
resonance imaging in a patient
with severe aortic stenosis.
Predominant asymmetrical
hypertrophy of the anteroseptum
is seen with associated patchy
mid-wall late gadolinium
enhancement (LGE, red arrows).
These areas are also identified
visually using native and post-
contrast T1 maps (white arrows)
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[84], LV mass, haemodynamic assessments of severity and
patient functional status [83]. However, its ability to differen-
tiate healthy patients from controls is dependent on the popu-
lation studied [78•, 83] with a significant degree of overlap in
T1 values between these groups particularly subjects with less
advanced stenosis. In a population of non-ischaemic dilated
cardiomyopathy patients, native T1 has recently been shown
to be an independent predictor of all-cause mortality and heart
failure events [85] although this has not been demonstrated in
aortic stenosis patients.
ECV
The extracellular volume fraction is used as a surrogate for the
extracellular space, which is expanded with collagen deposi-
tion in diffuse fibrosis. Our centre has demonstrated superior
intra- and inter-observer and scan-rescan variability in aortic
stenosis compared to the other T1 measures, and ECV corre-
lates with LV diastolic dysfunction [78•] and functional status
[86]. However, prognostic data is currently lacking. There is
also significant overlap between ECV values obtained in
healthy volunteers and AS patients, and normal ECV values
have been observed in a hypertensive population (another
condition characterised by LV pressure overload) [87].
Another disadvantage is that ECV measures fibrosis rela-
tive to the volume (or mass) of the left ventricle. Balanced
increases in both LVmass and diffuse fibrosis with progressive
aortic stenosis are therefore not detected using this approach.
In fact, an important study by Krayenbeuhl et al. involving
serial myocardial biopsies demonstrated that histological myo-
cardial fibrosis as a percentage of the myocardium (which is
estimated by ECV calculation on CMR) actually increased
early following aortic valve surgery as a result of significant
reduction in LVmass with no change in the amount of fibrosis.
However, the overall fibrous content (which can be estimated
on CMR by fibrosis volume; ECV × end-diastolic myocardial
volume) did eventually decrease at a later stage (repeat biopsy
an average of 70 months post AVR) [75]. This is partly sup-
ported by a recent CMR study which found that ECV did not
change at 6 months following AVR, whereas there was signif-
icant regression of cellular hypertrophy [86]. There is however
no CMR data regarding late regression of diffuse fibrosis mea-
sures. We believe the use of the fibrosis volume as a measure
of absolute fibrosis may better reflect disease progression and
be able to track changes across interval scans, although this
requires investigation in prospective studies.
Clinical Risk Score
CMR is an expensive technique with limited availability in
many centres. We have devised a clinical risk score [88] based
on five readily measured variables: age, sex, peak aortic valve
velocity, high sensitivity troponin I concentration and pres-
ence of LV strain pattern on ECG, which is highly predictive
of the presence of mid-wall replacement fibrosis on CMR and
mortality. Ultimately, this could be used clinically in place of
CMR imaging or as a screening tool for LV decompensation
in aortic stenosis.
Valve Assessment
CT imaging is able to detect macroscopic calcium deposits in
the aortic valve but is unable to identify fibrosis or lipid depo-
sition, which are key components in the stenotic valve. CMR
offers superior tissue characterisation as demonstrated in a
proof of concept study where 30 explanted aortic valves were
scanned ex-vivo and compared with histological analysis.
CMR showed excellent sensitivity and specificity for the iden-
tification of both mineralisation (calcification) and fibrosis,
with lower accuracy for lipid-rich tissues [89]. Although this
is an exciting field for further research, in vivo imaging with
this approach is not currently feasible due to leaflet motion.
Table 1 T1 mapping measures available for assessment of myocardial fibrosis
Measure Unit Calculation Advantages Limitations
Native T1 ms T1 relaxation curve No gadolinium requirement
(can use in severe renal failure)
T1 signal represented a composite of
myocardium and extracellular space
Post-contrast T1 ms T1 relaxation curve following
gadolinium administration
Improved sensitivity in identifying
myocardial fibrosis
Significant variability due to individual
variation in gadolinium kinetics and
time to imaging post-contrast injection
Partition coefficient (λ) Ratio Ratio of T1 signal change
(pre- and post-contrast) in
myocardium and blood pool
Excellent scan-rescan reproducibility Does not account for plasma volume of
distribution of gadolinium contrast
Extracellular volume
fraction (ECV)
% ECV= λ × (1—haematocrit) Excellent scan-rescan reproducibility.
Conceptually attractive measure
Gives a measure of relative fibrosis
which may not best track changes in
aortic stenosis
Fibrosis volume ml ECV × end-diastolic volume Quantitative measure of absolute
fibrosis volume
Limited evidence at current time
May require indexing to body size to
enable comparison between individuals
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Aortic Regurgitation
Echocardiography
TTE remains the first-line imaging modality in the investiga-
tion of patients with aortic regurgitation, allowing assessment
of mechanism, valve morphology and severity of regurgita-
tion as well as measures of LV remodelling and function.
Imaging of the aortic root and ascending aorta is essential,
although in patients with poor acoustic windows, cross-
sectional imaging may be required for accurate assessment.
The assessment of aortic regurgitation severity is more nu-
anced than aortic stenosis, requiring the integration of differ-
ent visual, semi-quantitative and quantitative parameters as
recommended by clinical guidelines [5, 6]. Visual assessment
of the valve leaflets allows appreciation of prolapse or non-
coaptation, whilst the length and width of the regurgitant jet
on colour Doppler gives a qualitative impression of severity.
Whilst useful, these measures correlate onlymodestly with the
following more objective measures of AR severity which also
require assessment [90].
Semiquantitative Parameters
Calculating the ratio of the regurgitant jet width to that of the
LVOT gives a semiquantitative measure of AR severity (se-
vere if >65 %) [91]. The vena contracta (the narrowest part of
the regurgitant jet) can also be measured, and a width of
>0.6 cm suggests severe AR. Both these techniques are limit-
ed by a single plane of assessment and the assumption of a
circular regurgitant orifice. 3D TTEmay therefore allow more
accurate measurements [92].
Doppler-Based Measures
Although continuous wave AR Doppler jet density is a poor
marker of severity, the rate of deceleration (pressure half-time,
PHT) is a useful adjunct to other measures. A value of
<200 ms is considered severe with measurements critically
dependent on obtaining an aligned Doppler signal. PHT is best
used in addition to other parameters as it is affected by LV
compliance, blood pressure and usually reduced in acute AR
of any severity. Doppler assessment of aortic flow direction is
highly useful where imaging windows allow. Holodiastolic
flow reversal in the descending aorta, especially when associ-
ated with an end-diastolic velocity of >20 cm/s, is specific but
not sensitive for severe AR [93].
Quantitative Parameters
Calculation of effective regurgitant orifice area (EROA) or
regurgitant volume (RV) is possible in some patients using
the flow-convergence zone (PISA) method, which is less
sensitive to loading conditions than other measures and also
useful if the jet is eccentric. It is however less well studied than
in mitral regurgitation, assumes a circular orifice (with a hemi-
spheric flow convergence zone) and is impossible to measure
in a substantial proportion of patients [90]. An alternative is
the regurgitant fraction (RF), which can be calculated by the
Doppler volumetric method. This involves comparing the sys-
temic stroke volume (calculated by assessing the flow over
either the mitral or pulmonary valves assuming no significant
valvular regurgitation) with the total stroke volume (calculated
from LVOT flow.) This is time-consuming and the potential
for compounding multiple small measurement errors can lead
to substantial overall inaccuracies. Again, the use of 3D TTE
may be superior in calculating regurgitant fraction [94].
LV Dimensions and Function
The response of the LV to chronic volume overload is cham-
ber dilatation and hypertrophy. Left ventricular end-systolic
diameter (LVESd) is an independent predictor of the develop-
ment of cardiac symptoms or LV dysfunction [95, 96] and the
risk of progression or mortality approaches 20 % when
LVESd >5.0 cm [97]. LV systolic impairment occurs late in
the disease process and is associated with poor prognosis [98]
which is improved following AVR [99]. Current clinical
guidelines advise valve intervention for asymptomatic severe
AR in the presence of significant LV dilatation (LVESd
>5.0 cm) or LV systolic impairment [5, 6]. Other measures
of LV function such as global strain and strain rate may detect
earlier decompensation, and further research on outcomes is
needed [100–103].
TOE
As with aortic valve replacement for aortic stenosis,
transoesophageal echocardiography is frequently used (with
significant variation between centres) both pre- and intraoper-
atively to aid in prosthesis sizing, confirm satisfactory pros-
thesis functioning and detect immediate post-operative com-
plications. In centres with appropriate expertise, TOE also
allows detailed assessment of valve morphology permitting
valve preserving repair procedures in selected patients, partic-
ularly those with aortic root aneurysms or regurgitant non-
calcified bicuspid valves [104].
CMR
As discussed, CMR provides the gold-standard assessment of
LV volumes and ejection fraction [105]. Perhaps unsurprising-
ly, therefore, left ventricular dilatation detected by CMR (end-
diastolic volume (EDV) >246ml) has shown strong predictive
ability for the future development of symptoms and need for
valve surgery in AR [106••]. However, CMR is also able to
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determine the aortic regurgitant volume to a high degree of
accuracy using phase-contrast velocity mapping. This map,
created in an orthogonal plane to that of aortic flow (usually
at the level of the sinotubular junction [107]), encodes flow to
each voxel and covers the whole cardiac cycle. It can therefore
be used to calculate both anterograde and retrograde flow
(and ultimately regurgitant volume and fraction, Fig. 5).
It shows superior reproducibility to echocardiography
[108] and excellent correlation with both TTE assess-
ment [109] and invasive measures of stroke volume
[110]. There is some debate as to the optimal cut-off in
the regurgitant fraction to define severe regurgitation. A
value of 50 % as used in TTE would seem logical, but
there is evidence of superior discrimination at a lower
value of 30 % [111] and a RF above 33 % strongly
predicted the need for surgery within 3 years in a series
of 113 patients [106••]. Although there are some techni-
cal reasons why a discrepancy may exist, further work is
required to corroborate this single centre study and to
demonstrate improvement in patient outcomes using this
more expensive imaging modality. However, there may
be a place for CMR assessment of aortic regurgitation in
clinical practice when there is diagnostic uncertainty as
to severity of regurgitation.
Conclusions
Aortic valve imaging is a rapidly expanding and exciting
field. Although transthoracic echocardiography has limi-
tations, it remains the first-line imaging modality of
choice. However, other techniques are emerging which
provide complimentary information and may aid clinical
decision-making. In particular, CT can quantify the cal-
cium burden in aortic stenosis as an alternative measure
of disease severity. CMR can quantify the aortic
regurgitant volume and provide detailed assessment of
the hypertrophic response whilst PET can directly mea-
sure disease activity in the valve. Further research is
required to investigate the role that these approaches
may play in the future, where incremental clinical benefit
to standard echocardiographic approaches will need to be
demonstrated.
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Fig. 5 Phase-contrast velocity mapping for aortic regurgitation
quantification. The slice location for through plane measurement is
shown on a three chamber still image (top) with a jet of aortic
regurgitation visible (white arrow). Through plane images are shown
(middle) in systole depicting magnitude (left) and flow (middle) and
diastole showing regurgitation in black (right). Regurgitant volume and
fraction can then be calculated from a time-flow curve (bottom). LV left
ventricle, Ao aorta, LA left atrium. Reproduced from Myerson et al.
[106••] with permission from Wolters Kluwer Health, Inc./Circulation
21 Page 10 of 14 Curr Cardiovasc Imaging Rep (2016) 9: 21
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG,
Enriquez-Sarano M. Burden of valvular heart diseases: a
population-based study. Lancet. 2006;368:1005–11.
2. Carabello BA. Introduction to aortic stenosis. Circulation
Research. Lippincott Williams & Wilkins; 2013;113:179–85.
3. Pawade TA, Newby DE, Dweck MR. Calcification in aortic ste-
nosis: the skeleton key. J Am Coll Cardiol. 2015;66:561–77.
4. Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis.
JACC. Elsevier Inc; 2012;60:1854–63.
5. Joint task force on the management of valvular heart disease of the
European Society of Cardiology (ESC), European Association for
Cardio-Thoracic Surgery (EACTS), Vahanian A, Alfieri O,
Andreotti F, Antunes MJ, et al. Guidelines on the management
of valvular heart disease (version 2012). European Heart
Journal. The Oxford University Press; 2012. pp. 2451–96.
6. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP,
Guyton RA, et al. 2014 AHA/ACC guideline for the management
of patients with valvular heart disease: executive summary: a re-
port of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines. Circulation.
Lippincott Williams & Wilkins; 2014. pp. 2440–92.
7. Lancellotti P, Donal E, Magne J, Moonen M, O’Connor K,
Daubert J-C, et al. Risk stratification in asymptomatic moderate
to severe aortic stenosis: the importance of the valvular, arterial
and ventricular interplay. Br Heart J. BMJ Publishing Group Ltd
and British Cardiovascular Society; 2010;96:1364–71.
8. Connolly HM, Oh JK, Orszulak TA, Osborn SL, Roger VL,
Hodge DO, et al. Aortic valve replacement for aortic stenosis with
severe left ventricular dysfunction. Prognostic indicators.
Circulation. 1997;95:2395–400.
9. Connolly HM, Oh JK, Schaff HV, Roger VL, Osborn SL, Hodge
DO, et al. Severe aortic stenosis with low transvalvular gradient
and severe left ventricular dysfunction:result of aortic valve re-
placement in 52 patients. Circulation. 2000;101:1940–6.
10. Rask LP, Karp KH, Eriksson NP. Flow dependence of the aortic
valve area in patients with aortic stenosis: assessment by application
of the continuity equation. J Am Soc Echocardiogr. 1996;9:295–9.
11. Minners J, AllgeierM,Gohlke-Baerwolf C, Kienzle R-P, Neumann
F-J, Jander N. Inconsistent grading of aortic valve stenosis by cur-
rent guidelines: haemodynamic studies in patients with apparently
normal left ventricular function. Heart. BMJ Publishing Group Ltd
and British Cardiovascular Society; 2010;96:1463–8.
12. Clavel M-A, Messika-Zeitoun D, Pibarot P, Aggarwal SR, Malouf
J, Araoz PA, et al. The complex nature of discordant severe calci-
fied aortic valve disease grading: new insights from combined
Doppler echocardiographic and computed tomographic study. J
Am Coll Cardiol. 2013;62:2329–38.
13. Tribouilloy C, Levy F, Rusinaru D, Guéret P, Petit-Eisenmann H,
Baleynaud S, et al. Outcome after aortic valve replacement for
low-flow/low-gradient aortic stenosis without contractile reserve
on dobutamine stress echocardiography. J Am Coll Cardiol.
2009;53:1865–73.
14. Cramariuc D, Cioffi G, Rieck AE, Devereux RB, Staal EM, Ray
S, et al. Low-flow aortic stenosis in asymptomatic patients:
valvular-arterial impedance and systolic function from the SEAS
Substudy. JACC Cardiovasc Imaging. 2009;2:390–9.
15. Kusunose K, Goodman A, Parikh R, Barr T, Agarwal S, Popovic
ZB, et al. Incremental prognostic value of left ventricular global
longitudinal strain in patients with aortic stenosis and preserved
ejection fraction. Circ Cardiovasc Imaging. 2014;7:938–45.
16. Dweck MR, Joshi S, Murigu T, Gulati A, Alpendurada F, Jabbour
A, et al. Left ventricular remodeling and hypertrophy in patients
with aortic stenosis: insights from cardiovascular magnetic reso-
nance. J Cardiovasc Magn Reson. 2012;14:1–1.
17.• Cioffi G, Faggiano P, Vizzardi E, Tarantini L, Cramariuc D,
Gerdts E, et al. Prognostic effect of inappropriately high left
ventricular mass in asymptomatic severe aortic stenosis. Heart.
BMJ Publishing Group Ltd and British Cardiovascular
Society; 2011;97:301–7. This is the first paper suggesting
that increased LV mass is an independent predictor of out-
come in aortic stenosis.
18. Duncan AI, Lowe BS, Garcia MJ, Xu M, Gillinov AM,
Mihaljevic T, et al. Influence of concentric left ventricular remod-
eling on early mortality after aortic valve replacement. Ann
Thorac Surg. 2008;85:2030–9.
19. Orsinelli DA, Aurigemma GP, Battista S, Krendel S, Gaasch WH.
Left ventricular hypertrophy and mortality after aortic valve re-
placement for aortic stenosis. A high risk subgroup identified by
preoperative relative wall thickness. JACC. 1993;22:1679–83.
20.•• Gerdts E, Rossebø AB, Pedersen TR, Cioffi G, Lønnebakken MT,
CramariucD, et al. Relation of left ventricular mass to prognosis in
initially asymptomatic mild to moderate aortic valve stenosis. Circ
Cardiovasc Imaging. 2015;8:e003644. This large prospective
study showed that increased LV mass is a predictor of cardio-
vascular event and all-cause mortality independent of age, sex,
ejection fraction and presence of hypertension.
21. Monin J-L, Quéré J-P, Monchi M, Petit H, Baleynaud S, Chauvel
C, et al. Low-gradient aortic stenosis: operative risk stratification
and predictors for long-term outcome: a multicenter study using
dobutamine stress hemodynamics. Circulation. Lippincott
Williams & Wilkins; 2003;108:319–24.
22. Nishimura RA, Grantham JA, Connolly HM, Schaff HV, Higano
ST, Holmes DR. Low-output, low-gradient aortic stenosis in pa-
tients with depressed left ventricular systolic function: the clinical
utility of the dobutamine challenge in the catheterization laborato-
ry. Circulation. 2002;106:809–13.
23. Levy F, Laurent M, Monin J-L, Maillet JM, Pasquet A, Le
Tourneau T, et al. Aortic valve replacement for low-flow/low-gra-
dient aortic stenosis operative risk stratification and long-term
outcome: a European multicenter study. J Am Coll Cardiol.
2008;51:1466–72.
24. de Filippi CR,Willett DL, BricknerME, Appleton CP, Yancy CW,
Eichhorn EJ, et al. Usefulness of dobutamine echocardiography in
distinguishing severe from nonsevere valvular aortic stenosis in
patients with depressed left ventricular function and low
transvalvular gradients. Am J Cardiol. 1995;75:191–4.
25. Quéré J-P, Monin J-L, Levy F, Petit H, Baleynaud S, Chauvel C,
et al. Influence of preoperative left ventricular contractile reserve
on postoperative ejection fraction in low-gradient aortic stenosis.
Circulation. Lippincott Williams & Wilkins; 2006;113:1738–44.
26. Hachicha Z, Dumesnil JG, Bogaty P, Pibarot P. Paradoxical low-
flow, low-gradient severe aortic stenosis despite preserved ejection
fraction is associated with higher afterload and reduced survival.
Circulation. Lippincott Williams & Wilkins; 2007;115:2856–64.
27.•• Dayan V, Vignolo G, Magne J, Clavel M-A, Mohty D, Pibarot P.
Outcome and impact of aortic valve replacement in patients with
preserved LVEF and low-gradient aortic stenosis. J Am Coll
Cardiol. 2015;66:2594–603. This meta-analysis provides the
strongest evidence to date of increased mortality and survival
benefit of AVR in patients with low-flow low-gradient severe
aortic stenosis. Similar findings in patients with normal-flow
Curr Cardiovasc Imaging Rep (2016) 9: 21 Page 11 of 14 21
low-gradient severe aortic stenosis are novel and require fur-
ther research.
28. Eleid MF, Sorajja P, Michelena HI, Malouf JF, Scott CG, Pellikka
PA. Flow-gradient patterns in severe aortic stenosis with preserved
ejection fraction: clinical characteristics and predictors of survival.
Circulation. Lippincott Williams & Wilkins; 2013;128:1781–9.
29. Clavel M-A, Dumesnil JG, Capoulade R, Mathieu P, Sénéchal M,
Pibarot P. Outcome of patients with aortic stenosis, small valve
area, and low-flow, low-gradient despite preserved left ventricular
ejection fraction. J Am Coll Cardiol. 2012;60:1259–67.
30. O’Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Hosek N,
Buellesfeld L, et al. Clinical outcomes of patients with low-flow,
low-gradient, severe aortic stenosis and either preserved or re-
duced ejection fraction undergoing transcatheter aortic valve im-
plantation. European Heart Journal. The Oxford University Press;
2013;34:3437–50.
31. Ozkan A, Hachamovitch R, Kapadia SR, Tuzcu EM, Marwick
TH. Impact of aortic valve replacement on outcome of symptom-
atic patients with severe aortic stenosis with low gradient and
preserved left ventricular ejection fraction. Circulation.
Lippincott Williams & Wilkins; 2013;128:622–31.
32. Mehrotra P, Jansen K, FlynnAW, Tan TC, Elmariah S, PicardMH,
et al. Differential left ventricular remodelling and longitudinal
function distinguishes low flow from normal-flow preserved ejec-
tion fraction low-gradient severe aortic stenosis. European Heart
Journal. The Oxford University Press; 2013;34:1906–14.
33. Jander N, Hochholzer W, Kaufmann BA, Bahlmann E, Gerdts E,
Boman K, et al. Velocity ratio predicts outcomes in patients with
low gradient severe aortic stenosis and preserved EF. Br Heart J.
BMJ Publishing Group Ltd and British Cardiovascular Society;
2014;100:1946–53.
34. Lancellotti P, Lebois F, SimonM, Tombeux C, Chauvel C, Pierard
LA. Prognostic importance of quantitative exercise Doppler echo-
cardiography in asymptomatic valvular aortic stenosis.
Circulation. 2005;112:I377–82.
35. Maréchaux S, Hachicha Z, Bellouin A, Dumesnil JG, Meimoun P,
Pasquet A, et al. Usefulness of exercise-stress echocardiography
for risk stratification of true asymptomatic patients with aortic
valve stenosis. European Heart Journal. The Oxford University
Press; 2010;31:1390–7.
36. Saura D, de la Morena G, Flores-Blanco PJ, Oliva MJ, Caballero
L, González-Carrillo J, et al. Aortic valve stenosis planimetry by
means of three-dimensional transesophageal echocardiography in
the real clinical setting: feasibility, reliability and systematic devi-
ations. Echocardiography. 2015;32:508–15.
37. Qizilbash B, Couture P, Denault A. Impact of perioperative trans-
esophageal echocardiography in aortic valve replacement. Semin
Cardiothorac Vasc Anesth. SAGE Publications; 2007;11:288–
300.
38. Michelena HI, Abel MD, Suri RM, Freeman WK, Click RL,
Sundt TM, et al. Intraoperative echocardiography in valvular heart
disease: an evidence-based appraisal. Mayo Clin Proc. 2010;85:
646–55.
39. Ionescu AA, West RR, Proudman C, Butchart EG, Fraser AG.
Prospective study of routine perioperative transesophageal echo-
cardiography for elective valve replacement: clinical impact and
cost-saving implications. J Am Soc Echocardiogr. 2001;14:659–
67.
40. Flachskampf FA, Wouters PF, Edvardsen T, Evangelista A, Habib
G, Hoffman P, et al. Recommendations for transoesophageal echo-
cardiography: EACVI update 2014. Eur Heart J - Cardiovasc
Imaging. 2014;15:353–65.
41. Hahn RT, Little SH,MonaghanMJ, Kodali SK,WilliamsM, Leon
MB, et al. Recommendations for comprehensive intraprocedural
echocardiographic imaging during TAVR. JACC Cardiovasc
Imaging. 2015. pp. 261–87.
42. Wang H, Hanna JM, Ganapathi A, Keenan JE, Hurwitz LM,
Vavalle JP, et al. Comparison of aortic annulus size by transesoph-
ageal echocardiography and computed tomography angiography
with direct surgical measurement. Am J Cardiol. 2015;115:1568–
73.
43. Tsuneyoshi H, Komiya T, Shimamoto T. Accuracy of aortic annu-
lus diameter measurement: comparison of multi-detector CT,
Two- and three-dimensional echocardiography. J Card Surg.
2016;31:18–22.
44. Altiok E, Koos R, Schröder J, Brehmer K, Hamada S, Becker M,
et al. Comparison of two-dimensional and three-dimensional im-
aging techniques for measurement of aortic annulus diameters
before transcatheter aortic valve implantation. Heart. BMJ
Publishing Group Ltd and British Cardiovascular Society;
2011;97:1578–84.
45.•• Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M,
et al. Predictors of outcome in severe, asymptomatic aortic steno-
sis. N Engl J Med. 2000;343:611–7. This seminal paper sug-
gested the strong prognostic importance of aortic valve calci-
fication, outperforming traditional assessment of hemody-
namic severity.
46.•• Rosenhek R, Klaar U, SchemperM, Scholten C, Heger M, Gabriel
H, et al. Mild andmoderate aortic stenosis. Natural history and risk
stratification by echocardiography. Eur Heart J. The Oxford
University Press; 2004;25:199–205. The value of using the
above echocardiography-based calcium scoring system was
subsequently demonstrated in patients with mild and moder-
ate AS.
47. Messika-Zeitoun D, AubryM-C, Detaint D, Bielak LF, Peyser PA,
Sheedy PF, et al. Evaluation and clinical implications of aortic
valve calcification measured by electron-beam computed tomog-
raphy. Circulation. Lippincott Williams & Wilkins; 2004;110:
356–62.
48. Cowell SJ, Newby DE, Burton J, White A, Northridge DB, Boon
NA, et al. Aortic valve calcification on computed tomography
predicts the severity of aortic stenosis. Clin Radiol. 2003;58:
712–6.
49. Cueff C, Serfaty J-M, Cimadevilla C, Laissy J-P, Himbert D,
Tubach F, et al. Measurement of aortic valve calcification using
multislice computed tomography: correlation with haemodynamic
severity of aortic stenosis and clinical implication for patients with
low ejection fraction. Heart. BMJ Publishing Group Ltd and
British Cardiovascular Society; 2011;97:721–6.
50. Messika-Zeitoun D, Bielak LF, Peyser PA, Sheedy PF, Turner ST,
Nkomo VT, et al. Aortic valve calcification: determinants and
progression in the population. Arterioscler. Thromb. Vasc. Biol.
Lippincott Williams & Wilkins; 2007;27:642–8.
51. Nguyen V, Cimadevilla C, Estellat C, Codogno I, Huart V,
Benessiano J, et al. Haemodynamic and anatomic progression of
aortic stenosis. Br Heart J. BMJ Publishing Group Ltd and British
Cardiovascular Society; 2015;101:943–7.
52. Dweck MR, Jenkins WSA, Vesey AT, Pringle MAH, Chin CWL,
Malley TS, et al. 18F-sodium fluoride uptake is a marker of active
calcification and disease progression in patients with aortic steno-
sis. Circ Cardiovasc Imaging. Lippincott Williams & Wilkins;
2014;7:371–8.
53.•• Clavel M-A, Pibarot P, Messika-Zeitoun D, Capoulade R, Malouf
J, Aggarval S, et al. Impact of aortic valve calcification, as mea-
sured by MDCT, on survival in patients with aortic stenosis: re-
sults of an international registry study. J Am Coll Cardiol.
2014;64:1202–13. This multicentre observational study
showed that previously defined sex-specific values for severe
aortic stenosis based on CT assessment of aortic valve calcifi-
cation provided incremental prognostic information beyond
echo-derived measures.
21 Page 12 of 14 Curr Cardiovasc Imaging Rep (2016) 9: 21
54. Aksoy O, Cam A, Agarwal S, Ige M, Yousefzai R, Singh D, et al.
Significance of aortic valve calcification in patients with low-
gradient low-flow aortic stenosis. Clin Cardiol. Wiley
Periodicals, Inc; 2014;37:26–31.
55. Clavel M-A, Malouf J, Messika-Zeitoun D, Araoz PA, Michelena
HI, Enriquez-Sarano M. Aortic valve area calculation in aortic
stenosis by CT and Doppler echocardiography. JACC
Cardiovasc Imaging. 2015;8:248–57.
56. Chin CWL, Khaw HJ, Luo E, Tan S,White AC, Newby DE, et al.
Echocardiography underestimates stroke volume and aortic valve
area: implications for patients with small-area low-gradient aortic
stenosis. Can J Cardiol. 2014;30:1064–72.
57. Irkle A, Vesey AT, Lewis DY, Skepper JN, Bird JLE, Dweck MR,
et al. Identifying active vascular microcalcification by (18)F-sodi-
um fluoride positron emission tomography. Nat Commun. Nature
Publishing Group; 2015;6:7495.
58. Dweck MR, Jones C, Joshi NV, Fletcher AM, Richardson H,
White A, et al. Assessment of valvular calcification and inflam-
mation by positron emission tomography in patients with aortic
stenosis. Circulation. Lippincott Williams & Wilkins; 2012;125:
76–86.
59. Jenkins WSA, Vesey AT, Shah ASV, Pawade TA, Chin CWL,
White AC, et al. Valvular (18)F-fluoride and (18)F-
fluorodeoxyglucose uptake predict disease progression and clini-
cal outcome in patients with aortic stenosis. J Am Coll Cardiol.
2015;66:1200–1.
60. Dweck MR, Khaw HJ, Sng GKZ, Luo ELC, Baird A, Williams
MC, et al. Aortic stenosis, atherosclerosis, and skeletal bone: is
there a common link with calcification and inflammation?
European Heart Journal. The Oxford University Press; 2013;34:
1567–74.
61. Tawakol A,Migrino RQ, Bashian GG, Bedri S, VermylenD, Cury
RC, et al. In vivo 18F-fluorodeoxyglucose positron emission to-
mography imaging provides a noninvasive measure of carotid
plaque inflammation in patients. J Am Coll Cardiol. 2006;48:
1818–24.
62. Gunther S, Grossman W. Determinants of ventricular function in
pressure-overload hypertrophy inman. Circulation. 1979;59:679–88.
63. Salcedo EE, Korzick DH, Currie PJ, Stewart WJ, Lever HM,
Goormastic M. Determinants of left ventricular hypertrophy in
patients with aortic stenosis. Cleve Clin J Med. 1989;56:590–6.
64. Hein S, Arnon E, Kostin S, Schönburg M, Elsässer A, Polyakova
V, et al. Progression from compensated hypertrophy to failure in
the pressure-overloaded human heart: structural deterioration and
compensatory mechanisms. Circulation. 2003;107:984–91.
65. Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C,
Athanasiadis A, et al. Comparative evaluation of left and right
ventricular endomyocardial biopsy: differences in complication
rate and diagnostic performance. Circulation. Lippincott
Williams & Wilkins; 2010;122:900–9.
66. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O,
et al. Relationship of MRI delayed contrast enhancement to irre-
versible injury, infarct age, and contractile function. Circulation.
1999;100:1992–2002.
67. de Jong S, van Veen TAB, de Bakker JMT, Vos MA, van Rijen
HVM. Biomarkers of myocardial fibrosis. J Cardiovasc
Pharmacol. 2011;57:522–35.
68. Wu E, Judd RM, Vargas JD, Klocke FJ, Bonow RO, Kim RJ.
Visualisation of presence, location, and transmural extent of
healed Q-wave and non-Q-wave myocardial infarction. Lancet.
Elsevier; 2001;357:21–8.
69. Rudolph A, Abdel-Aty H, Bohl S, Boyé P, Zagrosek A, Dietz R,
et al. Noninvasive detection of fibrosis applying contrast-
enhanced cardiac magnetic resonance in different forms of left
ventricular hypertrophy relation to remodeling. J Am Coll
Cardiol. 2009;53:284–91.
70.• DweckMR, Joshi S,Murigu T, Alpendurada F, Jabbour A,Melina
G, et al. Midwall fibrosis is an independent predictor of mortality
in patients with aortic stenosis. J Am Coll Cardiol. 2011;58:1271–
9. The presence of mid-wall fibrosis on CMR was associated
with an eight-fold increase in all-cause mortality.
71.• Barone-Rochette G, Piérard S, de deMeester Ravenstein C, Seldrum
S,Melchior J,Maes F, et al. Prognostic significance of LGEbyCMR
in aortic stenosis patients undergoing valve replacement. J Am Coll
Cardiol. 2014;64:144–54. Again, mid-wall fibrosis is an indepen-
dent predictor of all-cause mortality following AVR.
72. . Weidemann F, Herrmann S, Störk S, Niemann M, Frantz S,
Lange V, et al. Impact of myocardial fibrosis in patients with
symptomatic severe aortic stenosis. Circulation. Lippincott
Williams & Wilkins; 2009;120:577–84.
73.• Azevedo CF, Nigri M, Higuchi ML, Pomerantzeff PM, Spina GS,
Sampaio RO, et al. Prognostic significance of myocardial fibrosis
quantification by histopathology and magnetic resonance imaging
in patients with severe aortic valve disease. JACC. 2010;56:278–
87. A key study showing that mid-wall fibrosis is associated
with worse improvement in LV function post-AVR and is an
independent predictor of long-term survival.
74. Chin CWL, Shah ASV, McAllister DA, Joanna Cowell S, Alam S,
Langrish JP, et al. High-sensitivity troponin I concentrations are a
marker of an advanced hypertrophic response and adverse outcomes
in patients with aortic stenosis. Eur Heart J. 2014;35:2312–21.
75. Krayenbeuhl HP, Hess OM, Monrad ES, Schneider J, Mall G,
Turina M. Left-ventricular myocardial structure in aortic-valve
disease before, intermediate, and late after aortic-valve replace-
ment. Circulation. 1989;79:744–55.
76. Higgins DM, Moon JC. Review of T1 mapping methods: com-
parative effectiveness including reproducibility issues. Curr
Cardiovasc Imaging Rep. Springer US; 2014;7:1–10.
77. Khawaja AZ, Cassidy DB, Shakarchi Al J, McGrogan DG, Inston
NG, Jones RG. Revisiting the risks ofMRI with gadolinium based
contrast agents-review of literature and guidelines. Insights
Imaging. Springer Berlin Heidelberg; 2015;6:553–8.
78.• Chin CWL, Semple S, Malley T, White AC, Mirsadraee S, Weale
PJ, et al. Optimization and comparison of myocardial T1 tech-
niques at 3T in patients with aortic stenosis. Eur Heart J-
Cardiovasc Imaging. 2014;15:556–65. This paper demonstrated
superior intra, inter observer and scan-rescan reproducibility
in ECVassessment of patients with aortic stenosis.
79. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM,
Elliott PM, et al. Equilibrium contrast cardiovascular magnetic
resonance for the measurement of diffuse myocardial fibrosis:
preliminary validation in humans. Circulation. Lippincott
Williams & Wilkins; 2010;122:138–44.
80. Fontana M, White SK, Banypersad SM. Comparison of T1 map-
ping techniques for ECV quantification. Histological validation
and reproducibility of ShMOLLI versus multibreath-hold T1
quantification …. J Cardiovasc Magn…. 2012.
81. White SK, Sado DM, Fontana M, Banypersad SM, Maestrini V,
Flett AS, et al. T1 mapping for myocardial extracellular volume
measurement by CMR: bolus only versus primed infusion tech-
nique. JACC Cardiovasc Imaging. 2013;6:955–62.
82. Kammerlander AA, Marzluf BA, Zotter-Tufaro C, Aschauer S,
Duca F, Bachmann A, et al. T1 mapping by CMR imaging: from
histological validation to clinical implication. JACC Cardiovasc
Imaging. 2016;9:14–23.
83. Bull S, White SK, Piechnik SK, Flett AS, Ferreira VM, Loudon
M, et al. Human non-contrast T1 values and correlation with his-
tology in diffuse fibrosis. Heart. BMJ Publishing Group Ltd and
British Cardiovascular Society; 2013;99:932–7.
84. Lee S-P, Lee W, Lee JM, Park E-A, Kim H-K, Kim Y-J, et al.
Assessment of diffuse myocardial fibrosis by using MR imaging
Curr Cardiovasc Imaging Rep (2016) 9: 21 Page 13 of 14 21
in asymptomatic patients with aortic stenosis. Radiology.
Radiological Society of North America; 2015;274:359–69.
85. Puntmann VO, Carr-White G, Jabbour A, Yu C-Y, Gebker R,
Kelle S, et al. T1-mapping and outcome in nonischemic cardio-
myopathy: all-cause mortality and heart failure. JACCCardiovasc
Imaging. 2016;9:40–50.
86. Flett AS, Sado DM, Quarta G, Mirabel M, Pellerin D, Herrey AS,
et al. Diffuse myocardial fibrosis in severe aortic stenosis: an equi-
librium contrast cardiovascular magnetic resonance study.
European Heart Journal - Cardiovascular Imaging. The Oxford
University Press; 2012;13:jes102–826.
87. Hinojar R, Varma N, Child N, Goodman B, Jabbour A, Yu C-Y,
et al. T1 Mapping in discrimination of hypertrophic phenotypes:
hypertensive heart disease and hypertrophic cardiomyopathy:
findings from the International T1 Multicenter Cardiovascular
Magnetic Resonance Study. Circ Cardiovasc Imaging.
Lippincott Williams & Wilkins; 2015;8:e003285.
88. Chin CWL,Messika-Zeitoun D, Shah ASV, Lefevre G, Bailleul S,
Yeung ENW, et al. A clinical risk score of myocardial fibrosis
predicts adverse outcomes in aortic stenosis. European Heart
Journal. The Oxford University Press; 2015;:ehv525.
89. Le Ven F, Tizón-Marcos H, Fuchs C, Mathieu P, Pibarot P, Larose
E. Valve tissue characterization by magnetic resonance imaging in
calcific aortic valve disease. Can J Cardiol. 2014;30:1676–83.
90. Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA,
Edvardsen T, Pierard LA, et al. Recommendations for the echocar-
diographic assessment of native valvular regurgitation: an execu-
tive summary from the European Association of Cardiovascular
Imaging. European Heart Journal - Cardiovascular Imaging.
Oxford University Press; 2013;14:611–44.
91. Perry GJ, Helmcke F, Nanda NC, Byard C, Soto B. Evaluation of
aortic insufficiency by Doppler color flow mapping. JACC.
1987;9:952–9.
92. Fang L, Hsiung MC, Miller AP, Nanda NC, Yin WH, Young MS,
et al. Assessment of aortic regurgitation by live three-dimensional
transthoracic echocardiographic measurements of vena contracta
area: usefulness and validation. Echocardiography. Blackwell
Science Inc; 2005;22:775–81.
93. Tribouilloy C, Avinée P, Shen WF, Rey JL, Slama M, Lesbre JP.
End diastolic flow velocity just beneath the aortic isthmus
assessed by pulsed Doppler echocardiography: a new predictor
of the aortic regurgitant fraction. Br Heart J. BMJ Group;
1991;65:37–40.
94. Choi J, Hong G-R, Kim M, Cho IJ, Shim CY, Chang H-J, et al.
Automatic quantification of aortic regurgitation using 3D full vol-
ume color doppler echocardiography: a validation study with car-
diac magnetic resonance imaging. Int J Cardiovasc Imaging.
Springer Netherlands; 2015;31:1379–89.
95. Tornos MP, Olona M, Permanyer-Miralda G, Herrejon MP,
Camprecios M, Evangelista A, et al. Clinical outcome of severe
asymptomatic chronic aortic regurgitation: a long-term prospec-
tive follow-up study. Am Heart J. 1995;130:333–9.
96. Dujardin KS, Enriquez-Sarano M, Schaff HV, Bailey KR, Seward
JB, Tajik AJ. Mortality and morbidity of aortic regurgitation in
clinical practice. A long-term follow-up study. Circulation.
1999;99:1851–7.
97. Bonow RO, Lakatos E, Maron BJ, Epstein SE. Serial long-term
assessment of the natural history of asymptomatic patients with
chronic aortic regurgitation and normal left ventricular systolic
function. Circulation. 1991;84:1625–35.
98. Turina J, Milincic J, Seifert B, Turina M. Valve replacement in
chronic aortic regurgitation. True predictors of survival after extend-
ed follow-up. Circulation. 1998;98:II100–6–discussionII106–7.
99. Chaliki HP, Mohty D, Avierinos J-F, Scott CG, Schaff HV, Tajik
AJ, et al. Outcomes after aortic valve replacement in patients with
severe aortic regurgitation and markedly reduced left ventricular
function. Circulation. 2002;106:2687–93.
100. Marciniak A, Sutherland GR, Marciniak M, Claus P, Bijnens B,
Jahangiri M. Myocardial deformation abnormalities in patients
with aortic regurgitation: a strain rate imaging study. Eur J
Echocardiogr. The Oxford University Press; 2009;10:112–9.
101. Smedsrud MK, Pettersen E, Gjesdal O, Svennevig JL, Andersen
K, Ihlen H, et al. Detection of left ventricular dysfunction by
global longitudinal systolic strain in patients with chronic aortic
regurgitation. J Am Soc Echocardiogr. 2011;24:1253–9.
102. Ewe SH, Haeck MLA, Ng ACT, Witkowski TG, Auger D, Leong
DP, et al. Detection of subtle left ventricular systolic dysfunction in
patients with significant aortic regurgitation and preserved left
ventricular ejection fraction: speckle tracking echocardiographic
analysis. European Heart Journal - Cardiovascular Imaging.
Oxford University Press; 2015;16:992–9.
103. Park SH, Yang YA, Kim KY, Park SM, Kim HN, Kim JH, et al.
Left ventricular strain as predictor of chronic aortic regurgitation. J
Cardiovasc Ultrasound. 2015;23:78–85.
104. David TE. Surgical treatment of aortic valve disease. Nat Rev
Cardiol. Nature Publishing Group; 2013;10:375–86.
105. Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ, Cleland
JG, et al. Comparison of left ventricular ejection fraction and vol-
umes in heart failure by echocardiography, radionuclide ventricu-
lography and cardiovascular magnetic resonance; are they inter-
changeable? European Heart Journal. The Oxford University
Press; 2000;21:1387–96.
106.•• Myerson SG, d’Arcy J, Mohiaddin R, Greenwood JP, Karamitsos
TD, Francis JM, et al. Aortic regurgitation quantification using
cardiovascular magnetic resonance: association with clinical out-
come. Circulation. Lippincott Williams & Wilkins; 2012;126:
1452–60. Regurgitant fraction calculated by phase-encoded
velocity mapping can classify AR severity with high accuracy
and is strongly predictive of progression to symptoms or AVR
within 3 years, although the RV cut-off appeared to be lower
that with echocardiography.
107. Chaturvedi A, Hamilton-Craig C, Cawley PJ,Mitsumori LM,Otto
CM, Maki JH. Quantitating aortic regurgitation by cardiovascular
magnetic resonance: significant variations due to slice location
and breath holding. Eur Radiol. Springer Berlin Heidelberg;
2015:1–10.
108. Cawley PJ, Hamilton-Craig C, Owens DS, Krieger EV, Strugnell
WE, Mitsumori L, et al. Prospective comparison of valve regurgi-
tation quantitation by cardiac magnetic resonance imaging and
transthoracic echocardiography. Circ Cardiovasc Imaging.
Lippincott Williams & Wilkins; 2013;6:48–57.
109. Honda N, Machida K, Hashimoto M, Mamiya T, Takahashi T,
Kamano T, et al. Aortic regurgitation: quantitation with MR im-
aging velocity mapping. Radiology. 1993;186:189–94.
110. Søndergaard L, Lindvig K, Hildebrandt P, Thomsen C, Ståhlberg
F, Joen T, et al. Quantification of aortic regurgitation by magnetic
resonance velocity mapping. Am Heart J. 1993;125:1081–90.
111. Gabriel RS, Renapurkar R, Bolen MA, Verhaert D, Leiber M,
Flamm SD, et al. Comparison of severity of aortic regurgitation
by cardiovascular magnetic resonance versus transthoracic echo-
cardiography. Am J Cardiol. 2011;108:1014–20.
21 Page 14 of 14 Curr Cardiovasc Imaging Rep (2016) 9: 21
Review
Assessment of myocardial fibrosis with T1
mapping MRI
R.J. Everett a,*, C.G. Stirrat a, S.I.R. Semple a,b, D.E. Newby a,b, M.R. Dweck a,
S. Mirsadraee a,b
aBritish Heart Foundation/University Centre for Cardiovascular Science, University of Edinburgh, UK
bClinical Research Imaging Centre, University of Edinburgh, UK
article information
Article history:
Received 10 November 2015
Received in revised form
15 January 2016
Accepted 9 February 2016
Myocardial fibrosis can arise from a range of pathological processes and its presence correlates
with adverse clinical outcomes. Cardiac magnetic resonance (CMR) can provide a non-invasive
assessment of cardiac structure, function, and tissue characteristics, which includes late gad-
olinium enhancement (LGE) techniques to identify focal irreversible replacement fibrosis with
a high degree of accuracy and reproducibility. Importantly the presence of LGE is consistently
associated with adverse outcomes in a range of common cardiac conditions; however, LGE
techniques are qualitative and unable to detect diffuse myocardial fibrosis, which is an earlier
form of fibrosis preceding replacement fibrosis that may be reversible. Novel T1 mapping
techniques allow quantitative CMR assessment of diffuse myocardial fibrosis with the two
most common measures being native T1 and extracellular volume (ECV) fraction. Native T1
differentiates normal from infarcted myocardium, is abnormal in hypertrophic cardiomyopa-
thy, and may be particularly useful in the diagnosis of AndersoneFabry disease and
amyloidosis. ECV is a surrogate measure of the extracellular space and is equivalent to the
myocardial volume of distribution of the gadolinium-based contrast medium. It is reproducible
and correlates well with fibrosis on histology. ECV is abnormal in patients with cardiac failure
and aortic stenosis, and is associated with functional impairment in these groups. T1 mapping
techniques promise to allow earlier detection of disease, monitor disease progression, and
inform prognosis; however, limitations remain. In particular, reference ranges are lacking for
T1 mapping values as these are influenced by specific CMR techniques and magnetic field
strength. In addition, there is significant overlap between T1 mapping values in healthy con-
trols and most disease states, particularly using native T1, limiting the clinical application of
these techniques at present.
! 2016 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
Introduction
Myocardial fibrosis is integral to the pathology of a
number local and systemic disease processes affecting the
heart and its presence adversely predicts prognosis.1e3
Myocardial fibrosis has traditionally been defined by his-
tology of endomyocardial biopsies: the reference standard
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investigation for tissue characterisation of cardiomyopa-
thies; however, this invasive technique brings with it a risk
of serious complications (0.6e0.8%)4 and is prone to sam-
pling error. As such a non-invasive whole-heart method of
assessing myocardial fibrosis is required.
Cardiac magnetic resonance imaging (CMR) is non-
invasive and allows accurate assessment of cardiac struc-
ture and function. Most importantly, it provides detailed
tissue characterisation, which is the key strength of CMR
and is integral to its ability to aid diagnosis, prognosis, and
treatment decisions. Over the last two decades, late gado-
linium enhancement (LGE) imaging techniques have been
developed that identify areas of focal replacement fibrosis
in the myocardium. Their widespread clinical use is sup-
ported by expanding data showing that the presence of LGE
is strongly associated with an adverse prognosis in several
pathologies including myocardial infarction (MI),5e8 dilated
cardiomyopathy (DCM),9 hypertrophic cardiomyopathy
(HCM),10,11 and aortic stenosis (AS).1,12,13
Although LGE is a useful imaging biomarker, it detects
end-stage, irreversible tissue damage with replacement
fibrosis. There is, therefore, considerable interest in devel-
oping novel techniques that allow earlier detection of
potentially reversible diffuse fibrosis, frequently missed
using LGE. Such early tissue characterisation can be ach-
ieved using MRI techniques that quantify myocardial T1
values and are starting to enter clinical practice. In this re-
view, wewill examine the novel imaging techniques used in
the assessment of myocardial fibrosis, primarily focussing
on the development of T1 mapping techniques, and discuss
their clinical application.
LGE
This technique was first described in 199914 using the
administration of gadolinium pentetate digmeglumine (Gd-
DTPA). Following intravenous bolus administration, Gd-
DTPA enters healthy myocardium down a concentration
gradient (wash-in) within 1e3 minutes. As gadolinium is
cleared from the blood pool by the kidneys, the contrast
medium slowly exits the myocardium along the reverse
concentration gradient (wash-out) over 10e30 minutes.
The large molecular size of gadolinium chelate prevents
it from crossing cell membranes leading to accumulation in
the extracellular space. Gadolinium potently shortens T1
related to its concentration in the tissue being imaged.
Expansion of extracellular space will retain a higher con-
centration of gadolinium and therefore appear bright on
inversion-recovery T1-weighted (T1W) sequence.15 The
inversion time (TI) can be manually adjusted to “null” the
normal myocardium so that it appears black, providing the
optimum visual contrasts for LGE detection. Newer phase-
sensitive inversion recovery (PSIR) techniques use a back-
ground phase map, which is acquired at the same time as
the image that can be used to produce intensity normalised
images. This is less sensitive to TI selection, and so can avoid
artefact. Although PSIR images have a lower spatial reso-
lution, they also reduce background noise and improve the
contrast-to-noise ratio16 making them particularly useful in
smaller volume centres.
Extracellular matrix (ECM) expansion and replacement
fibrosis is seen in chronic MI leading to accumulation of
gadolinium in these areas. In the acute setting of myocardial
necrosis, there is a loss of cell membrane integrity leading to
intracellular accumulation of gadolinium in the area of
infarction. LGE sequences have shown excellent reproduc-
ibility and validation with histology in MI.14 LGE imaging in
the days following acuteMI relates to acute cellular necrosis
andmyocardial oedema rather than scar and fibrosis, which
usually occupies a smaller volume when it ultimately
forms.17 LGE is the reference-standard imaging technique to
diagnose prior MI and offers important information on
infarct size, myocardial salvage, and microvascular
obstruction, all predictors of adverse outcome.5e8,18
Importantly, these measures provide incremental prog-
nostic information above clinical risk scores and left ven-
tricular (LV) ejection fraction (LVEF).8 In addition, LGE is
present in a significant proportion of patients with DCM,
HCM and advanced AS. Its presence in these conditions is
also strongly linked with poor prognosis.9
LGE is essentially a difference test providing a binary
assessment as to the presence or absence of LGE and
requiring regions of normal myocardium to provide the
necessary contrast; therefore, it has several major limita-
tions. First, interpretation of LGE images requires a com-
parison between affected and unaffected myocardium and
is therefore less able to detect diffuse pathological processes
affecting the entire myocardium homogeneously. Second,
the requirement to select manually an appropriate inver-
sion time in order to “null” normal myocardium requires
radiographer expertise and experience and introduces a
potential source of error. Third, although quantification of
fibrosis volume (FV) is possible, there is no universally
accepted technique, and it has not been sufficiently vali-
dated for routine clinical use.19 Finally, there is a small risk
of nephrogenic systemic fibrosis with gadolinium admin-
istration, precluding its use in those with severe renal
impairment,20 although this is less of a concern with the
newer cyclic agents.
T1 mapping technique
The most studied technique for assessment of diffuse
myocardial fibrosis is assessment of T1 relaxation times,
termed T1 mapping. A T1 map is a two-dimensional slice
image where each voxel of the image displays the T1
relaxation time as signal intensity using a colour scheme for
easier visual assessment. High T1 relaxation times are
observed in diffuse fibrosis, protein deposition, and water in
oedema. Low T1 values are seen in iron or lipid deposition.21
The multipoint approach to T1 sampling first described
by Look and Locker (LL) in the 1970s involved continuous
sampling of the T1 relaxation curve at multiple time points
after an initial preparation pulse22; however, cardiacmotion
prevented the acquisition of a voxel-by-voxel T1 map and
limited spatial resolution. Subsequently, the development
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of the modified LookeLocker inversion (MOLLI) recovery
sequence in 2004 allowed acquisition during a single
breath-hold23 by selectively acquiring data at a given time
point in the cardiac cycle (using electrocardiogram [ECG]
gating) and merging multiple LL sequences with varying
inversion times into a single dataset (Fig 1); however, there
are several limitations of theMOLLI technique. T1 values are
consistently underestimated at high T1 values (>800 ms)24
and higher heart rates, although newer MOLLI sequences
have shownmuch less heart rate dependence.25 In addition,
the relatively long breath-hold required (over 17 cardiac
cycles: roughly 15 seconds) may be challenging in some
patients, particularly in the elderly or thosewith pulmonary
disease or bradycardia.
The shortened MOLLI (ShMOLLI) recovery sequence was
developed to address these limitations. Full recovery of
longitudinal magnetisation is not achieved in ShMOLLI, but
an algorithm allows conditional interpretation of T1 values
to obtain precise measurements (Fig 2) with a consistent
underestimation of T1 values, which can be corrected. This
results in a halving of breath-hold times to approximately
7e9 seconds. Furthermore, the sequence is independent of
heart rate, easier to post-process, and is accurate and
reproducible over a wider range of T1 values.24,26
Several other variations of both inversion and saturation
recovery techniques have been proposed. The saturation
recovery single-shot acquisition (SASHA) pulse sequence
consists of 10 single-shot balanced steady state free pro-
cession (bSSFP) images with ECG gating in diastasis. The
sequence appeared to have good accuracy and to be both T1
and heart rate independent.27 Several other novel tech-
niques have been proposed but are beyond the scope of this
article; the above techniques are the most common at the
time of writing.
Following data acquisition, the images undergo post-
processing. T1 maps are produced by combining data
from 11 (MOLLI) or 5e7 (ShMOLLI) images. This may
introduce errors due to through-plane motion. Position of
source images may need to be corrected for misregistration
caused by movement in between cardiac cycles due to a
Figure 1 Use of MOLLI recovery sequence to calculate an estimate of T1 time. Three inversion recovery experiments are performed with three,
three, and five images acquired. Images are ECG gated (acquired at consistent time delay from previous R wave to capture mid-diastole). The
resulting raw images are then ordered by TI and signal values used to plot a T1 recovery curve, which is used to derive the T1 value. T1 values are
then used to create a two-dimensional voxel map.
Figure 2 The ShMOLLI recovery sequence. Three inversions are still
performed, however, five, one, and one images are acquired, but
longitudinal magnetisation is not allowed to completely recover
before the next inversion. A conditional algorithm is then applied
leading to the creation of the final T1 map.
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poor breath-hold,28 which can be performed by automated
non-rigid registration.
Gadolinium-based T1 measures
T1 mapping can also be performed after administration
of gadolinium-based contrast medium administration,
which shortens T1 relaxation times (Fig 3). Although
providing increased signal, these post-contrast T1 values
need to be corrected for a range of factors including indi-
vidual variation in gadolinium kinetics and time from
contrast medium administration to imaging. Gadolinium
concentration has a strong non-linear relationship with the
R1 relaxation rate (1/T1) and measuring the change in T1 in
both the myocardium and blood pool following contrast
medium administration allows the concentration of gado-
linium in these compartments to be estimated. The ratio of
myocardial contrast medium concentration to blood con-
centration is termed the partition coefficient (l) and cor-
rects for many of the above confounders. At contrast
equilibrium, the gadolinium concentration will be equal in
the myocardium and blood pool. Knowing the blood vol-
ume of distribution (1ehaematocrit) allows the myocardial
volume of distribution to be calculated as a surrogate for the
extracellular space. This has been termed the extracellular
volume (ECV) fraction. The absolute FV can then be calcu-
lated by multiplying the ECV by the myocardial volume.
Calculation of the ECV requires a steady state between
myocardial and blood contrast agent, which was first ach-
ieved using a continuous contrast medium infusion. This
approach, called equalisation-contrast CMR (EQ-CMR) was
well validated against collagen volume fraction (CVF; the
percentage of myocardial volume occupied by collagen on
histological staining) but required an extra 10 minutes of
scanning time plus 30e90 minutes of total patient time.29
Alternative bolus techniques that are less cumbersome have
been developed, such as dynamic-equilibrium CMR. This
technique assumes that a dynamic equilibrium between the
myocardium and blood pool is reached 15e20minutes after
the contrast medium bolus and so that the impact of gad-
olinium kinetic effects is negligible. This too has been his-
tologically validated30 with the optimal correlation
observed using T1 measurements taken 15 minutes
following contrast medium bolus.31
Reference values
There are a number of factors that influence the specific
T1 values measured during scanning, including the image
acquisition protocol, post-processing, scanner magnetic
Figure 3 Common T1 mapping measurements are derived from regions of interest (ROI) drawn onto each myocardial segment and repeated
following gadolinium administration.
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field strength (T), contrast medium dose, and time delay to
post-contrast imaging. The establishment of a normal range
of values in healthy individuals is critical in order to use
these quantitative techniques to diagnose disease states.
These have, however, been delayed by the wide range of
different approaches that are frequently site and vendor
specific, and concentrated within a few specialist research
centres. Although several small studies have been per-
formed,32,33 these have demonstrated a large overlap in
values between healthy controls and most disease states,
particularly with respect to native T1. Further research into
new techniques or measures is required to address this key
issue. Indeed a consensus statement from the Society of
CMR (SCMR) has recently been produced to accelerate this
development.21 In particular, commercially available
standardised sequences are awaited.
Histological validation
The myocardium can be divided conceptually into the
cellular mass comprising myocytes and the extracellular
interstitial space, containing the ECM. The ECM consists
predominately of collagen (type I, 85% and type III, 11%), as
well as basement membrane (including small amounts of
collagen types IV and V), proteoglycans, glycosaminogly-
cans, and bioactive signalling molecules.34
ECV
The predominant change in myocardial fibrosis is the
accumulation of excess type I collagen, which results in
expansion of the ECM (and hence extracellular interstitial
space) in relation to the total myocardial volume. Expansion
of myocardial extracellular interstitial space is also seen
with protein deposition in amyloidosis and acute myocar-
dial oedema in MI, myocarditis, and Takotsubo
cardiomyopathy.
No T1 mapping technique directly measures the extra-
cellular matrix. The ECV, however, measures a useful sur-
rogate; the extracellular space, which is occupied by the
extracellular matrix, and therefore, is assumed to reflect
diffuse myocardial fibrosis in the absence of protein depo-
sition or oedema.
Several studies have been performed validating various
T1 mapping measures against CVF determined by histo-
logical staining of myocardial biopsy samples in various
cardiac pathologies (Table 1). A strong correlation was
observed between native T1 and histological fibrosis in
patients with severe AS as assessed on myocardial biopsy
taken during aortic valve replacement (AVR).35,36 Native T1
values were significantly different between these patients
with AS and healthy controls,36 and was also correlated
with global longitudinal strain35; however, in a subsequent
study of patients with less advance AS no difference was
observed in native T1 values between age- and sex-
matched control patients and those with AS.37
Isolated post-contrast T1 measurements have demon-
strated mixed results. One study31 demonstrated a poor
correlation with histological fibrosis, whilst in AS this
measurement had poor scan-rescan reproducibility and
ability to differentiate disease states.37 By contrast, other
studies at 1.5 Tobserved a good correlationwith histological
fibrosis in patients with heart failure38 and a mixture of
pathologies including DCM, ischaemic cardiomyopathy,
HCM, and amyloidosis.39 Post-contrast T1 was also associ-
ated with ECM expansion in patients with heart failure with
preserved ejection fraction, although this was thought to
represent non-collagen ECM components.40
ECV is well validated against CVF. Excellent correlation
has been shown at 1.5 T using EQ-CMR29 and dynamic-
equilibrium CMR30 in patients with AS and intra-operative
septal myocardial biopsy at the time of AVR. Comparable
results were obtained in a similar patient group using a
more contemporary ShMOLLI sequence.41 Additional vali-
dation of ECV in whole-heart specimens explanted during
cardiac transplantation showed strong correlation between
ECV and CVF measured in 288 myocardial segments.31
These patients comprised a mixture of ischaemic cardio-
myopathy and DCM and were imaged at 1.5 T using a MOLLI
dynamic contrast sequence.
Clinical application in specific myocardial
pathologies
MI
Replacement myocardial fibrosis following MI starts in
the subendocardium and extend transmurally towards the
epicardium depending on the extent of infarction (Fig 4).
Transmural infarction predicts a lack of functional recovery
in the affected myocardial segment following coronary ar-
tery bypass grafting,42,43 and increasing infarct size on LGE
assessment correlates with reduced systolic LVEF and the
risk of future cardiovascular events.5e8
The use of T1 mapping may allow more precise quanti-
fication of area of infarction. Native T1 is particularly
attractive in the 20% of MI patients with severe renal
impairment in whom gadolinium is contraindicated.44
Native T1 relaxation times increase in both acute infarction
and the scar that later forms.24 Focal decreases in native T1
values can also be observed that are thought to relate to fat
or iron deposition following haemorrhage into the infarcted
area.
Native T1 is able to identify areas of acute infarction (<8
days, 1.5 T) with excellent sensitivity and specificity (96%
and 91%, respectively) compared to LGE using a threshold-
based approach (abnormal if T1 value of region >3 stan-
dard deviations [SD] above mean of healthy reference
subjects). It is less useful at 1.5 T in the assessment of
chronic infarctionwith a sensitivity of<50%17 in this group;
however, at 3 T both sensitivity (87e89%) and specificity
(95e98%) are significantly improved. Interestingly, for this
purpose a qualitative assessment performs less well
(sensitivity 60e64%, specificity 86e91%) than the threshold
based approach.44 ECV is almost double in regions of prior
MI (defined by the presence of LGE) compared to remote
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Table 1
Histological validation of T1 mapping techniques.
Reference Year Area Population N Measure Method Correlation
Iles et al.38 2008 Australia DCM 25 Post-contrast
T1
1.5 T, Inversion-recovery VAST
sequence
r¼e0.7, p¼0.03
Flett et al.29 2010 UK AS/HCM 26 ECV 1.5 T, EQ-CMR. Myocardial biopsy
during AVR or septal myomectomy
r2¼0.80, p<0.001








1.5 T, inversion recovery Look
Locker
All patients who had undergone
CMR and myocardial biopsy
r¼e0.57,
p<0.0001
Mascherbauer et al.40 2013 Austria HFpEF 9 Post-contrast
T1
1.5 T, inversion recovery FLASH r¼0.98, p<0.01
White et al.30 2013 UK AS/HCM/IHD/
amyloid




Miller et al.31 2013 UK DCM/IHD 6 ECV 1.5 T, DynEQ-CMR. Whole-heart
explant, 288 segments analysed in
total
r2¼0.555, p<0.001
Bull et al.36 2013 UK Severe AS
(AVR)
19 Native T1 1.5 T, ShMOLLI r¼0.65, p¼0.002




20 Native T1 3 T, MOLLI r¼0.777, p<0.001
DCM, dilated cardiomyopathy; AS, aortic stenosis; HCM, hypertrophic cardiomyopathy; IHD, ischaemic heart disease; HFpEF, heart failure with preserved
ejection fraction; AVR, aortic valve replacement; n, number of patients.
Figure 4 CMR short axis images with LGE and T1 mapping in different cardiac conditions. Areas of subendocardial (myocardial infarction, red
arrow) and mid wall (AS and HCM, white arrows) late gadolinium enhancement are also identified visually with pre and post-contrast T1 maps.
There is an increase in diffuse fibrosis in the AS patients as represented by higher ECV values. There is significant overlap between native T1
values in healthy controls and disease states.
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normal myocardium (51 # 8% versus 27 # 3% respectively,
p<0.00145).
Heart failure with reduced ejection fraction (HFrEF)
Myocardial fibrosis is a common end point in a range of
cardiomyopathies and is identified in both systolic and
diastolic heart failure.46,47 Approximately 30% of patients
with DCMhave evidence of LGE in amid-wall pattern that is
associated with ventricular arrhythmias and cardiovascular
mortality.9,48 The identification of diffuse fibrosis using T1
mapping may be useful for further assessing prognosis and
response to treatment.
The first study to validate post-contrast T1 measures
against histological fibrosis in patients with heart failure
showed that these values were lower in such patients
compared to controls and correlated with diastolic func-
tion.38 Abnormal post-contrast T1,39,49,50 partition coeffi-
cient (l)51 and ECV52 are associated with impaired ejection
fraction (EF). Post-contrast T1 also correlates inversely with
end-diastolic volume (EDV).49 ECV is theoretically more
sensitive in identifying early disease compared to EF and, as
one would expect, increases in interstitial diffuse fibrosis
appear to precede the onset of overt LV systolic impairment.
Similar to LGE, ECV also appears to provide prognostic in-
formation on cardiovascular outcomes.53,54
Heart failure with preserved EF (HFpEF)
It has been estimated that 50% of individuals with the
clinical syndrome of cardiac failure have a normal EF, with a
similar prognosis to those with impaired systolic func-
tion.55,56 These patients have abnormalities of LV relaxation
rather than contraction, termed diastolic dysfunction,
which is associated with increasing age, obesity, hyperten-
sion, diabetes mellitus, and atrial fibrillation. Echocardiog-
raphy assessment using tissue Doppler, assessment of left
atrial size and LV filling pattern is instrumental in making
the diagnosis, but there is often clinical uncertainty. In
addition, a proportion of the general population have some
evidence of diastolic dysfunction on echocardiography.55
ECM expansion and diffuse myocardial fibrosis are thought
to be the key pathological processes underlying the devel-
opment of this condition. CMR is, therefore, ideally placed
to evaluate such patients although data in this ubiquitous
population remains relatively sparse.
In one study, post-contrast T1 values were inversely
associated with diastolic function, pulmonary vascular
resistance, and adverse cardiac outcomes in 100 patients
with HFpEF.40 Another study demonstrated an increased
ECV compared to healthy controls that was associated with
reduced peak LV filling rate. ECV was higher still in patients
with systolic heart failure, correlating inversely with EF,
although there was significant overlap between these
groups.52 Focal replacement fibrosis is also common in
HFpEF with 36% of 111 patients having evidence of LGE at
1.5 T (albeit using a relatively low threshold of 2 SD of signal
intensity above remote myocardium to define presence of
LGE). As with other conditions the presence of LGE was
associated with an adverse prognosis in terms of cardio-
vascular death and heart failure admissions.57
Aortic stenosis and hypertension
Aortic stenosis is the most common valve disease in the
Western world and responsible for significant morbidity.
Valvular calcification and stenosis lead to progressive LV
hypertrophy (LVH) and ultimately LV decompensation and
heart failure unless AVR is performed. This decompensation
is characterised by myocyte cell death and myocardial
fibrosis.58 Severity of valvular stenosis (as assessed on
echocardiography) correlates poorly with the degree of LVH
and LV impairment emphasising the importance of assess-
ing both the valve and myocardium independently.59
Contemporary guidelines advise AVR in the presence of
symptoms (exertional angina, syncope, or dyspnoea) or
reduction in LVEF. The poor prognosis following develop-
ment of symptoms was described in 1968 in younger pa-
tients with bicuspid or rheumatic heart disease.60 The
demographics of AS have since shifted with most patients
developing calcific disease of normal valves. Patients are
now usually elderly with multiple comorbidities, which can
make attributing symptoms to valve disease difficult. LV
systolic impairment is recognised as an insensitive marker
of LV dysfunction and often is irreversible following AVR.61
In contrast diffuse myocardial fibrosis may regress
following AVR.62 There is therefore considerable interest in
the use of CMR to assess fibrosis burden and to optimise the
timing of AVR.
Diffuse fibrosis progresses to irreversible focal replace-
ment fibrosis, which is detectable using LGE imaging,63 and
tends to be present in the LVmid-wall (Fig 4). LGE correlates
with CVF on histology, myocardial injury,64 appears irre-
versible post-AVR, predicts functional recovery following
surgery and is an independent predictor of all-cause
mortality.1,12,13
The assessment of diffuse fibrosis, while more chal-
lenging, may allow detection of LV decompensation before
the development of irreversible replacement fibrosis or LV
systolic impairment. T1 measures such as native T135,36 and
ECV65 are well validated against histology in populations
with AS and can differentiate those patients from controls.
Native T1 correlates with global longitudinal strain,35 echo
measures of AS severity, LV mass, and functional status36;
however, native T1 lacked sensitivity to differentiate
healthy controls from patients in a population with less
severe AS.37 Whilst uncorrected post-contrast T1 values
lack reproducibility, both the partition co-efficient and ECV
appear of promise in AS. In particular, ECV demonstrated
the best intra- and interobserver and scanerescan repro-
ducibility,37 and is associated with diastolic dysfunction and
impaired functional status as measured by 6-minute walk
test65; however, once again each of these T1 mapping
techniques are limited by significant overlap in values be-
tween patients with AS and controls highlighting the need
for novel techniques and measures.
Like AS, systolic hypertension is also associated with
prolonged exposure of the LV to an increased afterload. The
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myocardial response to this afterload is also similar, with
LVH initially restoring wall stress but ultimately decom-
pensating, driving the transition to heart failure and
adverse events. Diffuse myocardial fibrosis is also seen on
myocardial biopsy of hypertensive patients with LVH, with
progressive fibrosis being associated with impairment in
LVEF66 and LV chamber stiffness.67 Importantly, this
diffuse fibrosis may regress with anti-hypertensive treat-
ment,67 and can be quantified with CMR T1 mapping.
Indeed, ECV progressively increases moving from non-
hypertensive controls, to hypertensive patients without
LVH to hypertensive patients with evidence of LVH,68,69
suggesting that ECM expansion could precede onset of
overt LVH. Hypertensive patients with LVH also have
higher native T1 compared to controls. ECV and native T1
are associated with reduced peak systolic and early dia-
stolic strain rate69 supporting their use as markers of early
LV decompensation.
HCM
HCM refers to a heterogeneous group of genetic diseases
characterised by LVH not explained by abnormal loading
conditions (such as AS or systolic hypertension). The ma-
jority of cases involve mutations in genes encoding sarco-
meric proteins but phenotypic expression and clinical
manifestations are variable. The predominant pathology is
myocyte hypertrophy with myofibril disarray but ECM ab-
normalities, such as diffuse interstitial and focal replace-
ment fibrosis, are frequently present. HCM patients have an
increased risk of heart failure, arrhythmias, and sudden
cardiac death (SCD), although the risk factors for developing
these complications are poorly characterised.
ECM remodelling and myocardial fibrosis is associated
with stiffening of the ventricle leading to diastolic and
systolic dysfunction, and can provide a substrate for
dangerous re-entrant arrhythmias. Supporting this is the
high prevalence of fibrosis demonstrated at post-mortem of
patients with HCM who suffered SCD.2,3 In addition, in the
analysis of an explanted heart, CVF correlated inversely
with segmental contractility on preoperative CMR in
contrast to myocyte disarray.70
LGE identifies focal areas of replacement fibrosis in
approximately two-thirds of patients with HCM (Fig 4).10,11
It has been shown that LGE correlates well with myocardial
fibrosis in an explanted heart70 and predicts the develop-
ment of heart failure, arrhythmia, and SCD.10,11,71 In spite of
growing evidence supporting the prognostic value of LGE,
assessment is not currently recommended as part of risk
stratification in clinical guidelines.
Given the high prevalence of replacement fibrosis in this
population, T1 mapping measures may be of use in
providing further risk stratification. Although the early data
are somewhat limited and inconsistent, it hints at some
exciting possibilities. Post-contrast T1 correlates inversely
with CVF on histology, can distinguish HCM patients from
normal individuals, and is associated with dyspnoea and
diastolic dysfunction.72 As discussed, there are, however,
limitations and issues with reproducibility using this
measure. ECV shows excellent spatial agreement with focal
LGE in HCM73 and can also differentiate patients from
controls74,75; however, most early studies analysed ECV
averaged across the whole heart, including areas of LGE.
When ECV of non-LGE segments was analysed separately
no change was observed compared to controls.76 This is
somewhat surprising and in contrast to the data using
native T1,26,77 which appears to provide the best discrimi-
nation between HCM and controls (97% specificity, 100%
sensitivity, 99% diagnostic accuracy).26,74,77 This may be
because native T1 relaxation times are also influenced by
the intracellular compartment which is also abnormal in
patients with HCM. Although native T1 has not been vali-
dated against histology, it is associated with increasing LV
mass74 and strongly correlates with areas of LGE.26 The use
of T1 mapping (in particular native T1) in the identification
of early phenotypes with subclinical fibrosis is an exciting
area for future research.
Use of T1 mapping in assessment of non-
fibrotic pathology
T1 mapping is also of potential benefit in the identifica-
tion of several non-fibrotic cardiac diseases. Full exploration
of these areas is beyond the scope of this review; however,
we will discuss these conditions in brief.
AFD is an X-linked storage disorder characterised by
accumulation of glycosphingolipid within lysosomes lead-
ing to heart failure, arrhythmia, stroke, and renal impair-
ment. Importantly recombinant enzyme administration can
lead to slowing or reversal of progression if initiated before
end-stage disease is present. Native T1 (low values in areas
of lipid) can readily distinguish AFD from other causes of
LVH with no overlap.78 This is one of the most compelling
indications for T1 mapping assessment in an albeit rare
clinical condition.
Cardiac involvement in amyloidosis is confirmed by the
presence of LGE, although this is associated with late-stage
disease and may not be sensitive in detecting earlier dis-
ease. Other techniques used to identify amyloid protein
deposition, such as radiolabelled serum amyloid P and
99mTc-DPD scintigraphy are challenging in the heart due to
cardiac motion. Native T1 is raised in those with suspected
or confirmed cardiac amyloidosis, correlates with measures
of systolic and diastolic dysfunction, and is raised compared
to healthy controls in patients with no evidence of cardiac
abnormality on echocardiography. It may, therefore, be of
clinical use in detecting the early stages of cardiac amyloid
involvement, although no validation with cardiac biopsy
has been performed.79
Native T1 is decreased in iron overload, and there is ev-
idence for superior inter-study reproducibility and
increased sensitivity for mild iron loading compared to the
conventionally used T2* sequence.80 Myocardial oedema is
traditionally best imaged with T2-weighed sequences,
although acute oedema prolongs both T2 and T1 relaxation
times (Fig 5). There is evidence that T1 mapping can
differentiate acute from chronic MI and diagnose
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myocarditis.81 Although full review of T2 imaging is beyond
the scope of this review, T1 mapping may be superior to
T2W sequences as a reference region of interest (skeletal
muscle or remote myocardium) is not required for
comparison.
Summary of current status and future
directions
T1 mapping is able to assess diffuse fibrosis in a non-
invasive manner and offers significant advantages of LGE
assessment; the technique is fully quantitative, able to
detect earlier diffuse fibrosis and no inversion time needs to
be set, reducing the likelihood of operator error. The two
most promising T1 measures are native T1 and ECV; both
correlate well with histological fibrosis in a number of
cardiac pathologies. Native T1 is reproducible, able to
differentiate patients from healthy volunteers in a number
of conditions and most importantly does not require gad-
olinium contrast medium enabling its use in patients with
renal dysfunction. It is likely to be most useful in identifi-
cation and quantification of MI in patients with severe renal
impairment for whom gadolinium is contraindicated. It has
also found a compelling role in the diagnosis of rarer causes
of LVH such as AFD and amyloidosis.
ECV has excellent reproducibility37 and offers a measure
of myocardial fibrosis relative to total LV volume, which is
conceptually attractive to clinicians. It promises to be useful
in patients with heart failure with either reduced or pre-
served EF as an additional method of disease staging and
prognostication, although further research is required. In
addition, the linear relationship between blood native T1
and haematocrit may enable estimation of ECV without
requirement for venous blood sampling (so called “syn-
thetic ECV”).82 The utility of ECV in pressure-overload
states, such as AS, appears to be more limited. Our experi-
ence with AS patients shows that LV mass and diffuse
fibrosis increase simultaneously with progressive disease,
making ECV, a marker of relative fibrosis, insensitive in
detecting an increase.We believe that the use of an absolute
measure of whole-heart fibrosis, such as the FV (ECV$ end-
diastolic LV volume) may be more sensitive in tracking the
progression of LV decompensation. This will need to be
tested in future studies.
Important limitations persist, namely the overlap be-
tween healthy volunteers and disease states and the paucity
of data on normal reference ranges, which are specific to
manufacturer, acquisition technique, and magnetic field
strength. Further research on these areas is keenly awaited.
Collagen- and elastin-specific contrast media
Whereas current gadolinium-based contrast media
allow quantification of the ECV (a surrogate for the extra-
cellular space), novel contrast agents that bind to specific
components of the ECM could allow its composition to be
assessed non-invasively. Both collagen- and elastin-specific
MR contrast media have been developed and tested in a
preclinical mouse model of MI. Collagen-specific gadolin-
ium-based media bind to myocardial collagen and accord-
ingly have a longer washout time from areas of replacement
fibrosis leading to improved contrast-to-noise ratio on
delayed CMR imaging.83 Elastin-specific MR contrast agents
(ESMA) bind to tropoelastin, which is involved in post-MI
scar remodelling and thought to preserve elasticity in the
infarcted heart. ESMA also displayed a greater contrast-to-
noise ratio compared to current contrast media and corre-
lated with increased synthesis of tropoelastin on histolog-
ical analysis, which also correlated with improved LVEF.84
ESMA may also be able to monitor the effects of novel
therapies targeted at altering ECM composition and further
clinical trials of both these agents are awaited.
Conclusion
Myocardial fibrosis is an important predictor of poor
prognosis in many cardiac diseases. T1 mapping techniques
continue to evolve allowing quantification of diffuse and
Figure 5 CMR images of a patient with myocarditis. A large area of myocardial oedema is visible in the lateral wall detectable on late gadolinium,
T1 and T2 mapping.
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replacement fibrosis burden, and earlier detection and se-
rial assessment of myocardial pathology. These novel
techniques are clearly well placed to inform future clinical
practice and help direct treatment strategies.
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ABSTRACT
OBJECTIVES Cardiac magnetic resonance (CMR) was used to investigate the extracellular compartment and myocardial
fibrosis in patients with aortic stenosis, as well as their association with other measures of left ventricular decompen-
sation and mortality.
BACKGROUND Progressive myocardial fibrosis drives the transition from hypertrophy to heart failure in aortic stenosis.
Diffuse fibrosis is associated with extracellular volume expansion that is detectable by T1 mapping, whereas late
gadolinium enhancement (LGE) detects replacement fibrosis.
METHODS In a prospective observational cohort study, 203 subjects (166 with aortic stenosis [69 years; 69% male];
37 healthy volunteers [68 years; 65% male]) underwent comprehensive phenotypic characterization with clinical imaging
and biomarker evaluation. On CMR, we quantified the total extracellular volume of the myocardium indexed to body
surface area (iECV). The iECV upper limit of normal from the control group (22.5 ml/m2) was used to define extracellular
compartment expansion. Areas of replacement mid-wall LGE were also identified. All-cause mortality was determined
during 2.9 ! 0.8 years of follow up.
RESULTS iECV demonstrated a good correlation with diffuse histological fibrosis on myocardial biopsies (r ¼ 0.87;
p < 0.001; n ¼ 11) and was increased in patients with aortic stenosis (23.6 ! 7.2 ml/m2 vs. 16.1 ! 3.2 ml/m2 in
control subjects; p < 0.001). iECV was used together with LGE to categorize patients with normal myocardium
(iECV <22.5 ml/m2; 51% of patients), extracellular expansion (iECV $22.5 ml/m2; 22%), and replacement fibrosis
(presence of mid-wall LGE, 27%). There was evidence of increasing hypertrophy, myocardial injury, diastolic dysfunction,
and longitudinal systolic dysfunction consistent with progressive left ventricular decompensation (all p < 0.05) across
these groups. Moreover, this categorization was of prognostic value with stepwise increases in unadjusted all-cause
mortality (8 deaths/1,000 patient-years vs. 36 deaths/1,000 patient-years vs. 71 deaths/1,000 patient-years,
respectively; p ¼ 0.009).
CONCLUSIONS CMR detects ventricular decompensation in aortic stenosis through the identification of myocardial
extracellular expansion and replacement fibrosis. This holds major promise in tracking myocardial health in valve disease
and for optimizing the timing of valve replacement. (The Role of Myocardial Fibrosis in Patients With Aortic Stenosis;
NCT01755936) (J AmColl Cardiol Img 2016;-:-–-)© 2016 by the American College of Cardiology Foundation. Published
by Elsevier. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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C alcific aortic stenosis is the mostcommon valvular heart conditionin the western world and a major
public health burden (1). In recent years, the
role of left ventricular (LV) remodeling in dis-
ease progression, symptom development,
and adverse cardiovascular events in aortic
stenosis has been increasingly appreciated
(2). In the initial phases, the increased after-
load imposed by aortic valve narrowing in-
duces adaptive left ventricular hypertrophy
(LVH) that acts to maintain wall stress and
cardiac output. Ultimately, this process de-
compensates, and patients transition from
hypertrophy to heart failure and the develop-
ment of symptoms and adverse cardiovascu-
lar events (2,3). This transition often
correlates poorly with the severity of aortic
valve narrowing and is predominantly driven
by myocardial fibrosis and myocyte cell death (4),
which is perhaps a consequence of supply–demand
mismatch and myocardial ischemia in the hypertro-
phied myocardium (2). Therefore, there is consider-
able interest in developing novel biomarkers to
detect the early signs of LV decompensation.
Cardiac magnetic resonance imaging (CMR) pro-
vides the noninvasive gold standard method for
measuring LV wall thickness, mass, volumes, and
ejection fraction. Moreover, it is able to detect struc-
tural changes in the LV myocardium, including
replacement fibrosis with the late gadolinium tech-
nique and expansion of the extracellular volume using
T1 mapping (5). The latter in part reflects increases in
diffuse myocardial fibrosis (a reversible early form of
fibrosis) (6) and potential changes in the intravascular
compartment. Early studies have suggested that CMR-
derived measures of LV mass and replacement
myocardial fibrosis are of prognostic significance (7,8).
However, these studies have largely been conducted in
small cohorts of patientswith end-stage aortic stenosis
who were referred to CMR on clinical grounds. There-
fore, these findings may have been confounded by
referral bias, which limited their applicability and
generalizability to the broad population of patients
with aortic stenosis. Moreover, comparisons with age-
and sex-matched control populations and prognostic
T1 mapping studies have been lacking.
We report the largest prospective study to evaluate
systematically the usefulness of CMR in patients with
aortic stenosis. In particular, we investigated its
ability to detect expansion of extracellular volume
(ECV) and replacement myocardial fibrosis, and how
these are related to other markers of LV decompen-
sation, functional capacity, and clinical outcomes.
METHODS
STUDY POPULATION. All stable patients with at least
mild aortic stenosis (aortic jet velocity $2 m/s) who
attended the Edinburgh Heart Centre between March
2012 and August 2014 were invited to participate in
this prospective observational cohort study. The
exclusion criteria were other forms of valvular heart
disease ($ moderate severity), significant co-
morbidities with limited life expectancy, contraindi-
cations to gadolinium-enhanced CMR, and acquired
or inherited nonischemic cardiomyopathies (as
assessed by clinical history or ultimately by CMR). In
addition, we recruited healthy volunteers from the
community with similar demographic characteristics
in terms of age and sex, but no history or clinical
features consistent with current cardiovascular dis-
ease. The study was conducted in accordance with
the Declaration of Helsinki and approved by the local
research committee. Written informed consent was
obtained from all participants.
SUBJECT CHARACTERIZATION. All subjects under-
went detailed clinical evaluation including history,
physical examination, and electrocardiography. In
addition, venous blood samples were obtained for
evaluation of biochemistry and cardiac biomarkers of
interest.
Cardiac biomarkers. Plasma cardiac troponin I concen-
trations (cTnI) were determined by the ARCHITECT
STAT high-sensitivity cTnI assay (Abbot Laboratories,
Abbott Park, Illinois) (9). The brain natriuretic peptide
(BNP) concentration was determined with Triage BNP
assay (Biosite Inc., San Diego, California).
6-min walk test. A 6-min walk test was performed in
156 (94%) patients as an objective measure of func-
tional capacity in our predominantly older adult
cohort, many of whom could not perform an exercise
tolerance test. Explicit instructions were given to
patients asking them to walk as far as possible for
6 min.
Echocardiography. Comprehensive transthoracic echo-
cardiography was performed in all patients (iE33,
Philips Medical Systems, the Netherlands) by a dedi-
cated research ultrasonographer (A.C.W.) and a
cardiologist certified in echocardiography (C.W.L.C.).
The severity of aortic stenosis and diastolic
function were assessed according to American
Society of Echocardiography (ASE) guidelines (Online
Appendix).
Cardiac magnetic resonance. CMR was performed using
a 3-T scanner (MAGNETOM Verio, Siemens AG,
Erlangen, Germany). Short-axis cine images were ac-
quired and used to calculate ventricular volumes,
ABBR EV I A T I ON S
AND ACRONYMS
AVR = aortic valve
replacement
BNP = brain natriuretic peptide
CMR = cardiac magnetic
resonance
cTnI = cardiac troponin I
ECV = extracellular volume
ECG = electrocardiogram
iECV = indexed extracellular
volume
IQR = interquartile range
LGE = late gadolinium
enhancement
LV = left ventricular
LVH = left ventricular
hypertrophy
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mass, and function. Left ventricular hypertrophy
(LVH) was defined as LV mass (indexed to body sur-
face area using the Du Bois formula) >95th percentile
using age- and sex-specific reference ranges (10). LV
longitudinal function was determined by measuring
the difference in mitral annular displacement be-
tween end-systole and end-diastole (Online
Appendix).
Focal replacement fibrosis and ECV expansion
were assessed in all patients using late gadolinium
enhancement (LGE) and myocardial T1 mapping,
respectively. LGE was performed 15 min after
administration of 0.1 mmol/kg of gadobutrol
(Gadovist, Bayer Pharma AG, Barmen, Germany). The
presence of mid-wall myocardial fibrosis was deter-
mined qualitatively by 2 independent and experi-
enced operators (M.R.D. and C.W.L.C.), and its
distribution was recorded (7,9).
T1 mapping was performed using the Modified
Look-Locker Inversion recovery (11) and a standard-
ized image analysis approach (12). In the short-axis
mid-cavity myocardium, 6 standard segments were
defined onnative T1maps, and these regionswere then
copied onto the corresponding 20-min post-contrast
maps (OsiriX version 4.1.1, Geneva, Switzerland).
Analysis of mid-ventricle segments has been shown to
correlate well with analysis of all 17 myocardial seg-
ments, is simpler to perform, and avoids partial vol-
ume effects in apical segments (12). Segments with
mid-wall LGE present were included in this analysis,
whereas segments that contained subendocardial,
infarct-pattern LGE were excluded. Four commonly
used T1 approaches were assessed: native and
post-contrast myocardial T1, partition coefficient
(lambda), and the ECV fraction. We recently reported
the reproducibility of these measures at 3-T (12).
We also investigated a novel marker, the indexed
extracellular volume (iECV), which modifies the ECV
fraction to act as a measure of the total volume of the
extracellular compartment in the left ventricle. It was
derived using the formula: ECV fraction # LV end-
diastolic myocardial volume normalized to the body
surface area.
HISTOLOGICAL VALIDATION OF MYOCARDIAL
FIBROSIS. All patients who underwent surgical aortic
valve replacement were approached regarding intra-
operative myocardial biopsy at the time of surgery.
Biopsies were obtained from the basal muscular
septum 2 cm below the outflow tract using a Tru-Cut
needle (Carefusion, Vernon Hills, Illinois), and then
were stained with picrosirius red and analyzed using
an automated segmentation tool (Online Appendix).
Two blinded and independent observers (A.T.V. and
G.E.) analyzed all the specimens, and the interob-
server reproducibility was 4.1 ! 2.6%.
CLINICAL OUTCOMES. We examined the prognostic
value of the different patterns of fibrosis on all-cause
mortality as our primary outcome. Patients were fol-
lowed between March 2012 and September 2015. All
deaths were identified through the General Register
of Scotland. We also assessed aortic stenosis–related
mortality. This was established from the official death
certificate and defined as any death in which aortic
stenosis was listed as either the primary cause or a
contributing factor to that death by the clinical care
team.
STATISTICAL ANALYSIS. We assessed the distribu-
tion of all continuous variables using the Shapiro-Wilk
test and presented them as mean ! SD or median
(interquartile range [IQR]). Comparisons were made
using the 2-sample t test and the Mann-Whitney test
where appropriate. We presented all categorical vari-
ables as percentages and used the chi-square test for
comparison. The relationship between 2 continuous
variables was assessed using either Pearson’s r or
Spearman’s rho, as appropriate. Potential confounders
were adjusted using multivariable linear regression
analyses. Time-to-first event survival curves associ-
ated with the categories of LV decompensation were
estimated using the Kaplan-Meier method and
compared with the log-rank test. All statistical ana-
lyses were performed using SPSS version 20 (IBM,
Armonk, New York) and GraphPad Prism version 6.0
(GraphPad, San Diego, California). A 2-sided p < 0.05
was considered statistically significant.
RESULTS
STUDY POPULATION. A total of 203 subjects were
recruited: 166 patients with aortic stenosis (peak
aortic valve velocity: 3.8 ! 0.90 m/s) and 37 healthy
volunteers. These 2 groups were well matched for
age, sex, chronic renal impairment, and diabetes.
Although a history of hypertension was more com-
mon in the aortic stenosis group, blood pressure was
well-controlled and similar between the 2 groups at
enrollment (Table 1).
LEFT VENTRICULAR HYPERTROPHY. Although the
severity of aortic stenosis correlated positively with
LVH (LV mass index: r ¼ 0.48; p < 0.001), it accounted
for less than one-quarter (r2 ¼ 0.23) of the variance
observed (Figure 1). Male sex and aortic stenosis
severity were the only independent predictors of LV
mass (p < 0.001 for both), independent of systolic
blood pressure, age, and coronary artery disease
status.
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TABLE 1 Baseline Characteristics of Patients With Aortic Stenosis and Healthy Volunteers
Healthy Volunteers (n ¼ 37) Aortic Stenosis (n ¼ 166) p Value
Age, yrs 68 (63$74) 69 (63$75) 0.44
Men 24 (65) 115 (69) 0.57
Hypertension 10 (27) 112 (67) <0.001
Diabetes mellitus 0 25 (15) —
Coronary artery disease 3 (8) 62 (37) —
Coronary CTA assessment 13 (35) 21 (13) —
Invasive coronary angiography 3 (8) 78 (47) —
Previous PCI 2 (5) 11 (6) —
Previous CABG 0 8 (5) —
Atrial fibrillation 0 4 (2) —
Body mass index, kg/m2 27.0 ! 3.6 28.9 ! 4.8 0.02
Body surface area, m2 1.86 ! 0.16 1.88 ! 0.19 0.54
NYHA functional class
I 36 (97) 74 (45)
II 1 (3) 56 (34) <0.001
III — 32 (19)
IV — 4 (2)
6-min walk test, m 430 (400$475) 400 (340$450) 0.001
Systolic blood pressure, mm Hg 148 ! 16 151 ! 21 0.53
Biomarkers
High sensitivity troponin I concentration, ng/l 3.1 (1.2$7.1) 6.6 (3.8$12.4) <0.001
Brain natriuretic peptide concentration, pg/ml 9.5 (5.1$20.6) 26.1 (10.7$54.3) 0.001
Echocardiography
Aortic valve area, cm2 2.4 ! 0.6 1.0 ! 0.4 <0.001
Peak aortic jet velocity, m/s 1.4 ! 0.2 3.8 ! 0.9 <0.001
Mean pressure gradient, mm Hg 4.2 ! 1.4 35 ! 19 <0.001
Dimensionless index 0.71 (0.67$0.81) 0.26 (0.22$0.32) <0.001
Valvulo-arterial impedance, mm Hg/ml/m2 4.0 (3.6$4.7) 4.3 (3.6$5.1) 0.38
Mean e’, cm/s 7.3 (6.2$8.1) 5.9 (4.9$7.5) <0.001
Mean E/e’ ratio 8.5 (7.0$10.4) 12.6 (10.3$16.9) <0.001
Mean diastolic dysfunction grade 0.5 ! 0.8 2.0 ! 0.9 <0.001
Cardiac magnetic resonance
EDVi, ml/m2 66 (60$80) 69 (61$78) 0.52
End-systolic volume (indexed), ml/m2 23 (19$29) 23 (18$27) 0.40
Stroke volume (indexed), ml/m2 44 (40$50) 47 (40$54) 0.16
Systolic ejection fraction, % 65 (62$68) 67 (63$71) 0.02
Longitudinal function, mm 14.8 ! 2.7 12.2 ! 2.9 <0.001
LVMi, g/m2 62 (54$71) 88 (73$99) <0.001
LVMi/EDVi, g/ml 0.92 (0.84$0.99) 1.24 (1.04$1.44) <0.001
Maximal myocardial wall thickness, mm 7.5 (6.8$8.7) 11.4 (8.8$14.2) <0.001
Mean myocardial wall thickness, mm 5.6 (5.0$6.3) 7.4 (6.3$9.0) <0.001
Indexed left atrial volume, ml/m2 28 ! 11 36 ! 15 0.01
Mid-wall late gadolinium enhancement 0 44 (27) —
Native myocardial T1, ms 1,166 ! 27 1,184 ! 42 0.02
20-min post-contrast myocardial T1, ms 645 ! 51 638 ! 46 0.47
Partition coefficient 0.45 ! 0.02 0.46 ! 0.04 0.06
Extracellular volume fraction, % 26.5 ! 1.3 27.7 ! 2.6 0.005
Fibrosis volume, ml 29.9 ! 7.3 44.4 ! 15.1 <0.0001
Indexed extracellular volume, ml/m2 16.1 ! 3.2 23.6 ! 7.2 <0.0001
Values are median (interquartile range), n (%), or mean ! SD. Coronary artery disease was defined by previous myocardial infarction, clinical symptoms of angina with
documented evidence of myocardial ischemia in the absence of severe aortic stenosis, a >50% luminal stenosis in a major epicardial coronary artery or previous coronary
revascularization. All patients with clinical symptoms of angina underwent coronary angiography.
CABG ¼ coronary artery bypass graft; CTA ¼ computed tomography angiography; EDVi ¼ end-diastolic volume (indexed); LVMi ¼ left ventricular mass (index); NYHA ¼ New
York Heart Association; PCI ¼ percutaneous coronary intervention.
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T1 MAPPING AND EXTRACELLULAR EXPANSION. Myo-
cardial biopsies were obtained in 11 of 37 patients who
underwent surgical aortic valve replacement. Strong
correlations were observed between the amount of
myocardial fibrosis on histology and T1 mapping
parameters (native T1: r ¼ 0.76; p ¼ 0.007; lambda:
r ¼ 0.82; p ¼ 0.002; ECV fraction: r ¼ 0.70; p ¼ 0.016;
and iECV: r ¼ 0.87; p < 0.001) (Figure 2), with the
exception of post-contrast myocardial T1 (r ¼ 0.01;
p ¼ 0.98). Indexed LV mass also correlated well with
histological fibrosis (r ¼ 0.83; p < 0.001).
Compared with the healthy volunteers, patients
with aortic stenosis had increased diffuse myocardial
fibrosis, with iECV providing the best discrimination
between cases and control subjects (23.6 ! 7.2 ml/m2
vs. 16.1 ! 3.2 ml/m2; p < 0.0001) (Table 1 and Figure 2).
Moreover, of all the T1 measures, only the iECV
demonstrated a progressive increase across patients
with mild, moderate, and severe aortic stenosis
(19.6 ! 4.6 ml/m2 vs. 22.9 ! 5.4 ml/m2 vs. 25.5 !
8.1 ml/m2, respectively; p < 0.001) (Table 2). Notably,
the ECV fraction did not vary with aortic stenosis
severity (as measured by peak aortic valve velocity;
p ¼ 0.30 (Online Table 1) and showed a high degree
of overlap between cases and control subjects
(26.5 ! 1.4% vs. 27.7 ! 2.6%; p ¼ 0.007).
We explored iECV in greater detail, dividing our
entire patient cohort into tertiles of iECV (Table 3).
Using this approach, a steady increase across the ter-
tiles was observed for each of the following markers of
disease severity and LV decompensation: indexed LV
mass, peak aortic valve velocity, plasma high-
sensitivity cTnI concentrations, serum BNP concen-
trations, diastolic dysfunction, longitudinal systolic
FIGURE 1 Factors Governing the Magnitude of the Hypertrophic Response in Aortic Stenosis
Only a modest correlation between the severity of valve narrowing and the magnitude of the hypertrophic response was observed. The other
predictor of left ventricular (LV) mass index on multivariate analysis was sex, with men having more hypertrophy than women.
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dysfunction, and the proportion of patients with mid-
wall fibrosis (p < 0.05 for all). Similar results were
obtained using tertiles of the ECV fraction (Online
Table 1), but by comparison, tertiles of LV mass index
were less discriminatory, with no differences in dia-
stolic function nor in serum BNP concentrations across
these groups (both p > 0.05) (Online Table 2).
REPLACEMENT MYOCARDIAL FIBROSIS. Replace-
ment mid-wall fibrosis, as assessed by LGE, was pre-
sent in 44 (27%) patients with aortic stenosis but in
none of the healthy volunteers. We examined the as-
sociation between mid-wall myocardial fibrosis and
the severity of aortic stenosis (Table 2). Although pa-
tients with mid-wall fibrosis had more severe aortic
FIGURE 2 iECV as a Marker of Extracellular Expansion in the Myocardium
(A) Regions of interest manually drawn onto native and post-contrast T1 maps are used to calculate indexed extracellular volume (iECV). (B)
Histology from a patient with aortic stenosis (AS) with areas of diffuse fibrosis stained with picrosirus red. (C) Excellent correlation between
iECV and diffuse myocardial fibrosis on histology. (D) iECV provided good discrimination between disease states. (E) iECV values were higher in
patients with replacement fibrosis than patients with normal myocardium or extracellular expansion.
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stenosis compared with those without (peak aortic
valve velocity: 4.1 m/s; IQR: 3.7 to 4.6 m/s vs. 3.8 m/s;
IQR: 3.4 to 4.6 m/s, respectively; p ¼ 0.001), this dif-
ference was small and unlikely to be of any clinical
significance. In contrast, patients with mid-wall
fibrosis demonstrated a marked 30% increase in LV
mass indicative of an advanced hypertrophic response
(LV mass index 107 ! 24 g/m2 vs. 82 ! 16 g/m2,
respectively; p < 0.001). LV mass index was inde-
pendently associated with mid-wall myocardial
fibrosis in those with hypertrophy (odds ratio: 1.09,
95% confidence interval: 1.04 to 1.14; p < 0.001) after
adjusting for aortic stenosis severity, age, sex, and
systolic blood pressure.
RELATIONSHIP BETWEEN MYOCARDIAL ECV AND
REPLACEMENT FIBROSIS. It has been suggested that
replacement fibrosis represents the irreversible final
stage of diffuse interstitial fibrosis and extracellular
expansion. Consistent with this hypothesis, patients
with replacement mid-wall fibrosis had evidence of
increased ECV on T1 mapping compared with patients
without (iECV: 32.0 ml/m2; IQR: 29.1 to 34.9 ml/m2 vs.
21.5 ml/m2; IQR: 20.6 to 22.4 ml/m2; p < 0.0001; ECV
fraction: 29.1 ! 2.4% vs. 26.9 ! 2.1%; p < 0.001). The
iECV was independently associated with mid-wall
fibrosis after adjusting for age, sex, severity of aortic
stenosis, and even LV mass (odds ratio: 1.22; 95%
confidence interval: 1.11 to 1.35; p < 0.001). Similar
associations were observed using the ECV fraction.
CATEGORIZATION OF LV DECOMPENSATION. We
proceeded to categorize patients into 3 groups ac-
cording to our CMR measures of myocardial fibrosis:
normal myocardium, extracellular expansion, and
replacement mid-wall fibrosis (Figure 3). The upper
limit of normal for iECV in the healthy volunteers
(defined by 2 SDs above the mean, 22.5 ml/m2) was
used to define expansion of the extracellular
myocardium. Values below this threshold defined
normal myocardium. This categorization was then
validated in the 11 patients who underwent myocar-
dial biopsy, with the percentage fibrosis on histology
increasing progressively across the 3 groups (normal
myocardium: 8.9 ! 4.0% vs. extracellular expansion:
12.4 ! 2.5% vs. replacement fibrosis: 22.4 ! 4.9%;
p < 0.004) (Table 4).
In the larger imaging cohort of patients with aortic
stenosis (after exclusion of patients with an infarct
pattern of LGE, n ¼ 22, or incomplete T1 mapping
data, n ¼ 5), 71 patients had normal myocardium
(iECV <22.5 ml/m2). These patients had largely
mild-to-moderate aortic stenosis, a mild hypertro-
phic response, minimal cardiac injury, and good
TABLE 2 Cardiovascular Magnetic Resonance Measures of Myocardial Fibrosis and Functional Status by Severity of Aortic Stenosis
Mild (n ¼ 34) Moderate (n ¼ 45) Severe (n ¼ 87) p Value
Age, yrs 67 (56$75) 72 (66$77) 71 (65$76) 0.048
Men 20 (59) 32 (71) 63 (72) 0.33
EDVi, ml/m2 69 (60$77) 68 (64$81) 69 (61$79) 0.72
End-systolic volume (indexed), ml/m2 24 (19$26) 23 (20$27) 22 (17$27) 0.87
Stroke volume (indexed), ml/m2 47 (39$52) 47 (42$56) 47 (40$54) 0.56
Systolic ejection fraction, % 67 (63$69) 66 (63$70) 67 (63$72) 0.65
Longitudinal function, mm 13.6 ! 2.4 13.2 ! 2.9 11.2 ! 2.8 <0.001
LVMi, g/m2 71 (61$86) 87 (74$98) 93 (80$104) <0.001
LVMi/EDVi, g/ml 1.08 ! 0.20 1.21 ! 0.23 1.36 ! 0.28 <0.001
Maximal myocardial wall thickness, mm 8.2 ! 2.1 11.1 ! 3.3 13.4 ! 3.4 <0.001
Mean myocardial wall thickness, mm 5.9 ! 1.1 7.3 ! 1.6 8.7 ! 1.9 <0.001
Patients with LVH 6 (17) 24 (53) 59 (68) <0.001
Native myocardial T1, ms 1,170 ! 30 1,180 ! 37 1,192 ! 46 0.02
20-min post-contrast myocardial T1, ms 637 ! 45 643 ! 48 636 ! 45 0.73
Partition coefficient 0.466 ! 0.03 0.466 ! 0.04 0.466 ! 0.05 0.07
ECV fraction, % 27.8 ! 2.5 27.5 ! 2.0 27.8 ! 3.0 0.79
iECV, ml/m2 19.6 ! 4.6 22.9 ! 5.4 25.5 ! 8.1 <0.001
Extracellular expansion (iECV $22.5 ml/m2) 9 (26) 23 (51) 47 (54) 0.021
Mid-wall late gadolinium enhancement 2 (5.9) 14 (31) 28 (32) 0.008
Diastolic function (E/e’) 11.1 (8.0$14.2) 12.2 (10.1$16.4) 13.5 (11.4$18.6) 0.009
Natural log (hs troponin I) 1.25 (0.72$1.55) 1.76 (1.33$2.34) 2.16 (1.59$2.81) <0.0001
6-min walk test, m 420 (363$448) 400 (340$450) 390 (320$440) 0.05
Values are median (interquartile range), n (%), or mean ! SD.
ECV ¼ extracellular volume; LVH ¼ left ventricular hypertrophy; other abbreviations as in Tables 1 and 2.
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LV performance (Table 4, Figures 3 and 4).
Thirty-one patients had extracellular expansion
(iECV $22.5 ml/m2), with values for aortic stenosis
severity, LV mass, myocardial injury, diastolic func-
tion, and longitudinal systolic function that were in-
termediate between patientswith normalmyocardium
and replacement fibrosis. Finally, 37 patients had evi-
dence of replacement myocardial fibrosis on LGE.
These patients were confirmed as having the most se-
vere aortic stenosis, LVH, myocardial injury, and
impairment in LV performance (Table 4). Compared
with patients with extracellular expansion, they had
even higher iECV values (30.4 ! 8.2 ml/m2 vs. 25.4 !
3.1 ml/m2; p < 0.0001) (Figure 2), whereas compared
with patients with normal myocardium, they had
increased serum BNP concentrations (16.7 pg/ml; IQR:
6.1 to 36.0 pg/ml vs. 34.4 pg/ml; IQR: 10.5 to 76.2 pg/ml,
respectively, p ¼ 0.026) and impaired functional ca-
pacity (6-min walk test: 405 ! 74 m vs. 359 ! 138 m,
respectively; p ¼ 0.03). Both mid-wall fibrosis and the
ECV fraction were predictors of functional capacity
independent of age, sex, LV mass, and peak velocity
(Table 5). These findings were unchanged when pa-
tientswithmild aortic stenosis were excluded from the
analysis (Online Table 3).
CLINICAL OUTCOMES. Participants were followed up
for an average of 2.9 ! 0.8 years during which a total
of 14 patients with aortic stenosis died: 2 with normal
myocardium, 4 with extracellular expansion and 8
with replacement fibrosis. Unadjusted all-cause
mortality rates rose progressively across the groups
(8 deaths/1,000 patient-years vs. 36 deaths/1,000
patient-years vs. 71 deaths/1,000 patient-years;
TABLE 3 Progressive Increase in Markers of LV Hypertrophy and Decompensation With Increasing iECV Stratified Into Tertiles
Tertile 1 (n ¼ 54) Tertile 2 (n ¼ 54) Tertile 3 (n ¼ 53) p Value
Age, yrs 70 (63$75) 70 (65$70) 72 (64$78) 0.30
Men 27 (50) 42 (78) 43 (81) 0.0006
Echocardiography
Peak aortic jet velocity, m/s 3.45 ! 0.78 3.77 ! 0.81 4.25 ! 0.96 <0.0001
Aortic valve area, cm2 1.01 ! 0.37 0.95 ! 0.36 0.90 ! 0.35 0.32
Mean AV pressure gradient, mm Hg 27.6 !12.7 32.7 ! 15.0 42.6 ! 23.7 <0.0001
Mild aortic stenosis 19 12 3
Moderate aortic stenosis 13 17 15
Severe aortic stenosis 22 25 35
Valvulo-arterial impedance, mm Hg/ml/m2 4.4 ! 1.1 4.0 ! 1.0 3.8 ! 1.0 0.019
Mean e’, cm/s 6.9 ! 2.0 6.4 ! 1.7 5.4 ! 1.8 <0.0001
Mean E/e’ ratio 11.6 (9.8$14.4) 12.4 (9.3$16.5) 14.3 (11.9$19.2) 0.02
Mean diastolic dysfunction grade 1.5 ! 1.0 2.0 ! 0.8 2.5 ! 0.7 <0.0001
CMR
LVMi, g/m2 68 ! 9 88 ! 9 110 ! 19 <0.0001
Ejection fraction, % 68 (63$71) 67 (64$73) 66 (61$71) 0.44
Longitudinal function, mm 13.0 ! 2.7 12.8 ! 2.7 11.0 ! 3.0 0.0004
Mid-wall fibrosis 2 (4) 6 (11) 36 (68) 0.0001
Indexed left atrial volume, ml/m2 29 ! 13 36 ! 14 38 ! 13 0.004
Biomarkers
Natural log (hs troponin I) 1.3 (0.8$1.6) 2.1 (1.5–2.4) 2.5 (1.9$3.3) <0.0001
Natural log (BNP) 2.8 (1.9$3.5) 3.1 (2.4$3.9) 4.0 (2.8$4.7) <0.0001
Functional status
6-min walk test, m 410 (345$445) 410 (358$453) 385 (295$443) 0.09
NYHA functional class, %
I 27 (50) 23 (43) 24 (45)
II 20 (37) 19 (35) 15 (28)
III 6 (11) 12 (22) 11 (21)
IV 1 (2) 0 (0) 3 (6)
Outcomes
All-cause mortality 2 2 10 —
Mortality rate (per 1,000 patient-years) 12 12 72 0.005
Aortic stenosis$related mortality 0 2 8 —
Values are median (interquartile range), n (%), or mean ! SD. Five patients had insufficient data to calculate the indexed extracellular volume.
AV ¼ aortic valve; BNP ¼ brain natriuretic peptide; CMR ¼ cardiac magnetic resonance; hs ¼ high-sensitivity; other abbreviations as in Table 1.
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log-rank test: p ¼ 0.009 (Table 4, Figure 4). AS-related
mortality also increased in a stepwise fashion
(0 deaths/1,000 patient-years vs. 36 deaths/1,000
patient-years vs. 52 deaths/1,000 patient-years;
p ¼ 0.0045) with no AS-related deaths in the normal
myocardium group. Tertiles of ECV fraction
(p ¼ 0.0006) (Online Table 1) and iECV (p ¼ 0.005)
(Table 3) also displayed prognostic ability in this
unadjusted analysis but no difference in mortality
was observed across tertiles of the indexed LV mass
(p ¼ 0.23) (Online Table 2).
DISCUSSION
This is the largest prospective CMR study to sys-
tematically evaluate both extracellular expansion
and replacement fibrosis in the myocardium of
patients with aortic stenosis and healthy control
subjects. Both measures are increased in aortic ste-
nosis, but are only weakly associated with the
severity of valve narrowing. In contrast, they
demonstrate a close association with the magnitude
of the hypertrophic response, the presence of LV
dysfunction, the functional capacity of the patient,
and, ultimately, clinical outcome. We believe these
findings demonstrate that the structural changes in
the LV myocardium are as important a consideration
as the severity of the valvular disease itself. Based on
these results, we propose that patients with aortic
stenosis be categorized into 3 groups—those with
normal myocardium, extracellular expansion, and
replacement myocardial fibrosis. We believe this
FIGURE 3 CMR Categorization of Myocardial Fibrosis in Aortic Stenosis
Patients with aortic stenosis were categorized into 3 groups based upon cardiac magnetic resonance (CMR) assessments of fibrosis.
iECV ¼ indexed extracellular volume; LGE ¼ late gadolinium enhancement.
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(n ¼ 37) p Value
Age, yrs 70 (63$75) 70 (63$75) 71 (65$78) 0.59
Sex (male ¼ 1) 0.56 (0.44$0.68) 0.81 (0.67$0.96) 0.76 (0.62$0.90) 0.023
Hypertension 48 (68) 20 (65) 22 (59) 0.70
Diabetes 8 (11) 7 (23) 2 (5) 0.09
Body mass index, kg/m2 28.2 ! 4.5 28.9 ! 4.6 29.3 ! 4.3 0.44
Echocardiography
Peak aortic jet velocity, m/s 3.53 ! 0.82 3.79 ! 1.0 4.23 ! 0.92 <0.001
Aortic valve area, cm2 0.98 (0.73$1.18) 0.88 (1.2$0.7) 0.83 (0.73$0.91) 0.049
Mean AV pressure gradient, mm Hg 29.1 ! 14.2 34.8 ! 21.1 41.1 ! 23.5 0.007
Mild AS 24 7 2
Moderate AS 18 10 11
Severe AS 29 14 24
Valvulo-arterial impedance, mm Hg/ml/m2 4.1 ! 1.0 3.9 ! 0.9 4.0 ! 1.0 0.46
Mean e’, cm/s 6.7 ! 2.0 6.5 ! 1.8 5.2 ! 1.4 0.0004
Mean E/e’ ratio 13.1 ! 7.7 13.2 ! 4.8 16.5 ! 6.5 0.04
Mean diastolic dysfunction grade 1.5 ! 0.9 2.0 ! 0.9 2.7 ! 0.5 <0.0001
CMR
LVMi, g/m2 73 ! 11 96 ! 11 107 ! 25 <0.0001
Relative wall thickness 0.60 ! 0.12 0.61 ! 0.09 0.67 ! 0.11 0.018
ECVi, ml/m2 18.3 ! 2.5 25.4 ! 3.1 30.4 ! 8.2 <0.0001
Ejection fraction, % 68 (63$71) 66 (64$71) 67 (64$72) 0.94
Longitudinal systolic function, mm 13.2 ! 2.6 12.5 ! 2.4 11.2 ! 3.1 0.002
Indexed left atrial volume, ml/m2 31 ! 13 37 ! 11 38 ! 15 0.027
Biomarkers
Natural log (hs troponin I) 1.43 ! 0.96 2.02 ! 0.93 2.60 ! 0.90 <0.0001
Natural log (BNP) 2.95 ! 1.00 3.06 ! 0.96 3.41 ! 1.10 0.12
Functional status
6-min walk test, m 406 ! 74 385!95 359 ! 138 0.08
NYHA functional class
I 33 (46) 18 (58) 17 (46)
II 27 (38) 6 (19) 12 (32)
III 11 (15) 7 (23) 5 (14)
IV 0 (0) 0 (0) 3 (8)
Outcomes
All-cause mortality 2 4 8 —
All-cause mortality rate (per 1,000 patient- years) 8 36 71 0.009
AS-related mortality, n 0 4 6 —




on CMR (n ¼ 3)
Extracellular
Expansion on CMR (n ¼ 5)
Replacement
Fibrosis on CMR (n ¼ 3) p Value
Histological fibrosis, % 8.9 ! 4.0 12.4 ! 2.5 22.4 ! 4.9 0.004
Aortic valve area, cm2 0.57 ! 0.10 0.94 ! 0.29 0.81 ! 0.44 0.29
Peak aortic jet velocity, m/s 4.6 (4.4$5.1) 4.5 (4.0$5.9) 4.9 (4.1$8.0) 0.63
LVMi, g/m2 76 ! 15 98 ! 4 162 ! 6 <0.0001
Native myocardial T1, ms 1,189 ! 23 1,183 ! 16 1,277 ! 15 0.0002
Post-contrast myocardial T1, ms 676 ! 45 615 ! 24 672 ! 84 0.22
Partition coefficient 0.43 ! 0.05 0.47 ! 0.02 0.55 ! 0.02 0.008
ECV fraction, % 25.3 ! 3.1 27.3 ! 1.4 32.2 ! 1.9 0.019
iECV, ml/m2 18.8 ! 1.9 25.6 ! 0.7 49.6 ! 4.8 <0.0001
Values are median (interquartile range), n (%), or mean ! SD.
Abbreviations as in Tables 1 to 3.
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classification has major potential in the early detec-
tion of subclinical ventricular decompensation in
aortic stenosis and ultimately may be able to guide
decisions regarding the timing of aortic valve
replacement.
Our data demonstrated an association between
the severity of valve narrowing and the degree of
hypertrophy in aortic stenosis. However, this only
explained approximately one-quarter of the
observed variance in LV mass, confirming that the
hypertrophic response in aortic stenosis cannot
be accurately predicted from the degree of valve
narrowing alone and should be assessed
independently.
T1 mapping techniques (ECV fraction and iECV) can
provide an assessment of myocardial ECV expansion.
Potentially, this can reflect increased myocardial
fibrosis, myocardial infiltration, or expansion in the
intravascular compartment (13). In aortic stenosis,
myocardial fibrosis has been established pathologi-
cally as a key process that drives the transition from
hypertrophy to heart failure (4). Moreover, we and
others have observed a close correlation between these
parameters and histological assessments of myocar-
dial fibrosis (5,14–16). However, there is some
debate as to whether T1 mapping can provide direct
assessment of the myocardium because of recent evi-
dence that indicated that increased intravascular

































































































All-cause Mortality by Group
n = 80 n = 80 n = 80 n = 74 n = 26 n = 24 n = 4
n = 38 n = 38 n = 36 n = 32 n = 27 n = 13 n = 1























On moving from normal myocardium to extracellular expansion and then replacement fibrosis, there was a stepwise increase in the following
measures: (A) the severity of valve narrowing; (B) the degree of hypertrophy; (C)myocardial injury; (D) left ventricular (LV) performance; and
(E) all-cause-mortality. hsTni ¼ high-sensitivity troponin I concentration.
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volume may also influence native T1 values (17,18).
Pressure overload conditions such as aortic stenosis
are associated with reduced capillary density (19) and
myocardial ischemia (20). Mahmod et al. (17) recently
suggested that this ischemia might result in coronary
vasodilatation and increased intravascular volume
potentially contributing to increased native T1.
Although confirmation of this interesting hypothesis
is required, it may be that T1 values are also related to
myocardial ischemia that is believed to trigger fibrosis
and the transition from hypertrophy to heart failure.
Regardless, T1 mapping remains at the very least a
useful surrogate of myocardial fibrosis and LV
decompensation in aortic stenosis.
Controversy remains as to the optimal T1 image
analysis strategy (12,13,21). Consistent with previous
research (12), both native T1 and the ECV fraction
demonstrated major overlap with values in control
groups and little difference among patients with
mild, moderate, and severe aortic stenosis (Table 2).
We sought to tackle this issue by developing a novel
parameter, the iECV, which provides an assessment
of the total ECV in the myocardium. This effectively
combines the prognostic information provided by the
ECV fraction with the improved discrimination be-
tween groups associated with indexed LV mass into a
single measure (Table 3, Online Tables 1 and 2).
iECV demonstrated good correlation with histolog-
ical assessment of fibrosis burden. Moreover, there
was a clear stepwise increase across tertiles of iECV in
each of the different clinical and imaging measures of
LV decompensation, as well as clinical outcomes,
supporting iECV as a marker of decompensation.
Finally, iECV provided the best discrimination among
disease states, being the only T1 measure to differen-
tiate among patients with mild, moderate, and severe
aortic stenosis. In combination, iECV would therefore
appear to provide the most useful marker of LV
decompensation in aortic stenosis with advantages
compared with both the ECV fraction and LV mass in
isolation.
How do extracellular expansion and diffuse
fibrosis relate to the development of replacement
fibrosis as detected using mid-wall LGE? In agree-
ment with previous studies (7,8), regions of mid-wall
LGE were observed in 27% of our patients, with
approximately two-thirds with severe aortic
stenosis and one-third with moderate aortic stenosis.
Importantly, patients with mid-wall replacement
fibrosis also had marked increases in iECV as a sur-
rogate for diffuse fibrosis in their remote myocar-
dium. Indeed, iECV was an independent predictor of
the presence of mid-wall LGE. This was confirmed
by our histological data and suggests that replace-
ment fibrosis does not occur until the end stages of
myocardial matrix remodeling and is preceded by
an intermediate stage of extracellular expansion
reflecting increasing diffuse fibrosis. Longitudinal
studies using serial CMR imaging are required to
confirm this hypothesis.
Using our CMR assessments, we categorized our
patients into 3 stages of LV decompensation. We
used iECV to differentiate patients with normal
myocardium from those with extracellular expansion
and then LGE to define replacement fibrosis
(Figure 3). Across these groups, patients had
advancing LVH, histological fibrosis, myocyte cell
injury, diastolic dysfunction, and longitudinal sys-
tolic dysfunction, which suggested progressive, sub-
clinical LV decompensation. Most importantly, there
was a steady decline in prognosis, with unadjusted
all-cause mortality rates quadrupling from the normal
myocardium groups to the extracellular expansion
groups and more than doubling again in those with
replacement fibrosis. Moreover, these groups also
predicted aortic stenosis$related deaths on unad-
justed analysis, with no aortic stenosis$related
deaths occurring in the normal myocardium group.
TABLE 5 Univariable and Multivariable Linear Regression Analysis to Examine the Association of Fibrosis Assessments With Functional Status
Univariable Analysis Multivariable Analysis
Relative Change in
6-Min Walk (95% CI) p Value
Model 1 (ECV fraction) Model 2 (mid-wall fibrosis)
Relative Change in
6-Min Walk (95% CI) p Value
Relative Change in
6-Min Walk (95% CI) p Value
Age $70 yrs $50.3 ($83.0 to $17.6) 0.003 $41.4 ($74.5 to $8.36) 0.01 $50.3 ($83.0 to $17.7) 0.003
Men $0.81 ($37.7 to 36.1) 0.97 $19.9 ($61.3 to 21.6) 0.35 $8.88 ($48.5 to 30.7) 0.66
Peak aortic jet velocity, m/s $12.25 ($30.6 to 6.14) 0.19 $14.9 ($35.4 to 5.73) 0.16 $11.9 ($32.4 to 8.64) 0.26
LVMi, g/m2 $0.22 ($1.00 to 0.56) 0.57 0.62 ($0.44 to 1.68) 0.25 0.45 ($0.62 to 1.52) 0.41
ECV fraction, % $9.09 ($15.4 to $2.81) 0.005 $9.77 ($17.0 to $2.58) 0.01 — —
Presence of mid$wall fibrosis $40.9 ($78.5 to $3.24) 0.03 — — $45.6 ($89.1 to $2.11) 0.04
CI ¼ confidence interval; other abbreviations as in Tables 2 and 3.
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More simple categorization using LV mass was less
discriminatory and not of prognostic value (Online
Table 2).
Our categorization holds promise as a means of
monitoring the development of LV decompensation
and helping to optimize the timing of aortic valve
replacement. Currently, the development of symp-
toms guides the need for surgery. However, symp-
toms are frequently difficult to assess in older adult
patients with multiple co-morbidities. Objective
imaging assessments that monitor the changes in
myocardial structure that are themselves responsible
for progressive LV decompensation are therefore
potentially attractive (2,3). This is the first study to
describe iECV in aortic stenosis, so that confirmation
of our findings in larger studies with longer follow-up
is required. However, we presented the fourth sepa-
rate cohort to demonstrate the adverse prognosis
associated with mid-wall LGE in aortic stenosis
(7,8,22) and demonstrated its association with
patient functional capacity, LV performance, and
multiple other parameters of LV decompensation.
These data have now led to the EVOLVED (Early
Valve Replacement guided by Biomarkers of Left
Ventricular Decompensation in Asymptomatic Pa-
tients with Advanced Aortic Stenosis) study. This
multicenter, randomized controlled trial will begin
enrollment next year and assess whether early valve
intervention in patients with asymptomatic severe
aortic stenosis and mid-wall fibrosis on CMR im-
proves clinical outcomes compared with standard
care.
STUDY LIMITATIONS. There were insufficient deaths
to perform multivariate analysis. Studies with longer
follow-up are required to confirm whether iECV is of
independent prognostic value and to assess the
contribution of the intravascular volume to T1 map-
ping values. Finally, although similar to previous
studies (14–16), the number of patients who agreed to
intraoperative myocardial biopsy was modest, which
perhaps reflected the invasive nature of this
assessment.
CONCLUSIONS
CMR can detect progressive fibrosis in aortic stenosis
and can be used to categorize patients with normal
myocardium, extracellular expansion, or replacement
fibrosis. Across these groups, there was a stepwise in-
crease in myocardial injury, fibrosis, LV dysfunction,
and unadjusted mortality that was consistent with
progressive ventricular decompensation. This catego-
rization may be able to track the transition of hyper-
trophy to heart failure in patients with aortic stenosis.
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Aortic stenosis (AS) is the most common valve disease requiring operative intervention in high-income countries.1 Traditional assessments of 
AS severity focus on the degree of hemodynamic ob-
struction in the valve. However, the importance of the 
myocardial response to pressure overload has been in-
creasingly appreciated, especially when considering the 
development of symptoms and long-term prognosis 
after valve intervention.2 Left ventricular hypertrophy 
(LVH) initially normalizes wall stress and maintains car-
diac output for many years, if not decades. However, 
with time, the left ventricle (LV) decompensates and the 
patient transitions toward heart failure, symptoms, and 
adverse events.
Pathological studies have suggested that this tran-
sition from hypertrophy to heart failure is driven by a 
combination of myocyte cell death and myocardial 
fibrosis.3 Magnetic resonance imaging (MRI) can detect 
focal myocardial fibrosis using late gadolinium enhance-
ment (LGE) and estimates diffuse interstitial fibrosis with 
T1 mapping. A midwall pattern of LGE observed in AS 
acts as a marker of LV decompensation and is associated 
with an adverse prognosis after surgery.4–8 However, to 
date, we have lacked longitudinal studies to assess how 
LVH and fibrosis progress with time and how aortic valve 
replacement (AVR) affects these processes. The aims of 
this prospective multicenter study were to assess the 
time course of LVH and fibrosis in patients with asymp-
tomatic AS and to determine how they are affected in 
symptomatic patients who undergo AVR.
METHODS
Study Population
Patients were recruited from 2 large prospective observa-
tional MRI studies investigating the natural history of AS 
(NCT01755936, Edinburgh Heart Centre, United Kingdom,7 
and NCT01679431, Quebec Heart and Lung Institute, 
Canada9). In both studies, patients underwent comprehensive 
clinical and echocardiographic assessment including repeat 
MRI. Eligible participants had undergone at least 2 serial MRI 
scans. Symptomatic patients had AVR shortly after baseline 
MRI allowing us to assess the reverse remodeling effect of sur-
gery on repeat scans. The study was conducted in accordance 
with the Declaration of Helsinki and approved by the local 
research committees. Written informed consent was obtained 
from all participants. Study data can be made available to other 
researchers on request to the corresponding author.
Echocardiography
Comprehensive transthoracic echocardiography was per-
formed in all patients to assess AS severity as per clinical 
guidelines (Data Supplement).
Cardiac Magnetic Resonance
MRI was performed using both 1.5T and 3T scanners, and 
standard cine images of the LV were acquired. LGE was per-
formed 15 minutes after administration of gadobutrol. T1 
mapping was performed using the Modified Look-Locker 
Inversion-recovery sequence10 before and 15 to 20 minutes 
after gadolinium contrast administration. Although there 
was variation in the scanners used at the different centers, all 
patients underwent standardized baseline and repeat imag-
ing within their respective institutions (Data Supplement). To 
account for potential interscanner variation in T1 measure-
ments,11 extracellular volume (ECV)–derived T1 mapping 
measures were obtained to normalize myocardial T1 values to 
blood-pool measurements.
CLINICAL PERSPECTIVE
Left ventricular hypertrophy and myocardial fibro-
sis are key processes in aortic stenosis that can be 
assessed by cardiovascular magnetic resonance. 
However, longitudinal changes in myocardial 
hypertrophy and fibrosis before and after aortic 
valve replacement are not well studied. We per-
formed a multicenter prospective cohort study of 
99 subjects who underwent serial echocardiog-
raphy and cardiovascular magnetic resonance 
with assessment of left ventricular mass, diffuse 
fibrosis (T1 mapping), and replacement fibrosis 
(late gadolinium enhancement). Sixty-one sub-
jects were asymptomatic allowing us to assess 
the natural history of hypertrophy and fibrosis for 
2.1±0.7 years. Thirty-eight symptomatic subjects 
underwent aortic valve replacement with repeat 
imaging after 1 year allowing us to assess the left 
ventricular remodeling response to surgery. Our 
data demonstrate that in patients with aortic ste-
nosis, cellular hypertrophy and diffuse interstitial 
fibrosis increase in a balanced and exponential 
manner before reversing (at different rates) after 
aortic valve replacement. Midwall replacement 
fibrosis also accumulates rapidly once established 
in the ventricle but crucially seems irreversible after 
aortic valve replacement. The myocardial scar bur-
den that patients develop while waiting for sur-
gery, therefore, persists into the long term. This is 
an important observation because midwall fibro-
sis has consistently demonstrated an association 
with adverse outcome in a proportionate manner 
across multiple patient cohorts. Our data, there-
fore, suggest that prompt valve replacement as 
soon as midwall fibrosis develops may hold prom-
ise in improving clinical outcomes in patients with 
aortic stenosis, and this hypothesis will be exam-
ined in the currently-recruiting EVOLVED trial (Early 
Valve Replacement guided by Biomarkers of Left 
Ventricular Decompensation in Asymptomatic 
Patients with Severe Aortic Stenosis).
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Image Analysis
Analysis of all MRI scans from both centers was performed at 
the Edinburgh Core Lab using CVI42 (Circle Cardiovascular 
Imaging Inc, Calgary, Canada) by a single reporter (R.J.E.) 
blinded to the scan time point (Data Supplement). Short-
axis cine images were used to calculate ventricular volumes, 
mass, and function. The presence of midwall LGE was deter-
mined both qualitatively and quantitatively by 2 experienced 
operators (R.J.E. and M.R.D.), and its distribution recorded. 
LGE was quantified in a semiautomated manner using a sig-
nal intensity threshold of >3 SDs above the mean value in 
a region of normal myocardium.12 Although segments with 
midwall late enhancement were included in the overall T1 
calculation, segments with subendocardial infarct pattern 
LGE were excluded. ECV fraction (ECV%) and indexed ECV 
(iECV: ECV%× LV end-diastolic myocardial volume nor-
malized to body surface area) were calculated using the 
motion-corrected native and postcontrast T1 maps (Data 
Supplement). We have previously reported the reproducibil-
ity of these measures at 3T13 and demonstrated that iECV 
acts as a marker of LV decompensation in AS, correlates with 
the burden of diffuse fibrosis on histology, and is associated 
with future clinical events.7 Other groups have also recently 
used the same parameter.14
Statistical Analysis
All statistical analyses were performed using GraphPad 
Prism version 7.0 and SPSS version 23. A 2-sided P<0.05 
was considered statistically significant. Given heterogeneity 
in timing of follow-up imaging, changes in the LV remodel-
ing variables were annualized. Annualized change was cal-
culated as the difference between the baseline and final 
follow-up MRI scans, divided by the number of days in 
between time points and multiplied by 365. This approach 
assumes that progression is linear. In a sensitivity analysis, 
we restricted analysis of progression and reverse remodel-
ing in those patients who had repeat imaging at the same 
time interval (2 years in the natural history cohort and 1 
year in the AVR cohort) and examined absolute change in 
the LV remodeling variables.
We assessed the distribution of all continuous variables 
using the Shapiro–Wilk test and presented them as appro-
priate using mean±SD or median (interquartile range). 
Annualized change was assessed using a 1 sample t test or 
Wilcoxon signed-rank test where appropriate to compare 
with a hypothetical mean (or median) of 0. Other compari-
sons were made using the Kruskal–Wallis test where appro-
priate. We presented all categorical variables as percentages 
and used the χ2 test for comparison. Absolute change in 
the sensitivity analysis was analyzed using the paired t test 
or Wilcoxon-matched pairs signed-rank test. Univariate lin-
ear regression was performed on both cohorts to investi-
gate the change in indexed LV mass (LVMi) using variables 
known or suspected to influence LVM change (including 
age, sex, history of hypertension, and valvuloarterial imped-
ance). Multivariable linear regression analysis was then per-
formed with change in LVMi as the dependent variable, and 
the same relevant clinical variables included as covariates. 
R.J.E. had full access to study data and is responsible for 
data integrity and analysis.
RESULTS
Repeat MRI was performed in a total of 99 patients (n=63 
from United Kingdom, n=36 from Canada; Table 1), 38 
underwent AVR (AVR cohort: age, 66±8 years; 76% 
men; peak aortic-jet velocity, 4.70±0.83 m/s) and 61 
remained under medical surveillance without interven-
tion (natural history cohort: age, 61±12 years; 66% 
men; peak aortic-jet velocity, 3.24±0.76 m/s).
Natural History Cohort (LV Remodeling)
At baseline, AS was graded as mild in half of the cohort, 
with the remainder split between moderate (34%) and 
severe (23%; Table 1). No patient had symptoms attrib-
utable to valve disease. Follow-up MRI was performed 
at 2.1±0.7 years after baseline scan.
As expected, AS severity increased (peak aortic-jet 
velocity, 0.15 m/s per year [0–0.29 m/s per year]; mean 
gradient, 3 mm Hg/y [1–5 mm Hg/y]; aortic valve area: 
−0.05 cm2/y [−0.08 to −0.01 cm2/y]; P<0.001 for all; 
Table 2) with concurrent increases in both LVMi (3 g/m2 
per year [1–5 g/m2 per year]; P<0.001) and maximum LV 
wall thickness (0.5 mm/y [0–1 mm/y]; P<0.001). These 
changes were accompanied by a reduction in longitu-
dinal systolic function (−0.5 mm/y [−1.5 to 0.3 mm/y]; 







Age, y 61±12 66±8
Male sex, n (%) 40 (66) 29 (76)
Body mass index, kg/m2 28.3±5.6 27.3±3.6
Body surface area, m2 1.88±0.21 1.86±0.16
Past medical history
  Hypertension, n (%) 35 (58) 23 (61)
  Diabetes mellitus, n (%) 21 (34) 6 (16)
  Hyperlipidemia, n (%) 17 (28) 19 (50)
  Obstructive coronary artery disease, 
n (%)
15 (25) 16 (42)
  Previous percutaneous coronary 
intervention, n (%)
9 (15) 6 (16)
  Previous coronary artery bypass 
graft, n (%)
3 (5) 0 (0)
  Systolic blood pressure, mm Hg 139±22 146±22
  Diastolic blood pressure, mm Hg 82±11 85±13
Echocardiography
  Aortic stenosis severity, n (%)
   Mild 26 (43) 0
   Moderate 21 (34) 0
   Asymptomatic severe 14 (23) 0
   Symptomatic severe 0 38 (100)
AVR indicates aortic valve replacement.
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P=0.003) and an increase in LV filling pressures (E/e′, 
0.6 /y [−0.4 to 1.3 /y]; P=0.006; Table 3). There was no 
significant change in LV stroke volume or ejection frac-
tion over time (both P≥0.20).
When classified by baseline AS severity, there 
was a stepwise increase in the progression of both 
the valve stenosis severity (change in peak aortic-jet 
velocity: mild AS, 0.05 m/s per year [−0.03 to 0.20 
m/s per year]; moderate AS, 0.16 m/s per year [−0.04 
to 0.29 m/s per year]; and severe AS, 0.33 m/s per 
year [0.16–0.42 m/s per year]; P=0.002) and the 
hypertrophic response (change in LVMi: mild AS, 2 g/
m2 per year [1–4 g/m2 per year]; moderate AS, 3 g/
m2 per year [2–5 g/m2 per year]; and severe AS, 5 g/
Table 2. Baseline and Annualized Change in Markers of Left Ventricular Remodeling Among Patients in the Natural History and AVR Groups
LV Assessment
Natural History Group, n=61 (2.1±0.7 y  










Change, units/y P Value
Indexed left ventricular end-
diastolic volume, mL/m2
70±12 −1 (−4, 2) 0.015 67±15 … −3 (−9, 2) 0.009
Indexed left ventricular end-
systolic volume, mL/m2
18±7 −1 (−3, 1) 0.03 19±13 … −2 (−5, 1) 0.19
Indexed stroke volume, mL/m2 52±9 0 (−3, 2) 0.31 49±8 … −3 (−7, 1) 0.009
Ejection fraction, % 75±8 0 (−2, 4) 0.23 74±8 … 0 (−4, 4) 0.78
Left ventricular mass index, g/m2 75±20 3 (1, 5) <0.0001 93±21 … −10 (−19, −5) <0.0001
Maximum left ventricular wall 
thickness, mm
12±3 0.5 (0, 1) <0.0001 15±3 … −2 (−2, −1) <0.0001
Mass/volume, g/mL 1.09±0.28 0.08 (0.02, 0.14) <0.0001 1.43±0.32 … −0.08 (−0.19, 0.02) 0.003
Longitudinal systolic function, mm 14±3 −0.5 (−1.5, 0.3) 0.0003 12±3 … 1 (−1, 3) 0.10
Indexed left atrial volume, mL/m2 37±12 0 (−3, 3) 0.99 37±11 … −1 (−8, 4) 0.33
Infarct late gadolinium 
enhancement, n (%)
8 (13) … … 5 (13) … … …
Infarct late gadolinium 
enhancement mass, g
7.6±4.5 −0.1 (−1.4, 0.7) 0.56 4.8±2.8 … 0 (−0.7, 1.7) 0.72
Midwall late gadolinium 
enhancement, n (%)
16 (26) … … 10 (26) … … …
Midwall late gadolinium 
enhancement mass, g
2.5 (0.8, 4.8) 1.6 (0.4, 4.1) <0.0001 3.3 (2.6, 8.0) … −0.9 (−1.2, 0.5) 0.22
T1 mapping measures
  Extracellular volume fraction, % 26.6±3.1 0 (−1, 1) 0.80 27.2±2.8 … 1.2 (0.4, 2.2) 0.003
  Total extracellular volume, mL 40±13 0.8 (0.1, 4.0) <0.0001 47±18 … −3 (−12, −1) <0.0001
  Indexed extracellular volume, 
mL/m2
21±6 0.5 (0, 2.3) <0.0001 25±8 … −2 (−3, −1) <0.0001
Echocardiography
  Peak aortic-jet velocity, m/s 3.24±0.76 0.15 (0, 0.29) <0.0001 4.70±0.83 −2.05 (−2.70, 1.56) … <0.0001
  Mean aortic valve gradient, 
mm Hg
24±12 3 (1, 5) <0.0001 52±22 −32 (−44, −26) … <0.0001
  Aortic valve area, cm2 1.08±0.31 −0.05 (−0.08, −0.01) <0.0001 0.79±0.20 0.73 (0.46, 0.91) … <0.0001
  Indexed stroke volume, mL/m2 42±7 0 (−1, 2) 0.31 48±10 … −1 (−9, 4) 0.13
  Mean systolic blood pressure, 
mm Hg
139±22 −1 (−6, 2) 0.011 146±22 … −2 (−22, 11) 0.46
  Valvuloarterial impedance (Zva), 
mm Hg/mL per m2
4.06±0.99 −0.01 (−0.15, 0.20) 0.86 4.29±1.05 −0.60 (−1.19, 0.08) … <0.0001
  E/A ratio 1.1±0.3 0 (−0.1, 0.1) 0.71 1.0±0.3 … 0.16 (−0.06, 0.42) 0.004
  Mean e′, cm/s 7.47±2.34 −0.10 (−0.59, 0.42) 0.20 6.15±2.04 … 1.35 (0.26, 2.91) 0.0004
  E/e′ ratio 10.9 (8.7, 12.8) 0.6 (−0.4, 1.3) 0.006 12.9 (10.2, 18.0) … −1.3 (−4.3, 1.1) 0.02
Variables are expressed as mean±SD or median (IQR) as appropriate. For the annualized changes, the unit is the unit mentioned after the name of the variable 
per year: for example, for indexed left ventricular volumes (mL/m2), the unit for the annualized change is mL/m2 per year. AVR indicates aortic valve replacement; 
and IQR, interquartile range.
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m2 per year [2–9 g/m2 per year]; P=0.07; Table 4; Fig-
ure 1). Indeed, a moderate correlation was observed 
between the rate of peak aortic-jet velocity pro-
gression and the rate of LVMi progression (r=0.41; 
P=0.001) with both baseline and annualized peak 
aortic-jet velocity change being predictors of the rate 
of LVMi progression on univariable analysis. Annual-
ized change in peak aortic-jet velocity was the only 
independent predictor of LVMi progression on multi-
variable analysis (P=0.02; Table 5).
Myocardial Fibrosis
iECV increased over time (0.5 mL/m2 per year [0–2.3 
mL/m2 per year]; P<0.0001; Table  2; Figure  1), with 
progression again appearing to increase in a stepwise 
Table 3.  Diastolic Function Grade at Baseline and Follow-Up in the Natural History and AVR Groups
Diastolic Function Grade, 
n (%)
Natural History Group, n=61 (2.1±0.7 y Follow-Up) AVR Group, n=38 (0.9±0.3 y Follow-Up)
Baseline Follow-Up Baseline Follow-Up
0 5 (8) 0 0 0
1 34 (56) 39 (64) 23 (61) 24 (63)
2 22 (36) 21 (34) 15 (39) 13 (34)
3 0 1 (2) 0 1 (3)
AVR indicates aortic valve replacement.
Table 4. Annualized Change in Markers of Progression and Left Ventricular Remodeling According to Aortic Stenosis Severity in the 
Natural History Group
LV Assessment
Aortic Valve Stenosis Severity
P ValueMild, n=26 Moderate, n=21 Severe, n=14
  Indexed left ventricular end-diastolic volume, mL/m2 
per year
−1 (−5, 3) −1 (−4, 2) −2 (−5, 3) 0.93
  Indexed left ventricular end-systolic volume, mL/m2 per 
year
−1 (−5, 4) −1 (−7, 2) −3 (−5, 3) 0.43
  Indexed stroke volume, mL/m2 per year −1 (−3, 1) 0 (−3, 3) 0 (−3, 2) 0.55
  Ejection fraction, %/y 0 (−3, 2) 0 (−1, 4) 2 (−2, 4) 0.26
  Left ventricular mass index, g/m2 per year 2 (1, 4) 3 (2, 5) 5 (2, 9) 0.07
  Maximum left ventricular wall thickness, mm/y 0.5 (0.0, 1.0) 0.5 (−0.3, 1.2) 0.5 (0.0, 1.0) 0.91
  Mass/volume, g/mL per year 0.06 (−0.01, 0.11) 0.06 (0.02, 0.12) 0.14 (0.08, 0.27) 0.01
  Longitudinal systolic function, mm/y −0.5 (−1.1, 0.3) −1.2 (−2.0, −0.3) −0.1 (−1.5, 0.5) 0.08
  Indexed left atrial volume, mL/m2 per year −1 (−3, 2) 1 (−2, 5) 0 (−5, 2) 0.30
  Infarct late gadolinium enhancement, n (%) 2 (8) 3 (14) 3 (21) …
  Midwall late gadolinium enhancement, n (%) 1 (4) 10 (48) 5 (36) …
  Midwall late gadolinium enhancement mass, g/y 0 1.2 (0.3, 2.4) 4.1 (2.8, 7.2) 0.02
T1 mapping measures
  Extracellular volume fraction, %/y 0 (−1.9, 0.8) 0 (−0.8. 1.7) 0 (0.5, 0.9) 0.61
  Total extracellular volume, mL/y 0.7 (0.0, 1.0) 1.5 (−0.2, 6.8) 3.7 (0.4, 6.0) 0.08
  Indexed extracellular volume, mL/m2 per year 0.3 (−0.1, 0.6) 0.8 (−0.1, 2.9) 2.0 (0.2, 2.9) 0.07
Echocardiography
  Peak aortic-jet velocity, m/s per year 0.05 (−0.03, 0.20) 0.16 (−0.04, 0.29) 0.33 (0.16, 0.42) 0.002
  Mean aortic valve gradient, mm Hg/y 2 (0, 3) 2 (0, 5) 7 (3, 10) <0.001
  Aortic valve area, cm2/y −0.05 (−0.12, −0.02) −0.03 (−0.07, 0.00) −0.06 (−0.09, 0.00) 0.47
  Indexed stroke volume, mL/m2 per year −1 (−2, 1) 0 (−1, 2) 3 (−2, 5) 0.06
  Mean systolic blood pressure, mm Hg/y −2 (−6, 1) −1 (−7, 3) −5 (−15, 1) 0.65
  Valvuloarterial impedance, mm Hg/mL per m2 per year 0 (−0.15, 0.28) 0 (−0.15, 0.49) 0.36 (−0.32, 1.19) 0.50
  E/A ratio 0 (−0.1, 0.1) 0 (−0.1, 0.2) 0 (−0.2, 0.1) 0.91
  Mean e′, cm/s per year −0.17 (−0.56, 0.18) −0.04 (−0.73, 0.58) −0.15 (−0.78, 0.51) 0.82
  E/e′ ratio 0.6 (−0.4, 1.2) −0.1 (−0.9, 1.1) 1.6 (0.9, 2.3) <0.001
Results expressed as median (IQR). IQR indicates interquartile range; and LV, left ventricle.
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manner across patients with mild (0.3 mL/m2 [−0.1 to 
0.6 mL/m2]), moderate (0.8 mL/m2 [−0.1 to 2.9 mL/m2]), 
and severe (2.0 mL/m2 [0.2–2.9 mL/m2]) AS (P=0.07; 
Table 4). Indeed, iECV increased ≈7-fold faster in those 
with severe versus mild AS (P=0.01; Figure 1). By con-
trast, no progression in ECV% was observed over time 
either across the cohort as a whole (0% [−1% to 1%); 
P=0.80) or within severity subgroups (P=0.61).
Midwall LGE was present at baseline in 16 patients 
(26%) and progressed rapidly with time (change in LGE 
mass, 1.6 g/y [0.4–4.1 g/y]; P<0.0001; Table 2), equivalent 
to a relative annual progression of 78% (50%–158%). 
Figure 1. Annualized changes in aortic valve obstruction, left ventricular hypertrophy, and diffuse fibrosis in the natural history and aortic valve replacement (AVR) 
groups. Annualized progression in peak aortic-jet velocity (A), left ventricular mass (B), and diffuse fibrosis (indexed extracellular volume [iECV], C) increased in a 
stepwise fashion with severity of aortic stenosis. The slowest progression for each parameter was observed in patients with mild aortic stenosis and the fastest 
progression in those with severe stenosis. Extracellular volume fraction (ECV%) did not change (D), suggesting balanced progression in cellular hypertrophy and 
interstitial fibrosis. After AVR, there was significant regression in valve obstruction (A), left ventricular mass index (LVMi; B), and iECV (diffuse fibrosis, C). ECV% 
increased (D) suggesting more rapid regression in cellular hypertrophy than interstitial diffuse fibrosis (all P<0.005). *Significant (P<0.005) annualized change 
comparing pre- and post-AVR values for each measure.
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This occurred both at the sites of existing LGE and, in a 
quarter of patients, at remote sites with the development 
of new areas of midwall LGE (Figures  2 and 3). Again 
faster rates of progression were observed in patients with 
more advanced valve stenosis (P=0.02) and greater levels 
of diffuse fibrosis (P=0.019, by tertiles of iECV; Figure 2). 
Moreover, patients with the most midwall LGE at baseline 
demonstrated the fastest subsequent progression (tertile 
1 baseline LGE, 0.3 g/y [0.1–0.9 g/y]; tertile 2, 1.6 g/y 
[1.0–3.8 g/y]; and tertile 3, 4.1 g/y [3.4–7.2 g/y]; P=0.007; 
Figure 2). Eight patients (13%) had a subendocardial pat-
tern of LGE at baseline. On repeat MRI, there were no new 
areas of subendocardial LGE and no change in the sub-
endocardial LGE mass (P=0.56; Table 2), consistent with 
these areas representing previous myocardial infarction.
AVR Cohort (Reverse Remodeling)
Patients underwent AVR for a guideline-based indica-
tion 32 days (13–66 days) after baseline imaging with 
repeat imaging performed 0.9±0.3 years after AVR. 
Twenty-nine patients received a bioprosthetic AVR, 
and in 9 patients, a mechanical prosthesis was used. 
No patient underwent transcatheter valve replacement. 
As expected, echocardiographic assessments of aortic 
valve obstruction improved after surgery (change in 
peak aortic-jet velocity, −2.05 m/s [−2.70 to 1.56 m/s]; 
change in mean gradient, −32 mm Hg [−44 to −26 
mm Hg]; change in aortic valve area, 0.73 cm2 [0.46–
0.91 cm2]; change in valvuloarterial impedance, −0.60 
[−1.19 to 0.08]; all P<0.0001; Table 2).
There was a 19% reduction in LVMi (−10 g/m2 per year 
[−19 to −5 g/m2 per year]; P<0.0001; Table 2) after AVR, 
accompanied by a corresponding reduction in maximal 
LV wall thickness (−2 mm/y [−2 to −1 mm/y]; P<0.0001). 
A moderate correlation was observed between the mag-
nitude of LVM regression and the reduction in peak aor-
tic-jet velocity after valve intervention (ρ=0.35; P=0.03). 
On multivariable regression analysis, a high pre-AVR 
LVMi and the absence of hypertension were both asso-
ciated with greater LVM regression (Table 5) as was a 
lower post-AVR Vmax although this last variable did not 
reach statistical significance (P=0.06).
Measures of LV relaxation and filling pressure improved 
after AVR (mean e′, 1.35 [0.26–2.91]; P=0.0004; E/e′, 
−1.3 [−4.3 to 1.1]; P=0.02), and there was an apparent 
trend toward improved longitudinal LV systolic function 
(1 mm/y [−1 to 3 mm/y]; P=0.10). No change in ejection 
fraction was observed (P=0.78) although the indexed 
end-diastolic LV volume did decrease modestly (−3 mL/
m2 per year [−9 to 2 mL/m2 per year]; P=0.009).
Myocardial Fibrosis
There was a 11% reduction in iECV on repeat imag-
ing after AVR (−2 mL/m2 per year [−3 to −1 mL/m2 
Table 5. Univariable and Multivariable Linear Regression Analysis to Examine the Predictors of Annualized Progression and 
Regression of Left Ventricular Mass Over Time
Univariable Analysis Multivariable Analysis
Change in Left Ventricular 
Mass Index, β (95% CI), g/
m2 per Year P Value
Change in Left Ventricular 
Mass Index, β (95% CI), g/
m2 per Year P Value
Natural history group: factors influencing left ventricular mass progression
  Age, y 0.03 (−0.05 to 0.10) 0.50 0.05 (−0.04 to 0.13) 0.30
  Men 0.66 (−1.33 to 2.64) 0.51 0.95 (−1.16 to 3.05) 0.37
  Hypertension −1.38 (−3.25 to 0.49) 0.14 −1.75 (−3.95 to 0.44) 0.12
  Valvuloarterial impedance −0.24 (−1.49 to 1.01) 0.70 −0.08 (−1.35 to 1.20) 0.91
  Baseline peak aortic-jet velocity, m/s 1.44 (0.26 to 2.63) 0.02 0.67 (−0.73 to 2.07) 0.34
  Annualized peak aortic-jet velocity change, 
m/s per year
7.10 (2.90 to 11.30) 0.001 4.98 (0.53 to 9.91) 0.048
  Presence midwall late gadolinium 
enhancement
0.45 (−1.67 to 2.56) 0.68 −0.17 (−2.28 to 1.95) 0.88
AVR group: factors influencing left ventricular mass regression
  Age, y 0.45 (0.01 to 0.90) 0.047 −0.11 (−0.46 to 0.24) 0.53
  Men −3.0 (−12.1 to 6.1) 0.50 5.23 (−1.10 to 11.55) 0.10
  Hypertension 10.4 (3.9 to 16.8) 0.002 5.52 (0.29 to 10.75) 0.04
  Valvuloarterial impedance 1.9 (−1.4 to 5.2) 0.26 −0.69 (−3.18 to 1.79) 0.57
  Pre-AVR left ventricular mass index, g/m2 −0.37 (−0.49 to −0.25) <0.001 −0.39 (−0.53 to −0.26) <0.001
  Peak aortic-jet velocity at 1 y post-AVR, m/s 2.2 (−4.3 to 8.8) 0.49 4.33 (−0.27 to 8.93) 0.06
  Presence midwall late gadolinium 
enhancement
−9.3 (−17.5 to −1.1) 0.027 −4.7 (−10.5 to 1.12) 0.11
AVR indicates aortic valve replacement; and CI, confidence interval.
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per year]; P<0.001; Table 2; Figure 1). In contrast, the 
ECV% increased (1.2% /y [0.4%–2.2% /y]; P=0.003; 
Figure 1) consistent with faster regression of LVM than 
diffuse fibrosis. The type of replacement valve implant-
ed did not influence the degree of LVM (P=0.61) or 
iECV (P=0.97) regression.
On visual assessment, midwall LGE was present in 
10 patients (26%) at baseline. No patient went on to 
develop new areas of LGE on repeat imaging nor did 
any patient with existing LGE demonstrate resolution 
of any established areas post-AVR (Figure 3). Quantita-
tively, there was no significant change in LGE mass after 
AVR (P=0.22; Table 2) even in patients rescanned after 
2 years. Infarct pattern LGE was observed at baseline 
in 5 patients (13%). One new infarct was detected on 
repeat imaging, but overall no change was observed in 
LGE mass in these patients (P=0.72).
Sensitivity analysis was performed in patients who 
underwent repeat imaging at the same time interval (2 
years in the natural history cohort, n=50; 1 year in the 
AVR cohort, n=27). Our findings were unchanged from 
those made across the cohort as a whole (Figure I and 
Table I in the Data Supplement).
DISCUSSION
This is the first study to characterize how LVH and fibro-
sis progress in AS and how these processes then reverse 
remodel after AVR. Using a multicenter multimodality 
imaging approach with serial echocardiography and 
MRI, we have demonstrated that both hypertrophy and 
fibrosis progress in an increasingly rapid manner as AS 
severity advances. Once midwall patterns of replace-
ment fibrosis (LGE) have become established, further 
scarring seems to accumulate rapidly. Although LVH 
and diffuse fibrosis reverse after AVR, midwall LGE does 
not and seems to be irreversible. Given the adverse 
prognosis associated with midwall fibrosis burden, our 
data suggest prompt AVR at the first sign of midwall 
LGE or just before its development might improve long-
term patient outcomes.
In the natural history cohort, we observed a slow and 
steady progression in each of the echocardiographic 
measures of valvular stenosis as anticipated.15 This 
valve progression was strongly influenced by baseline 
AS severity, with the slowest progression in patients 
with mild stenosis and the most rapid progression in 
Figure 2. Serial magnetic resonance images in a patient with severe aortic stenosis and progression of replacement fibrosis. Top row, Midwall late gadolinium 
enhancement (LGE) is present baseline magnetic resonance imaging (MRI; white arrow, baseline image). New areas of LGE can be seen on follow-up MRI after 1 
y (red arrows). The patient subsequently developed exertional breathlessness and underwent aortic valve replacement (AVR). Repeat imaging 1 y after AVR dem-
onstrated no change in the pattern or volume of LGE. In patients with established midwall LGE, rapid accumulation of further LGE was observed with the fastest 
progression in those with the most severe aortic stenosis (A), the highest baseline burden of LGE (B), and the most advanced indexed extracellular volume (iECV; 







Circ Cardiovasc Imaging. 2018;11:e007451. DOI: 10.1161/CIRCIMAGING.117.007451 June 2018 9
Everett et al; Myocardial Fibrosis Progression in Aortic Stenosis
those with severe obstruction. This was mirrored by a 
similar pattern of increasing LVM progression. Indeed, 
a moderate correlation was observed between valve 
stenosis progression and LVM progression, with the 
annualized increase in peak aortic-jet velocity, the only 
independent predictor of LVM progression on multi-
variable analysis. Consistent with this, AVR resulted in 
a substantial reduction in aortic valve obstruction that 
was accompanied by a ≈20% reduction in the LVM. 
Again, there was a strong correlation between the 
reduction in transvalvular gradient and LVM regression, 
with the former emerging as an independent predictor 
of reverse remodeling on multivariable analysis. One 
surprising finding was a small but significant reduction 
in stroke volume after AVR. This may relate to accom-
panying reductions in LV end-diastolic volume but 
requires further study.
What about myocardial fibrosis? MRI is the only 
noninvasive imaging technique capable of assessing 
both diffuse interstitial (T1 mapping techniques) and 
replacement fibrosis (LGE). T1 mapping provides mul-
tiple different measurements that demonstrate close 
agreement with collagen volume fraction on histology 
and therefore act as surrogates of interstitial myocardial 
fibrosis.7,16 We here investigated the ECV% and iECV 
because of the advantages these measures hold when 
comparing values acquired in a multicenter setting 
on different scanners and at different field strengths. 
Although ECV% gives an indication of the proportion 
of the myocardium made up of fibrosis, iECV is a sur-
rogate of the total fibrosis burden in the LV. Togeth-
er these 2 measures can provide unique insights into 
how the extracellular and intracellular compartments 
of the myocardium change in AS and in response to 
AVR. Like peak aortic-jet velocity and LVMi, the iECV 
increased with time suggesting progressive expansion 
of the extracellular compartment and diffuse interstitial 
fibrosis. Once again, this progression appeared to occur 
quickest in those with the most advanced valvular ste-
nosis. By comparison, ECV% did not demonstrate any 
evidence of progression, suggesting balanced increases 
in the size of the cellular and extracellular compart-
ments as LV remodeling advances.
After AVR, reductions in iECV were observed similar 
to those observed in peak aortic-jet velocity and LVM, 
confirming that diffuse interstitial fibrosis is indeed 
reversible. However, the accompanying rise in ECV% 
suggests that regression in cellular hypertrophy occurs 
faster and to a greater degree than this reduction in 
diffuse fibrosis. These novel imaging findings are in 
keeping with historical data from myocardial biopsies 
performed after AVR showing an initial increase of per-
centage interstitial fibrosis on histology at 18 months.17
Midwall LGE represents a more advanced stage of 
focal replacement fibrosis18 in the myocardium and 
has been described in numerous AS populations.4,6,19 
Midwall LGE is a marker of LV decompensation dem-
onstrating a close association with myocardial injury, 
LV diastolic function, LV systolic function, and exercise 
capacity.7 Moreover, multiple different studies from 
multiple centers have confirmed midwall LGE as a pow-
erful prognostic marker of long-term all-cause and car-
diovascular mortality.4–7 Most of these adverse events 
occur after AVR,20 and there seems to be a proportion-
ate relationship: the more myocardial LGE, the worse 
the clinical outcomes.4,5
Figure 3. Changes in left ventricular mass (LVM), diffuse fibrosis, and replacement fibrosis in aortic stenosis before and after valve replacement. Longitudinal 
changes in LVM index (LVMi), diffuse fibrosis (indexed extracellular volume [iECV]), and replacement fibrosis (late gadolinium enhancement [LGE]) before and after 
valve replacement (AVR) are illustrated with 2 example patients (A and B). All 3 measures increase exponentially as stenosis severity increases (patient A, natural 
history cohort), and new areas of LGE are seen on follow-up imaging (red arrows). However, after AVR, cellular hypertrophy regresses more quickly than diffuse 
fibrosis, and replacement fibrosis seems unchanged (patient B, white arrows). AVR indicates aortic valve replacement; and Vmax, peak aortic-jet velocity.
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For the first time, we have demonstrated that the 
burden of midwall LGE increases while asymptomat-
ic patients are being monitored in the clinic. Indeed, 
once midwall LGE has become established, then fur-
ther accumulation of such scarring is relatively rapid, 
increasing on average by 75% each year especially in 
patients with a high baseline fibrosis burden. Impor-
tantly, we go on to demonstrate that although this 
progressive scarring is arrested by AVR, it does not 
reverse even out to 2 years after AVR. This is consis-
tent with smaller short-term studies and implies that 
the scar that patients develop while waiting for surgery 
remains with them for the rest of their life, contribut-
ing to their poorer long-term prognosis. These findings 
could have important clinical implications for optimiz-
ing patient care and the timing of AVR. For example, 
based on our data, prompt AVR could be undertaken 
when midwall LGE is first identified to prevent the 
accumulation of further scarring and to improve long-
term patient outcomes. This strategy requires prospec-
tive confirmation and is currently being tested in the 
EVOLVED (Early Valve Replacement guided by Biomark-
ers of Left Ventricular Decompensation in Asymptom-
atic Patients with Severe Aortic Stenosis) randomized 
controlled trial (NCT03094143).
Our study does have some limitations. Given the 
heterogeneity in the timing of follow-up imaging, we 
used annualized change for our primary analysis. This 
assumes linear progression or regression of variables 
which may not be the case. In the sensitivity analysis, 
we repeated our analysis of the data using absolute 
change in the subgroup of patients who underwent 
repeat imaging after the same time interval (2 years 
in the natural history cohort [n=50] and 1 year in the 
AVR cohort [n=27]). Our results were consistent with 
the annualized analysis. Further studies are still required 
to investigate how LV remodeling and reverse remod-
eling progress over multiple time points in individual 
patients. The ECV measurements (ECV%, iECV) reflect 
the size of the extracellular compartment and therefore 
potentially represent multiple different factors, includ-
ing the intravascular space and myocardial infiltration. 
However, in patients with AS (and in the absence of 
associated cardiac amyloidosis), there is a close associa-
tion between these ECV measurements and histological 
markers of interstitial fibrosis, confirming that they pro-
vide a useful surrogate measure of interstitial fibrosis, 
as here presented.
CONCLUSIONS
We have used echocardiography and MRI to character-
ize the structural changes in the myocardium that occur 
in patients with AS both during routine surveillance 
and after AVR. In patients with AS, cellular hypertrophy 
and diffuse interstitial fibrosis increase in a balanced 
and exponential manner before reversing at different 
rates after AVR. Once established, midwall replacement 
fibrosis accumulates rapidly but seems irreversible after 
AVR. The myocardial scar burden that patients develop 
while waiting for surgery, therefore, persists into the 
long term along with prognostic implications that this 
entails. Prompt valve replacement as soon as midwall 
fibrosis develops holds promise in improving clinical 
outcomes in patients with AS.
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